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Lecture 1.
1 Lecture 1 PROTEINS
1. Amino acids
All proteins are made up from the same set 20 standard amino acids. A 
typical amino acid has a primary amino group, a carboxyl group, a 
hydrogen atom and a side-chain (R group) attached to a central a-carbon 
atom (Ca). Proline is the exception to the rule in that it has a secondary 
amino group.
All of the 20 standard amino acids, except for glycine, have four 
different groups arranged tetrahedrally around the Ca atom and thus can 
exist in either the D or L configuration. These two enantiomers are 
nonsuperimposable mirror images that con only be distinguished on the 
basis of their different rotation of plane-polarized light. Only the L isomer 
is found in proteins.
The standard set of 20 amino acids have different side chains or R 
groups and display different physicochemical properties (polarity, acidity, 
basicity, aromaticity, bulkiness, conformational inflexibility, ability to form 
hydrogen bonds, ability to cross-link and chemical reactivity).
Glycine (Gly, G) has a hydrogen atom as its R group. Alanine (Ala, A), 
valine (Val, V), leucine (Leu, L), isoleucine (lie, I) and methionine (Met, 
M) have aliphatic side-chains of differing structures that are hydrophobic 
and chemically inert. The aromatic side-chains of phenylalanine (Phe, F), 
tyrosine (Tyr, Y) and tryptophan (Trp, W) are also hydrophobic in nature. 
The conformationally rigid proline (Pro, P) has its aliphatic side-chain 
bonded back on to the amino group and thus is really an amino acid. The 
hydrophobic, sulfur-containing side-chain of cysteine (Cys, C) is highly 
reactive and can form a disulfide bond with another cysteine residue. The 
basic amino acids arginine (Arg, R) and lysine (Lys, K) have positively 
charged side-chains, whilst the side-chain of histidine (His, H) can be 
either positively charged or uncharged at neutral pH. The side-chains of the 
acidic amino acids aspartic acid (Asp, D) and glutamic acid (Glu, E) are 
negatively charged at neutral pH. The amide side-chains of asparagine 
(Asn, N) and glutamine (Gin, Q), and the hydroxyl side-chains of serine 
(Ser, S) and threonine (Thr, T) are uncharged and polar, and can form 
hydrogen bonds.
2. Acids, bases, pH, buffers and ionization of amino acids
PH is a measure of the concentration of H+ in a solution. An acid is a 
proton donor; a base is a proton acceptor. Ionization of an acid yields its
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conjugate base, and the two are termed a conjugate acid-base pair, for 
example acetic acid (CH3COOH) and acetate (CH3COO'). The pK of an 
acid is the pH at which it is half dissociated. The Henderson-Hasselbach 
equation expresses the relationship between pH, pK and the ration of acid 
to base, and can be used to calculate these values.
An acid-base conjugate pair can act as a buffer, resisting changes in pH. 
From a titration curve of an acid the inflexion point indicates the pK value. 
The buffering capacity of the acid-base pair is the pK ± 1 pH unit. In 
biological fluids the phosphate and carbonate ions act as buffers. Amino 
acids, proteins, nucleic acids and lipids also have some buffering capacity. 
In the laboratory other compounds, such as TRIS, are used to buffer 
solutions at the appropriate pH.
The a-amino and a-carboxyl groups on amino acids act as acid-base 
groups, donating or accepting a proton as the pH is altered. At low pH, both 
groups are fully protOnated, but as the pH is increased first the carboxyl 
group and then the amino group loses a hydrogen ion. For the standard 20 
amino acids, the pK is in the range 1.8-2.9 for the a-carboxyl group and 
8.8-10.8 for the a-amino group. Those amino acids with an ionizable side- 
chain have an additional acid-base group with a distinctive pK.
3. Protein structure
3.1. Peptide bond
A protein is a linear sequence of amino acids linked together by peptide 
bonds. The peptide bond is a covalent bond between the a-amino group of 
one amino acid and the a-carboxyl group of another. The peptide bond has 
partial double bond character and is nearly always in the trans­
configuration. The backbone conformation of a polypeptide is specified by 
the rotation angles about the Ca-N bond (phi, tp) and Ca-C bond (psi, ip) of 
each of its amino acid residues. The sterically allowed values of <p and ip 
are visualized in a Ramachandran plot. When two amino acids are joined 
by a peptide bond they form a dipeptide. Addition of further amino acids 
results in long chains called oligopeptides and polypeptides.
3.2. Primary structure
The linear sequence of amino acids joined together by peptide bonds is 
termed the primary structure of the protein. The position of covalent 
disulfide bonds between cysteine residues is also included in the primary 
structure.
The primary level of structure in a protein is the linear sequence of 
amino acids joined together by peptide bonds. This sequence is determined 
by the sequence of nucleotide bases in the gene encoding the protein. Also
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included under primary structure is the location of any other covalent 
bonds. These are primarily disulfide bonds between cysteine residues that 
are adjacent in space but not in the linear amino acid sequence. These 
covalent cross-links between separate polypeptide chains or between 
different parts of the same chain are formed by the oxidation of the SH 
groups on cysteine residues that are juxtaposed in space. The resulting 
disulfide is called a cystine residue. Disulfide bonds are often present in 
extracellular proteins, but are rarely found in intracellular proteins. Some 
proteins, such as collagen, have covalent cross-links formed between the 
side-chains of Lys residues.
3.3. Secondary structure
Secondary structure in a protein refers to the regular folding of regions 
of the polypeptide chain. The two most common types of secondary 
structure are the a-helix and the P-pleated sheet. The a-helix is а 
cylindrical, rod-like helical arrangement of the amino acids in the 
polypeptide chain, which is maintained by hydrogen bonds parallel to the 
helix axis. In a P-pleated sheet, hydrogen bonds form between adjacent 
sections of polypeptides that are either running in the same direction 
(parallel р-pleated sheet) or in the opposite direction (antiparallel p-pleated 
sheet). P-Tums reverse the direction of the polypeptide chain and are often 
found connecting the ends of antiparallel P-pleated sheet.
The secondary level of structure in a protein is the regular folding of 
regions of the polypeptide chain. The two most common types of protein 
fold are the a-helix and the P-pleated sheet. In the rod-like a-helix, the 
amino acids arrange themselves in a regular helical conformation. The 
carbonyl oxygen of each peptide bond is hydrogen bonded to the hydrogen 
on the amino group of the fourth amino acid away. With the hydrogen 
bonds running nearly parallel to the axis of the helix. In an a-helix there are 
3.6 amino acids per turn of the helix covering a distance of 0.54 nm, and 
each amino acid residue represents an advance of 0.15 nm along the axis of 
the helix. The side-chains of the amino acids are all positioned along the 
outside of the cylindrical helix. Certain amino acids are more often found 
in a-helices than others. In particular, Pro is rarely found in a-helical 
regions, as it cannot form the correct pattern of hydrogen bonds due to the 
lack of a hydrogen atom on its nitrogen atom. For this reason, Pro is 
direction of the polypeptide chain and terminates the helix.
Different proteins have a different amount of the polypeptide chain 
folded up into a-helices. For example, the single polypeptide chain of 
myoglobin has eight a-helices. In the P-pleated sheet hydrogen bonds form 
between the peptide bonds either in different polypeptide chain. The 
planarity of the peptide bond forces the polypeptide to be pleated with the 
side-chains of the amino acids protruding above and below the sheet.
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Adjacent polypeptide chains in P-pleated sheets can be either parallel or 
antiparallel depending on whether they run in the same direction or in 
opposite directions, respectively. The polypeptide chain within a p-pleated 
sheet is fully extended, such that there is a distance of 0.35 nm from on a-C 
atom to the next. p-Pleated sheets are always slightly curved and, if several 
polypeptides are involved, the sheet can close up to from a p-barrel. 
Multiple р-pleated sheets provide strength and rigidity in many structural 
proteins, such as silk fibroin, which consists almost entirely of stacks of 
antiparallel P-pleated sheets.
In order to fold tightly into the compact shape of a globular protein, the 
polypeptide chain often reverses direction, making a hairpin or p-tum. In 
these P-turns the carbonyl oxygen of one amino acid is hydrogen bonded 
to the hydrogen on the amino group of the fourth amino acid along, p- 
Turns are often found connecting the ends of antiparallel р-pleated sheets. 
Region of the polypeptide chain that are not in a regular secondary 
structure are said to, have a coil or loop conformation. About half the 
polypeptide chain of a typical globular protein will be in such a 
conformation.
3.4. Tertiary structure
Tertiary structure in a protein refers to the three-dimensional 
arrangement of all the amino acids in the polypeptide chain. This 
biologically active, native conformation is maintained by multiple 
noncovalent bonds.
The third level of structure found in proteins, tertiary structure refers to 
the spatial arrangement of amino acids that are far apart in the linear 
sequence as well as those residues that are adjacent. Again, it is the 
sequence of amino acids that specifies this final three-dimensional 
structure. In water-soluble globular proteins such as myoglobin, the main 
driving force behind the folding of the polypeptide chain is the energetic 
requirement to bury the nonpolar amino acids in the hydrophobic interior 
away from the surrounding aqueous, hydrophilic medium. The polypeptide 
chain folds spontaneously so that the majority of its hydrophobic side- 
chains are buried in the interior, and the majority of its polar, charged side- 
chains are on the surface.
Once folded, the three-dimensional, biologically active (native) 
conformation of the protein is maintained not only by hydrophobic 
interactions, but also by electrostatic forces, hydrogen bonding and, of 
present, the covalent disulfide bonds. The electrostatic forces include salt 
bridges between oppositely charged groups and the multiple weak van der 
Waals interactions between the tightly packed aliphatic side-chains in the 
interior of the protein.
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The native three-dimensional conformation of a protein is maintained by 
a range of noncovalent interactions (electrostatic forces, hydrogen bonds, 
hydrophobic forces) and covalent interactions (disulfide bonds), in addition 
to the peptide bonds between individual amino acids.
3.5. Quaternary structure
If a protein is made up of more than one polypeptide chain it is said to 
have quaternary structure. This refers to the spatial arrangement of the 
polypeptide subunits and the nature of the interactions between them.
Proteins containing more than one polypeptide chain, such as 
hemoglobin, exhibit a fourth level of protein structure refers to the spatial 
arrangement of the polypeptide subunits and the nature of the interactions 
between them. These interactions may be covalent links or noncovalent 
interactions (electrostatic forces, hydrogen bonding, hydrophobic 
interactions).
3.6. Protein folding
Proteins spontaneously fold into their native conformation, with the 
primary structure of the protein dictating its three-dimensional structure. 
Protein folding is driven primarily by hydrophobic forces and proceeds 
through an ordered set of pathways. Accessory proteins, including protein 
disulfide isomerases, peptidyl prolyl cis-trans isomerases, isomerases, and 
molecular chaperones, assist proteins to fold correctly in the cell.
4. Hemoglobin and myoglobin
Hemoglobin and myoglobin are the two oxygen-binding proteins 
present in large multicellular organisms. Hemoglobin transports oxygen in 
the blood and is located in the erythrocytes; myoglobin stores the oxygen in 
the muscles.
Myoglobin was the first protein to have its three-dimensional structure, 
solved by X-ray crystallography. It is a globular protein made up of a 
single polypeptide chain of 153 amino acid residues that is folded into eight 
a-helices. The heme prosthetic group is located within a hydrophobic cleft 
of the folded polypeptide chain.
Hemoglobin has quaternary structure as it is made up of four 
polypeptide chains; two а-chains and two P-chains (a2p2), each with a heme 
prosthetic group. Despite little similarity in their primary sequences, the 
individual polypeptides of hemoglobin have a three-dimensional structure 
almost identical to the polypeptide chain of myoglobin.
The heme prosthetic group consists of a protoporphyrin IX ring and a 
central Fe + atom, which forms four bonds with the porphyrin ring. In 
addition, on one side of the porphyrin ring the Fe2+ forms a bond with the
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proximal histidine (His F8); a residue eight amino acids along the F-helix 
of hemoglobin. The sixth bond from the Fe2+ is to a molecule of 02. Close 
to where the 02 binds is another histidine residue, the distal histidine (His 
E7), which prevents carbon monoxide binding most efficiently.
Hemoglobin is an allosteric protein. The binding of 02 is cooperative; 
the binding of 02 to one subunit increases the ease of binding of farther 02 
molecules to the other subunits. The oxygen dissociation curve for 
hemoglobin is sigmoidal whereas that for myoglobin is hyperbolic. 
Myoglobin has a greater affinity for 02 than does hemoglobin.
Oxyhemoglobin has a different quaternary structure from 
deoxyhemoglobin. As 02 binds to the Fe2+ it distorts the heme group and 
moves the proximal histidine. This in turn moves helix F and alters the 
interactions between the four subunits.
H+, C 02 and 2,3-bisphosphogiycerate are allosteric effectors, promoting 
the release of 02 from hemoglobin. H+ and C 02 bind to different parts of 
the polypeptide chains, while 2,3-bisphosphoglycerate binds in the central 
cavity between the four subunits.
Hemoglobin F (HbF) which consists of two а -chains and two y-chains 
(a2y2) is present in the fetus. HbF binds 2,3-bisphosphoglycerate less 
strongly than adult hemoglobin (HbA) and thus has a higher affinity for 02, 
which promotes the transfer of 02 from the maternal to the fetal circulation.
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Lecture 2
PROTEIN PURIFICATION
1. Principles of protein purification
1. The aim of protein purification is to isolate one particular protein 
from all the others in the starting material. A combination of fractionation 
techniques is used that exploits the solubility, size, charge or/and specific 
binding affinity of the protein of interest.
2. Because proteins have different distributions in biological 
materials, it is important to make the right choice of starting material 
from which to purify the protein. This will usually be a source that is 
relatively rich in the protein of interest and which is readily available.
3. The protein has to be obtained in solution prior to its purification. 
Thus tissues and cells must be disrupted by homogenization or osmotic 
lysis and then subjected to differential centrifugation to isolate the 
subcellular fraction in which the protein is located. For membrane-bound 
proteins, the membrane structure has to be solubilized with a detergent to 
liberate the protein.
4. Certain precautions have to be taken in order to prevent proteins 
being denatured or inactivated during purification by physical or biological 
factors. These include buffering the pH of the solutions, undertaking the 
procedures at a low temperature and including protease inhibitors to 
prevent unwanted proteolysis.
5. In order to monitor the progress of the purification of a protein it is 
necessary to have an assay for it. Depending on the protein, the assay 
may involve measuring the enzyme activity or ligand-binding properties, 
or may quantify the protein present using antibodies directed against it.
6. The solubility of proteins decreases as the concentration of 
ammonium sulfate in the solution is increased. The concentration of 
ammonium sulfate at which a particular protein comes out of solution and 
precipitates may be sufficiently different from other proteins in the 
mixture to effect a separation.
7. Proteins can be separated from small molecules by dialysis through a 
semipermeable membrane, which has pores that allow small molecules to 
pass through but not proteins.
8. Proteins with large differences in molecular mass can be separated 
by rate zonal centrifugation using a gradient of a dense material such as 
sucrose.
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2. Selection of a protein source
Before attempting to purify a protein, the first thing to consider is the 
source of starting material. Proteins differ in their cellular and tissue 
distribution, and thus if a protein is known to be abundant in one 
particular tissue (e.g. kidney) it makes sense to start the purification from 
this source. Also, some sources are more readily available than others and 
this should be taken into account too. Nowadays, with the use of 
recombinant DNA techniques, even scarce proteins can be expressed in 
bacteria or eukaryotic ceils and relatively large amounts of the protein 
subsequently obtained.
3. Homogenization and solubilization
Once a suitable source has been identified, the next step is to obtain the 
protein in solution. For proteins in biological fluids, such as blood 
serum, this is already the case, but for the majority of proteins the tissues 
and cells need to be disrupted by homogenization and broken open (lysed) 
and subsequent differential centrifugation.
Another simple way of breaking open cells that do not have a rigid cell 
wall to release the cytosolic contents is osmotic lysis. When animal cells are 
placed in a hypotonic solution (such as water or a buffered solution 
without added sucrose), the water in the surrounding solution diffuses 
into the more concentrated cytosol, causing the cell to swell and burst. 
Differential centrifugation is then employed to remove contaminating 
subcelluiar organelles. Those proteins that are bound to membranes require 
a further solubilization step.
After isolation by differential centrifugation, the appropriate membrane 
is treated with a detergent such as Triton X-100 to disrupt the lipid bilayer 
and to release the integral membrane proteins into solution.
4. Ammonium sulfate precipitation.
A commonly employed first separation step is ammonium sulfate 
precipitation. This technique exploits the tact that the solubility of 
most proteins is lowered at high salt concentrations. As the salt 
concentration is increased, a point is reached where the protein comes out 
of solution and precipitates.
The concentration of salt required for this salting out effect varies from 
protein to protein, and thus this procedure can be used to fractionate a 
mixture of proteins. For example, 0.8M ammonium sulfate precipitates 
out the clotting protein fibrinogen from blood serum, whereas 2.4 M 
ammonium sulfate is required to precipitate albumin. Salting out is also
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sometimes used at later stages in a purification procedure to concentrate a 
dilute solution of the protein since the protein precipitates and can then be 
redissolved in a smaller volume of buffer.
5. Dialysis
Proteins can be separated from small molecules by dialysis through a 
semi-permeable membrane such as cellophane (cellulose acetate). Pores 
in the membrane allow molecules up to approximately 10 kDa to pass 
through, whereas larger molecules are retained inside the dialysis bag 
(Fig.l). As most proteins have molecular masses greater than 10 kDa, this 
technique is not suitable for fractionating proteins, but is often used to 
remove small molecules such as salts from a protein solution. It should be 
noted that at equilibrium, the concentration of small molecules inside a 
dialysis bag will be equal to that outside (Fig. lb), and so several changes 
of the surrounding solution are often required to lower the concentration of 
the small molecule in the protein solution sufficiently.
Fig. 1. Separation o f molecules on the basis o f size by dialysis: (a) starting point, (b) at 
equilibrium.
6. Fractionation techniques.
The basic aim in protein purification is to isolate one particular 
protein of interest from other contaminating proteins so that its structure 
and/or other properties can be studied. Once a suitable cellular source of 
the protein has been identified, the protein is liberated into solution and 
then separated from contaminating material by sequential use of a series of 
different fractionation techniques or separations.
These separations exploit one or more of the following basic 
properties of the protein: its solubility, its size, its charge or its specific 
binding affinity.
These separations may be chromatographic techniques such as ion 
exchange, gel filtration or affinity chromatography, hydrophobic 
interaction chromatography, in which the protein binds to a hydrophobic
12
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material, or electrophoretic techniques such as isoelectric focusing. Other 
electrophoretic procedures, mainly sodium dodecyl sulfate (SDS) 
polyacrylamide gel electrophoresis (PAGE) but also native PAGE, are 
used to monitor the extent of purification and to determine the molecular 
mass and subunit composition of the purified protein.
6.1. Chromatography of proteins.
6.1.1. Gel filtration chromatography.
In gel filtration chromatography (size exclusion chromatography or 
molecular sieve chromatography), molecules are separated on the basis of 
their size and shape. The protein sample in a small volume is applied to the 
top of a column of porous beads (diameter 0.1mm) that are made of an 
insoluble but highly hydrated polymer such as polyacrylamide (Bio-Gel) 
or the carbohydrates dextran (Sephadex) or agarose (Sepharose) (Fig. 2a).
Small molecules can enter the pores in the beads whereas larger or more 
elongated molecules cannot. The smaller molecules therefore have a larger 
volume of liquid accessible to them: both the liquid surrounding the 
porous beads and that inside the beads. If contrast, the larger molecules 
have only the liquid surrounding the beads accessible to them, and thus 
move through the column faster, emerging out of the bottom (eluting) first 
(Fig.2a and b). The smaller molecules move more slowly through the 
column and elute later. Beads of differing pore sizes are available, allowing 
proteins of different sizes to be effectively separated. Gel filtration 
chromatography is often used to de-salt a protein sample for example for 
remove the ammonium sulfate after ammonium sulfate precipitation since 
the salt enters the porous beads and is eluted late, whereas the protein 
does not enter the beads and is eluted early.
Gel filtration chromatography can also be used to estimate the 
molecular mass of a protein. There is a linear relationship between the 
relative elution volume of a protein (Ve/V0 where Ve is the elution volume 
of a given protein and V0 is the void volume of the column that is the 
volume of the solvent space surrounding the beads; Fig. 2b) and the 
logarithm of its molecular mass. Thus a 'standard' curve of V/V0 against 
logio molecular mass can be estimated for the column using proteins of 
known mass. The elution volume of any sample protein then allows its 
molecular mass to be estimated by reference to its position on the 
standard curve (Fig. 2c).
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Fig. 2. Gel filtration Chromatography, (a) Schematic illustration of gel filtration 
chronuitography; (b) elution diagram indicating the separation; (c) a plot of relative 
elution volunu- versus the logarithm o f molecular mass for known proteins, indicating how 
the molecular mass o f an unknown can be read off when its relative elution volume is 
known.
6.1.2. Ion exchange chromatography.
In ion exchange chromatography, proteins are separated on the basis 
of their overall (net) charge. If a protein has a net negative charge at pH 7, 
it will bind to a column containing positively charged beads, whereas a 
protein with no charge or a net positive charge will not bind (Fig. 3a). The 
negatively charged proteins bound to such a column can then be eluted by 
washing the column with an increasing gradient (increasing concentration) 
of a solution of sodium chloride (Na+, СГ ions) at the appropriate pH. The 
СГ ions compete with the protein for the positively charged groups on the 
column. Proteins having a low density of negative charge elute first, 
followed by those with a higher density of negative charge (Fig. 3b). 
Columns containing positively charged diethylaminoethyl (DEAE) groups 
(such as DEAE-cellulose or DEAE-Sephadex) are used for separation of 
negatively charged proteins (anionic proteins).
This is called anion exchange chromatography. Columns containing 
negatively charged carboxyl methyl (CM) groups (such as CM-cellulose 
or CM-Sephadex) are used for they separation of positively charged 
proteins (cationic proteins). This is called cation exchange
14
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chromatography. As an alternative to elution with a gradient of NaCl, 
proteins can be eluted from anion exchange columns by decreasing the pH 
of the buffer, and from cation exchange columns by increasing the pH of the 
buffer, thus altering the ionization state of the amino acid side-chains and 
hence the net charge on the protein.
Fig.S. Ion exchange chromatography, (a) Schematic illustration o f ion exchange 
chromatography; {b) elution diagram indicating the separation o f a protein o f net 
positive charge tltat does not bind to the positively charged beads and passes straight 
through the column, and oj two proteins with different net negative charges that bind to 
the positively charged beads and are eluted on increasing the concentration of NaC! 
applied to the column. The protein with the lower density o f negative charge elutes 
earlier than the protein with the higher density of negative charge.
6.1.3. Affinity chromatography.
Affinity chromatography exploits the specific, high affinity, noncovalent 
binding of a protein to another molecule, the ligand. First, the ligand is 
covalently attached to an inert and porous matrix (such as Sepharose). The 
protein mixture is then passed down a column containing the immobilized 
ligand. The protein of interest will bind to the ligand, whereas all other 
proteins pass straight through (Fig.4).
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Fig. 4. Affinity chromatography, (a) Schematic diagram of affinity 
chromatography; (b) elution diagram indicating that nonspecific proteins that do not 
bind to the immobilized ligand pass straight through the column, while the specific 
protein binds to the immobilized ligand and is eluted from the column only on addition 
o f soluble ligand.
After extensive washing of the column with buffer to remove 
nonspecifically bound proteins, the bound protein is released from the 
immobilized ligand either by adding soluble ligand which competes with 
the immobilized ligand for the protein, or by altering the properties of the 
buffer (changing the pH or salt concentration).
If soluble ligand is used to elute the protein from the column, extensive 
dialysis often then has to be used to remove the small ligand from the larger 
protein.
Because this technique exploits the specific, often unique, binding 
properties of the protein, it is often possible to separate the protein from a 
mixture of hundreds of other proteins in a single chromatographic step. 
Commonly employed combinations of immobilized ligand and protein to be 
purified used in affinity chromatographic systems include an inhibitor to 
purify an enzyme, an antibody to purify its antigen, a hormone (e.g. insulin) 
to purify its receptor.
6.2. Electrophoresis of proteins.
6.2.1. Native PAGE
In native polyacrylamide gel electrophoresis (PAGE) proteins are applied 
to a porous polyacrylamide gel and separated in an electric field on the basis 
of their net negative charge and their size. Small/more negatively charged 
proteins migrate further through the gel than largcr/'less negatively charged 
proteins.
16
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6.2.2. SDS-PAGE.
In SDS-PAGE, the protein sample is treated with a reducing agent to 
break disulfide bonds and then with the anionic detergent sodium dodecyl 
sulfate (SDS), which denatures the proteins and covers them with an 
overall negative charge. The sample is then fractionated by 
electrophoresis through a polyacrylamide gel. As all the proteins now 
have an identical charge to mass ratio, they are separated on the basis of 
their mass. The smallest proteins move farthest. SDS-PAGE can be used to 
determine the degree of purity of a protein sample, the molecular mass of a 
protein and the number of polypeptide subunits in a protein.
6.2.3. Isoelectric focusing.
In isoelectric focusing, proteins are separated by electrophoresis in a 
pH- gradient in a gel. They separate on the basis of their relative content 
of positively and negatively charged residues. Each protein migrates 
through the gel until it reaches the point where it has no net charge, its 
isoelectric point (PI).
17
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Lecture 3
INTRODUCTION TO ENZYMES
1. Enzymes as catalysts
Enzymes are catalysts that increase the rate of a chemical reaction
without being changed themselves in the process. In the absence of an 
enzyme, the reaction may hardly proceed at all, whereas in its presence 
the rate can be increased up to 107-fold. Enzyme catalyzed reactions 
usually take place under relatively mild conditions (temperatures well 
below 100°C, atmospheric pressure arid neutral pH) as compared to the 
corresponding chemical reactions. Enzymes are also highly specific with 
respect to the substrates that they act on and the products that they form. 
In addition, enzyme activity can be regulated, varying in response to the 
concentration of substrates or other molecules. Nearly all enzymes are 
proteins, although a few catalytically active RNA molecules have been 
identified.
2. Active site
The active site of an enzyme is the region that binds the substrate and 
converts it into product. It is usually a relatively small part of the whole 
enzyme molecule and is a three-dimensional entity formed by amino 
acid residues that can lie far ap art in the linear polypeptide chain. 
The active site is often a cleft or crevice on the surface of the enzyme 
that forms a predominantly nonpolar environment which enhances the 
binding of the substrate. The substrate(s) is bound in the active site by 
multiple weak forces (electrostatic interactions, hydrogen bonds, van der 
Waals bonds, and hydrophobic interactions) and in some cases by 
reversible covalent bonds. Having bound the substrate molecule, and 
formed an enzyme-substrate complex, catalytically active residues within 
the active site of the enzyme act on the substrate molecule to transform it 
first into the transition state complex and then into product, which is 
released into solution. The enzyme is now free to bind another molecule 
of substrate and begin its catalytic cycle again.
Two models have been proposed to explain how an enzyme binds 
its substrate. In the lock-and-key model proposed by Emil Fischer in 
1894, the shape of the substrate and the active site of the enzyme are 
thought to fit together like a key into its lock (Fig. la). The two shapes are 
considered as rigid and fixed, and perfectly complement each other when
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brought together in the right alignment. In the induced-fit model 
proposed in 1958 by Daniel E.
(«)
6 *•—(3
Enzyme Substrate Enzyme-substrate
complex
Fig. 1. Binding o f  a substrate to the enzyme, (a) Lock-and-key model;
(b) induced-fit model
3. Substrate specificity
The properties and spatial arrangement of the amino acid residues 
forming the active site of an enzyme will determine which molecules can 
bind and be substrates for that enzyme. Substrate specificity is often 
determined by changes in relatively few amino acids in the active site. 
This is clearly seen in the three digestive enzymes trypsin, chymotrypsin 
and elastase. These three enzymes belong to a family of enzymes called the 
serine proteases - ‘serine’ because they have a serine residue in the active 
site that is critically involved in catalysis and ‘proteases’ because they 
catalyze the hydrolysis of peptide bonds in proteins. The three enzymes 
cleave peptide bonds in protein substrates on the carboxyl side of certain 
amino acid residues.
Trypsin cleaves on the carboxyl side of positively charged Lys or Arg 
residues, chymotrypsin cleaves on the carboxyl side of bulky aromatic and 
hydrophobic amino acid residues, and elastase cleaves on the carboxyl side 
of residues with small uncharged side chains. Their differing specificities 
are determined by the nature of the amino acid groups in their substrate 
binding sites, which are complementary to the substrates that they act upon.
4. Enzyme classification
Many enzymes are named by adding the suffix '-ase' to the name 
o f their substrate. Thus urease is the enzyme that catalyzes the 
hydrolysis of urea, and fructose-1,6-bisphosphatase hydrolyzes fructose- 
1,6-bisphosphate. However, other enzymes, such as trypsin and 
chymotrypsin, have names that do not denote their substrate. Some 
enzymes have several alternative names. To rationalize enzyme names, 
a system of enzyme nomenclature has been internationally agreed. This 
system places all enzymes into one of six major classes based on the type 
of reaction catalyzed (Table I).
Enzyme Substrate Enzyme-substrate
complex
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Each enzyme is then uniquely identified with a four-digit 
classification number. Thus trypsin has the Enzyme Commission (EC) 
number 3.4.21.4, where the first number (3) denotes that it is a hydrolase, 
the second number (4) that it is a protease that hydrolyzes peptide bonds, 
the third number (2 1) that it is a serine protease with a critical serine 
residue at the active site, and the fourth number (4) indicates that it was 
the fourth enzyme to be assigned to this class. For comparison, 
chymotrypsin has the EC number 3.4.21.1, and elastase 3.4.21.36.
5. Enzyme assays
The amount of enzyme protein present can be determined (assayed) in 
terms of the catalytic effect it produces, that is the conversion of substrate 
to product. In order to assay (monitor the activity of) an enzyme, the 
overall equation of the reaction being catalyzed must be known, and an 
analytical procedure must be available for determining either the 
disappearance of substrate or the appearance of product. In addition, one 
must take into account whether the enzyme requires any cofactors, and the 
pH and temperature at which the enzyme is optimally active. For 
mammalian enzymes, this is usually in the range 25-37°C. Finally, it is 
essential that the rate of the reaction being assayed is a measure of the 
enzyme activity present and is not limited by an insufficient supply of 
substrate. Therefore, very high substrate concentrations are generally 
required so that the initial reaction rate, which is determined 
experimentally, is proportional to the enzyme concentration.
An enzyme is most conveniently assayed by measuring the rate of 
appearance of product or the rate of disappearance of substrate. If the 
substrate (or product) absorbs light at a specific wavelength, then changes 
in the concentration of these molecules can be measured by following the 
change of absorbance at this wavelength. Typically this is carried out using 
a spectrophotometer. Since absorbance is proportional to concentration, the 
rate of change in absorbance is proportional to the rate of enzyme activity 
in moles of substrate used (or product formed) per unit time.
Enzyme units
Enzyme activity may be expressed in a number of ways. The 
commonest is by the initial rate (V0) of the reaction being catalyzed (e.g. 
pmol of substrate transformed per minute; pmol min'1). There are also two 
standard units of enzyme activity, the enzyme unit (U) and the katal 
(kat). An enzyme unit is that amount of enzyme, which will catalyze the 
transformation of 1 pmol of substrate per minute at 25°C under optimal 
conditions for that enzyme. The katal is the accepted SI unit of enzyme
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activity and is defined as that catalytic activity which will raise the rate of a 
reaction by one mole per second in a specified system. It is possible to 
convert between these different units of activity using 1 pmol min = 1 U = 
16.67 nanokat. The term activity (or total activity) refers to the total units 
of enzyme in the sample, whereas the specific activity is the number of 
enzyme units per milligram of protein (units mg"1). The specific activity is 
a measure of the purity of an enzyme; during the purification of the 
enzyme its specific activity increases and becomes maximal and constant 
when the enzyme is pure.
6. Coenzymes and prosthetic groups
Many enzymes require the presence of small, nonprotein units or 
cofactors to carry out their particular reaction. Cofactors may be either 
one or more inorganic ions, such as Zn2+ or Fe2+, or a complex organic 
molecule called a coenzyme. A metal or coenzyme that is covalently attached 
to the enzyme is called a prosthetic group. A complete catalytically active 
enzyme together with its coenzyme or metal ion is called a holoenzyme. 
The protein part of the enzyme on its own without its cofactor is termed 
an apoenzyme. Some coenzymes, such as NAD+, are bound and released by 
the enzyme during its catalytic cycle and in effect function as cosubstrates. 
Many coenzymes are derived from vitamin precursors, which are often 
essential components of the organism's diet, thus giving rise to deficiency 
diseases when in inadequate supply.
7. Isoenzymes
Isoenzymes (isozymes) are different forms of an enzyme, which 
catalyze the same reaction, but which exhibit different physical or kinetic 
properties, such as isoelectric point, pH optimum, substrate affinity or 
effect of inhibitors. Different isoenzyme forms of a given enzyme are 
usually derived from different genes and often occur in different tissues 
of the body.
An example of an enzyme, which has different isoenzyme forms, is 
lactate dehydrogenase (LDH), which catalyzes the reversible conversion 
of pyruvate into lactate in the presence of the coenzyme NADH.
LDH is a tetramer of two different types of subunits, called H and M, 
which have small differences in amino acid sequence. The two subunits can 
combine randomly with each other, forming five isoenzyme that have the 
compositions H4, H3M, H2M2, HM3 and M4. The five isoenzyme can be 
resolved electrophoretically. M subunits predominate in skeletal muscle and 
liver, whereas H subunits predominate in the heart. НЦ and H3M 
isoenzymes are found predominantly in the heart and red blood cells; H2M2
21
Lecture 3.
is found predominantly in the brain and kidney; while HM3 and M4 are found 
predominantly in the liver and skeletal muscle. Thus, the isoenzyme pattern 
is characteristic of a particular tissue, a factor which is of immense diag­
nostic importance in medicine. Myocardial infarction, infectious hepatitis 
and muscle diseases involve cell death of the affected tissue, with release of 
the cell contents into the blood. As LDH is a soluble, cytosolic protein it is 
readily released in these conditions. Under normal circumstances there is 
little LDH in the blood. Therefore the pattern of LDH isoenzymes in the 
blood is indicative of the tissue that released the isoenzymes and so can be 
used to diagnose a condition, such as a myocardial infarction, and to monitor 
the progress of treatment.
8. Activation energy and transition state
The energy changes that take place during the course of a particular 
biochemical reaction are shown in Fig.2. In all reactions there is an 
energy barrier that has to be overcome in order for the reaction to 
proceed. This is the energy needed to transform the substrate 
molecules into the transition  state - an unstable chemical form 
partway between the substrates and the products. The transition state has 
the highest free energy of any component in the reaction pathway. The 
Gibbs free energy of activation (AG$) is equal to the difference in free 
energy between the transition state and the substrate (Fig. 2). An enzyme 
works by stabilizing the transition state of a chemical reaction and 
decreasing AGJ (Fig. 2). The enzyme does not alter the energy levels of 
the substrates or the products. Thus an enzyme increases the rate at which 
the reaction occurs, but has no effect on the overall change in energy of 
the reaction.
The change in Gibbs free energy (AG) dictates whether a reaction will 
be energetically favorable or not. Figure 2 shows an example where the 
overall energy change of the reaction makes it energetically favorable (i.e. 
the products are at a lower energy level than the substrates and AG is 
negative). It should be noted that AG is unrelated to AGJ. The AG of a 
reaction is independent of the path of the reaction, and it provides no 
information about the rate of a reaction since the rate of the reaction is 
governed by AGJ. A negative AG indicates that the reaction is 
thermodynamically favorable in the direction indicated (i.e. that it is 
likely to occur without an input of energy), whereas a positive AG 
indicates that the reaction is not thermodynamically favorable and 
requires an input off energy to proceed in the direction indicated. In 
biochemical systems, this input of energy is often achieved by coupling 
the energetically unfavorable reaction with a more energetically 
favorable one (coupled reactions).
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Non-enzym e-catalyzed
Fig. 2. The energy changes taking place during the course o f  a biochemical reaction.
9. Enzyme kinetics
9.1. Substrate concentration
The normal pattern of dependence of enzyme rate on substrate 
concentration ([S]) is that at low substrate concentrations a doubling of 
[S] will lead to a doubling of the initial velocity (V0). However, at higher 
substrate concentrations the enzyme becomes saturated, and further 
increases in [S] lead to very small changes in V0. This occurs because at 
saturating substrate concentrations effectively all of the enzyme 
molecules have bound substrate. The overall enzyme rate is now 
dependent on the rate at which the product can dissociate from the 
enzyme, and adding further substrate will not affect this. The shape of 
the resulting graph when V0 is plotted against [S] is called a hyperbolic 
curve (Fig. 3).
Fig.3. The relationship between substrate concentration[S]and initial velocity
(Vo)
9.1.1. Michaeiis-Menten model
The Michaeiis-Menten model uses the following concept of enzyme 
catalysis:
k| k3
E + S ES ------- E + P
кг
The enzyme (E), combines with its substrate (S) to form an enzyme- 
substrate complex (ES). The ES complex can dissociate again to form E
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+ S, or can proceed chemically to form E and the product P. The rate 
constants ki, k2 and k3 describe the rates associated with each step of the 
catalytic process. It is assumed that there is no significant rate for the 
backward reaction of enzyme and product (E+P) being converted to ES 
complex. [ES] remains approximately constant until nearly all the 
substrate is used, hence the rate of synthesis of ES equals its rate of 
consumption over most of the course of the reaction; that is, [ES] maintains 
a steady state. From the observation of the properties of many enzymes it 
was known that the initial velocity (V0) at low substrate concentrations is 
directly proportional to [S], while at high substrate concentrations the 
velocity tends towards a maximum value, that is the rate becomes 
independent of [S] (Fig. 4a). This maximum velocity is called Vmax (pmol 
min'1). The initial velocity (V0) is the velocity measured experimentally 
before more than approximately 10% of the substrate has been converted to 
product in order to minimize such complicating factors as the effects of 
reversible reactions, inhibition of the enzyme by product, and progressive 
inactivation of the enzyme.
Michaelis and Menten derived an equation to describe these 
observations, the Michaelis-Menten equation:
Vmax x [SI
Km + [S]
The equation describes a hyperbolic curve of the type shown for the 
experimental data in Fig. 4a. In deriving the equation, Michaelis and 
Menten defined a new constant, Km, the Michaelis constant [units: Molar 
(i.e. per mole), M]:
k2 + k3
Kra = ------------
ki
K„ is a measure of the stability of the ES complex, being equal to the 
sum of the rates of breakdown of ES over its rate of formation. For many 
enzymes k2 is much greater than k3. Under these circumstances Km 
becomes a measure of the affinity of an enzyme for its substrate since 
its value depends on the relative values of k) and k2 for ES formation and 
dissociation, respectively. A high Km indicates weak substrate binding 
(k2 predominant over ki); a low Km indicates strong substrate binding (kt 
predominant over k2). Km can be determined experimentally by the fact 
that its value is equivalent to the substrate concentration at which the 
velocity is equal to halfofV max.
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Fig. 4. The relationship between substrate concentration [S] and initial velocity 
(V0):(a)A direct plot, (b) l.ineweaver-Burk double reciprocal plot
9.1.2. Lineweaver-Burk plot
Because Vmax is achieved at infinite concentration, it is impossible to 
estimate Vmax (and hence Km) from a hyperbolic plot. However, Vmaxand 
Kmcan be determined experimentally by measuring V0at different substrate 
concentrations (Fig. 4). Then a double reciprocal or Lineweaver-Burk plot 
of 1/V0 against 1/[S] is made (Fig. 4b). This plot is a derivation of the 
Michaelis-Menten equation:
_ L  „ _JL + _L
v„ V™ v „  [SI
which gives a straight line, with the intercept on the у-axis equal to 1/Vmax 
and the intercept on the x-axis equal to -1/Km. The slope of the line is equal 
to Kra/Vmax (Fig. 4b). The Lineweaver-Burk plot is also a useful way of 
determining how an inhibitor binds to an enzyme.
Although the Michaelis-Menten model provides a very good model of 
the experimental data for many enzymes, a few enzymes do not conform to 
Michaelis-Menten kinetic. These enzymes, such as aspartate 
transcarbamoylase ( ATCase), are called allosteric enzymes.
9.2. Enzyme concentration
In situations where the substrate concentration is saturating (i.e. all the 
enzyme concentration molecules are bound to substrate), a doubling of 
the enzyme will lead to a doubling of VO. This gives a straight line graph 
when VO is plotted against enzyme concentration.
9.3. Temperature
Temperature affects the rate of enzyme-catalyzed reactions in two ways. 
First, a rise in temperature increases the thermal energy of the substrate 
molecules. This raises the proportion of substrate molecules with sufficient 
energy to overcome the Gibbs free energy of activation (AGA), and hence
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increases the rate of the reaction. However, a second effect comes into play 
at higher temperatures. Increasing the thermal energy of the molecules 
which make up the protein structure of the enzyme itself will increase the 
chances of breaking the multiple weak, noncovalent interactions (hydrogen 
bonds, van der Waals forces, etc.) which hold the three-dimensional 
structure of the enzyme together. Ultimately this will lead to the 
denaturation (unfolding) of the enzyme, but even small changes in the 
three-dimensional shape of the enzyme can alter the structure of the active 
site and lead to a decrease in catalytic activity. The overall effect of a rise 
in temperature on the reaction rate of the enzyme is a balance between 
these two opposing effects. A graph of temperature plotted against VO will 
therefore show a curve, with a well-defined temperature optimum (Fig. 5a). 
For many mammalian enzymes this is around 37°C, but there are also 
organisms, which have enzymes adapted to working at considerably higher 
or lower temperatures.
Each enzyme has an optimum pH at which the rate of the reaction that it 
catalyzes is at its maximum. Small deviations in pH from the optimum 
value lead to decreased activity due to changes in the ionization of groups 
at the active site of the enzyme. Larger deviations in pH lead to the 
denaturation of the enzyme protein itself, due to interference with the many 
weak noncovalent bonds maintaining its three-dimensional structure. A 
graph of VO plotted against pH will usually give a bell shaped curve (Fig. 
5b). Many enzymes have a pH optimum of around 6.8, but there is great 
diversity in the pH optima of enzymes, due to the different environments in 
which they are adapted to work. For example, the digestive enzyme pepsin 
is adapted to work at the acidic pH of the stomach (around pH 2.0). 
w ю
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Fig. 5. The effect o f  (a) temperature and (b) pH  on enzyme activity.
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4
1. Enzyme inhibition
Many types of molecule exist which are capable of interfering with the 
activity of an individual enzyme. Any molecule which acts directly on an 
enzyme to lower its catalytic rate is called an inhibitor. Some enzyme 
inhibitors are normal body metabolites that inhibit a particular enzyme as 
part of the normal metabolic control of a pathway. Other inhibitors may 
be foreign substances, such as drugs or toxins, where the effect of enzyme 
inhibition could be either therapeutic or, at the other extreme, lethal.
Enzyme inhibition may be of two main types: irreversible or reversible, 
with reversible inhibition itself being subdivided into competitive and 
noncompetitive inhibition. Reversible inhibition can be overcome by 
removing the inhibitor from the enzyme, for example by dialysis, but this 
is not possible for irreversible inhibition, by definition.
Inhibitors which bind irreversibly to an enzyme often form a covalent 
bond to an amino acid residue at or near the active site, and permanently 
inactivate the enzyme. Susceptible amino acid residues include Ser and 
Cys residues which have reactive -OH and -SH groups, respectively.
The compound diisopropylphosphofluoridate (DIPF), a component of 
nerve gases, reacts with a Ser residue in the active site of the enzyme 
acetylcholinesterase, irreversible inhibiting the enzyme and preventing the 
transmission of nerve impulses. Iodoacetamide modifies Cys residues and 
hence may be used as a diagnostic tool in determining whether one or more 
Cys residues are required for enzyme activity. The antibiotic penicillin 
irreversibly inhibits the glycopeptide transpeptidase enzyme that forms the 
cross-links in the bacterial cell wall by covalently attaching to a Ser residue 
in the active site of the enzyme.
A competitive inhibitor typically has close structural similarities to the 
substrate for the enzyme. Thus it competes with substrate molecules to 
bind to the active site (Fig. la). The enzyme may bind either a substrate 
or an inhibitor molecule, but not both at the same time (Fig. lb). The 
competitive inhibitor binds reversibly to the active site. At high substrate
1.1. Irreversible inhibition
1.2. Reversible competitive inhibition
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concentrations the action of a competitive inhibitor is overcome because a 
sufficiently high substrate concentration will successfully compete out the 
in molecule in binding to the active site. Thus there is no change in the 
Vmax the enzyme but the apparent affinity of the enzyme for its substrate 
decreases in the presence of the competitive inhibitor, and hence Km 
increases.
о»
i - E S ------ - E + P
Enzyme
1/V0
+ Comoetitive inhibitor
y y
-1  lKm \
No tnrtbrto*
Fig. I. The characteristics o f  competitive inhibition, (a) a competitive inhibitor 
competes with the substrate fo r  bin at the active site; (b) the enzyme can bind either 
substrate or the competitive inhibitor but not both; (c) Lineweaver Burk plot shoving 
the effect o f  a competitive inhibitor on Km and Vmox.
Many drugs work by mimicking the structure of the substrate of a 
target enzyme, and hence act as competitive inhibitors of the enzyme. 
Competitive inhibition can be recognized by using a Lineweaver-Burk plot. 
V0 is measured at different substrate concentrations in the presence of a 
fixed concentration of inhibitor. A competitive inhibitor increases the 
slope of the line on the Lineweaver-Burk plot, and alters the intercept on 
the x-axis (since Km is increased), but leaves the intercept on the y-axis 
unchanged (since Vmax remains constant)( Fig. Ic).
A good example of competitive inhibition is provided by succinate 
dehydrogenase. This enzyme uses succinate as its substrate and is 
competitively inhibited by malonate which differs from succinate in 
having one rather than two methylene groups (Fig. 2).
COO'
CH2 +FAD Succinate
dehydrogenase
COO'
Succinate
COO'
CH +FADH2 
CH
COO'
COO'
СЦ,
Succinate
/ /
II
duhydrogenase
COO
Fumarate
Fig. 2. Inhibition o f  succinate dehydrogenase by malonate.
No reaction
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1.3. Reversible noncompetitive inhibition
A noncompetitive inhibitor binds reversibly at a site other than the 
active site (Fig. 3a) and causes a change in the overall three-dimensional 
shape of the enzyme that leads to a decrease in catalytic activity. Since 
the inhibitor binds at a different site to the substrate, the enzyme may 
bind the inhibitor, the substrate or both the inhibitor and substrate 
together (Fig. 3b). The effects of a noncompetitive inhibitor cannot be 
overcome by increasing the substrate concentration, so there is a 
decrease in Vmax. In noncompetitive inhibition the affinity of the enzyme 
for the substrate is unchanged and so Km remains the same. An example 
of noncompetitive inhibition is the action of pepstatin on the enzyme 
renin.
Noncompetitive inhibition can be recognized on a Lineweaver-Burk 
plot, since it increases the slope of the experimental line, and alters the 
intercept on the у-axis (since Vmax is decreased), but leaves the intercept 
on the x-axis unchanged (since Km remains constant) (Fig. 3c).
Fig-3. The charactensitics o f  noncompetitive inhibition, (a) A noncompetitive inhibitor 
bonds at a site distinct from the active site; (b) the enzyme can bond either substrate or 
the noncompetitive inhibitor or both; (c) Lineweaver-Burk plot showing the effect o f  a 
noncompetitive inhibitor on Km and Vmax.
2. Feedback regulation
In biological systems the rates of many enzymes are altered by the 
presence of other molecules such as activators and inhibitors (collectively 
known as effectors). A common theme in the control of metabolic 
pathways is when an enzyme early on in the pathway is inhibited by an 
end-product of the metabolic pathway in which it is involved. This is 
called feedback inhibition and often takes place at the committed step in 
the pathway (conversion of A to В in Fig. 4a). The committed step is the 
first step to produce an intermediate, which is unique to the pathway in 
question, and therefore normally commits the metabolite to further 
metabolism along that pathway. Control of the enzyme which carries out 
the committed step of a metabolic pathway conserves the metabolic energy
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supply of the organism, and prevents the build up of large quantities of 
unwanted metabolic intermediates further along the pathway.
As many metabolic pathways are branched, feedback inhibition must 
allow the synthesis of one product of a branched pathway to proceed 
even when another is present in excess. Here a process of sequential 
feedback inhibition may operate where the end-product of one branch of 
a pathway will inhibit the first enzyme after the branchpoint (the 
conversion of C to D or C to E in Fig. 4b). When this branchpoint 
intermediate builds up, it in turn inhibits the first committed step of the 
whole pathway (conversion of A to В in Fig. 4b). Since the end-product 
of a metabolic pathway involving multiple enzyme reactions is unlikely 
to resemble the starting compound structurally, the end-product will bind 
to the enzyme at the control point at a site other than the active site. Such 
enzymes are always allosteric enzymes.
(a) __ _____
E| E2 E3 E4
E | inhibited by product Z
E3 inhibited by product Y
E4 En
A ------ ►  В ------ ► C ,
c .  F ,  1 С Л “
E | inhibited b y C  *------ ----------------------------
E3 inhibited by product Z
Fig.4. Feedback inhibition (a) and sequential feedback inhibition (b) in metabolic 
pathways.
3. Allosteric enzymes
A plot of V0 against [S] for an allosteric enzyme gives a sigmoidal 
curve rather than the hyperbolic plots predicted by the Michaelis-Menten 
equation . The curve has a steep section in the middle of the substrate 
concentration range, reflecting the rapid increase in enzyme velocity, 
which occurs over a narrow range of substrate concentrations. This allows 
allosteric enzymes to be particularly sensitive to small changes in substrate 
concentration within the physiological range. In allosteric enzymes, the 
binding of a substrate molecule to one active site affects the binding of 
substrate molecules to other active sites in the enzyme; the different
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active sites are said to behave cooperatively in binding and acting on 
substrate molecules. Thus allosteric enzymes are often multisubunit 
proteins, with one or more active sites on each subunit. The binding of 
substrate at one active site induces a conformational change in the protein 
that is conveyed to the other active sites, altering their affinity for 
substrate molecules.
In addition, allosteric enzymes may be controlled by effector molecules 
(activators and inhibitors) that bind to the enzyme at a site other than the 
active site (either on-the same subunit or on a different subunit), there by 
causing a change in the conformation of the active site which alters the rate 
of enzyme activity (i.e. the binding of C 02, H+ and 2,3-bisphosphoglycerate 
to hemoglobin). An allosteric activator increases the rate of enzyme activity, 
while an allosteric inhibitor decreases the activity of the enzyme.
4. Reversible covalent modification
Reversible covalent modification is the making and breaking of a 
covalent bond between a nonprotein group and an enzyme molecule. 
Although a range of nonprotein groups may be reversibly attached to 
enzymes, which affect their activity, the most common modification is 
the addition and removal of a phosphate group (phosphorylation and 
dephosphorylation, respectively). Phosphorylation is catalyzed by protein 
kinases, often using ATP as the phosphate donor, and dephosphorylation is 
catalyzed by protein phosphatases (Fig. 5). The addition and removal of 
the phosphate group causes changes in the tertiary structure of the enzyme 
that alter its catalytic activity. One class of protein kinases transfers the 
phosphate specifically on to the hydroxyl group of Ser or Thr residues on 
the target enzyme [serine/threonine protein kinases, typified by 3',5'- 
cyclic adenosine monophosphate (cAMP)-dependent protein kinase], 
while a second class transfers the phosphate on to the hydroxyl group of 
Tyr residues (tyrosine kinases). Protein phosphatases catalyze the 
hydrolysis of phosphate groups from proteins to regenerate the 
unmodified hydroxyl group of the amino acid and release Pi (Fig. 5).
A phosphorylated enzyme may be either more or less active than its 
dephosphorylated form. Thus phosphorylation/dephosphorylation may be 
used as a rapid, reversible switch to turn a metabolic pathway on or off 
according to the needs of the cell. For example, glycogen phosphorylase, 
an enzyme involved in glycogen breakdown, is active in its 
phosphorylated form, and glycogen synthase, involved in glycogen 
synthesis, is most active in its unphosphorylated form.
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Fig. 5. The reversible phosphorylation and dephosphorylation o f an enzyme.
5. Proteolytic activation
Some enzymes are synthesized as larger inactive precursors called 
proenzymes or zymogens. These are activated by the irreversible hydrolysis 
of one or more peptide bonds. The pancreatic proteases trypsin, 
chymotrypsin and elastase are all derived from zymogen precursors 
(trypsinogen, chymotrypsinogen and proelastase, respectively) by 
proteolytic activation. Premature activation of these zymogens leads to the 
condition of acute pancreatitis. The blood clotting cascade also involves a 
series of zymogen activations that brings about a large amplification of the 
original signal.
6. Regulation of enzyme synthesis and breakdown
The amount of enzyme present is a balance between the rates of its 
synthesis and degradation. The level of induction or repression of the gene 
encoding the enzyme, and the rate of degradation of its mRNA, will alter 
the rate of synthesis of the enzyme protein. Once the enzyme protein has 
been synthesized, the rate of its breakdown (half-life) can also be altered as 
a means of regulating enzyme activity.
Proteins and enzymes in disease.
Lecture 5
PROTEINS AND ENZYMES IN DISEASE
1. Plasma proteins
Plasma contains a variety of proteins with different functions. There are 
many characterized proteins whose function remains to be determined. The 
biochemistry laboratory routinely measures ‘total protein’ and ‘albumin’ 
concentrations, usually in a serum specimen, and reports the ‘globulin’ 
fraction as the difference between the first two results. Other proteins (e.g. 
immunoglobulins) are measured as classes, and immunochemical methods 
are available for measuring specific proteins and hormones. Enzymes are 
measured both by determining their activity and by immunochemical 
methods.
Simple electrophoresis of a serum sample separates its proteins into five 
bands and is especially useful in demonstrating the presence of a 
paraprotein derived from neoplastic cells.
2. Total protein
Changes in total protein concentration are common. An elevated total 
protein concentration may mean the presence of a paraprotein. A decreased 
total protein usually means that the albumin concentration is low.
Albumin
Albumin is the major plasma protein and is synthesized and secreted by 
the liver. It accounts for about 50% of the total hepatic protein production. 
Albumin has a biological half-life in plasma of about 20 days and a 
significant decrease in albumin concentration in plasma is slow to occur if 
there is reduced synthesis. Albumin makes the biggest contribution to the 
plasma oncotic pressure. If the albumin concentration falls very low, 
oedema is the result (Fig. 1).
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Norm al
Fig 1. Pathogenesis o f  oedema in hypoalbuminaemia
There are main reasons for the occurrence of a low plasma albumin 
concentration:
1. Decreased synthesis. This may be due to malnutrition or 
malabsorption. Decreased synthesis is also a feature of advanced 
chronic liver disease.
2. Abnormal distribution or dilution. Hypoalbuminaemia can be 
induced by overhydration or if there is increased capillary 
permeability as occurs in septicaemia.
3. Abnormal excretion or degradation. The causes include the nephrotic 
syndrome, protein losing enteropathies, bums, haemorrhage and 
catabolic states.
Although serum albumin measurements have been used to monitor a 
patient’s response to long-term nutritional support, they are unreliable and 
insensitive.
3. Specific proteins
Measurement of a number of specific proteins gives useful information 
in the diagnosis and management of disease (Table 1). Characteristic 
changes in the concentration of certain plasma proteins are seen following 
surgery or trauma, or during infection or tumour growth. The proteins 
involved are called acute phase reactants. These acute phase proteins may 
be used to monitor progress of the condition or its treatment.
34
Proteins and enzymes in disease..
Serum enzymes in disease
Enzymes may by classified in two groups. Some, such as the enzymes 
of the coagulation cascade, have a defined function in blood. Others were 
originally cell constituents, or were made within cells to be secreted into 
the gastrointestinal tract. They appear in the blood incidentally and their 
measurement is of value in diagnosis. Damage to the tissues of origin, or 
proliferation of the cells from which these enzymes arise, will lead to an 
increase in the activity of these enzymes in plasma (Fig. 2). It should be 
noted that increases in serum enzyme activity are only roughly proportional 
to the extent of tissue damage.
Table l. Specific protein, which are measured in serum
Protein name Function Reason for assay
a, - antitrypsin deficiency Protease inhibitor Reduced in щ- antitrypsin
p2 - microglobuiin on all 
cell membranes
A subunit o f the HLA 
antigen
Raised in renal tubular 
dysfunction
Caeruloplasmin Oxidizing enzyme Reduced in Wilson’s 
disease
C-reactive protein (CRP) Involved in immune 
response
Increased in acute illness, 
especially infection
Ferritin Binds iron in tissues Gives an indication of 
body iron stores
Haptoglobin Binds haemolglobin Reduced in haemolytic 
conditions
Thyroid-binding globulin 
(TBG)
Thyroid hormone binding Investigation of thyroid 
disease
Sex hormone binding 
globulin (SHBG)
Binds testosterone and 
cestradiol
Investigation o f raised 
testosterone
Transferrin Iron transport Assessing response to 
nutritional support
Enzymes that have been shown to have a diagnostic value are:
1. Acid phosphatase: a tumour marker in prostatic carcinoma.
2. Alanine aminotransferase (ALT): an indicator of hepatocellular 
damage.
3. Alkaline phosphatase: increases in cholestatic liver disease and is a 
marker of osteoblast activity in bone disease.
4. Amylase: an indicator of cell damage in acute pancreatitis.
5. Aspartate aminotransferase (AST): an indicator of hepatocellular 
damage, or as a marker of muscle damage, such as a myocardial 
infarction (MI).
6. Creatine kinase: a marker of muscle damage and acute MI.
7. y-glutamy] transpeptidase: a sensitive marker of liver cell damage.
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8. Lactate dehydrogenase: a marker of muscle damage.
Fig. 2. Plasma levels o f  intracellular enzymes.
A further enzyme of practical interest is cholinesterase. Cholinesterase, 
normally involved in the process of neuromuscular conduction, incidentally 
hydrolyses succinylcholine, a muscle-relaxing drug used in anaesthesia. 
Patients with abnormal cholinesterase may fail to hydrolyze the drug 
normally and as a result suffer prolonged paralysis after anaesthesia. This is 
called scoline apnoea. Cholinesterase measurements are also useful in the 
diagnosis of poisoning with pesticides, which are cholinesterase inhibitors.
4. Isoenzyme determination
Some enzymes are present in the plasma in two or more molecular forms. 
These variants are known as isoenzymes, and although they have different 
structures they perform the same catalytic, function. Different isoenzymes 
may arise from different tissues and their specific detection may give clues to 
the site of pathology. Alkaline phosphatase isoenzymes may distinguish between 
bone and liver disease, especially in patients in whom metastases of bone or 
liver are suspected. A specific isoenzyme of creatine kinase (CK MB) is 
useful in the early detection of myocardial infarction. Heart muscle contains 
proportionally more of this isoenzyme than skeletal muscle, and raised levels 
of CK MB indicate that a myocardial infarction has occurred.
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Conclusion
Proteins and enzymes
1. An increase in total protein concentration in a serum specimen is usually 
due to an increase in the globulin fraction and may indicate the presence 
of a paraprotein.
2. A decreased total protein concentration is usually due to 
hypoalbuminaemia.
3. Albumin is the main determinant of plasma oncotic pressure. A very low 
albumin leads to oedema.
4. Increased enzyme activities in serum indicate cell damage or increased 
cell proliferation.
5. Isoenzymes are forms of an enzyme, which are structurally different but 
have similar catalytic properties.
6. Measurement of the isoenzymes of alkaline phosphatase and creatine 
kinase are of clinical value.
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Lecture 6
MEMBRANES
Membranes form boundaries both around the cell (the plasma 
membrane) and around distinct subcellular compartments (e.g. nucleus, _ 
mitochondria, lysosomes, etc.). They act as selectively permeable barriers 
allowing the inside environment of the cell or organelle to differ from 
that outside. Membranes are involved in signaling processes; they contain 
specific receptors for external stimuli and are involved in both chemical 
and electrical signal generation. All membranes contain two basic 
components: lipids and proteins. Some membranes also contain
carbohydrate. The composition of lipid, protein and carbohydrate varies 
from one membrane to another. For example, the inner mitochondrial 
membrane has a larger amount of protein than lipid due to the presence of 
numerous protein complexes involved in oxidative phosphorylation and 
electron transfer, whereas the myelin sheath membrane of nerve cells, 
which serves to electrically insulate the cell, has a larger proportion of 
lipid.
1. Membrane lipids
Lipids were originally classified as biological substances that were 
insoluble in water but soluble in organic solvents such as chloroform and 
methanol. In addition to being structural components of membranes, lipids 
have several other biological roles. They serve as fuel molecules, as 
concentrated energy stores (e.g. triacylglycerol) and as signaling molecules. 
Within membranes there are three major types of lipid: the
glycerophospholipids, the sphingolipids and the sterols.
Glycerophospholipids
The glycerophospholipids are made up of three components: a 
phosphorylated headgroup, a three-carbon glycerol backbone and two 
hydrocarbon fatty acid chains (Fig.l). The simplest glycerophospholipid is 
phosphatidate (diacylglycerol 3-phosphate) which has only a phosphoric 
acid group esterified to carbon-3 of the glycerol. Although phosphatidate 
itself is present in small amounts in membranes, the major 
glycerophospholipids are derived from it. In these other lipids the 
phosphate is further esterified to the hydroxyl group of one of several 
alcohols (choline, ethanolamine, glycerol, inositol or serine). The major 
glycerophospholipids found in membranes include phosphatidylcholine,
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phosphatidylethanolamine, phosphatidylglycerol, phosphatidylinositol 
and phosphatidylserine (Tig.]).
Diphosphatidylglycerol (or cardiolipin) is found predominantly in the
inner mitochondrial membrane.
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Fig. I. Structures o f  membrane glycerophospholipids. Rt and R2 represent 
hydrocarbon chains o f fatty acids.
Sphingolipids
Sphingomyelins, the commonest sphingolipids, have a sphingosine 
backbone (Fig.2a) in place of the glycerol in glycerophospholipids. Like 
the glycerophospholipids, they also have a phosphorylated headgroup 
(either choline or ethanolamine) and two hydrocarbon chains (Fig.2a). The 
sphingomyelins are particularly abundant in the myelin sheath that 
surrounds nerve cells. The glycosphingolipids, such as the cerebrosides 
and gangliosides, are also derived from sphingosine, but in place o f the 
phosphorylated headgroup they have one or more sugar residues. The 
galactocerebrosides have a single galactose residue (Fig. 2a) and are found 
predominantly in the neuronal cell membranes of the brain. The 
gangliosides have several sugar residues including at least one sialic acid 
(N-acetylneuraminic acid) residue and are a major constituent of most 
mammalian plasma membranes, being particularly abundant in brain 
cells.
Sterols
The sterol cholesterol (Fig.2b) is a major constituent of animal plasma 
membranes but is absent from prokaryotes. The fused ring system of 
cholesterol means that it is more rigid than other membrane lipids. As well 
as being an important component of membranes, cholesterol is the 
metabolic precursor of the steroid hormones. Plants contain little
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cholesterol but have instead a number of other sterols, mainly stigmastero! 
and P-sitosterol which differ from cholesterol only in their aliphatic side 
chains.
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Fig. 2. Structures o f  (a) the sphingolipids sphingmyelin and galactocerebroside; (b) 
cholesterol R: represents the hydrocarbon chain o f  fatty acids.
Fatty acid chains
The two fatty acid chains of glycerophospholipids and the single fatty 
acid chain and the hydrocarbon chain of the sphingosine in sphingolipids 
consist of long chains of carbon atoms. Usually these chains have an 
even number of carbon atoms (e.g. palmitate, C l6; stearate, C l8) and are 
unbranched. The chains can either be fully saturated with hydrogen atoms 
or unsaturated and have one or more double bonds that are usually in the 
cis configuration (e.g. oleate С 18:1 which has 18 carbon atoms and one 
double bond; arachidonic acid C20:4 which has 20 carbon atoms and four 
double bonds). The two fatty acid chains on a glycerophospholipid are 
usually not identical (e.g. l-stearoyl-2-oleoyl-3-phosphatidylcholine (Fig 
3)1
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Fig. 3. Structure o f J-stearoyl-2-oleoyl-3-phosphatidylcholine showing the saturated 
stearoyl (C18:0) and the monounsaturated oleoyl (C18;l) hydrocarbon chains. The 
hydrogen atoms surrounding the C = C  bond are in the cis-conftguration.
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2. Lipid bilayer
Amphipathic (or amphiphilic) molecules contain both hydrophilic 
(water-loving) and hydrophobic (water-hating) regions. Membrane lipids 
are amphipathic molecules as they are made up of hydrophobic fatty acid 
chains and a hydrophilic polar headgroup. In the glycerophospholipids, the 
two hydrocarbon chains are hydrophobic whereas the glycerol backbone 
and the phosphorylated headgroup are hydrophilic. In the sphingolipids, 
the fatty acid chain and the hydrocarbon chain of the sphingosine are 
hydrophobic whereas the phosphorylated or sugar headgroup is 
hydrophilic. In the case of cholesterol, the entire molecule apart from the 
hydroxyl group on carbon-3 is hydrophobic in nature.
In aqueous solution, amphipathic molecules will orientate themselves 
in such a way as to prevent the hydrophobic region coming into contact 
with the water molecules. In the case of those fatty acid salts which contain 
only one fatty acid chain (such as sodium palmitate, a constituent of 
soap), the molecules form a spherical micellar structure (diameter 
usually <20nm) in which the hydrophobic fatty acid chains are hidden 
inside the micelle and the hydrophilic headgroups interact with the 
surrounding water molecules (Fig.4a). Because the two fatty acid chains 
of phospholipids are too bulky to fit into the interior of a micelle, the 
favored structure for most phospholipids in aqueous solution is a two- 
dimensional bimolecular sheet or lipid bilayer (Fig.4b). Such lipid 
bilayers, in which the phospholipid molecules are orientated with their 
hydrophobic chains in the interior of the structure and their hydrophilic 
headgroups on the surfaces, can be relatively large structures of up to 
about 1 mm in area. The two layers of lipids in the bilayer are referred to 
as the inner and outer leaflets. In biological membranes the individual 
lipid species are asymmetrically distributed between the two leaflets.
For example, in the plasma membrane of erythrocytes, sphingomyelin 
and phosphatidylcholine are preferentially located in the outer leaflet, 
whereas phosphatidylethanolamine and phosphatidylserine are mainly in 
the inner leaflet.
Fig. 4. Structure o f  (a) a micelle and (b) a lipid bilayer.
41
Lecture 6.
3. Membrane fluidity
Because there are no covalent bonds between the lipids in the bilayer, 
the membrane is not a static structure but has fluidity. The lipids are 
generally free to move within the plane of the inner or outer leaflet of the 
bilayer by either rotational or lateral movement (Fig. 5). However, they 
cannot readily flip from one leaflet of the bilayer to the other, so called 
transverse movement, due to the unfavorable energetics involved in 
moving a hydrophilic headgroup through the hydrophobic interior of the 
bilayer.
Rotation C  ~
Transverse
movement
Fig. 5. Movement o f  lipids in membranes.
4. Fluid mosaic model of membrane structure
In 1972 S. Jonathan Singer and Garth Nicholson proposed the fluid 
mosaic model for the overall structure of biological membranes, in 
which the membranes can be viewed as two-dimensional solutions of 
oriented lipids and globular proteins (Fig.6). The integral membrane 
proteins can be considered as 'icebergs' floating in a two-dimensional 
lipid 'sea'. They proposed that the bilayer organization o f the lipids 
would act both as a solvent for the amphipathic integral membrane 
proteins and as a permeability barrier. They also proposed that some 
lipids may interact with certain membrane proteins, that these 
interactions would be essential for the normal functioning of the protein 
and that membrane proteins would be free to diffuse laterally in the 
plane of the bilayer unless restricted in some way, but would not be able 
to flip from one side of the bilayer to the other. This model is now 
supported by a wide variety of experimental observations.
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Fig. 6. The fluid mosaic model o f membrane structure.
5. Integral membrane proteins
Membrane proteins are classified as either peripheral (extrinsic) or 
integral (intrinsic) depending on how tightly they are associated with the 
membrane. Integral membrane proteins are tightly bound to the
membrane through interactions with the hydrophobic core of the bilayer 
and can be extracted from them only by using agents that disrupt the
membrane structure, such as organic solvents (e.g. chloroform) or
detergents. Most integral proteins have one or more regions of the
polypeptide chain that span the lipid bilayer and interact noncovalently 
with the hydrophobic fatty acid chains. However, some are anchored in 
the membrane by a covalently attached fatty acid or hydrocarbon chain. 
Like lipids, integral proteins are amphipathic, having both hydrophobic 
and hydrophilic regions, and are asymmetrically distributed across the 
bi layer.
6. Peripheral membrane proteins
Peripheral membrane proteins are less tightly bound to the lipid 
bilayer than integral membrane proteins and can be readily removed by 
washing the membranes with a solution of high ionic strength (e.g. llyl NaCl) 
or high PH. These procedures leave the lipid bilayer intact but disrupt the 
ionic and hydrogen bond interactions that hold the peripheral proteins on the 
surface of the membrane. No part of a peripheral protein interacts with the 
hydrophobic core of the bi layer. Peripheral membrane proteins can be found
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either on the outer or the inner surface of the bilayer and can be associated 
with the membrane through noncovalent interactions with either the lipid 
headgroups and/or other proteins in the membrane. Once removed from the 
membrane, peripheral proteins behave as water-soluble globular proteins and 
can be purified as such.
Cytoskeleton
The cytosolic surface of the erythrocyte plasma membrane is covered by 
a network of peripheral membrane proteins that make up the cytoskeleton 
(Fig.7). The major component of this cytoskeleton is spectrin which folds 
into a triple-stranded a-helical coiled coil to form long chains. The 
spectrin chains are attached to the plasma membrane through interactions 
with two other peripheral proteins, ankyrin and protein band 4.1. Ankyrin 
forms a cross-link between spectrin and the cytosolic domain of the 
integral anion exchanger band 3 protein, while band 4.1 promotes the 
binding of actin filaments to the spectrin chains linking them to the 
cytosolic domain of glycophorin. The cytoskeleton gives the erythrocyte 
plasma, membrane great strength and flexibility, and is important in 
maintaining and altering the shape of the cell. In other mammalian cells 
the cytoskeleton has fewer attachment points on the inner surface of the 
plasma membrane and criss-crosses throughout the cytoplasm.
Fig. 7. The erythrocyte cytoskeleton.
7. Membrane carbohydrate
The extracellular surface of the plasma membrane is often covered with 
a protective coat of carbohydrate. The sugar residues of this carbohydrate 
coat can be attached either to certain lipids such as the glycosphingolipids, 
or to the polypeptide chains of peripheral or integral membrane proteins. 
These glycolipids and glycoproteins are abundant in the plasma membrane
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of eukaryotic cells but are virtually absent from most intracellular 
membranes, particularly the inner mitochondrial membrane and the 
chloroplast lamellae. In glycoproteins the sugar residues can be attached to 
the polypeptide chain either through the hydroxyl group in the side chain 
of Ser or Thr residues as О-linked oligosaccharides, or through the amide 
group in the side-chain of Asn as N-linked oligosaccharides. In the case of 
the N-Iinked sugars, in order to be modified the Asn must lie in the 
tripeptide consensus sequence Asn-Xaa-Ser or Asn-Xaa-Thr, where Xaa is 
any amino acid except Pro. О-linked oligosaccharides usually consist of 
only a few (approximately four) sugar residues, whereas N-linked 
oligosaccharides can be quite large structures with a dozen or more 
different sugars attached to the Asn side-chain. The carbohydrate on the 
extracellular face of the membrane not only serves a protective role but is 
also involved in intercellular recognition and in maintaining the asymmetry 
of the membrane.
8. Membrane permeability
A pure phospholipid bilayer is permeable to water, gases (0 2, C 02, N2) 
and small uncharged polar molecules (e.g. urea, ethanol), but is 
impermeable to large uncharged polar molecules (e.g. glucose), ions (Na+, 
К , СГ, Ca *) and charged polar molecules (e.g. amino acids, ATP, glucose 
6-phosphate). The first group of molecules can cross the membrane 
unaided and without an input of energy, whereas the latter group require 
the presence of integral membrane transport proteins and, in some cases, 
an input of energy to travel through the otherwise impermeable 
membrane barrier. Thus the plasma membrane and the membranes of 
internal organelles are selectively permeable barriers, maintaining a 
distinct internal environment.
9. Passive transport
The passive transport of molecules across a membrane does not 
require an input of metabolic energy. The rate of transport (diffusion) is 
proportional to the concentration gradient of the molecule across the 
membrane. There are two types of passive transport: simple diffusion 
and facilitated diffusion.
9.1. Simple diffusion
Only relatively small uncharged or hydrophobic molecules (H20 , 0 2, 
C 02, other gases, urea and ethanol) cross the lipid bilayer by simple' 
diffusion. No membrane proteins are involved, so there is no specificity. 
The molecule in aqueous solution on one side of the membrane
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dissolves into the lipid bilayer, crosses it, and then dissolves into the 
aqueous solution on the opposite side. The rate of diffusion is directly 
proportional to the concentration gradient of the molecule across the 
membrane and the process is not saturable.
9.2. Facilitated diffusion
Unlike simple diffusion, the facilitated (or carrier-mediated) diffusion of 
a molecule across a biological membrane is dependent on specific integral 
membrane proteins, often called uniporters. The molecule binds to the 
protein on one side o f the membrane; the protein then undergoes a 
conformational change, transports the molecule across the membrane 
and then releases it on the other side. Molecules transported across 
membranes in this way include hydrophilic molecules such as glucose, 
other sugars and amino acids. The transport proteins are specific for one 
particular molecule or a group of structurally similar molecules. The 
transport proteins are capable of being saturated, and are influenced by 
temperature, pH and inhibitor molecules in a similar manner to enzymes.
An example of facilitated diffusion is the uptake of glucose into 
erythrocytes by the glucose transporter. The erythrocyte glucose 
transporter is an integral membrane protein of mass 45kDa that is 
asymmetrically orientated in the plasma membrane. This uniporter 
protein structure traverses the membrane with 12 a-helices, which form а 
central pore through which the glucose molecule is passed upon 
conformational changes in the protein (Fig.8). All the steps in the 
transport of glucose into the cell are freely reversible, the direction of 
movement of glucose being dictated by the relative concentrations o f 
glucose on either side of the membrane.
W  Glucose
\
Fig. 8. Facilitated diffusion o f  glucose into erythrocytes.
10. Active transport
The active transport of molecules requires an input of metabolic 
energy. This can be derived either from direct coupling to the hydrolysis 
of ATP or by coupling to the movement of an ion down its 
concentration gradient.
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10.1. ATP-driven active transport
In this case, the energy required for the transport of the molecule across 
the membrane is derived from the coupled hydrolysis of ATP, for example 
the movement of Na+- and K+ ions by the Na+/K+-ATPase. All cells maintain 
a high internal concentration of K+ and a low internal concentration ofN a+. 
The resulting Na7K+ gradient across the plasma membrane is important for 
the active transport of certain molecules, and the maintenance of the 
membrane electrical potential. The movement across the membrane of Na+, 
K+, Ca2+ and H+, as well as a number of other molecules, is directly coupled 
to the hydrolysis of ATP.
Structure and action of the Na+/K+- ATPase
The Na+/K+-ATPase is an integral membrane protein consisting of 110 
kDa and 55 kDa p- subunits. The functional unit is either a 
heterotetramer (афр  or, more likely, a heterodimer (ap; Fig.9). Upon 
hydrolysis of one molecule of ATP to ADP and Pi (the Pi transiently 
binds to an aspartyl residue in the protein), the protein undergoes a 
conformational change and three Na+ ions are pumped out of the cell 
across the plasma membrane and two K+ ions are pumped in the opposite 
direction into the cell. Both ions are being moved up their concentration 
gradients across the membrane; hence the requirement for an input of 
energy. No transport occurs unless ATP is hydrolyzed, and no ATP is 
hydrolyzed if there is no Na+ and K+ to transport (i.e. it is a coupled 
system).
ADP+P. High K* 
Low Na*
Fig. 9. The N a'/fC  -ATPase, shown as an o.p heterodimer.
10.2. Ion-driven active transport
The movement of the molecule to be transported across the 
membrane is coupled to the movement of an ion, usually either Na+ or H . 
The energy for the movement of the molecule across the membrane 
against its concentration gradient comes from the movement of the ion 
down its concentration gradient. If both the molecule and the ion move in 
the same direction, it is termed symport, and the protein involved in the 
process is called a symporter (e.g. Na+/glucose transporter; Fig. 10a); if the
47
Lecture 6.
molecule and the ion move in the opposite direction, it is termed antiport, 
and the protein involved in the process is called an antiporter (e.g. 
erythrocyte band 3 anion transporter; Fig. 10b).
m
=#=
Na* Glucose
Fig. 10. Ion-driven cotransport mechanisms, (a) Symport process involving a svmporler 
(e.g. Na V  glucose transporter); (b) antiport process involving an anliporter (e.g. 
erythrocyte band 3 anion transporter).
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Lecture 7
METABOLISM
1. Intermediary metabolism
Intermediary metabolism, the synthesis and degradation of small 
molecules, serves two functions:
1. it supplies the energy needed for the synthesis of macromolecules or 
other energy-requiring processes
2. it furnishes these processes with the necessary starting materials— 
amino acids for protein synthesis, fatty acids for lipid synthesis, 
nucleoside triphosphates for nucleic acid synthesis, and sugars for 
polysaccharide synthesis.
The rates at which different biological processes require energy and 
materials vary widely. To compensate for these fluctuating needs, the rates of 
the reaction sequences in intermediary metabolism must be adjustable over 
broad ranges so that energy and intermediates will always be available to 
meet a given need. Quite miraculously, these rates are adjusted so that the 
concentrations of key metabolites are remarkably stable. This constancy of 
key intermediates is achieved by maintaining a rate of synthesis for each 
intermediate that is equivalent to its rate of utilization. The term steady 
state is used to describe this nonequilibrium situation.
2. Organisms differ in sources of energy, reducing power, and starting 
materials for biosynthesis.
To maintain the steady state and to permit growth and reproduction as 
well, all living cells require energy (obtained from ATP) and starting 
materials for biosynthesis. They also require reducing power (obtained from 
NADPH), since most biosynthesis involves converting compounds to a more 
reduced state. Although the needs of different organisms for these three 
components are quite similar, the way in which organisms satisfy their 
needs can be quite different. Indeed, the most fundamental metabolic 
distinction between organisms relates to the ways in which they satisfy their 
basic metabolic needs (Table I).
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Table 1.
Metabolic classification o f  organisms
T y p e  o f  
o rg an ism
S o u rce  o f  
A T P
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tro p h
O x id a tio n  o f
in o rg an ic
co m p o u n d s
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in o rg an ic  co m p o u n d s
C02 H ydrogen , su lfu r, iron, 
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o rg an ic
co m p o u n d s
O x id a tio n  o f  o rg an ic  
co m p o u n d s
O rgan ic
co m p o u n d s
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to sy n th e tic  p lan t cells
Autotrophs exploit the inorganic environment without depending on 
compounds produced by other organisms. Thus all of their carbon 
compounds are synthesized from the only widely available inorganic 
compounds of carbon—carbonates or carbon dioxide.
Different kinds of chemoautotrophs can obtain reducing power by oxidation 
of a wide variety of inorganic materials such as hydrogen or reduced 
compounds of sulfur or nitrogen (each species is usually quite specific as to 
the electron donors that it can utilize). The same reduced compounds supply 
electrons for regeneration of ATP by electron-transfer phosphorylation.
Photoautotrophs obtain ATP by electron-transfer phosphorylation during 
the cycling of a photochemicaliy excited electron back to groundstate 
chlorophyll. They are also able to use these excited electrons for the 
reduction of NADP while obtaining electrons from water to replace them 
in the chlorophyll system. Photoautotrophs have thereby achieved in 
dependence of all sources of energy except for the sun and all sources of 
electrons except for water. For this reason, photoautotrophic fixation of 
carbon dioxide is the predominant bat of the food chain in the biosphere.
Common heterotrophs depend on preformed organ compounds for all 
three primary needs. Although some carbodioxide is fixed in heterotrophic 
metabolism, notably in the synthesis of amino acids, the heterotrophic cell 
thrives at the expense of compounds formed by other cells, and is not 
capable of the net conversion (fixation) of carbon dioxide into organic 
compounds.
Some bacteria, referred to as photoheterotrophs, are able to regenerate 
ATP photochemicaliy, but they cannot supply electrons to NADP+ as a result 
of photochemical reactions. Such organisms are like other heterotrophs in 
that they are dependent on preformed organic compounds. But because of 
their photochemical apparatus, the photoheterotrophs are able to use available 
organic food more efficiently than common heterotrophs.
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Although all heterotrophs are dependent on preformed organic 
compounds, they differ markedly in the numbers and types of compounds 
they require. Some species can make all required compounds when supplied 
with a single carbon source; others have lost some or many biosynthetic 
capabilities. Mammals must obtain about half of their amino acids from 
external sources and are also unable to make several metabolic cofactors, as 
evidenced by their well-known nutritional requirements for vitamins. Some 
bacteria and some parasites have even more extensive nutritional 
requirements.
3. Pathways show functional coupling.
Metabolic chemistry is sometimes taught by reference to large charts 
that have been designed to display all the major biochemical pathways. 
Such charts, however, include a bewildering array of interconnections; the 
functional relationships between different pathways tend to be obscured by 
the complexity of presentation. The overall operational aspects of 
metabolism are easier to grasp when they are presented in simpler block 
diagrams that omit details and focus on functional relationships. Such a 
diagram for a typical heterotrophic aerobic cell is shown in Fig. 1, where 
the metabolism of the cell is symbolized by two functional blocks:
1. Catabolism, or degradative metabolism.
Foods are oxidized to carbon dioxide. Most of the electrons liberated in 
this oxidation are transferred to oxygen, with concomitant production of 
ATP (electron-transport phosphorylation). Other electrons are used in the 
regeneration of NADPH, the most frequently used reducing agent for 
biosynthesis. The major pathways in this block are the glycolytic sequence 
and the tricarboxylic acid (TCA) cycle. These same sequences, with the 
pentose phosphate pathway, also supply carbon skeletons for the cell’s 
biosynthetic processes.
2. Biosynthesis, or anabolism.
This block includes much greater chemical complexity than the first. 
The starting materials produced by glycolysis and the TCA cycles are 
converted into hundreds of cell components, with NADPH serving as a 
reducing agent when necessary, and with ATP as the universal coupling 
agent or energytransducing compound. This conversion is rapidly followed 
by the synthesis of macromolecules and growth.
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The starting materials consumed in biosynthetic sequences must be 
continuously replaced by catabolic processes. The energy sources and 
reducing sources, ATP and NADPH, are used in veiy different ways. When 
they contribute to biosynthesis, these coupling agents are converted to 
NADP+ and ADP or AMP. They must be regenerated, reduced, or 
rephosphorylated at the expense of substrate oxidation in the catabolic block 
of reactions. As figure 1 indicates, ATP and NADPH are the fundamental 
coupling agents in metabolism - the compounds that have primary roles in 
coupling between the major functional blocks. Other coupling agents are 
essential but less broad in scope. For example, NADH and FADH2 
participate within the catabolic block in the transfer of electrons from 
substrate to oxygen in electron-transfer phosphorylation, but they are not 
significantly involved in coupling between major ftinctional blocks.
The block diagram of Fig. 1 does not represent the total metabolism of 
organisms other than aerobic heterotrophs. The photochemical production 
of ATP in photoheterotrophs would require the addition of a photochemical 
block, with ATP production in the catabolic block being deleted.
For a photoautotroph, two blocks would be needed in addition to those 
shown in Fig. 1:
(1) a block for the photochemical processes that regenerate ATP from 
ADP or AMP and reduce NADP+ to NADPH, while consuming 
water and producing a stoichiometric amount of oxygen and
(2) a block that shows the use of ATP and NADPH in the reduction of 
carbon dioxide to various products. These photosynthetic 
products provide the input to the catabolic block, which in this 
case serves only one function—the production of the starting 
materials for synthesis.
Nutrients
\>
Catabolism
Fig. I. A schematic block diagram o f the metabolism o f  a typical aerobic 
heterotroph. The block labeled "Catabolism " represents pathways by which nutrients 
are converted to small-molecule starting materials. Catabolism also supplies the energy 
(ATP) and reducing power (NADPH) needed for activities that occur in the second
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block; these compounds shuttle between the two boxes. The block labeled 
"Biosynthesis" represents the synthesis o f  low- to medium-molecular-weight 
components o f the cell as well as the synthesis o f proteins, nucleic acids, lipids, and 
carbohydrates and the assembly o f  membranes, organelles, and the other structures o f  
the cell
4. Introduction in digestion and absorption.
Most foodstuffs are ingested in forms that are unavailable to the 
organism, since they cannot be absorbed from the digestive tract until they 
have been broken down into smaller molecules. This disintegration of the 
naturally occurring foodstuffs into assimilable forms constitutes the 
process of digestion.
The chemical changes incident to digestion are accomplished with the 
aid of hydrolase enzymes of the digestive tract that catalyze the hydrolysis 
of native proteins to amino acids, of starches to monosaccharides, and of 
triacylglycerols to monoacylglycerols, glycerol, and fatty acids. In the 
course of these digestive reactions, the minerals and vitamins of the 
foodstuffs are also made more assimilable.
Digestion involves splitting of food molecules by hydrolysis into smaller 
molecules that can be absorbed through the epithelium of the 
gastrointestinal tract.
Carbohydrates such as starch and glycogen are attacked initially by 
salivary amylase followed by pancreatic amylase in the intestine. The 
resulting maltose plus oligosaccharides together with other 
disaccharides from the diet are attacked by specific intestinal hydrolases 
to form monosaccharides, chiefly glucose, fructose and galactose.
Protein digestion is initiated by the endopeptidase pepsin in the acid 
medium of the stomach and continued by other endopeptidases in the 
pancreatic secretion (eg, trypsin, chymotrypsin, and elastase) together with 
the exopeptidase carboxypeptidase, which splits off successive amino acids 
from the carboxyl terminal. Protein digestion is completed by intestinal 
secretions including the exopeptidase, aminopeptidase, plus dipeptidases 
with various specificities, which result in formation of free amino acids.
Lingual and gastric lipases initiate triacylglycerol hydrolysis in the 
stomach, after which the contents are emulsified with bile salts in the 
duodenum and finally attacked by pancreatic lipase.
The products of digestion are absorbed in the intestine, ie, 
monosaccharides, amino acids, some dipeptides, together with glycerol, 
free fatty acids, and 2-monoacylglycerols from triacylglycerol digestion. 
The water-soluble monosaccharides, amino acids, glycerol, and short- 
and medium-chain fatty acids are transported to the liver in the hepatic 
portal vein. Long-chain fatty acids and monoacylglycerols are
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resynthesized to triacylglyceroi in the intestinal epithelium to form 
chylomicrons. These are secreted into the circulation via the thoracic duct.
Digestive disorders include those due to deficiency of enzymes such 
as lactase and sucrase. Others are due to malabsorption, eg, defects in the 
Na+- glucose cotransporter (SGLT 1) leading to glucose and galactose 
malabsorption. Still others may be due to immunologic responses to the 
absorption of unhydrolyzed polypeptides, such as in nontropical sprue. 
Gallstones are caused because cholesterol, owing to its low solubility, is 
precipitated in bile, leading to crystallization and stone formation (Table 
2) .
Table 2. Summary o f digestive processes
S o u rc e  o f  
s e c re tio n  an d  
s t im u lu s  fo r  
s e c re tio n
E n z y m e
M e th o d  o f  
a c t iv a t io n  a n d  
o p t im a l  c o n d i t io n s  
fo r  a c t iv i ty
S u b s tra te E n d  p ro d u c t
S a l iv a ry  g la n d s : 
s e c re te  sa liv a  in 
re fle x  re sp o n se  to 
p re se n c e  o f  food  in 
o ra l cav ity .
S a liv a ry
am y lase
C h lo r id e  ion  
n e c e ssa ry  p H  6 .6 -  
6  8.
S tarch ,
g ly co g en
M altose  p lu s 1:6 
g lycosides 
(o ligosacchari­
des) p lus 
m alto trio se
L in g u a l  g la n d s L in g u a l
lip ase
p H  ra n g e  2 .0 -7 .5 ; 
o p tim a l 3 .0 -6 .0 .
P rim a ry  es te r 
lin k  a t srt-3 o f  
tr ia cy lg ly c e ro ls
Fatty acids plus 
1,2-diacylgly- 
cerols.
S to m a c h  g lan d s : 
c h i e f  c e lls  an d  
p a rie ta l c e lls  se c re ­
te  g a s tr ic  ju ic e  in 
re sp o n s e  to  re flex  
s tim u la tio n  and  
ac tio n  o f  gastrin .
P ep s in  A  
( fu n d u s )  
P ep sin  В 
(D vlorust
P e p s in o g e n  
c o n v e r te d  to  a c tiv e  
p e p s in  b y  H C I. p H  
1 .0-2.0.
P ro te in Peptides.
G as tric
lip a se
A s  fo r lingua! 
lip ase .
A s  fo r lingual 
lip ase
A s for lingual 
lipase
R en n in C a lc iu m  n ecessa ry  
fo r  ac tiv ity . p H  4 .0 .
C a se in  o f  m ilk C o a g u la te s  m ilk
P an c rea s : p re sen c e  
o f  a c id  c h y m e  fro m  
th e  s to m a c h  
a c tiv a te s  d u o d e ­
n u m  to  p ro d u c e  (1) 
se c re tin , w h ich  
h o rm o n a lly  s tim u ­
la te s  flo w  o f  p a n ­
c re a tic  ju ic e ;  (2) 
c h o le c y s to k in in , 
w h ic h  s tim u la te s  
th e  p ro d u c tio n  o f  
en zy m es .
T ry p s in T ry p s in o g e n  
c o n v e r te d  to  ac tiv e  
t ry p s in  by  
e n te ro p e p tid a se  o f  
in te s tin e  a t p H  5 .2 -  
6 .0  A u to c a ta ly tic  
a t p H  7.
P ro te in ,
p ep tid es
Polypeptides,
dipeptides.
C h y m o try -
p sin
S e c re te d  as 
ch y m o try p s in o g e n  
an d  co n v e r te d  to  
a c tiv e  fo rm  by  
try p s in . p H  8 .0
P ro te in  P ep tid es Same as trypsin, 
more coagulating 
power for milk
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E lastase S ec re ted  as p ro- 
e la s ta se  and  
c o n v e rted  to  ac tiv e  
fo rm  b y  try p sin .
P ro te in  P ep tid es Polypeptides,
Dipeptides.
C a rb o x y -
p ep tid ase
S ec re ted  as p ro c a r­
b o x y p ep tid a se , 
a c tiv a ted  by  
try p sin .
P o ly p ep tid e s  a t 
th e  free  c a rb o ­
xyl en d  o f  the  
chain .
S m a l l  p e p t i ­
d e s .  F reeam ino 
acid
P an c rea tic
am y lase
p H  7 .1 . S ta rch ,
g ly co g en
M alto se  p lu s  1:6 
g lycosides 
(o ligosaccha­
rid es) p lus 
m alto triose
L ipase C o m b in e d  
ac tiv a tio n  by  b ile  
sa lts ,
p h o sp h o lip id s , 
co lip ase . p H  8 .0 .
P rim a ry  e s te r  
lin k ag es  o f  
tr ia cy lg ly c e ro l
Fatty adds, 2 -m o-
n o acy lg ly ce -ro ls ,
g ly ce ro l
B ile  sa lt-  
a c tiv a ted  
lip a se  (the  
sa m e  en ­
z y m e  is p re ­
se n t in 
m ilk )
A c tiv a te d  by  b ile  
sa lts .
T ria c y lg ly c e ro l 
e s te rs , eg , 
c h o le s te ry l 
es te r, v itam in  
e s te rs ; ly so -  
p h o sp h o lip id s
F ree  fa tty  acids
vitamins,
ch o les te ro l.
R ib o n u c-
lease
R ib o n u c le ic
ac id
Nucleotides.
D e o x y rib o ­
n u c lea se
D e o x y r ib o n u ­
c le ic  ac id s
Nucleotides
C h o les te ry l
es te r
h y d ro lase
A c tiv a te d  by  b ile  
sa lts .
C h o le s te ry l
e s te rs
Free cholesterol plus 
fatty adds.
P h o sp h o li­
pase  a 2
S ec re ted  as p ro ­
en zy m e , a c tiv a te d  
b y  try p s in  an d  C a2b.
P h o sp h o lip id s Fatty adds, 
lysophospholipides
L iv e r  a n d  g a l lb la ­
d d e r: ch o lecy s to k i-  
n in , a  h o rm o n e  
fro m  th e  in te s tin a l 
m u co sa  and  
p o ss ib ly  a lso  
g a s tr in  and  se c re tin  
-  s tim u la te  the  ga ll­
b lad d e r  and 
se c re tio n  o f  b ile  by 
th e  liver.
(B ile  sa lts  
and  a lk a lin )
F ats —  also  
neu tra lize  ac id  
ch y m e
F a tty  a c id  b ile  
sa lt  co m p lex es  
a n d  f in e ly  em u l­
s if ie d  neu tra l fat 
b ile  sa lt  m icelles 
a n d  lip o so m es
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Sm all intestine: 
secre-tions o f  
B runner's g lands o f  
the duode-num  and 
glands ofLieberiarhn.
A m in o p e p -
tid ase
P o ly p ep tid e s  at 
the  free  am in o  
en d  o f  the  
ch a in
S m all p ep tid es . 
F re e  am in o  
acids.
D ip ep tid a se D ip ep tid es A m in o  acids.
S u crase p H  5 .0 -7 .0 . S u cro se F ruc tose ,
g lucose.
M a lta se p H  5 .8 -6 .2 . M a lto se G lucose.
L ac tase p H  5 .4 -6 .0 . L ac to se G lu co se ,
g a lac to se .
T reh a lase T reh a lo se G lucose.
P h o sp h a ta se p H  8.6. O rgan ic
p h o sp h a tes
F ree  p h ospha te .
Iso m alta se
o r
1:6 g lucosides G lucose.
P o ly n u c le o ­
tid ase
N u c le ic  acid N ucleo tides.
N u c le o s id a ­
ses (n u c leo ­
s id e  p h o s-  
p h o ry la se s )
P u rin e  o r
p y rim id in e
n u c leo s id e s
P u rin e  o r 
p y rim id in e  
b ases , p en to se  
ph o sp h a te .
5. The basic metabolic pathways process the major products of 
digestion.
The nature o f the diet sets the basic pattern of metabolism in the 
tissues. Mammals such as humans need to process the absorbed products 
of digestion of dietary carbohydrate, lipid, and protein. These are 
mainly glucose, fatty acids and glycerol, and amino acids, respectively. 
In ruminants (and to a lesser extent, other herbivores), cellulose in the 
diet is digested by symbiotic microorganisms to lower fatty acids (acetic, 
propionic, butyric), and tissue metabolism in these animals is adapted to 
utilize lower fatty acids as major substrates. All these products of 
digestion are processed by their respective metabolic pathways to a 
common product, acetylCoA, which is then completely oxidized by the 
citric acid cycle (Fig. 2).
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Fig.2. Outline o f  the pathways for the catabolism o f dietary carbohydrate, protein, and 
fat. All the pathways lead to the production o f  acetylCoA, which is oxidized in the citric 
acid cycle, ultimately yielding ATP in the process o f oxidative phosphorylation.
The products of digestion provide the tissues with the building blocks 
for the biosynthesis of complex molecules and also with the fuel to power 
the living processes.
Nearly all products of digestion of carbohydrate, fat, and protein are 
metabolized to a common metabolite, acetylCoA, before final oxidation to 
C 02 in the citric acid cycle.
AcetylCoA is also used as the building block for the biosynthesis of 
long-chain fatty acids, cholesterol, and other steroids from carbohydrate 
and of cholesterol and ketone bodies from fatty acids.
Glucose provides carbon skeletons for the glycerol moiety of fat and of 
several nonessential amino acids.
All water-soluble products of digestion are transported directly to the 
liver via the hepatic portal vein for processing. This often involves 
oxidation or synthesis of molecules, some of which are exported to the rest 
of the body, eg, plasma proteins. The liver has a direct role in regulating 
the concentration of many blood constituents, including glucose and 
amino acids, since its primary function is to serve the extrahepatic tissues.
In addition to the nucleus, there are three primary subcellular 
metabolic compartments. The cytosol contains the pathways of glycolysis, 
glycogenesis, glycogenolysis, the pentose phosphate pathway, and 
lipogenesis. The mitochondrion contains the principal enzymes of 
oxidation including those of the citric acid cycle, P-oxidation of fatty acids, 
and the respiratory chain. Amino acid metabolism takes place, not only 
in the cytosol and mitochondria but also in the endoplasmic reticulum, 
where at the ribosomal site, amino acids are converted into proteins. The 
membranes of the endoplasmic reticulum also contain the enzymes for
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many other processes including glycerolipid formation and drug 
metabolism.
Metabolic pathways are regulated by rapid mechanisms affecting the 
activity of existing enzymes, eg, allosteric and covalent modification. The 
latter is often initiated by the action of hormones. Hormones also regulate 
by longer term mechanisms, by promotion or inhibition of the synthesis 
of enzyme protein through changes in gene expression.
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BIOENERGETICS
Bioenergetics, or biochemical thermodynamics, is the study of the 
energy changes accompanying biochemical reactions. It provides the 
underlying principles to explain why some reactions may occur while others 
do not. Nonbiologic systems may utilize heat energy to perform work, but 
biologic systems are essentially isothermic and use chemical energy to 
power the living processes.
1. Biomedical importance
Suitable fuel is required to provide the energy that enables the animal to 
carry out its normal processes. How the organism obtains this energy from 
its food is basic to the understanding of normal nutrition and metabolism. 
Death from starvation occurs when available energy reserves are depleted, 
and certain forms of malnutrition are associated with energy imbalance 
(marasmus). The rate of energy release, measured by the metabolic rate, is 
controlled by the thyroid hormones, whose malfunction is a cause of 
disease. Storage of surplus energy results in obesity, one of the most 
common diseases of occidental society.
2. Free energy is the useful energy in a system
Change in free energy (AG) is that portion of the total energy change 
in a system that is available for doing work; i.e., it is the useful energy, also 
known in chemical systems as the chemical potential.
3. Biologic systems conform to the general laws of thermodynamics
The first law of thermodynamics states that the total energy of a system, 
including its surroundings, remains constant. This is also the law of 
conservation of energy.
It implies that within the total system, energy is neither lost nor gained 
during any change. However, within that total system, energy may be 
transferred from one part to another or may be transformed into another 
form of energy. For example, chemical energy may be transformed into 
heat, electrical energy, radiant energy, or mechanical energy in living 
systems.
The second law of thermodynamics states that the total entropy of a 
system must increase if a process is to occur spontaneously.
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Entropy represents the extent of disorder or randomness of the system 
and becomes maximum in a system as it approaches true equilibrium.
Under conditions of constant temperature and pressure, the relationship 
between the free energy change (AG) of a reacting system and the change 
in entropy (AS) is given by the following equation which combines the 2 
laws of thermodynamics:
AG = AH -  TAS,
where AH is the change in enthalpy (heat) and T is the absolute 
temperature.
If AG is negative in sign, the reaction proceeds spontaneously with 
loss of free energy; i.e., it is exergonic. If, in addition, AG is of great 
magnitude, the reaction goes virtually to completion and is essentially 
irreversible. On the other hand, if AG is positive, the reaction proceeds 
only if free energy can be gained; i.e., it is endergonic. If, in addition, the 
magnitude of AG is great, the system is stable with little or no tendency for a 
reaction to occur. If AG is zero, the system is at equilibrium and no net 
change takes place.
When the reactants are present in concentrations of 1.0 mol/1, AG° is the 
standard free energy change. For biochemical reactions, a standard state is 
defined as having a pH of 7.0. The standard free energy change at this 
standard state is denoted by AG0’.
The standard free energy change can be calculated from the equilibrium 
constant K'cq
AG0’ = -2.303 RT log K'eq
where R is the gas constant and T is the absolute temperature.
It is important to note that AG may be larger or smaller than AG0’ 
depending on the concentrations of the various reactants.
In a biochemical reaction system, it must be appreciated that an enzyme 
only speeds up the attainment of equilibrium; it never alters the final 
concentrations of the reactants at equilibrium.
4. Endergonic processes proceed by coupling to exergonic processes
The vital processes - e.g., synthetic reactions, muscular contraction, nerve 
impulse conduction, and active transport - obtain energy by chemical linkage, 
or coupling, to oxidative reactions. In its simplest form, this type of coupling 
may be represented as shown in Fig. 1.
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Fig. I . Coupling o f  an exergonic to an endergonic reaction
The conversion of metabolite A to metabolite В occurs with release of free 
energy. It is coupled to another reaction, in which free energy is required to 
convert metabolite C to metabolite D.
As some of the energy liberated in the degradative reaction is transferred 
to the synthetic reaction in a form other than heat, the normal chemical terms 
exothermic and endothermic cannot be applied to these reactions. Rather, the 
terms exergonic and endergonic are used to indicate that a process is 
accompanied by loss or gain, respectively, of free energy, regardless of 
the form of energy involved. In practice, an endergonic process cannot exist 
independently but must be a component of a coupled exergonic/endergonic 
system where the overall net change is exergonic.
The exergonic reactions are termed catabolism (the breakdown or 
oxidation of fuel molecules), whereas the synthetic reactions that build up 
substances are termed anabolism. The total of all of the catabolic and 
anabolic processes is metabolism.
If the reaction shown in Fig. 1 is to go from left to right, then the overall 
process must be accompanied by loss of free energy as heat. One possible 
mechanism of coupling could be envisaged if a common obligatory 
intermediate (I) took part in both reactions, i.e.,
A + C - >  I —> B  + D
Some exergonic and endergonic reactions in biologic systems are coupled 
in this way. It should be appreciated that this type of system has a built-in 
mechanism for biologic control of the rate at which oxidative processes are 
allowed to occur, since the existence of a common obligatory intermediate 
allows the rate of utilization of the product of the synthetic path (D) to 
determine by mass action the rate at which A is oxidized.
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Indeed, these relationships supply a basis for the concept of respiratory 
control, the process that prevents an organism from burning out of control. 
An extension of the coupling concept is provided by dehydrogenation 
reactions, which are coupled to hydrogenations by an intermediate carrier 
(Fig. 2).
Fig. 2. Coupling o f  dehydrogenation and hydrogenation reactions by an intermediate 
carrier.
An alternative method of coupling an exergonic to an endergonic process is to 
synthesize a compound of high-energy potential in the exergonic reaction and 
to incorporate this new compound into the endergonic reaction, thus affecting 
transference of free energy from the exergonic to the endergonic pathway
Fig.3. Transfer offree energy from an exergonic to an endergonic reaction via a high- 
energy intermediate compound.
In Fig. 3, ~E is a compound of high potential energy and E is the 
corresponding compound of low potential energy. The biologic advantage of 
this mechanism is that E, unlike I in the previous system, need not be 
structurally related to А, В, C, or D. This would allow E to serve as a 
transducer of energy from a wide range of exergonic reactions to an equally 
wide range of endergonic reactions or processes, as shown in Fig. 4.
In the living cell, the principal high-energy intermediate or carrier 
compound (designated ~E) is 
adenosine triphosphate (ATP).
(Fig. 3).
A
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Endergonic
p ro c e s s e s
Fig. 4. Transduction o f  energy through a common high-energy compound to energy- 
requiring (endergonic) biologic processes.
5. High - energy phosphates play a central role 
in energy capture and transfer
In order to maintain living processes, all organisms must obtain supplies of 
free energy from their environment.
Autotrophic organisms couple their metabolism to some simple 
exergonic process in their surroundings:
1. green plants utilize the energy of sunlight
2. some autotrophic bacteria utilize the reaction Fe2+—> Fe3+.
On the other hand, heterotrophic organisms obtain free energy by 
coupling their metabolism to the breakdown of complex organic molecules 
in their environment. In all of these processes, ATP plays a central role in the 
transference of free energy from the exergonic to the endergonic processes 
(Figs 3 and 4). As can be seen from Fig.5, ATP is a specialized nucleotide 
containing adenine, ribose and 3 phosphate groups. In its reactions in the cell 
it functions as the Mg2+complex (Fig. 6).
0
-О --------- P -------О -Adenosine
1
O'
Fig. 5. Adenosine triphosphate (ATP). Fig. 6. The magnesium complex o f  ATP.
The importance of phosphates in intermediary metabolism became evident 
with the discovery of the chemical details of glycolysis and of the role of ATP, 
adenosine diphosphate (ADP), and inorganic phosphate (Pi) in this process
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(ATP was considered a means of transferring phosphate radicals in the 
process of phosphorylation. The role of ATP in biochemical energetics was 
indicated in experiments demonstrating that ATP and creatine phosphate 
were broken down during muscular contraction and that their resynthesis 
depended on supplying energy from oxidative processes in the muscle. It was 
not until Lipmann introduced the concept of "high-energy phosphates" and 
the "high-energy phosphate bond" that the role of these compounds in 
bioenergetics was clearly appreciated.
6. The intermediate value for the free energy of hydrolysis of ATP 
compared to other organophosphates has important 
bioenergetic significance
The standard free energy of hydrolysis of a number of biochemically 
important phosphates is shown in Table 1.
Table 1. Standard free energy o f  hydrolysis o f some organophosphates 
o f  biochemical importance
C o m p o u n d A G "
K J / m ol K.cal/m oI
P h o sp h o en o lp y ru v a te - 6 1 .9 - 1 4 .8
C a rb am o y l p h o sp h a te -5 1 .4 -1 2 .3
1,3 -B isp h o sp h o g ! y ce ra te -4 9 .3 -1 1 .8
C re a tin e  n h o sn h a te -4 3 .1 -1 0 .3
A T P  — ► A D P + P i -3 0 .5 -7 .3
A D P  — ► A M P + P i - 2 7 .6 - 6 .6
P yrophosphate - 2 7 .6 - 7 .4
G lu co se-1 -phosphate -2 0 .9 - 5 .0
F ruc tose-6 -phosphate -1 5 .9 - 3 .8
A M P -1 4 .2 - 3 .4
G lu c o se -6 -p h o sp h a te - 1 3 .8 -3 .3
G ly ce ro l-3 -  p h o sp h a te -9 .2 - 2 .2
An estimate of the comparative tendency of each of the phosphate groups 
to transfer to a suitable acceptor may be obtained from the AG0’ of hydrolysis 
(measured at 37 °C).
It may be seen from the table that the value for the hydrolysis of the 
terminal phosphate of ATP of—30.5 kJ/mol divides the list into 2 groups:
1. One group of low-energy phosphates, exemplified by the ester 
phosphates found in the intermediates of glycolysis, has AG° values 
smaller than that of ATP,
2. while in the other group, designated high-energy phosphates, the 
value is higher than that of ATP.
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The components of this latter group, including ATP and ADP, are 
usually:
1. anhydrides (e.g., the 1 -phosphate of 1,3-Bisphosphoglycerate)
2. enolphosphates (e.g., Phosphoenolpyruvate)
3. phosphoguanidines (e.g., Creatine phosphate, Arginine phosphate).
The intermediate position of ATP allows it to play an important role 
in energy transfer. Other biologically important compounds that are classed 
as "high-energy compounds" are thiol esters involving coenzyme A (e.g., 
acetyl-CoA), acyl carrier protein, amino acid esters involved in protein 
synthesis, S-adenosylmethionine (active methionine), UDPGlc (uridine 
diphosphate glucose), and PRPP (5-phosphoribosyl-l-pyrophosphate).
7. High-energy phosphates are designated by the symbol ~ P
To indicate the presence of the high-energy phosphate group, Lipmann 
introduced the symbol ~P, indicating high-energy phosphate bond. The 
symbol indicates that the group attached to the bond, on transfer to an 
appropriate acceptor, results in transfer of the larger quantity of free energy. 
For this reason, some to “high-energy bond” prefers the term group transfer 
potential.
Thus, ATP contains 2 high-energy phosphate groups and ADP contains 
one, whereas the phosphate in AMP (adenosine monophosphate) is of the 
low-energy type, since it is a normal ester link.
8. High-energy phosphates act as “energy currency” of the cell
As a result of its position midway down the list of standard free energies of 
hydrolysis (Table 1), ATP is able to act as a donor of high-energy phosphate 
to those compounds below it in the table. Likewise, provided the necessary 
enzymatic machinery is available, ADP can accept high-energy phosphate to 
form ATP from those compounds above ATP in the table. In effect, an 
ATP/ADP cycle connects those processes which generate ~P to those 
processes that utilize ~P. Thus, ATP is continuously consumed and 
regenerated.
There are 3 major sources of ~P taking part in energy conservation or 
energy capture:
1. Oxidative phosphorylation.
This is the greatest quantitative source of ~P in aerobic organisms. The free 
energy to drive this process comes from respiratory chain oxidation within 
mitochondria.
2. Glycolysis.
A net formation of 2 ~P results from the formation of lactate from one
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molecule of glucose generated in 2 reactions catalyzed by phosphoglycerate 
kinase and pyruvate kinase, respectively.
3. The citric acid cycle.
One ~P is generated directly in the cycle at the succiny! thiokinase step.
Another group of compounds, phosphagens, act as storage forms of high- 
energy phosphate. These include creatine phosphate, occurring in vertebrate 
muscle and brain, and arginine phosphate, occurring in invertebrate muscle.
Under physiologic conditions, phosphagens permit ATP concentrations 
to be main tained in muscle when ATP is rapidly being utilized as a source of 
energy for muscular contraction.
On the other hand, when ATP is plentiful, their concentration can build up 
to act as a store of high-energy phosphate (Fig. 7). 
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Fig. 7. Transfer o f  high-energy phosphate between ATP and creatine
In muscle, a creatine phosphate shuttle has been described that 
transports high-energy phosphate from mitochondria to the sarcolemma and 
that acts as a high-energy phosphate buffer. In the myocardium, this buffer may 
be of significance in affording immediate protection against the effects of 
infarction.
When ATP acts as a phosphate donor to form those compounds of lower 
free energy of hydrolysis the phosphate group is invariably converted to 
one of low energy, e.g.
Glycerol + Adenosine -  P~P~P Glycerol -  P + Adenosine -  P~P
9. ATP allows the coupling of thermodynamically unfavorable 
reactions to favorable ones
The energetics of coupled reactions is depicted in more detail in Fig 1 or
3. Such a reaction is the first in the glycolytic pathway, the phosphorylation of 
glucose to glucose-6-phosphate, which is highly endergonic and cannot 
proceed as such under physiologic conditions.
(1) Glucose + Pi—> Glucose 6-phosphate + H20  (A G° = +13.8kJ/mol)
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To take place, the reaction must be coupled with another reaction that is 
more exergonic than the phosphorylation of glucose is endergonic. Such a 
reaction is the hydrolysis of the terminal phosphate of ATP.
(2) ATP - >  ADP + Pi (AG0’ - 30.5 kJ/mol)
When (1) and (2) are coupled in a reaction catalyzed by hexokinase, 
phosphorylation of glucose readily proceeds in a highly exergonic reaction 
that under physiologic conditions is far from equilibrium and thus irreversible 
for practical purposes.
Glucose + ATP —>Glucose 6-phosphate + ADP (AG0’ = -16.7kJ/mol) 
Many "activation" reactions follow this pattern.
10. Adenylate kinase allows interconversion of adenine nucleotides
The enzyme adenylate kinase (myokinase) is present in most cells. It 
catalyzes the interconversion of ATP and AMP on the one hand and ADP on 
the other:
ATP + AMP 2ADP
This reaction has 3 functions:
1. It allows high-energy phosphate in ADP to be used in the synthesis of 
ATP.
2. It allows AMP, formed as a consequence of several activating 
reactions involving ATP, to be recovered by rephosphorylation to 
ADP.
3. It allows AMP to increase in concentration when ATP becomes 
depleted and act as a metabolic (allosteric) signal to increase the rate 
of catabolic reactions, which in turn leads to the generation of more 
ATP.
11. When ATP reacts to form AMP, inorganic 
pyrophosphate (PPi) is formed
This occurs for example, in the activation of long-chain fatty acids:
ATP + CoA -SH + R -COOH AMP + PPi + R - CO-SCoA
This reaction is accompanied by loss of free energy as heat, which ensures 
that the activation reaction will go to the right; this is further aided by the
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hydrolytic splitting of PPi, catalyzed by inorganic pyrophosphatase, a 
reaction that itself has a large AG°' o f —27.6 kJ/mol. Note that activations 
via the pyrophosphate pathway result in the loss of 2 ~P rather than one ~P 
as occurs when ADP and Pi are formed.
PPi + H20  —> 2Pi
A combination of the above reactions makes it possible for phosphate to 
be recycled and the adenine nucleotides to interchange.
12. Other nucleoside triphosphates take part in the transfer of high- 
energy phosphate
By means of the enzyme nucleoside diphosphate kinase, nucleoside 
triphosphates similar to ATP but containing an alternative base to adenine 
can be synthesized from their diphosphates, e.g.,
ATP + UDP ~ ^  ADP + UTP (uridine triphosphate)
ATP+ GTP —> ADP + GTP (guanosine triphosphate)
ATP+ CDP ADP + CTP (cytidine triphosphate)
All of these triphosphates take part in phosphorylation in the cell. 
Similarly, nucleoside monophosphate kinases, specific for each purine or 
pyrimidine nucleoside, catalyze the formation of nucleoside diphosphates 
from the corresponding monophosphates.
ATP + Nucleoside - P ADP + Nucleoside -  P ~ P
Thus, adenylate kinase is a specialized monophosphate kinase.
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9 BIOLOGIC OXIDATION
Chemically, oxidation is defined as the removal of electrons and, reduction 
is the gain of electrons, as illustrated by the oxidation of ferrous to ferric ion.
e'(electron)
Fe2+--------> Fe3+
It follows that oxidation is always accompanied by reduction of an electron 
acceptor. This principle of oxidation-reduction applies equally to biochemical 
systems and is an important concept underlying understanding of the nature of 
biologic oxidation. It will be appreciated that many biologic oxidations can 
take place without the participation of molecular oxygen, eg, 
dehydrogenations. Although certain bacteria (anaerobes) survive in the 
absence of oxygen, the life of higher animals is absolutely dependent upon a 
supply of oxygen. The principal use of oxygen is in respiration, which may be 
defined as the process by which cells derive energy in the form of ATP from 
the controlled reaction of hydrogen with oxygen to form water. In addition, 
molecular oxygen is incorporated into a variety of substrates by enzymes 
designated as oxygenases; many drugs, pollutants, and chemical carcinogens 
(xenobiotics) are metabolized by enzymes of this class, known as the 
cytochrome P-450 system. Administration of oxygen can be lifesaving in the 
treatment of patients with respiratory or circulatory failure and, occasionally, 
administration of oxygen at high pressure (hyperbaric oxygen therapy) has 
proved of value, although this can result in oxygen toxicity.
In reactions involving oxidation and reduction, the free energy exchange is 
proportionate to the tendency of reactants to donate or accept electrons. 
Thus, in addition to expressing free energy change in terms of AG°, it is 
possible, in an analogous manner, to express it numerically as an oxidation- 
reduction or redox potential (Eo)-
1. Enzymes involved in oxidation and reduction are 
designaed oxidoreductases
In the following account, oxidoreductases are classified into 4 groups: 
oxidases, dehydrogenases, hydroperoxidases, and oxygenases.
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1.1. Oxidases use oxygen as a hydrogen acceptor
Oxidases catalyze the removal of hydrogen from a substrate using oxygen 
as a hydrogen acceptor. They form water or hydrogen peroxide as a reaction 
product (Fig. 1).
Some oxidases contain copper
Cytochrome oxidase is a hemoprotein widely distributed in many plant 
and animal tissues. It is the terminal component of the chain of respiratory 
carriers found in mitochondria and is therefore responsible for the reaction 
whereby electrons resulting from the oxidation of substrate molecules by 
dehydrogenases are transferred to their final acceptor, oxygen. The enzyme is 
poisoned by carbon monoxide, cyanide, and hydrogen sulfide. It has also been 
termed cytochrome a3. It was formerly assumed that cytochrome a and 
cytochrome a3 were separate compounds, since each has a distinct spectrum 
and different properties with respect to the effects of carbon monoxide and 
cyanide. More recent studies show that the 2 cytochromes are combined with 
the same protein, and the complex is known as cytochrome aa3. It contains 2 
molecules of heme, each having one Fe atom that oscillates between Fe3+ and 
Fe2+ during oxidation and reduction. Also, 2 atoms of Cu are present, each 
associated with a heme unit.
Fig. 1. Oxidation o f  a metabolite catalyzed by an oxidase (a) forming H /J. (b) forming 
H2O2.
1.2. Dehydrogenases cannot use oxygen as a hydrogen acceptor
Some dehydrogenases are dependent on nicotinamide coenzymes
A large number of dehydrogenases fall into this category. They are specific 
for either nicotinamide adenine dinucleotide (NAD1) or nicotinamide adenine 
dinucleotide phosphate (NADP1) as coenzymes. However, some 
dehydrogenases can use either NAD+ or NADP+. NAD+ and NADP+ are 
formed in the body from the vitamin niacin. The coenzymes are reduced by 
the specific substrate of the dehydrogenase and reoxidized by a suitable 
electron acceptor (Fig.2). They may freely and reversibly dissociate from 
their respective apoenzymes. Generally, NAD-linked dehydrogenases catalyze 
oxidoreduction reactions in the oxidative pathways of metabolism, particularly 
in glycolysis, in the citric acid cycle, and in the respiratory chain of mitochon­
dria. NADP-linked dehydrogenases are found characteristically in reductive
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syntheses, as in the extra-mitochondrial pathway of fatty acid synthesis and 
steroid synthesis. They are also to be found as coenzymes to the 
dehydrogenases of the pentose phosphate pathway (Fig. 3).
Fig. 2. Mechanism o f oxidation and reduction o f  nicotinamide coenzymes. There is 
stereospecificity about position 4 o f  nicotinamide when it is reduced by a substrate AH2. 
One o f  the hydrogen atoms is removed from the substrate as a hydrogen nucleus with 2 
electrons (hydride ion, IT) and is transferred to the 4 position, where it may be attached in 
either the A or the В position according to the specificity determined by the particular 
dehydrogenase catalyzing the reaction. The remaining hydrogen o f the hydrogen pair 
removedfrom the substrate remains free as a hydrogen ion.
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Fig. 3. Oxidation o f a metabolite by dehydrogenases and finally by an oxidase in a 
respiratory chain.
Other dehydrogenases are dependent on riboflavin
The flavin groups associated with these dehydrogenases are similar to 
FMN and FAD (Fig.4), occurring in oxidases. They are generally more 
tightly bound to their apoenzymes than are the nicotinamide coenzymes. 
Most of the riboflavin-linked dehydrogenases are concerned with electron 
transport in (or to) the respiratory chain. NADH dehydrogenase is a member of 
the respiratory chain acting as a carrier of electrons between NADH and the 
more electropositive components. Other dehydrogenases such as succinate 
dehydrogenase, acyl-CoA dehydrogenase, and mitochondrial glycerol-3- 
phosphate dehydrogenase transfer reducing equivalents directly from the 
substrate to the respiratory chain. Another role of the flavin-dependent 
dehydrogenases is in the dehydrogenation (by dihydrolipoyl 
dehydrogenase) of reduced lipoate, an intermediate in the oxidative 
decarboxylation of pyruvate and a-ketoglutarate. In this particular instance,
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owing to the low redox potential, the flavoprotein (FAD) acts as a hydrogen 
carrier from reduced Iipoate to NAD. The electron-transferring flavoprotein is 
an intermediary carrier of electrons between acyl-CoA dehydrogenase and the 
respiratory chain.
<м*.а •,
F ig  4. R ed u c tio n  o f  is o a llo x a z in e  r in g  in flav in  n u c leo tid es
Cytochromes may also be regarded as dehydrogenases
Except for cytochrome oxidase (previously described), the cytochromes 
are also classified as dehydrogenases. Their identification and study are 
facilitated by the presence in the reduced state of characteristic absorption 
bands that disappear on oxidation. In the respiratory chain, they are involved 
as carriers of electrons from flavoproteins on the one hand to cytochrome 
oxidase on the other. The cytochromes are iron-containing hemoproteins in 
which the iron atom oscillates between Fe3+ and Fe2+ during oxidation and 
reduction. Several identifiable cytochromes occur in the respiratory chain, ie, 
cytochromes b, cb c, a, and a3 (cytochrome oxidase). Of these, only 
cytochrome c is soluble. Besides the respiratory chain, cytochromes are found 
in other locations, eg, the endoplasmic reticulum (cytochromes P-450 and b5), 
plant cells, bacteria, and yeasts.
1.3. Hydroperoxidases use hydrogen peroxide or an 
organic peroxide as substrate
Two types of enzymes fall into this category, peroxidases and catalase. 
These 2 types are found both in animals and in plants. Hydroperoxidases 
protect the body against harmful peroxides. Accumulation of peroxides can 
lead to generation of free radicals, which in turn can disrupt membranes etc., 
and possibly cause cancer and atherosclerosis.
Peroxidases reduce peroxides using several 
substances as electron acceptor
Although originally considered to be plant enzymes, peroxidases are 
found in milk and in leukocytes, platelets, and other tissues involved in 
eicosanoid metabolism. The prosthetic group is protoheme, which, unlike the 
situation in most hemoproteins, is only loosely bound to the apoprotein. In
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the reaction catalyzed by peroxidase, hydrogen peroxide is reduced at the 
expense of several substances that will act as electron acceptors, such as 
ascorbate, quinones, and cytochrome c. The reaction catalyzed by peroxidase 
is complex, but the overall reaction is as follows:
Peroxidase
H20 2 + AH2 --------> 2 H20  + A
Catalases uses hydrogen peroxide as electron donor 
and electron acceptor
Catalase is a hemoprotein containing 4 heme groups. In addition to 
possessing peroxidase activity, it is able to use one molecule of H20 2 as a 
substrate electron donor and another molecule of H20 2 as oxidant or electron 
acceptor. Under most conditions in vivo, the peroxidase activity of catalase 
seems to be favored.
Catalase
2H20 2 --------> 2H20  + 0 2
Catalase is found in blood, bone marrow, mucous membranes, kidney, and 
liver. Its function is assumed to be the destruction of hydrogen peroxide 
formed by the action of oxidases. Microbodies or peroxisomes are found in 
many tissues, including liver. They are rich in oxidases and in catalase, which 
suggests that there may be a biologic advantage in grouping the enzymes that 
produce H20 2 with the enzyme that destroys it. In addition to the peroxisomal 
enzymes, mitochondrial and microsomal electron transport systems as well as 
xanthine oxidase must be considered as sources of H20 2.
Fig. 5. Role o f  catalase in the destruction o f  hydrogen peroxide.
1.4. Oxygenases catalyze the direct transfer and incorporation 
of oxygen into a substrate molecule.
Oxygenases are concerned with the synthesis or degradation of many 
different types of metabolites rather than taking part in reactions that have 
as their purpose the provision of energy to the cell. Enzymes in this group 
catalyze the incorporation of oxygen into a substrate molecule.
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This takes place in 2 steps: (1) oxygen binding to the enzyme at the 
active site, and (2) the reaction in which the bound oxygen is reduced or 
transferred to the substrate. Oxygenases may be divided into 2 subgroups:
Dioxygenases (Oxygen Transferases, True Oxygenases) incorporate 
both oxygen atoms into the substrate
The basic reaction is:
A + O2 ^  AO2
Examples of this type include enzymes that contain iron such as 
homogentisate dioxygenase and 3-hydroxyanthranilate dioxygenase from 
the supernatant fraction of the liver, and enzymes utilizing heme such as L- 
tryptophan dioxygenase from the liver.
Monooxygenases (Mixed-Function Oxidases, Hydroxylases) 
incorporate only one atom of oxygen into the substrate
The other oxygen atom is reduced to water, an additional electron donor 
or cosubstrate being necessary for this purpose
A - H + 0 2 + ZH2 — > A - OH + H20  + Z
Microsomal Cytochrome P-450 Monooxygenase systems are 
important for the hydroxylation of many drugs
These monooxygenases are found in the microsomes of the liver 
together with cytochrome P-450 and cytochrome bs. Both NADH and 
NADPH donate reducing equivalents for the reduction of these 
cytochromes (Fig.6), which in turn are oxidized by substrates in a series of 
enzymatic reactions collectively known as the hydroxylase cycle (Fig. 1).
Hydroxylase
DRUG - H + 0 2 + 2Fe2+ + 2 h t  -------------- > DRUG - OH + H20  + 2Fe3+
(P-450) (P-450)
Among the drugs metabolized by this system are benzpyrene, 
aminopyrine, aniline, morphine, and benzphetamine. Many drugs such as 
phenobarbital have the ability to induce the formation of microsomal 
enzymes and of cytochrome P-450.
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Fig.6. Electron transport chain in microsomes. Cuanide (CN~) inhibits 
the indicated step.
Substrate A -H
F ig . 7. Cytochrome P-450 hydroxylase cycle in microsomes. The system shown is typical o f 
steroid hydroxylases o f the adrenal cortex. Liver microsomal cytochrome P-450 hydroxybse 
does not require the iron-sulfur protein Fef>2. Carbon monoxide (CO) inhibits the indicated 
step.
Mitochondrial Cytochrome P-450 Monooxygenase systems catalyze 
steroidal hydroxylations
These systems are found in steroidogenic tissues such as adrenal cortex, 
testis, ovary, and placenta and are concerned with the biosynthesis of 
steroid hormones from cholesterol (hydroxy lation at C22 and Cm in side-chain 
cleavage and at the 11 (3 and 18 positions). Renal systems catalyze 10- and 
24-hydroxylations of 25-hydroxycholecalciferol, and the liver catalyzes 26- 
hydroxylation in bile acid biosynthesis. In the adrenal cortex, mitochondrial 
cytochrome P-450 is 6 times more abundant than cytochromes of the 
respiratory chain. The monooxygenase system consists of 3 components 
situated on the inside of the inner mitochondrial membrane: an NADP-specific 
FAD containing flavoprotein, and Fe2S2 protein (adrenodoxin), and cyto­
chrome P-450 (Fig.8).
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INNER
OUTSIDE MITOCHONDRIAL IN S ID E  
m e m b r a n e
Fig. 8. Mitochondrial cytochrome P-450 monooxygenase system. FeiS'2, iron-sulfur 
protein (adrenodoxin). Note that because NADP(H) cannot penetrate the 
mitochrondrial membrane, sources o f  reducing equivalents are confined to substrates 
such as malate and isocitrate fo r which there are intramitochondrial NADP-specific 
dehydrogenases.
2. The superoxide free radical may account for oxygen toxicity.
Oxygen is a potentially toxic substance, the toxicity of which has hitherto 
been attributed to the formation of H20 2. Recently, however, the ease with 
which oxygen can be reduced in tissues to the superoxide anion free radical 
(O’) and the occurrence of superoxide dismutase in aerobic organisms 
(although not in obligate anaerobes) have suggested that the toxicity of oxygen 
is due to its conversion to superoxide. However, no direct evidence of 
superoxide toxicity has yet been obtained.
Superoxide is formed when reduced flavins, present, for example, in 
xanthine oxidase, are reoxidized univalently by molecular oxygen. It is also 
formed during univalent oxidations with molecular oxygen in the respiratory 
chain:
EnzH2+O z— > EnzH + 0 2 + H+
Superoxide can reduce oxidized cytochrome c:
0 2 + Cyt c (Fe3+) ------> 0 2 + Cyt c (Fe2+)
or be removed by the presence of the specific enzyme superoxide dismutase: 
О / + 0 2- + 2H+------> H20 2 + 0 2
In this reaction, superoxide acts as both oxidant and reductant. The 
chemical effects of superoxide in the tissues are amplified by free-radical 
chain reactions. It has been proposed that 0 2' -bound to cytochrome P-450 is
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an intermediate in the activation of oxygen in hydroxylation reactions (Fig
7).
The function of superoxide dismutase seems to be that of protecting 
aerobic organisms against the potential deleterious effects of superoxide. The 
enzyme occurs in several different compartments of the cell. The cytosolic 
enzyme is composed of 2 similar subunits, each one containing one 
equivalent of Cu2" and Zn2*, whereas the mitochondrial enzyme contains 
Mn2*, similar to the enzyme found in bacteria. This finding supports the 
hypothesis that mitochondria have evolved from a prokaryote that entered into 
symbiosis with a protoeukaryote. The dismutase is present in all major aerobic 
tissues. Although exposure of animals to an atmosphere of 100% oxygen 
causes an adaptive increase of the enzyme, particularly in the lungs, prolonged 
exposure leads to lung damage and death. Antioxidants, eg, a-tocopherol 
(vitamin E), also act as scavengers of free radicals such as O' and reduce the 
toxicity of oxygen.
3. The respiratory chain collects and oxidizes reducing equivalents.
All of the useful energy liberated during the oxidation of fatty acids and 
amino acids and nearly all of that released from the oxidation of carbohydrate 
is made available within the mitochondria as reducing equivalents (H+ or 
electrons). The mitochondria (Fig. 9) contain the series of catalysts known as 
the respiratoiy chain that collect and transport reducing equivalents and direct 
them to their final reaction with oxygen to form water (Fig. 10).
Fig. 9. Structure o f  the mitochondrial membranes. Submitochondrial particles are "inside 
out" and allow study an enclosed membrane system where the phosphorylating subunits are 
on the outside.
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Also present is the machinery for trapping the liberated free energy as high- 
energy phosphate. Mitochondria also contain the enzyme systems responsible 
for producing most of the reducing equivalents in the first place, ie, the 
enzymes of p-oxidation and of the citric acid cycle. The latter is the final 
common metabolic pathway for the oxidation of all the major foodstuffs.
Substrate
NAD* ■ *PH2 - ■ ■
Ffcivoproteta Cytochromes
NADH —
i*  2H* 21
Fig. 10. Transport o f  reducing equivalents through the respiratory chain.
Hydrogen or electrons flow through the chain in steps from the more 
electronegative components to the more electropositive oxygen through a redox 
span of 1.1 volts from NAD+/ NADH to 0 2/2H20.
The main respiratory chain in mitochondria proceeds from the NAD- 
linked dehydrogenase systems, through flavoproteins and cytochromes, to 
molecular oxygen. Not all substrates are linked to the respiratory chain 
through NAD-specific dehydrogenases; some, because their redox potentials 
are more positive (eg, fumarate/succinate), are linked directly to flavoprotein 
dehydrogenases, which in turn are linked to the cytochromes of the 
respiratory chain (fig. 11).
3 rtjrdioicyacyi-CoA
l-Myoroxybuerrjt*
Fig. 11. Components o f  the respiratory chain in mitochondria showing the collecting 
points fo r  reducing equivalents from  important substrates. FeS occurs in the sequences 
on the sequences on the 0 2 side o f  Fp or Cyt b.
In recent years, it has become clear that an additional carrier is present in 
the respiratory chain linking the flavoproteins to cytochrome b, the member of 
the cytochrome chain of lowest redox potential. This substance, which has 
been named ubiquinone or Q (co-enzyme Q) (Fig. 12), exists in mitochondria
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in the oxidized quinone form under aerobic conditions and in the reduced 
quinol form under anaerobic conditions. Q is a constituent of the mitochondrial 
lipids. Q is a mobile component of the respiratory chain and that it collects 
reducing equivalents from the more fixed flavoprotein complexes and passes 
them on to the cytochromes.
ОfY »!H + •"> m CH,0-< NyH<) OH,
V  1
сир *Лч fCHrCH ССН»Ц4
о *c oti
Futfy cutjmc j  or Semi^anono io<rr> Reduced Of quint* fo*r>
qwncne foon {free radical» {hydroquioonei
Fig. 12. Structure o f  ubiquinone (Q). n -  Number o f  isoprenoid units, which is 10 in 
higher animals, ie. Он,.
An additional component found in respiratory chain preparations is the 
iron-sulfur protein (FeS; nonheme iron). It is associated with the 
flavoproteins. (metalloflavoproteins) and with cytochrome b. The sulfur and 
iron are thought to take part in the oxidoreduction mechanism, which involves 
only a single e' change.
At the electronegative end of the chain, dehydrogenase enzymes catalyze 
the transfer of electrons from substrates to NAD of the chain. Several 
differences exist in the manner in which this is carried out. The a-keto acids 
pyruvate and ketoglutarate have complex dehydrogenase systems involving 
lipoate and FAD prior to the passage of electrons to NAD of the respiratory 
chain. Electron transfers from other dehydrogenases such as Ц+)-3- 
hydroxyacyl-CoA, D(—)-3-hydroxybutyrate, proline, glutamate, malate, and 
isocitrate dehydrogenases appear to couple directly with NAD of the 
respiratory chain.
The reduced NADH of the respiratory chain is in turn oxidized by a 
metal loflavoprotein enzyme — NADH dehydrogenase. This enzyme contains 
FeS and FMN, is tightly bound to the respiratory chain, and passes reducing 
equivalents onto Q. Q is also the collecting point in the respiratory chain for 
reducing equivalents derived from other substrates that are linked directly to 
the respiratory chain through flavoprotein dehydrogenases. These substrates 
include succinate, choline, glycerol 3-phosphate, sarcosine, dimethylglycine, 
and acyl-CoA. The flavin moiety of all these dehydrogenases appears to be 
FAD.
Electrons flow from Q, through the series of cytochromes to molecular 
oxygen. The cytochromes are arranged in order of increasing redox potential. 
The terminal cytochrome aa3 (cytochrome oxidase) is responsible for the final 
combination of reducing equivalents with molecular oxygen. It has been 
noted that this enzyme system contains copper, a component of several 
oxidase enzymes. Cytochrome oxidase has a very high affinity for oxygen,
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which allows the respiratory chain to function at the maximum rate until the 
tissue has become virtually depleted of 0 2. Since this is an irreversible 
reaction (the only one in the chain), it gives direction to the movement of 
reducing equivalents in the respiratory chain and to the production of ATP, to 
which it is coupled.
The structural organization of the respiratory chain has been the subject of 
considerable study. Of significance is the finding of nearly constant molar 
proportions between the components. Functionally and structurally, the 
components of the respiratory chain are present in the inner mitochondrial 
membrane as 4 protein-lipid respiratory chain complexes. These findings 
have suggested that these components have a definite spatial orientation in the 
membranes. Cytochrome c is the only soluble cytochrome and, together with 
Q, seems to be a more mobile component of the respiratory chain connecting 
the fixed complexes (Fig. 13).
Fig. 13. Proposed sites o f  inhibition (-) o f the respiratory chain by specific drugs, 
chemicals, and antibiotics. The sites that appear to support phosphorylation are 
indicated. (BAL, dimercaprol. TTFA is an Fe-chelating agent. Complex 1, NADH: 
ubiquinone oxidoreductase; complex 11, succinate: ubiquinone oxidoreductase ; 
complex III, ubiquinol: ferricytochrome c  oxidoreductase; complex IV, 
ferrocytochrome c: oxygen oxidoreductase.
4. The respiratory chain is responsible for most of the energy 
captured in metabolism.
ADP is a molecule that captures, in the form of high-energy phosphate, 
some of the free energy released by catabolic processes. The resulting ATP 
passes on this free energy to drive those processes requiring energy. Thus, 
ATP has been called the energy "currency" of the cell.
There is a net capture of 2 high-energy phosphate groups directly in the 
glycolytic reactions, equivalent to approximately 61 kJ/mol of glucose. Since 
1 mol of glucose yields approximately 2780kJ on complete combustion, the 
energy captured by phosphorylation in glycolysis is small. The reactions of
I
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the citric acid cycle, the final pathway for the complete oxidation of glucose, 
include one phosphorylation step, the conversion of succinyl-CoA to succinate, 
which allows the capture of only 2 more high-energy phosphates per mole of 
glucose. All of the phosphorylations described occur at the substrate level. 
Examination of intact respiring mitochondria reveals that when substrates are 
oxidized via an NAD-linked dehydrogenase and the respiratory chain, 3 mol of 
inorganic phosphate are incorporated into 3 mol of ADP to form 3 mol of ATP 
per 1/2 mol of 0 2 consumed: ie, the P:0 ratio = 3 (Fig. 13). On the other hand, 
when a substrate is oxidized via a flavoprotein-linked dehydrogenase, only 2 
mol of ATP are formed; ie, P:0 = 2. These reactions are known as oxidative 
phosphorylation at the respiratory chain level. Dehydrogenations in the 
pathway of catabolism of glucose in both glycolysis and the citric acid cycle, 
plus phosphorylations at the substrate level, can now account for nearly 42% of 
the free energy resulting from the combustion of glucose, captured in the form 
of high-energy phosphate. It is evident that the respiratory chain is responsible 
for a large proportion of total ATP formation.
5. Respiratory control ensures a constant supply of ATP
The rate of respiration of mitochondria can be controlled by the 
concentration of ADP. This is because oxidation and phosphorylation are 
tightly coupled; ie, oxidation cannot proceed via the respiratory chain without 
concomitant phosphorylation of ADP. Chance and Williams have defined 5 
conditions that can control the rate of respiration in mitochondria (Table 1).
Generally, most cells in the resting state are in state 4, and respiration is 
controlled by the availability of ADP. When work is performed, ATP is 
converted to ADP, allowing more respiration to occur, which in turn 
replenishes the store of ATP (Fig. 14). It would appear that under certain 
conditions the concentration of inorganic phosphate could also affect the rate 
of functioning of the respiratory chain. As respiration increases (as in 
exercise), the cell approaches state 3 or state 5 when either the capacity of the 
respiratory chain becomes saturated or the P02 decreases below the K™ for 
cytochrome a3. There is also the possibility that the ADP/ATP transporter, 
which facilitates entry of cytosolic ADP into the mitochondrion, becomes rate 
limiting.
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Thus, the manner in which biologic oxidative processes allow the free. 
energy resulting from the oxidation of foodstuffs to become available and to 
be captured is stepwise, efficient (40-45%), and controlled - rather than 
explosive, inefficient, and uncontrolled. The remaining free energy that is not 
captured as high-energy phosphate is liberated as heat.
Table I. States o f respiratory control
Conditions Limiting the Rate o f Respiration
State 1 Availability of ADP and substrate
State 2 Availability of substrate only
State 3 The capacity of the respiratory chain itself, when all substrates and components
are present in saturating amounts Availability of ADP only
State 4 Availability of ADP only
State 5 Availability of oxygen only
This need not be considered as "wasted," since it ensures the respiratory 
system as a whole is sufficiently exergonic to be removed from equilibrium, 
allowing continuous unidirectional flow and constant provision of ATP. In the 
warm-blooded animal it contributes to maintenance of body temperature.
6. Many well-known poisons are inhibitors of the respiratory chain.
Much information about the respiratory chain has been obtained by the 
use of inhibitors, and their proposed loci of action. For descriptive purposes, 
they may be divided into inhibitors of the respiratory chain proper, inhibitors 
of oxidative phosphorylation, and uncouplers of oxidative phosphorylation.
Inhibitors that arrest respiration by blocking the respiratory chain act at 3 
loci. The first is inhibited by barbiturates such as amobarbital, by the antibiotic 
piericidin A, and by the fish poison rotenone. These inhibitors prevent the 
oxidation of substrates that communicate directly with the respiratory chain via 
an NAD-linked dehydrogenase, eg, 3-hydroxybutyrate.
Dimercaprol and antimycin A inhibit the respiratory chain between 
cytochrome b and cytochrome c. The classic poisons H2S, carbon monoxide, 
and cyanide inhibits cytochrome oxidase. Carboxin and TTFA specifically
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inhibit transfer of reducing equivalents from succinate dehydrogenase to Q, 
whereas malonate is a competitive inhibitor of succinate dehydrogenase.
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7. The chemiosmotic theory explains the mechanism of oxidative 
phosphorylation.
Two principal hypotheses have been advanced to account for the coupling 
of oxidation and phosphorylation. The chemical hypothesis postulated direct 
chemical coupling at all stages of the process, as in the reactions that generate 
ATP in glycolysis. However, energy-rich intermediates linking oxidation with 
phosphorylation were never isolated and the hypothesis has become 
discredited.
Other hypotheses have been advanced in which it is envisaged that energy 
from oxidation is conserved in conformational changes of molecules, which in 
turn lead to the generation of high-energy phosphate bonds.
The chemiosmotic theory postulates that oxidation of components in the 
respiratory chain generates hydrogen ions, which are ejected to the outside of a 
coupling membrane in the mitochondrion. The electrochemical potential 
difference resulting from the asymmetric distribution of the hydrogen ions 
(protons, H+) is used to drive the mechanism responsible for the formation of 
ATP (Fig. 15).
H*
Fig. 15. Principles o f  the chemiosmotic theory o f oxidative phosphorylation. F,, Fa protein 
subunits responsible fo r phosphorylation. The main proton circuit is created by the coupling 
o f oxidation to proton translocation from the inside to the outside o f the membrane, driven by 
the respiratory chain complexes I, III, and IV, each o f which acts as a proton pump. 
Uncoupling agents such as dinitrophenol allow leakage o f  FF across the membrane, thus 
collapsing the electrochemical proton gradient. Oligomycin specifically blocks conduction 
o f  FT through Fo.
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The respiratory chain is a proton pump
According to Mitchell, the primary event in oxidative phosphorylation is 
the translocation of protons (H*) to the exterior of a coupling membrane (ie, 
the mitochondrial inner membrane), driven by oxidation in the respiratory 
chain. Each of the respiratory chain complexes III, IV, and I act as a proton 
pump. It is also postulated that the membrane is impermeable to ions in 
general but particularly to protons, which accumulate outside the membrane, 
creating an electrochemical potential difference across the membrane 
(Дц.н J. This consists of a chemical potential (difference in pH) and an 
electrical potential. The electrochemical potential difference is used to drive a 
membrane-located ATP synthase which in the presence of Pj + ADP forms 
ATP (Fig. 15). Thus, there is no high-energy intermediate that is common to 
both oxidation and phosphorylation as in the chemical hypothesis.
It was originally proposed that the respiratory chain was folded into 3 
oxidation/reduction (o/r) loops in the membrane.
Scattered over the surface of the inner membrane are the phosphorylating 
subunits responsible for the production of ATP. These consist of several 
proteins, collectively known as an F subunit, which project into the matrix and 
which contain the ATP synthase (Fig. 15). These subunits are attached, possi­
bly by a stalk, to a membrane protein subunit known as F0, which probably 
extends through the membrane (Fig. 15). Protons pass through the F0-F| 
complex, leading to the formation of ATP from ADP and Pi. It is of interest that 
similar phosphorylating units are found inside the plasma membrane of bacteria 
but outside the thylakoid membrane of chloroplasts. It is significant that the 
proton gradient is from outside to inside in mitochondria and bacteria but in 
the reverse direction in chloroplasts.
The mechanism of coupling of proton translocation to the anisotropic 
(vectorial) ATP synthase system is conjectural. A proton pair attacks one 
oxygen of P to form H2O and an active form of P which immediately 
combines with ADP to form ATP. Other studies have suggested that ATP 
synthesis is not the main energy-requiring step - rather it is the release of ATP 
from the active site. This may involve conformational changes in the F| 
subunit.
Experimental findings support the chemiosmotic theory
(1) Addition of protons (acid) to the external medium of mitochondria 
leads to the generation of ATP.
Oxidative phosphorylation does not occur in soluble systems where there is 
no possibility of a vectorial ATP synthase. A closed membrane must be present 
in order to obtain oxidative hosphorylation (Fig. 15).
Biologic oxidation.
The respiratory chain contains components organized in a sided manner 
(transverse asymmetry) as required by the chemiosmotic theory.
The chemiosmotic theory can account for the phenomenon of 
respiratory control
The electrochemical potential difference across the membrane, once 
established as result of proton translocation, inhibits further transport of 
reducing equivalents through the respiratory chain unless discharged by back- 
translocation of protons across the membrane through the vectorial ATP 
synthase. This in turn depends on availability of ADP and P,
It explains the action of uncouplers
These compounds (eg, dinitrophenol) are amphipathic and increase the 
permeability of mitochondria to protons (Fig. 15), thus reducing the 
electrochemical potential and short-circuiting the ATP synthase. Thus, 
oxidation can proceed without phosphorylation.
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COMMON OF WAYS OF CATABOLISM
I Citric acid cycle
1. Role
The citric acid cycle, also known as the TCA (tricarboxylic acid) 
cycle or Krebs cycle (after its discoverer in 1937) oxidizes acetyl-CoA 
formed from pyruvate (which formed during the glycolytic breakdown of 
glucose) to C 0 2 and H20 ,  with the concomitant production of energy.
Acetyl-CoA from fatty acid breakdown and amino acid degradation 
products are it also oxidized. In addition, the cycle has a role in producing 
precursors for many biosynthetic pathways.
2. Location
The citric acid cycle occurs within the mitochondria of eukaryotes 
and in the cytosol of prokaryotes. Succinate dehydrogenase, the only 
membrane-bound enzyme in the citric acid cycle, is embedded in the 
inner mitochondrial membrane in eukaryotes and in the plasma 
membrane in prokaryotes.
3. The cycle
The cycle forms the central part o f a three-step process, which 
oxidizes organic fuel molecules into C 0 2 with the concomitant 
production of ATP.
Step 1 - Oxidation offuel molecules to acetyl Co A
A major source o f energy is glucose, which is converted by glycolysis 
into pyruvate.
Pyruvate dehydrogenase (a complex o f three enzymes and five 
coenzymes) then oxidizes the pyruvate (using NAD+ which is reduced to 
NADH) to form acetyl-CoA and C 0 2. Since the reaction involves both 
an oxidation and a loss o f C 0 2, the process is called oxidative 
decarboxylation.
Step 2 - The citric acid cycle
The citric acid cycle carries out the oxidation o f acetyl groups from 
acetyl CoA to C 0 2 with the production o f four pairs o f electrons,
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stored initially in the reduced electron carriers NADH and FADH2
(Fig. 1).
Fig. 1. Tne citric acid cycle (reactions 1-8 are described in the text).
The cycle has eight stages:
1. Citrate (6C) is formed from the irreversible condensation of acetyl 
CoA (2C) and oxaloacetate (4C) - catalyzed by citrate synthase.
2. Citrate is converted to isocitrate (6C) by an isomerization 
catalyzed by aconitase. This is actually a two-step reaction during 
which сй -aconitate is formed as an intermediate.
3. Isocitrate is oxidized to a-ketoglutarate (5C) and CO2 by isocitrate 
dehydrogenase. This mitochondrial enzyme requires NAD+, which 
is reduced to NADH.
4. a-Ketoglutarate is oxidized to succinyl CoA (4C) and CO2 by the 
a-ketoglutarate dehydrogenase complex. Like pyruvate 
dehydrogenase, this is a complex o f three enzymes and uses 
NAD+ as a cofactor.
5. Succinyl CoA is converted to succinate (4C) by succinyl CoA 
synthetase. The reaction uses the energy released by cleavage of 
the succinyl-CoA bond to synthesize either GTP (mainly in
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animals) or ATP (exclusively in plants) from Pi, and, 
respectively, GDP or ADP.
6. Succinate is oxidized to fumarate (4C) by succinate 
dehydrogenase. FAD is tightly bound to the enzyme and is 
reduced to produce FADH2.
7. Fumarate is converted to malate (4C) by fumarase; this is a 
hydration reaction requiring the addition o f a water molecule.
8. Malate is oxidized to oxaloacetate (4C) by malate 
dehydrogenase. NAD+ is again required by the enzyme as a 
cofactor to accept the free pair of electrons and produce NADH.
Step 3 - Oxidation of NADH and FADH2 produced by the citric
acid cycle
The NADH and FADH2 produced by the citric acid cycle are 
reoxidized and the energy released is used to synthesize ATP by 
oxidative phosphorylation.
4. Energy yield
For each turn of the cycle, 12 ATP molecules are produced: one 
directly from the cycle and 11 from the re-oxidation of the three NADH 
and one FADH2 molecules produced by the cycle by oxidative 
phosphorylation.
Each of the three NADH molecules produced per turn of the cycle 
yields 3 ATPs and the single FADH2 yields 2 ATPs by oxidative 
phosphorylation (although some measurements indicate that the quantities 
are 2.5 and 1.5 respectively). One GTP (or ATP) is synthesized directly 
during the conversion of succinyl CoA to succinate. Thus the oxidation 
of a single molecule of glucose via the citric acid cycle produces 12 ATP 
molecules.
5. Regulation
The citric acid cycle is regulated at the steps catalyzed by citrate 
synthase, isocitrate dehydrogenase and a-ketoglutarate 
dehydrogenase via feedback inhibition by ATP, citrate, NADH and 
succinyl CoA, and stimulation of isocitrate dehydrogenase by ADP.
Pyruvate dehydrogenase, which converts pyruvate to acetyl CoA to 
enter the cycle, is inhibited by acetyl CoA and NADH. In addition, this 
enzyme is inactivated by phosphorylation, a reaction catalyzed by 
pyruvate dehydrogenase kinase. A high ratio of NADH/NAD+, acetyl 
CoA/CoA or ATP/ADP stimulates phosphorylation of pyruvate 
dehydrogenase and so inactivates this enzyme. Pyruvate inhibits the 
kinase. Removal of the phosphate group (dephosphorylation) by a 
phosphatase reactivates pyruvate dehydrogenase.
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Regulation of the cycle is governed by substrate availability, 
inhibition by accumulating products, and allosteric feedback inhibition by 
subsequent intermediates in the cycle. Three enzymes in the cycle itself 
are regulated (citrate synthase, isocitrate dehydrogenase and a- 
ketoglutarate dehydrogenase) and so is the enzyme, which converts 
pyruvate to acetyl CoA to enter the cycle, namely pyruvate dehydrogenase 
(Fig. 2) :
мыыавуАТР, 
ocetyfCoA and 
NADH
inhibited by j
stxxinyiCoA J  
andNADH J r
Succinate <
GTP
Fig. 2. Regulation points o f  the citric acid cycle
1. citrate synthase is inhibited by citrate and also by ATP (the Km for 
acetyl CoA is raised as the level of ATP rises);
2. isocitrate dehydrogenase is inhibited by NADH and ATP but 
activated by ADP;
3. a-ketoglutarate dehydrogenase is inhibited by NADH and succinyl
CoA;
4. pyruvate dehydrogenase is inhibited by NADH and acetyl CoA 
(i.e. product inhibition).
However, in eukaryotes the enzyme is also controlled by 
phosphorylation/dephosphorylation via pyruvate dehydrogenase 
kinase and a phosphatase. The kinase catalyzes the phosphorylation of a 
specific Ser residue in pyruvate dehydrogenase, using ATP as the 
phosphate donor, and this inactivates the enzyme. Removal of the 
phosphate group by the phosphatase reactivates the enzyme. At any one 
time, the activity of pyruvate dehydrogenase is determined by the relative 
balance between the kinase and phosphatase reactions. Increasing the 
NADH/NAD+, acetyl CoA/CoA or ATP/ADP ratio stimulates 
phosphorylation and hence inactivates pyruvate dehydrogenase. As 
pyruvate builds up, it inhibits the kinase and hence allows the phosphatase
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to reactivate pyruvate dehydrogenase, thus stimulating pyruvate 
conversion to acetyl CoA.
Overall, the cycle speeds up when cellular energy levels are low (high 
ADP concentration, low ATP and NADH) and slows down as ATP (and 
then NADH2, succinyl CoA and citrate) accumulates.
6. Biosynthetic pathways
The intermediates in the cycle provide precursors for many 
biosynthetic pathways.
For example:
1. synthesis of fatty acids from citrate;
2. amino acid synthesis following transamination of a-ketoglutarate;
3. synthesis of purine and pyrimidine nucleotides from a- 
ketoglutarate and oxaloacetate;
4. oxaloacetate can be converted to glucose by gluconeogenesis;
5. succinyl CoA is a central intermediate in the synthesis of the 
porphyrin ring of heme groups.
II The oxidation of pyruvate to acetyl-CoA
Before pyruvate can enter the citric acid cycle, it must be transported 
into the mitochondrion via a special pyruvate transporter that aids its 
passage across the inner mitochondrial membrane. This involves a symport 
mechanism whereby one proton is cotransported.
Within the mitochondrion, pyruvate is oxidatively decarboxylated to 
acetyl-CoA. Several different enzymes working sequentially in a 
multienzyme complex catalyze this reaction. They are collectively 
designated as the pyruvate dehydrogenase complex and are analogous to 
the a-ketoglutarate dehydrogenase complex of the citric acid cycle.
Pyruvate is decarboxylated to a hydroxyethyl derivative of the thiazole 
ring of enzyme-bound thiamin diphosphate, which in turn reacts with 
oxidized lipoamide to form acetyl lipoamide (Fig 3). In the presence of 
dihydrolipoyl transacetylase, acetyl lipoamide reacts with coenzyme- A 
to form acetyl-CoA and reduced lipoamide.
The cycle of reaction is completed when the latter is reoxidized by a 
flavoprotein in the presence of dihydrolipoyl dehydrogenase. Finally, the 
reduced flavoprotein is oxidized by NAD, which in turn transfers reducing 
equivalents to the respiratory chain.
Pyruvate + NAD* + CoA ----> Acetyl-CoA + NADH + H+ + C 0 2
The pyruvate hydrogenase complex consists of a number of polypeptide 
chains of each of the 3 component enzymes, all organized in a regular spatial
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configuration. Movement of the individual enzymes appears to be restricted, 
and the metabolic intermediates do not dissociate freely but remain bound to 
the enzymes. Such a complex of enzymes, in which the substrates are handed 
on from one enzyme to the next, increases the reaction rate and eliminates side 
reactions, increasing overall efficiency.
It is to be noted that the pyruvate dehydrogenase system is sufficiently 
electronegative with respect to the respiratory chain that, in addition to 
generating a reduced coenzyme (NADH), it also generates a high-energy 
thioester bond in acetyl-CoA.
Fig.3. A: Oxidative decarboxylation o f  pyruvate by the pyruvate dehydrogenase 
complex. B: Lipoic acid. Lipoic acid is joined by an amide link to a lysine residue o f the 
transacetylase component o f  the enzyme complex.
1. Pyruvate dehydrogenase is regulated by end-product inhibition and 
covalent modification
Pyruvate dehydrogenase is inhibited by its products, acetyl-CoA and 
NADH (Fig 4). It is also regulated by phosphorylation involving an ATP- 
specific kinase that causes a decrease in activity, and by dephosphorylation by 
a phosphatase that causes an increase in activity of the dehydrogenase. The 
kinase is activated by increases in the acetyl-CoA / CoA, NADH / NAD+, 
or ATP/ADP ratios.
Thus, pyruvate dehydrogenase - and therefore glycolysis - is inhibited 
not only by a high energy potential, but also under conditions of fatty 
acid oxidation, which leads to increases in these ratios.
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In starvation, there is a decrease in the proportion of the enzyme in the
active form, and an increase in activity occurs after administration of insulin 
in adipose tissue but not in the liver.
Fig. 4. Regulation o f  pyruvate dehydrogenase (PDH). Arrows with wavy shafts 
indicate allosteric effects. A: Regulation by end-product inhibition. B: Regulation by 
interconversion o f  active and inactive forms.
2. Inhibition of pyruvate metabolism leads to lactacidosis
Arsenite or mercuric ions complex the — SH groups of lipoic acid and 
inhibit pyruvate dehydrogenase, as does a dietary deficiency of thiamin, 
allowing pyruvate to accumulate. Nutritionally deprived alcoholics are 
thiamin deficient and if administered glucose exhibit rapid accumulation of 
pyruvate and lactacidosis, which is frequently lethal.
Patients with inherited pyruvate dehydrogenase deficiency present with a 
similar lactacidosis, particularly after glucose load. Mutations have been 
reported for virtually all of the enzymes of carbohydrate metabolism, each 
associated with human disease. Inherited aldolase A deficiency and pyruvate 
kinase deficiency in erythrocytes cause hemolytic anemia.
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GLYCOLYSIS
The pathway
Glycolysis is a set of reactions that take place in the cytoplasm of 
prokaryotes and eukaryotes.
The roles of glycolysis are:
1. to produce energy (both directly and by supplying substrate for 
the citric acid cycle and oxidative phosphorylation)
2. to produce intermediates for biosynthetic pathways.
Glucose is phosphorylated to glucose 6-phosphate (by hexokinase), 
which is converted to fructose 6-phosphate (by phosphoglucoisomerase) 
and then to fructose 1,6-bisphosphate (by phosphofructokinase, PFK).
The fructose 1,6-bisphosphate is split into glyceraldehyde 3-phosphate 
and dihydroxyacetone phosphate (by aldolase) and these two trioses are 
interconverted by triose phosphate isomerase.
Glyceraldehyde 3-phosphate is converted to 1,3-bisphosphoglycerate 
(by glyceraldehyde 3-phosphate dehydrogenase), which reacts with ADP to 
give 3-phosphoglycerate and ATP (catalyzed by phosphoglycerate 
kinase).
The 3-phosphoglycerate is converted to 2-phosphoglycerate (by 
phosphoglycerate mutase) and then to phosphoenolpyruvate (PEP) by 
enolase.
Finally, PEP and ADP react to form pyruvate and ATP (catalyzed by 
pyruvate kinase).
Under aerobic conditions, pyruvate can be converted by pyruvate 
dehydrogenase to acetyl coenzyme A (CoA), which can then enter the 
citric acid cycle.
Under anaerobic conditions, pyruvate is converted to lactate by lactate 
dehydrogenase (LDH). The NAD+ regenerated by this reaction allows 
glycolysis to continue, despite the lack of oxygen. When oxygen becomes 
available, the lactate is converted back to pyruvate. In anaerobic conditions, 
yeast and other organisms carry out alcoholic fermentation that converts 
pyruvate to acetaldehyde and then to ethanol, regenerating N AD+ that 
allows glycolysis to continue.
Two ATPs are used in glycolysis and four ATPs are synthesized for 
each molecule of glucose so that the net yield is two ATPs per glucose. 
Under aerobic conditions, the two NADH molecules arising from glycolysis 
also yield energy via oxidative phosphorylation.
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Regulation of glycolysis
The main control step is that catalyzed by PFK but hexokinase and 
pyruvate kinase are additional control sites.
PFK is allosterically inhibited by ATP, but this inhibition is relieved by 
AMP.
Citrate also inhibits PFK.
The build up of fructose 6-phosphate stimulates the formation of 
fructose 2,6-bisphosphate that in turn stimulates PFK. The enzyme that 
synthesizes fructose 2,6-bisphosphate (phosphofructokinase 2; PFK2) and 
the enzyme that hydrolyzes it back to fructose 6-phosphate (fructose 
bisphosphatase 2; FBPase 2) are also regulated hormonally by glucagon 
that causes glycolysis to slow down when the blood glucose level falls.
PFK is also inhibited by H+ ions, thus preventing excessive formation of 
lactate under anaerobic conditions.
Hexokinase is inhibited by glucose 6-phosphate, which builds up after 
PFK is inhibited. Pyruvate kinase is activated by fructose 1,6-bisphosphate 
but allosterically inhibited by ATP and alanine. Like PFK, it is also 
regulated hormonally by glucagon.
1. The pathway
Glycolysis is a series of reactions (Fig. 1) that takes place in the 
cytoplasm of all prokaryotes and eukaryotes.
Glycolysis converts one molecule of glucose into two molecules of 
pyruvate (which are then converted to acetyl coenzyme A (CoA) ready 
for entry into the citric acid cycle).
Two ATP molecules are needed for early reactions in the glycolytic 
pathway but four ATPs are generated later, giving a net yield of two ATPs 
per molecule of glucose degraded.
Overall, glycolysis has a dual role.
The first is to generate ATP. Although only two ATPs per glucose are 
made directly from the reactions of the glycolytic pathway, it also feeds 
substrates into the citric acid cycle and oxidative phosphorylation, where 
most ATP is made.
The second role is to produce intermediates that act as precursors for 
a number o f biosynthetic pathways. Thus acetyl CoA, for example, is the 
precursor for fatty acid synthesis.
Glycolysis.
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Fig ! Reactions o f glycolysis.
The individual steps in glycolysis
1. Glucose is phosphorylated by ATP to form glucose 6-phosphate and 
ADP. The reaction is catalyzed by the enzyme hexokinase.
C H 2O H
Sbj H  H exokinase ♦ A T P , M g2* O H  -A D P
c h 2o p o 3h 2 
H
H O H
G lucose
H  H
O H
H O H H
G lucose -6 -p h o sp h a te
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2. Glucose-6-phosphate is converted to fructose-6-phosphate by 
phosphoglucoisomerase.
c h 2o p o 3h 2
' - ° x  H Ph, : " co* ' CH2OH
OH
H OH 
G lucose -6 -p h o sp h a te
H
H
OH
O H
F ru c to se-6 -phospha te
3. Fructose-6-phosphate is phosphorylated by ATP to form fructose-1,6 
bisphosphate and ADP. The enzyme catalyzing this step is 
phosphofructokinase (PFK).
F ru c to se -6 -p h o sp h a te  F ru c to se -1 ,6  b isp h o sp h a te
4. Aldolase splits fructose-1,6-bisphosphate (a six-carbon molecule) 
into two three-carbon molecules, glyceraldehydes-3-phosphate and 
dihydroxyacetone phosphate.
CH20 P 0 3H2 c h 2o p o 3h 2
H OH
ОН н  
F ruc to se-1 ,6  b isp h o sp h a te
H  Q
Ald o la se  C H 20 P 0 3H 2 ( f
--------------  ^  c=o + H  сон
C H 2O H  c h 2o p o 3h 2
D ih y d roxyace tone  G lycera ldehydes-3 - 
p h o sp h a te  ph o sp h a te
5. Glyceraldehyde-3-phosphate is the only molecule that can be used 
for the rest of glycolysis. However, the dihydroxyacetone phosphate 
formed in the previous step can rapidly be converted to 
glyceraldehydes-3-phosphate by triose phosphate isomerase. This is 
an equilibrium reaction; as the glyceraldehydes-3-phosphate is used by 
the rest of glycolysis, more dihydroxyacetone phosphate is converted to 
glyceraldehydes-3-phosphate as replacement. Thus effectively, for each 
molecule of fructose 1,6-bisphosphate that is cleaved in step 4, two 
molecules o f glyceraldehyde 3-phosphate continue down the 
pathway
c h 2o p o 3h 2 
c=°
CH2OH
D ih y d ro x y ace to n e  p h o sp h a te
Trio s e  phosphate 
Isom erase V
C O H
c h 2o p o 3h 2
G ly c e ra ld eh y d e -3 -p h o sp h a te
6. Glyceraldehyde-3-phosphate is converted to 1,3 
bisphosphoglycerate. The reaction is catalyzed by glyceraldehydes-3-
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phosphate dehydrogenase and uses inorganic phosphate and NAD+. 
The other product is NADH. The energy for creating this new high- 
energy phosphate bond comes from oxidation o f the aldehyde group 
of the glyceraldehydes-3-phosphate.
G lyce ra lde h yd e s -3 -p h o sp h a te  
D ehydro genase
Н Ч О ♦ 2NAD*+2PI
,  V „
2 O H  -2NADH+H+
c h 2o p o 3h 2
'c-o -  p o 3h 2 
2 h | : o h
c h 2o p o 3h 2
G ly c e ra ld eh y d e -3 -p h o sp h a te  1 ,3-B isphosphogly  ce ra te
7. The newly created high-energy phosphate bond of 1,3- 
bisphosphoglycerate is now used to synthesize ATP.
Phosphoglycerate kinase catalyzes the transfer of the phosphoryl 
group from the 1,3-bisphosphoglycerate to ADP, generating ATP and 
3-phosphoglycerate.
q  P ho sp h o glycerate
\\ л  . .  K inase
C - O  -  P 0 3H 2 +2ADP C O O H
2 H C  O H  2 H C  O H1 -2ATP «
c h 2o p o 3h 2 c h 2o p o 3h 2
1 ,3 -B isphosphog ly  c e ra te  3 -P hosphog ly  c e ra te
8. 3-Phosphoglycerate is converted to 2-phosphoglycerate by 
phosphoglyceratemutase. Thus the reaction is a movement of the 
phosphate group to a different carbon atom within the same molecule.
2
C O O H  
H C O H
C H 20 P O 3H 2
P ho s ph o g ly  cerate 
M utase C O O H
2 h c - o - p o 3h 2 
C H ,O H
3 -P h o sp h o g ly ce ra te  2 -p h o sp h o g ly ce ra te
9. Enolase catalyzes the dehydration of 2-phosphoglycerate to form 
phosphoenolpyruvate (PEP). This reaction converts the low-energy 
phosphate ester bond of 2-phosphoglycerate into the high-energy 
phosphate bond of PEP.
C O O H  Enolase C O O H
2 H C - 0 - P 0 3H 2 — — - d b . 2 C-o -  P 0 3H 2
C H 2O H  2°  C H 2
2-P h o sp h o g ly cera te P h o sp h o e n o lp y ru v a te
10 In the last reaction, pyruvate kinase catalyzes the physiologically 
irreversible transfer of the phosphoryl group from PEP to ADP to form 
ATP and pyruvate.
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C H 2
P h o sp h o e n o lp y ru v a te
Pyru vate  kinase 
♦ 2A D P  + H*
-2 A  TP
C O O H  
2 £=0 
C H 3
P y ru v a te
Substrate-level phosphorylation 
There are two distinct methods by which cells synthesize ATP.
In oxidative phosphorylation, involving the electron transport chain, 
the generation of ATP is linked to the oxidation of NADH and FADH2 to 
NAD+ and FAD respectively, and occurs via the generation of a proton 
gradient across the inner mitochondrial membrane.
In contrast, the two ATP synthetic reactions in glycolysis (catalyzed by 
phosphoglycerate kinase and pyruvate kinase) involve the direct transfer of 
a phosphate from a sugar-phosphate intermediate to ADP; these reactions 
are examples o f substrate-level phosphorylation.
A third example of substrate-level phosphorylation is the synthesis of 
GTP by succinate dehydrogenase in the citric acid cycle. The GTP can be 
used to phosphorylate ADP to form ATP.
2. Fates of pyruvate 
Entry into the citric acid cycle.
Glycolysis releases relatively little o f the energy present in a glucose 
molecule; much more is released by the subsequent operation of the 
citric acid cycle and oxidative phosphorylation.
Following this route under aerobic conditions, pyruvate is converted to 
acetyl CoA by the enzyme pyruvate dehydrogenase and the acetyl CoA 
then enters the citric acid cycle. The pyruvate dehydrogenase reaction is an 
oxidative decarboxylation:
Pyruvatedehydrogenase
pyruvate + NAD+ + CoA -----------------►acetyl CoA + C 02 + NADH
Conversion to fatty acid or ketone bodies.
When the cellular energy level is high (ATP in excess), the rate of the 
citric acid cycle decreases and acetyl CoA begins to accumulate. Under 
these conditions, acetyl CoA can be used for fatty acid synthesis or the 
synthesis of ketone bodies.
Conversion to lactate.
The NAD+ used during glycolysis (in the formation of 1,3- 
bisphosphoglycerate by gIyceraldehydes-3-phosphate dehydrogenase; Fig. 
1) must be regenerated if glycolysis is to continue. Under aerobic condi­
tions, NAD+ is regenerated by the reoxidation of NADH via the electron
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transport chain. When oxygen is limiting, as in muscle during vigorous 
contraction, the reoxidation of NADH to NAD+ by the electron transport 
chain becomes insufficient to maintain glycolysis. Under these conditions, 
NAD+ is regenerated instead by conversion of the pyruvate to lactate by 
lactate dehydrogenase:
Lactate dehydrogenase
pyruvate + NADH + H+ * lactate + NAD+
When sufficient oxygen becomes available once more, NAD+ levels 
rise through operation of the electron transport chain. The lactate 
dehydrogenase reaction then reverses to regenerate pyruvate that is 
converted by pyruvate dehydrogenase to acetyl CoA which can enter the 
citric acid cycle.
Thus the operation of lactate dehydrogenase in mammals is a 
mechanism for the reoxidation of NADH to NAD+ hence allowing 
glycolysis to continue, and ATP to be made, under anaerobic conditions. 
The process is even more sophisticated in the case of vigorously 
contracting skeletal muscle. Here the lactate produced is transported in the 
bloodstream to the liver where it is converted back to glucose and can 
return once again via the bloodstream to the skeletal muscle to be 
metabolized to yield energy. This is the Cori cycle.
Finally, in some microorganisms, lactate is the normal product from 
pyruvate.
Conversion to ethanoL
In yeast and some other microorganisms under anaerobic conditions, the 
NAD+ required for the continuation of glycolysis is regenerated by a 
process called alcoholic fermentation. The pyruvate is converted to 
acetaldehyde (by pyruvate decarboxylase) and then to ethanol (by alcohol 
dehydrogenase), the latter reaction reoxidizing the NADH to NAD+: 
Pyruvatedecarboxylase
pyruvate + H+ * acetaldehyde + CO2
Alcohol dehydrogenase
acetaldehyde + NADH + H+ -------------------*■ ethanol+ NAD+
3. Energy yield
Early in glycolysis, two ATPs are required for the conversion of 
glucose to glucose-6-phosphate by hexokinase and for the conversion of 
fructose-6-phosphate to fructose 1,6-bisphosphate by PFK. However, 
fructose 1,6-bisphosphate then gives rise to two three-carbon units, each of 
which generates two ATPs in subsequent steps (catalyzed by
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phosphogiycerate kinase and pyruvate kinase) giving a net yield of two 
ATPs per original glucose molecule 
The overall reaction is:
Glucose + 2 Pj + 2 ADP + 2 NAD+ ------ ►
2 pyruvate+ 2 ATP + 2 NADH +2 PT + 2 H20
Note that, under aerobic conditions, the two NADH molecules that are 
synthesized are reoxidized via the electron transport chain generating 
ATP. Given the cytoplasmic location of these NADH molecules, each is 
reoxidized via the glycerol 3-phosphate shuttle and produces 
approximately two ATPs during oxidative phosphorylation or via the 
malate-aspartate shuttle and produces approximately three ATPs during 
oxidative phosphorylation.
Gluconeogenesis, pentose phosphate pathway.
Lecture 12
GLUCONEOGENESIS, PENTOSE 
PHOSPHATE PATHWAY
I. GLUCONEOGENESIS
1. Overview
Gluconeogenesis synthesizes glucose from noncarbohydrate precursors 
and is important for the maintenance of blood glucose levels during 
starvation or during vigorous exercise. The brain and erythrocytes depend 
almost entirely on blood glucose as an energy source. Gluconeogenesis 
occurs mainly in the liver and to a lesser extent in the kidney. Most 
enzymes of gluconeogenesis are cytosolic, but pyruvate carboxylase and 
glucose-6-phosphatase are located in the mitochondrial matrix and bound 
to the smooth endoplasmic reticulum.
2. The pathway
Pyruvate is converted to oxaloacetate (by pyruvate
carboxylase). The oxaloacetate is decarboxylated and phosphorylated to 
phosphoenolpyruvate (PEP) by phosphoenolpyruvate carboxykinase (PEP 
carboxykinase). PEP is converted to fructose 1,6-bisphosphate by a direct 
reversal of several reactions in glycolysis. Next, fructose 1,6-bisphosphate 
is dephosphorylated to fructose-6-phosphate (by fructose 1,6-
bisphosphatase) and this is then converted to glucose 6-phosphate (by 
phosphoglucoisomerase). Finally, glucose 6- phosphate is
dephosphorylated (by glucose 6-phosphatase) to yield glucose.
Gluconeogenesis synthesizes glucose from noncarbohydrate 
precursors, including lactate and pyruvate, citric acid cycle intermediates, 
the carbon skeletons of most amino acids and glycerol. This is extremely 
important since the brain and erythrocytes rely almost exclusively on 
glucose as their energy source under normal conditions. The liver's store 
of glycogen is sufficient to supply the brain with glucose for only about 
half a day during fasting. Thus gluconeogenesis is especially important in 
periods of starvation or vigorous exercise. During starvation, the formation 
of glucose via gluconeogenesis particularly uses amino acids from protein 
breakdown and glycerol from fat breakdown. During exercise, the blood 
glucose levels required for brain and skeletal muscle function are
101
Lecture 12
maintained by giuconeogenesis in the liver using lactate produced by the 
muscle.
The main site of giuconeogenesis is the liver, although it also occurs to 
a far lesser extent in the kidneys. Very little giuconeogenesis occurs in 
brain or muscle. Within liver cells, the first enzyme of giuconeogenesis, 
pyruvate carboxylase, is located in the mitochondrial matrix. The last 
enzyme, glucose-6-phosphatase is bound to the smooth endoplasmic 
reticulum. The other enzymes o f the pathway are located in the cytosol.
In glycolysis, glucose is metabolized to pyruvate. In giuconeogenesis, 
pyruvate is metabolized to glucose. Thus, in principle, giuconeogenesis 
appears to be a reversal of glycolysis. Indeed, some of the reactions of 
glycolysis are reversible and so the two pathways have these steps in 
common.
However, three steps in glycolysis are essentially irreversible; those 
catalyzed by the enzymes hexokinase, phosphofructokinase (PFK) and 
pyruvate kinase. Indeed it is the large negative free-energy change in these 
reactions that normally drives glycolysis forward towards pyruvate 
formation. Therefore, in giuconeogenesis, these three steps have to be 
reversed by using other reactions as shown in Fig. 1; giuconeogenesis is 
not a simple reversal of glycolysis.
Precursors fo r  giuconeogenesis
Glycerol can act as a substrate for glucose synthesis by conversion to 
dihydroxyacetone phosphate, an intermediate in giuconeogenesis (Fig. I). 
In order for lactate, pyruvate, citric acid cycle intermediates and the 
carbon skeletons of most amino acids to act as precursors for 
giuconeogenesis, these compounds must first be converted to 
oxaloacetate. Some of the carbon skeletons of the amino acids give rise to 
oxaloacetate directly. Others feed into the citric acid cycle as
intermediates and the cycle then converts these molecules to oxaloacetate. 
Lactate is converted to pyruvate by the lactate dehydrogenase reaction and 
some amino acids also give rise to pyruvate. Therefore, for these 
precursors, the first step in the gluconeogenic pathway is the conversion of 
pyruvate to oxaloacetate.
The steps in giuconeogenesis (Fig. 1) are as follows:
1. Pyruvate is converted to oxaloacetate by carboxylation using the 
enzyme pyruvate carboxylase that is located in the mitochondrial matrix.
C O O ' P y ru v a te  C O O '
I c a rb o x y la s e  I
C = 0  +  C 0 2 +  A T P ------------------------> C =  О  +  A D P +  P,
1 1
C H 2 
I
C H 3
P y ru v a te COO'
Oxaloacetate
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This enzyme uses biotin as an activated carrier of C 0 2, the reaction 
occurring in two stages:
E-biotin + ATP + HC03'— —> E-biotin-CO, + ADP + P, 
E-biotin-C02 + pyruvate------> E-biotin + oxaloacetate
Hew*»»
Phosphofivciakinese
Glucose
®
GSucose 6 -o ^o sp n a ie
GlUCOCO^NESS
oe&phiitosQ
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Fructose 6 -p ho 80h ate
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PhoephoeneJpyruvate
A7P  +  C 0 2
Fig. 1. Comparison o f gluconeogenesis and g /yco /ys/s . The three steps o f  glycolysis that
are irreversible are numbered. (1) Hexokinase in glycolysis is reversed by glucose 6- 
phosphatase in gluconeogenesis; (2) PFK in glycolysis is reversed by fructose 1,6- 
bisphosphatase in gluconeogenesis; (3) pyruvate kinase in glycolysis is reversed by two 
sequential reactions in gluconeogenesis catalyzed by pyruvate carboxylase and PEP 
carboxykinase.
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2. The oxaloacetate is now acted on by phosphoenolpyruvate 
carboxykinase
which simultaneously decarboxylates and phosphorylates it to form 
phosphoenolpyruvate (PEP), releasing C 02 and using GTP in the 
process:
C O O '
I
Г 0
f H
C O O '
P h o sp h o e n o lp y ru v a te
c a rb o x y k in a se
+  G T P  •» ----- -----------------
<pOO'
O -
C H 2
?
Ij5 — O' + GDP + C02 
O'
O x a lo ace ta te P h o sp h o en o lp y ru v  ate
Thus, reversal of the glycolytic step from PEP to py ruvate requires two 
reactions in gluconeogenesis, pyruvate to oxaloacetate by pyruvate 
carboxylase and oxaloacetate to PEP by PEP carboxykinase. Given that 
the conversion of PEP to pyruvate in glycolysis synthesizes ATP, it is not 
surprising that the overall reversal of this step needs the input of a 
substantial amount of energy, one ATP for the pyruvate carboxylase step 
and one GTP for the PEP carboxykinase step.
3. PEP is converted to fructose 1,6-bisphosphate in a series of steps 
that are a direct reversal of those in glycolysis, using the enzymes 
enolase, phosphoglycerate mutase, phosphoglycerate kinase, 
glyceraldehydes-3-phosphate dehydrogenase, triose-phosphate isomerase 
and aldolase. This sequence o f reactions uses one ATP and one NADH 
for each PEP molecule metabolized.
4. Fructose-1,6-bisphosphate is dephosphorylated to form fructose-e- 
phosphate by the enzyme fructose 1,6-bisphosphatase in the reaction:
fructose 1,6-bisphosphate + H20  fructose 6-phosphate + Pi
5. Fructose 6-phosphate is converted to glucose 6-phosphate by the 
glycolytic enzyme phosphoglucoisomerase.
fructose 6-phosphate < glucose 6-phosphate
6. Glucose 6-phosphate is converted to glucose by the enzyme glucose- 
6-phos-phatase. This enzyme is bound to the smooth endoplasmic 
reticulum and catalyzes the reaction:
glucose 6-phosphate + H20  ~ > glucose + P,
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Energy used
The synthesis of one molecule of glucose from two molecules of 
pyruvate requires six molecules of ATP.
As would be expected, the synthesis of glucose by gluconeogenesis 
needs the input of energy. Two pyruvate molecules are required to 
synthesize one molecule of glucose. Energy is required at the following 
steps:
pyruvate carboxylase 1 ATP (x 2) = 2 ATP 
PEP carboxykinase 1 GTP ( x 2) = 2 ATP
phosphoglycerate kinase 1 ATP (x 2) = 2 ATP
Total = 6 ATP
This compares with only two ATPs as the net ATP yield from 
glycolysis. Thus extra four ATPs per glucose are required to reverse 
glycolysis.
In fact, the glyceraldehydes-3-phosphate dehydrogenase reaction 
also consumes NADH, equivalent to two molecules of NADH for each 
molecule of glucose synthesized.
Since each cytosolic NADH would normally be used to generate 
approximately two ATP molecules via the glyceroi-3-phosphate shuttle and 
oxidative phosphorylation, this is equivalent to the input of another four 
ATPs per glucose synthesized.
4. Transport of oxaloacetate
Pyruvate carboxylase is a mitochondrial matrix enzyme whereas the 
other enzymes o f gluconeogenesis are located outside the 
mitochondrion.
Thus oxaloacetate, produced by pyruvate carboxylase, needs to exit the 
mitochondrion. Oxaloacetate, the product of the first steps in 
gluconeogenesis, must leave the mitochondrion and enter the cytosol 
where the subsequent enzyme steps take place.
Since the inner mitochondrial membrane is impermeable to 
oxaloacetate, it is converted to malate inside the mitochondrion by 
mitochondrial malate dehydrogenase. The malate is transported through 
the mitochondrial membrane by a special transport protein and then the 
malate is converted back to oxaloacetate in the cytosol by cytoplasmic 
malate dehydrogenase (Fig. 2).
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Fig. 2. Transport o f  oxaloacatate out o f  the mitochondrion.
5. Pyruvate carboxylase activation
Oxaloacetate has two main roles. Oxaloacetate, the product of the 
pyruvate carboxylase reaction, functions both as an im portant citric acid 
cycle intermediate in the oxidation of acetyl CoA and as a precursor for 
gluconeogenesis.
It is an intermediate that is consumed in gluconeogenesis and it is also 
a key intermediate in the citric acid cycle where it fuses with acetyl CoA 
to form citrate, eventually being regenerated by the cycle. Thus pyruvate 
carboxylase generates oxaloacetate for gluconeogenesis but also must 
maintain oxaloacetate levels for citric acid cycle function.
For the latter reason, the activity of pyruvate carboxylase depends 
absolutely on the presence of acetyl CoA, so that more oxaloacetate is 
made when acetyl CoA levels rise; the biotin prosthetic group of the 
enzyme cannot be carboxylated unless acetyl CoA is bound to the enzyme.
This allosteric activation by acetyl CoA ensures that more oxaloacetate 
is made when excess acetyl CoA is present. In this role of maintaining the 
level o f citric acid cycle intermediates, the pyruvate carboxylase reaction 
is said to be anaplerotic that is 'filling up'.
Gluconeogenesis, pentose phosphate pathway.
6. Reciprocal regulation of glycolysis and gluconeogenesis
If glycolysis and gluconeogenesis operated simultaneously, the net 
effect would be a futile cycle resulting in the hydrolysis of two ATP and 
two GTP molecules.
This is prevented by reciprocal regulation at the enzyme steps that are 
distinct in each pathway. AMP activates phosphofructokinase (PFK) 
(glycolysis) but inhibits fructose-1,6-bisphosphatase (gluconeogenesis).
ATP and citrate inhibit PFK but citrate stimulates fructose 1,6- 
bisphosphatase.
Glycolysis and gluconeogenesis are also responsive to starvation 
conditions via the concentration of fructose-2,6-bisphosphate (F-2,6-BP). 
During starvation, glucagon is released into the bloodstream and inhibits 
the synthesis of F-2,6-BP. In the fed state, insulin is released into the 
bloodstream and causes the accumulation of F-2,6-BP. Since F-2.6-BP 
activates PFK and inhibits fructose-1,6-bisphosphatase, glycolysis is 
stimulated and gluconeogenesis is inhibited in the fed animal and vice 
versa, during starvation.
In liver, ATP and alanine inhibit pyruvate kinase (glycolysis) whilst 
ADP inhibits pyruvate carboxylase and PEP carboxykinase 
(gluconeogenesis).
Thus glycolysis is inhibited in times when ATP and biosynthetic 
intermediates are in excess whilst gluconeogenesis is inhibited in times 
when the ATP level is low (and ADP is high).
Pyruvate kinase is also stimulated by fructose-1,6-bisphosphate so its 
rate increases when glycolysis is active. During starvation, glycogen 
secretion into the bloodstream activates a cAMP cascade that leads to the 
phosphorylation and inhibition o f pyruvate kinase (glycolysis).
7. The Cori cycle
During vigorous exercise, pyruvate produced by glycolysis in muscle 
is converted to lactate by lactate dehydrogenase. The lactate diffuses into 
the bloodstream and is carried to the liver. Here it is converted to glucose 
by gluconeogenesis. The glucose is released into the bloodstream and 
becomes available for uptake by muscle (as well as other tissues, including 
brain). This cycle of reactions is called the Cori cycle.
Under the limiting oxygen conditions experienced during vigorous 
exercise, the formation of NADH by glycolysis exceeds the ability of the 
respiratory chain to oxidize it back to NAD+. The pyruvate produced by 
glycolysis in muscle is then converted to lactate by lactate dehydrogenase, 
a reaction that regenerates NADT and so allows glycolysis to continue to 
produce ATP. However, lactate is a metabolic dead-end in that it cannot
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be metabolized further until it is converted back to pyruvate. Lactate 
diffuses out of the muscle and is carried in the bloodstream to the liver. 
Here it diffuses into liver cells and is converted back to pyruvate by 
lactate dehydrogenase. The pyruvate is then converted to glucose by 
gluconeogenesis and the glucose is released back into the bloodstream 
ready to be taken up by skeletal muscle (and brain). This cycle of reactions 
(Fig. 3) is called the Cori cycle.
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QKjcose ----- ---- ► Glucose
. \
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Pyruvate blood Pyruvate
I NADH + H*
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Fig.3. The Cori cycle.
II. PEN TO SE PH O SPH A TE PATHW AY
1. Overview
The two major products of the pathway are nicotinamide adenine 
dinucleotide (reduced form- NADPH) and ribose-5-phosphate.
Reducing power is available in a cell both as NADH and NADPH but 
these have quite distinct roles.
NADH is oxidized by the respiratory chain to generate ATP via 
oxidative phosphorylation. NADPH is used for biosynthetic reactions that 
require reducing power. Despite their similar structures, NADH and 
NADPH are not metabolically interchangeable and so the cell must carry 
out a set of reactions that specifically create NADPH.
This set of reactions is the pentose phosphate pathway (also known 
as the hexose monophosphate shunt or the phosphogluconate 
pathway).
NADPH is required for many biosynthetic pathways and particularly 
for synthesis of fatty acids and steroids.
Hence the pathway takes place in the cytosol and is particularly 
important and very active in tissues such as adipose tissue, mammary 
gland and the adrenal cortex that synthesizes fatty acids and steroids from 
acetyl CoA.
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The activity of the pathway is very low in skeletal muscle, for example, 
which does not synthesize fatty acids or steroids. The core set of reactions 
of the pathway oxidize glucose-6-phosphate to ribose-5-phosphate and 
generate NADPH.
Thus, as well as generating NADPH, the pathway has a second 
important role in converting hexoses into pentoses, in particular ribose-5- 
phosphate.
Ribose-5-phosphate and its derivatives are components of important 
cellular molecules such as RNA, DNA, NAD+, flavine adenine 
dinucleotide (FAD), ATP and coenzyme A (CoA) and other important
molecules.
2. Main reactions of the pathway
The core reactions of the pathway can be summarized as:
Glucose-6-phosphate + 2NADP+—>
ribose-5-phosphate + 2NADPH + 2H+ + C 0 2 
The pathway has three stages:
Stage 1 - Oxidative reactions that convert glucose-6-phosphate into 
ribulose-5-phosphate, generating two NADPH molecules
Glucose-6-phosphate is oxidized by gIucose-6-phosphate 
dehydrogenase to 6-phosphogIucono-8-lactone (producing NADPH) and 
this is then hydrolyzed by lactonase to 6-phosphogluconate.
The 6-phosphogluconate is subsequently converted by 6- 
phosphogluconate dehydrogenase to ribulose-5-phosphate. This is an 
oxidative decarboxylation (i.e. the 6-phosphogluconate is oxidized and a 
carbon is removed as C 0 2).
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Stage 2 - Isomerization of ribulose-5-phosphate to ribose-5- 
phosphate and xylulose-5-phosphate
The ribulose-5-phosphate is now converted to ribose-5-phosphate
by isomerization, a reaction catalyzed by phosphopentose isomeraseand 
to xyiulose-5-phosphate as well as ribose-5-phosphate. Xylulose-5-
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phosphate is an epimer of ribulose-5-phosphate and is made by 
phosphopentose epimerase:
CHiOH CH2OH
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Stage 3 - Transketolase and transaldolase reactions 
If at any time only a little ribose-5-phosphate is required for nucleic 
acid synthesis and other synthetic reactions, it will tend to accumulate and 
is then converted to fructose-6-phosphate and gIyceraIdehydes-3- 
phosphate by the enzymes transketolase and transaldolase.
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3. Control of the pathway
The transketolase and transaldolase reactions are reversible, so the 
final products of the pentose phosphate pathway can change depending on 
the metabolic needs of the cell. And so allow either the conversion of 
ribose-5-phosphate into glycolytic intermediates when it is not needed for 
other cellular reactions, or the generation of ribose-5-phosphate from 
glycolytic intermediates when more is required.
Thus when the cell needs NADPH but not ribose 5-phosphate the 
latter is converted to glycolytic intermediates and enters glycolysis. At the 
other extreme, when the need for ribose 5-phosphate exceeds that for 
NADPH, fructose 6-phosphate and gIyceraldehydes-3-phosphate can be 
taken from glycolysis and converted into ribose 5-phosphate by reversal of 
the transketolase and transaldolase reactions.
The rate of the pentose phosphate pathway is controlled by NADP+ 
regulation of the first step, catalyzed by glucose 6-phosphate 
dehydrogenase.
The first reaction of the pathway, the oxidation of glucose 6-phosphate 
by glucose 6-phosphate dehydrogenase, is rate limiting and irreversible. 
The enzyme is regulated by NADP+. As the cell uses NADPH, the 
concentration of NADP+ rises, stimulating glucose 6-phosphate 
dehydrogenase and so increasing the rate of the pathway and NADPH 
regeneration.
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GLYCOGEN METABOLISM. 
METABOLISM OF FRUCTOSE AND 
GALACTOSE.
1. Roles of glycogen metabolism
Glycogen is a large polymer of glucose residues linked by a-1,4- 
glycosidic bonds with branches every 10 residues or so via a-1,6- 
glycosidic bonds. Glycogen provides an important energy reserve for the 
body. The two main storage sites are the liver and skeletal muscle where 
the glycogen is stored as granules in the cytosol. The granules contain not 
only glycogen but also the enzymes and regulatory proteins that are 
required for glycogen degradation and synthesis.
Glycogen metabolism is important because it enables the blood glucose 
level to be maintained between meals (via glycogen stores in the liver) and 
also provides an energy reserve for muscular activity. The maintenance of 
blood glucose is essential in order to supply tissues with an easily 
metabolizable energy source, particularly the brain which uses only 
glucose except after a long starvation period.
2. Glycogen degradation
Glycogen degradation is carried out by glycogen phosphorylase and 
glycogendebranching enzyme.
Glycogen phosphorylase (often called simply phosphorylase) 
removes glucose units sequentially from the nonreducing ends of a 
glycogen molecule, producing glucose 1-phosphate as the product. It 
breaks only a-l,4-glycosidic bonds and cannot break the ct-1,6- 
branchpoints. The other substrate required is inorganic phosphate (Pi). 
The reaction is an example of phosphorolysis, that is breakage of a 
covalent bond by the addition of a phosphate group. The (reversible) 
reaction is as follows:
glycogen + Pj glycogen + glucose 1-phosphate
(n residues) (n-1 residues)
However, glycogen phosphorylase can remove only those glucose 
residues that are more than five residues from a branchpoint. Glycogen­
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debranching enzyme removes the a-1,6- branches and so allows 
phosphorylase to continue degrading the glycogen molecule.
The glucose-l-phosphate is converted to glucose-6-phosphate by 
phosphoglucomutase.
glucose 1-phosphate <—> glucose 6-phosphate
The fate of the glucose-6-phosphate depends on the tissue. Liver 
contains the enzyme glucose-6-phosphatase, which converts the glucose- 
e-phosphate to glucose, which then diffuses out into the bloodstream and 
so maintains the blood glucose concentration:
glucose 6-phosphate + H20  ----> glucose + Pj
During glycogen degradation in muscle, the main aim is to produce 
energy quickly and so the glucose-6-phosphate is metabolized 
immediately via glycolysis and is oxidized to yield energy for muscle 
contraction. This tissue does not contain glucose-6-phosphatase.
3. Glycogen synthesis
Three enzymes are needed to synthesize glycogen:
1. UDP-glucose pyrophosphorylase catalyzes the synthesis of 
UDP-glucose from UTP and glucose-l-phosphate (Fig.l):
UTP + glucose 1-phosphate — > UDP-glucose + PP,
The pyrophosphate (PPi) is immediately hydrolyzed by inorganic 
pyrophosphatase, releasing energy. Thus the overall reaction is very 
exergonic and essentially irreversible.
Fig. 1. The UDP-glucose pyrophosphoridase reaction.
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2. Glycogen synthase now transfers the glucosyl-residue from UDP- 
glucose as a substrate to synthesize glycogen to the C4-OH group at 
the nonreducing end of a glycogen molecule, forming an a-1,4- 
glycosidic bond between neighboring glucosyl residues (Fig.2). 
Interestingly, glycogen synthase can only extend an existing chain. 
Thus it needs a primer; this is a protein called glycogenin in order to begin 
synthesis. Glycogenin contains eight glucosyl units joined by a-1,4- 
linkages, which are added to the protein by itself (i.e. autocatalysis). It is 
this molecule that glycogen synthase then extends. Each glycogen 
granule contains only a single glycogenin molecule at its core. The fact that 
glycogen synthase is fully active only when in contact with glycogenin 
limits the size of the glycogen granule.
Н О С И ,
H J ------O H
?\ И ______
H O  O - F r O  — P — Q - 4  U r ic tto e l
H OH cj-
U D P -gb _ »co »e
H O C H j,
о н  н  о н
Glycogen (n residues)
H O H  н  о н  H OH
U O P  Glycogen
(n + 1 reekluoa)
Fig. 2. Synthesis o f  glycogen by glycogen synthase.
3. Branching enzyme amylo-(l,4 —> 1,6) transglycosylase] is a
different enzyme from glycogen-debranching enzyme.
After a number of glucose units have been joined as a straight chain 
with a-1,4-linkages, branching enzyme breaks one of the a-1,4-bonds and 
transfers a block of residues (usually about seven) to a more interior site in 
the glycogen molecule, reattaching these by creating an a-1,6-bond. The 
branches are important because the enzymes that degrade and synthesize 
glycogen (glycogen synthase and glycogen phosphorylase, respectively) 
work only at the ends of the glycogen molecule. Thus the existence of 
many termini allows a far more rapid rate of synthesis and degradation 
than would be possible with a nonbranched polymer.
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4. Control of glycogen metabolism
Glycogen degradation and glycogen synthesis are controlled both by 
allosteric regulation and by hormonal control.
If glycogen synthesis and glycogen degradation were allowed to occur 
simultaneously, the net effect would be hydrolysis of UTP, a so-called 
futile cycle (Fig. 3). To avoid this, both pathways need to be tightly 
controlled. This control is carried out via allosteric regulation and 
covalent modification of both the glycogen synthase and phosphorylase. 
In addition, the covalent modification is under close hormonal control.
Phosphorylase exists in a phosphorylated active a form and a 
dephosphorylated norm ally inactive b form.
The two forms are interconverted by phosphorylase kinase and 
protein phosphatase I.
Phosphorylase b is a dimer and is converted into phosphorylase a by 
phosphorylation of a single serine residue on each subunit by the enzyme 
phosphorylase kinase. The process can be reversed and phosphorylase 
inactivated by removal o f the phosphate group by protein phosphatase I
(Fig. 4a).
In skeletal muscle, high concentrations of AMP can activate 
phosphorylase b (by acting at an allosteric site) but this is opposed by 
the concentrations of ATP and glucose 6-phosphate found in resting 
muscle so that in this condition phosphorylase b is indeed inactive. Since 
most of the phosphorylase in resting muscle is phosphorylase b, 
significant glycogen degradation does not occur under these conditions. 
However, during exercise, the concentrations of ATP and glucose 6- 
phosphate fall and the concentration of AMP rises. Thus phosphorylase b 
becomes activated and this leads to the rapid degradation of glycogen to 
yield energy as required. Phosphorylase a is unaffected by ATP, AMP or 
glucose 6-phosphate and so remains active under all conditions.
PP, UDP -Qkiccue
Gfycccjen
Fig. 3. Simultaneous operation o f glycogen synthesis and 
degradation resulting in net hydrolysis o f  UTP
4.1. Allosteric control and covalent modification
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In liver, phosphorylase b is not activated by AMP and is therefore 
always inactive. Unlike muscle, therefore, glycogen degradation in liver is 
not responsive to the energy status of the cell. Rather phosphorylase a is 
deactivated by glucose. This fits with the different role of glycogen 
storage in liver, namely to maintain blood levels of glucose. Thus as 
glucose levels rise, glycogen degradation by liver phosphorylase a is shut 
off and degradation starts again only as the glucose level falls.
Glycogen synthase is also regulated by covalent modification and 
allosteric interactions. The enzyme exists as an active glycogen synthase a 
and a normally inactive glycogen synthase b. However, in contrast to 
phosphorylase, it is the active form of glycogen synthase (synthase a) that 
is dephosphorylated whereas the inactive synthase b form is the 
phosphorylated form (Fig. 4b).A high concentration of glucose 6- 
phosphate can activate glycogen synthase b. During muscle contraction, 
gIucose-6-phosphate levels are low and therefore glycogen synthase b is 
inhibited. This is at the time when phosphorylase b is most active.
Thus glycogen degradation occurs and glycogen synthesis is inhibited, 
preventing the operation of a futile cycle. When the muscle returns to the 
resting state and ATP and glucose 6-phosphate levels rise, phosphorylase b 
is inhibited, turning off glycogen degradation, whereas glycogen synthase 
is activated to rebuild glycogen reserves. The synthase a form is active 
irrespective of the concentration of glucose-6-phosphate.
(а ) Phosphorylase kinase
PftOSfjtKxyiase b Phosphorylase a
{dephosphcrviaied. {phosphorated
inactive) active)
(b) Protein
phosphatase p
Gtycogen synthase b Glycogen synthase «
{phoeofxyytated, ;depix)sphorytated,'
inactive) active)
PrOtein
kinase A
Fig. 4. Regulation o f  (a) glycogen phosphorylase activity and (b) glycogen 
synthase activity by phosphorylation (covalent modification).
4.2. Hormonal control by epinephrine and glucagon
Glycogen metabolism is tightly controlled by hormones.
Epinephrine (adrenaline) stimulates glycogen degradation in skeletal 
muscle. Epinephrine and glucagon stimulate glycogen degradation in 
liver.
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When blood glucose levels fall, glucagon is secreted by the P-cells of 
the pancreas and acts on the liver to stimulate glycogen breakdown to 
glucose, which is then released into the bloodstream to boost blood 
glucose levels again.
Muscular contraction or nervous stimulation (the 'fight or flight’ 
response) causes the release of epinephrine (adrenaline) from the adrenal 
medulla and this acts on muscle to increase glycogen breakdown ready to 
supply the energy needs of the cells.
Consider first the activation of glycogen degradation by epinephrine in 
the liver. The hormone binds to a receptor, called the p-adrenergic 
receptor, in the plasma membrane of the target cell (Fig. 5).
Fig. 5. Mechanism o f  action o f  epinephrine
Binding of the hormone to the receptor causes a conformational change 
in the protein which in turn activates an enzyme called adenylate cyclase. 
The receptor does not activate adenylate cyclase directly but rather by 
activating a G-protein as an intermediary in the signaling process.
Activated adenylate cyclase converts ATP to 3'5' cyclic AMP (cAMP). 
The cAMP binds to protein kinase A (PKA), also known as cAMP- 
dependent protein kinase. This enzyme consists of two regulatory 
subunits (R) and two catalytic subunits (C), making a complex R2C, that 
is normally inactive (Fig. 5).
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The binding of two molecules of cAMP to each of the regulatory 
subunits leads to dissociation of the complex into an R2 complex and two 
free C subunits that are now catalyticaily active.
The active protein kinase A phosphorylates phosphorylase kinase, 
which can exist as an inactive dephosphorylated form and an active 
phosphorylated form.
Thus phosphorylase kinase is now also activated and in turn 
phosphorylates phosphorylase b, converting it to the active phosphorylase a 
that now carries out a rapid degradation of glycogen.
This set of reactions is called a cascade and is organized so as to greatly 
amplify the original signal of a small number of hormone molecules. For 
example, each bound hormone causes the production o f many cAMP 
molecules inside the cell; the activated protein kinase A in turn activates 
many molecules of phosphorylase kinase; each active phosphorylase kinase 
activates many molecules of phosphorylase.
Thus a small hormonal signal can cause a major shift in cell 
metabolism. To prevent the operation of a futile cycle, it is essential that 
glycogen synthesis is switched off during epinephrine or glucagon 
stimulation of glycogen breakdown. This is achieved by the activated 
protein kinase A that, as well as phosphorylating phosphorylase kinase, 
also phosphorylates glycogen synthase a, converting it to the inactive 
glycogen synthase b form (Fig. 6).
©
P ro io in  ktn&sei A
P n o s p h o ry ia s akinase
©
■Rhosphoryiaseb - (Inactive) P hosphoryla se  a  (active)
Fig. 6. Dual control o f g/ycogen degradation and 
glycogen synthesis by protein kinase A.
G lycog& n  
synthase  b  
(inactive)
Thus protein kinase A activates glycogen degradation and inhibits 
glycogen synthesis. When epinephrine and glucagon levels in the 
bloodstream fall again, the hormone dissociates from the receptor, no 
more cAMP is made and existing cAMP is converted to 5' AMP (i.e. 
'normal' AMP not the cyclic form) by cAMP phosphodiesterase, an enzyme 
that is constantly active in the cell. This decline in the cAMP level shuts 
off the activation cascade. The enzymes phosphorylase and synthase that 
had been phosphorylated are now dephosphorylated by protein 
phosphatase I, restoring them to their original condition.
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4.3. Hormonal control by insulin
Insulin is released into the bloodstream by the P-cells of the pancreas 
when blood glucose levels are high after feeding, and stimulates glycogen 
synthesis to store excess glucose as glycogen. This control is also achieved 
via phosphorylation events.
Insulin binds to and activates a receptor protein kinase in the plasma 
membrane of target cells. This receptor has tyrosine kinase activity (i.e. it 
will phosphorylate selected tyrosine residues on target proteins).
Its activation leads to the activation of an insulin-responsive protein 
kinase then activates protein phosphatase I by phosphorylation.
Activated protein phosphatase I ensures that glycogen synthase is 
dephosphorylated (and hence active) and that phosphorylase kinase is 
also dephosphorylated (and hence inactive). The net effect is to stimulate 
glycogen synthesis.
4.4. Calcium control of glycogen metabolism
During epinephrine or glucagon hormonal control, dephosphorylated 
phosphorylase kinase is activated by being phosphorylated by 
proteinkinase. This then activates phosphorylase and stimulates glycogen 
degradation.
However, there is also another way to activate dephosphorylated 
phosphorylase kinase, at least partially, and that is by a high concentration 
of Ca2+ ions. This is important in muscle contraction, which is triggered 
when Ca 2+ is released from the internal store in the sarcoplasmic 
reticulum. Thus, as well as allosteric control and hormonal control during 
muscle contraction, both of which stimulate glycogen degradation, there 
is also calcium control.
5. Metabolism of fructose
Fructose is an abundant sugar in the human diet; sucrose is a 
disaccharide which when hydrolyzed yields fructose and glucose and 
fructose is also a major sugar in fruits and honey. There are two 
pathways for the metabolism o f fructose; one occurs in muscle and 
adipose tissue, the other in liver.
In muscle and adipose tissue, fructose can be phosphorylated by 
hexokinase (which is capable o f phosphorylating both glucose and 
fructose) to form fructose 6-phosphate, which then enters glycolysis.
In liver, the cells contain mainly glucokinase instead of hexokinase 
and this enzyme phosphorylates only glucose. Thus in liver, fructose 
is metabolized instead by the fructose 1-phosphate pathway (Fig. 7).
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Fructose
Fruotokinase ATP
A D P
Fructose 1 -phospbate
F ru cto se  1 -p h o sp h a te  
akjtolese
Glyceraldehyde + dihydroxyacetone phosphate
Triose kinase
ATP
ADP
CilycoralcJQhyd© 3 -D h o sp h a te
Fig. 7. The fructose I -phosphate pathway.
1. Fructose is converted to fructose l-phosphate by fructokinase. 
Fructose l-phosphate is then split into glyceraldehyde and 
dihydroxyacetone phosphate by fructose l-phosphate aldolase. The 
dihydroxyacetone feeds into glycolysis at the triose phosphate' 
isomerase step.
2. The glyceraldehyde is phosphorylated by triose kinase to 
glyceraldehyde 3-phosphate and so also enters glycolysis.
6. Metabolism of galactose
The hydrolysis of the disaccharide lactose (in milk) yields galactose and 
glucose. Thus galactose is also a major dietary sugar for humans. Galactose 
and glucose are epimers that differ in their configuration at C-4. Thus the 
entry of galactose into glycolysis requires an epimerization reaction. This 
occurs via a four-step pathway called the galactose-glucose 
interconversion pathway (Fig. 8):
Galactose
G&tetctnMnasa If
J4** A D P
Galactose 1 -phosphate U D P  -glucose
Galactose 1 -phosphate Y 
u rid yty ! f r a n s /e r a s e  A
Glucose 1 -phosphate t JDP-Qaiactose
UDn-gatactcsa4-apfrr>or&se
F*ho§f>hoghjcormjtas& 
Glucose 6 -phosphate
Glycolysis
Fig. 8. The galactose-glucose interconversion pathway.
1. Galactose is phosphorylated by galactokinase to give Galactose-1- 
phosphate.
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2. Galactose-1-phosphate uridylyl transferase catalyzes the transfer of 
a uridyl group from UDP-glucose to galactose-1-phosphate to form 
UDP-galactose and glucose-1 phosphate.
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3. The UDP-galactose is converted back to UDP-glucose by UDP- 
galactose-4-epimerase. Thus, overall, UDP-glucose is not 
consumed in the reaction pathway.
4. Finally the glucose-l-phosphate is converted to glucose-e- 
phosphate by phosphoglucomutase. The glucose-6-phosphate then 
enters glycolysis.
Galactosemia is a genetic disease caused by an inability to convert 
galactose to glucose. Toxic substances accumulate such as galactitol, 
formed by the reduction of galactose, and lead to dire consequences for 
the individual. Children who have the disease fail to thrive, may vomit or 
have diarrhea after drinking milk, and often have an enlarged liver and 
jaundice. The formation of cataracts in the eyes, mental retardation and an 
early death from liver damage are also possible. Most cases of 
galactosemia are due to a deficiency of the galactose 1-phosphate uridylyl 
transferase enzyme and hence these individuals cannot metabolize 
galactose. The disease is treated by prescribing a galactose-free diet, which 
causes all the symptoms to regress except mental retardation, which may be 
irreversible. Since such patients have normal levels of UDP-galactose 4- 
epimerase, they can still synthesize UDP-galactose from UDP-glucose and 
so can still synthesize, for example, oligosaccharides in glycoproteins that 
involve Gal residues.
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DIAGNOSIS AND MONITORING 
OF DIABETES MELLITUS
1. Urine testing
1.1. Glucose in urine
Glycosuria allows for a good first-line screening test for diabetes 
mellitus; most occupational health checks and hospital admissions will 
include a urinary glucose test. Normally glucose does not appear in the urine 
until the plasma glucose rises above lOmmol/1 or thereabouts.
However, in some healthy individuals, glucose may spill over into the 
urine at much lower plasma concentrations. These individuals are said to 
have a low renal threshold for glucose and have glycosuria without 
having diabetes mellitus. Conversely, the renal glucose threshold increases 
with age and as a result many diabetics will not have glycosuria. It is 
important when interpreting urinary glucose measurements to remember 
that the urine glucose level is a reflection of integrated glycaemia over the 
time of the formation of the urine and does not reflect the exact level of 
blood glucose at the time of testing. A number of simple sideroom or home 
test kits are available for urine glucose measurement.
1.2. Ketones in urine/plasma
Ketone bodies (acetone, acetoacetate and 6-hydroxybutyrate) may 
accumulate in the plasma of a diabetic patient. Their presence is by no 
means diagnostic of ketoacidosis, a serious condition. Ketones may be 
present in a normal subject as a result of simple prolonged fasting. Dry 
reagent strips which detect acetoacetate but not 6-hydroxybutyrate might 
therefore provide an underestimate o f ketonaemia / ketonuria.
2. Blood glucose
Glucose is routinely measured in the laboratory on blood specimens, 
which have been collected into tubes containing fluoride, an inhibitor of 
glycolysis. Because of the need sometimes to obtain rapid blood glucose 
results and the widespread self-monitoring of diabetic patients, blood 
glucose is also assessed out with the laboratory using test strips. The 
modern tests employ specific enzymatic reactions and provide a fairly 
accurate measurement over the broad range of blood glucose 
concentrations. The concentration of glucose can be read visually or with
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the aid of portable reflectance meters. It is important to follow the 
measuring procedure exactly. Improper storage of reagent strips can 
affect the results. Any grossly abnormal or unexpected results should be 
confirmed in the laboratory.
The World Health Organization has published guidelines for the 
diagnosis of diabetes mellitus on the basis of blood glucose results and the 
response to an oral glucose load. These are shown in Table 1 and are further 
discussed below.
2.1. Random blood glucose (RBG)
RBG is the only test required in an emergency. An RBG of less than 8 
mmol/1 should be expected in non-diabetics. RBG higher than 11 mmol/1 
usually indicates diabetes mellitus (Table 1).
2.2. Fasting blood glucose (FBG)
FBG is measured after an overnight fast (at least 10 hours). An FBG is 
better than RBG for diagnostic purposes. In non-diabetics it is usually 
lower than 6 mmol/1. Fasting values of 6-8 mmol/1 should be interpreted 
as borderline. FBG equal to or above 8 mmol/1 on two occasions is 
diagnostic for diabetes mellitus. It is important in each case to recognize 
the differences between measurements performed on whole blood, 
plasma or capillary samples (Table 1).
2.3. Oral glucose tolerance test (OGTT)
Classically, the diagnosis of diabetes is made on the basis of a patient's 
response to an oral glucose load. A baseline blood sample is first taken 
after an overnight fast. The patient is then given 75 g of glucose orally, in 
about 300 ml of water, to be drunk within 5 minutes. Plasma glucose levels 
are measured every 30 minutes for 2 hours. Urine may also be tested for 
glucose at time 0 and after 2 hours. The patient should be sitting 
comfortably throughout the test, should not smoke or exercise and should 
have been on a normal diet for at least 3 days prior to the test. Normal and 
diabetic responses to an oral glucose load are shown in Fig 1.
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Plasm a glucose
M inutes after ingestion o f  75g glucose 
Fig. 1 Plasma glucose levels following an oral glucose load 
in normal and diabetic subjects.
Table I. WHO criteria for the diagnosis o f diabetes mellitus and impaired glucose 
tolerance (IGT).
R a n d o m  g lu co se  sam p l e (m m ol/1)
D iab e te s  lik e ly D iab e te s  u n ce rta in D iab e tes
un lik e ly
V e n o u s  p la sm a > H , 1 5,5 - <  11,1 < 5 ,5
V e n o u s b lo o d >  10,0 4 , 4 - <  10.0 < 4 ,4
C a p illa ry  p la sm a >  12,2 5 . 5 - <  12,2 < 5 ,5
C a p illa ry  b lo o d > 1 1 ,1 4 ,4  - <  11.1 < 4 ,4
S tan d a rd ized  O G T T  (m m ol/1)
D iab e tes IG T
V en o u s p la sm a F astin g > 7 ,8 < 7 ,8
2h > 1 1 ,1 7 ,8  - <  11,1
V en o u s b lo o d F astin g > 6 ,7 < 6 ,7
2h >  10,0 6 ,7 - < 1 0 ,0
C a p illa ry  p la s m a F astin g > 7 ,8 < 7 ,8
2h >  12,2 8 , 9 - <  12,2
C a p illa ry  b lo o d F astin g > 6 ,7 < 6 ,7
2h > 1 1 ,1 7 , 8 - <  11,1
Many OGTTs are performed unnecessarily. There are relatively few 
indications for the test. These include:
1. borderline fasting or post-prandial blood glucose
2. persistent glycosuria
3. glycosuria in pregnant women
4. pregnant women with a family history of diabetes mellitus and those 
who previously had large babies or unexplained fetal loss.
It is important to note that the OGTT is of little value in hospitalized 
patients or in patients immediately after a severe illness.
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2.4. Interpretation of an OGTT
The interpretation of an OGTT is summarized in Table 1. In 
asymptomatic patients, OGTT should be interpreted as diagnostic of 
diabetes mellitus only when there is an increased 2 h glucose level, and the 
blood glucose is also equal to or greater than 11 mmol/l at some other 
point during the test. If the patient has normal fasting plasma glucose and 
only the 2 h value in the diabetic range, the test should be repeated after 
approximately 6 weeks. Impaired glucose tolerance (IGT) should not be 
regarded as a disease. It signals that the patient is at an intermediate stage 
between normality and diabetes mellitus and is at an increased risk of 
developing diabetes. Such patients should be followed up yearly, and 
dietary treatment may be used.
3. Long-term indices of diabetic control
A high concentration of glucose in the ECF leads to its non-enzymatic 
attachment to the lysine residues of a variety of proteins. This is called 
glycation. The extent of this process depends on the ambient glucose 
level. It is virtually irreversible at physiological hydrogen ion 
concentration and therefore the glucose molecule will remain attached 
until the protein molecule is degraded. The concentration of glycated 
protein is therefore a reflection of a mean blood glucose level prevailing in 
the extracellular fluid during the life of that protein.
3.1. Haemoglobin A le or glycated haemoglobin
Glycated haemoglobin reflects the mean glycaemia over 2 months prior 
to its measurement, the half-life of haemoglobin. This test is accepted as a 
good index of diabetic control and is used routinely in most diabetic 
clinics to complement the information from single blood glucose 
levels, or indeed a patient's log of his or her own blood glucose 
measurements.
3.2. Microalbuminuria
Microalbuminuria may be defined as an albumin excretion rate 
intermediate between normality (2.5-25 mg/day) and macroalbuminuria 
(>250 mg/day). The small increase in urinary albumin excretion is not 
detected by simple albumin stick tests and requires confirmation by careful 
quantitation in a 24 h urine specimen. The importance of microalbuminuria 
in the diabetic patient is that it is a signal of early, reversible renal damage.
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1. The diagnosis of diabetes mellitus is made on the basis of blood glucose 
concentrations either alone or in response to an oral glucose load.
2. In asymptomatic patients the results of an oral glucose tolerance test 
should be interpreted as diagnostic of diabetes mellitus only when there 
is an increased 2 h glucose concentration, and the blood glucose is also 
equal to or greater than 11 mmol/1 at some other point during the test.
3. HbAIc and ffuctosamine are measures of protein glycation and serve as 
indices of long-term glucose control.
4. Microalbuminuria is a measure of early, reversible, diabetic 
nephropathy.
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STRUCTURES AND ROLES OF FATTY ACIDS. 
FATTY ACID BREAKDOWN. 
TRANSPORT OF LIPIDS.
1. Structure and properties of fatty acids
A fatty acid consists of a hydrocarbon chain and a terminal 
carboxylic acid group (Fig.l). Most fatty acids found in biology have an 
even number of carbon atoms arranged in an unbranched chain. Chain 
length usually ranges from 14 to 24 carbon atoms, with the most common 
fatty acids containing 16 or 18 carbon atoms. A saturated fatty acid has 
all of the carbon atoms in its chain saturated with hydrogen atoms (Fig. la). 
This gives the general formula CH3(CH2)nCOOH, where n is an even 
number. Mono- unsaturated fatty acids have one double bond in their 
structure (Fig. lb and c), while polyunsaturated fatty acids have two or 
more double bonds (Fig. Id). The double bonds in polyunsaturated fatty 
acids are separated by at least one methylene group.
The properties o f fatty acids depend on their chain length and the 
nu m b er of double bonds. Shorter chain length fatty acids have lower 
melting temperatures than those with longer chains. Unsaturated fatty 
acids have lower melting temperatures than saturated fatty acids o f the 
same chain length, whilst the corresponding polyunsaturated fatty 
acids have even lower melting temperatures.
Fatty acids are named according to the number of carbon atoms in the 
chain and the number and position of any double bonds. Some of the more 
common fatty acids are palmitate (C16:0), stearate (C18:0), oleate (C18:l), 
linoleate (С 18:2) and arachidonate (C20:4). The double bonds in a fatty 
acid are usually in the cis -configuration (Table 1).
H U  H H H H H H H H H  н н н  н о
H H  H H  H H H H H H H  I) H H H  \
(a) Palmitate (hexadeconoate) C l6:0
H H  H H H H H H H H H  н н н н  о
i  .1 i  i  A It i, . Ш  ,1 \
(b) Palmitoleate ( c i s - A 9 hexadecenoate) C l6:1
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(c ) ( Trans- A 9- o c tad ece n o a te )  C 18:1 
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(d ) L in o le a te  (els, cis- A l2-o c tad ecad ien o a tc )  C 1 8 :2
Fig. 1. Structures o f  (a) a saturated fatty acid (palmilate, C16:0); (b) a mono- 
unsaturated fa tty  acid with the double bond in the cis configuration (palmitoleate, 
C l6:1); (c) a mono-unsalurated fatty acid with the double bond in the trans 
configuration (C l 8:1); and (d) a polyunsaturated fatty acid (linoleate, C18:2).
Table 1. The names and formulae o f  some common fa tty  acids
F a tty  a c id F o rm u la N o . o f  d o u b le  
b o n d s
N o . o f  
c a r b o n  
a to m s
P a lm ita te C H 3(CH2)14C O a N o n e 16
S te a ra te С Н 3(СН 2)|бСОО- N o n e 18
O le a te СН з(СН 2)7СН =С Н (С Н 2)7СОО- 1 18
L in o le a te СН з(СН 2)4(СМ =СНСН2)2(СН 2)6СОО' 2 18
L in o le n a te СН зС Н 2(С Н =С Н С Н 2)з(С Н 2)6СОО- 3 18
A r a c h id o n a te  C H 3(C H 2)4( C H < :H C H 2)4(O T 2)2C O O ' 4 2 0
2. Roles
Fatty acids have four major biological roles:
1. They are used to make glycerophospholipids and sphingolipids 
that are essential components of biological membranes;
2. Numerous proteins are covalently modified by fatty acids. 
Myristate (C14:0) and palmitate (0 6 :0 )  are directly attached to 
some proteins, while phosphatidylinositol is covalently linked to 
the C terminus of other proteins via a complex glycosylated 
structure;
3. Fatty acids act as fuel molecules, being stored as triacylglycerols, 
and broken down to generate energy;
4. Derivatives of fatty acids serve as hormones (such as the 
prostaglandins) and intracellular second messengers (such as 
DAG and IP3).
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3. Prostaglandins
Prostaglandins, and the structurally related molecules prostacyclins, 
thromboxanes and leukotrienes, are called eicosanoids because they 
contain 20 carbon atoms (Greek eikosi = 20). These hormones are relatively 
short-lived and hence act locally near to their site of synthesis in the body. 
They are derived from the common precursor arftchidonate (Fig. 2). 
This polyunsaturated fatty acid is a derivative of linoleate (Table 1). 
Prostaglandins stimulate inflammation, modulate synaptic transmission 
between nerve cells, and induce sleep. Although aspirin (acetylsalicylic 
acid) has been used for centuries to decrease inflammation, pain and fever, 
it was not until 1974 that John Vane discovered how aspirin works. 
Aspirin inhibits the synthesis of prostaglandins by irreversibly inhibiting 
prostaglandin synthase. This enzyme catalyzes the first step in the 
Synthesis of prostaglandins, prostacyclins and thromboxanes (Fig.2).
A ra c h id o n a te
P ro s ta g la n d in  
sy n th a se^
P ro s ta g la n d in  H 2
■ /  \
P ro s ta c y c lin  O th e r  T h ro m b o x a n e s
p ro s ta g la n d in s
L e u k o tr ie n e s
Fig.2. Biosynthetic rela tionship  o f  the eicosanoids
4. Fatty acid breakdown
Fatty acid breakdown brings about the oxidation of long-chain fatty 
acids. The fatty acids are first converted to their acyl coenzyme A (CoA) 
derivatives and then degraded by the successive removal of two-carbon 
units from the end of the fatty acid as acetyl CoA. The pathway produces 
FADH2 and NADH directly. The acetyl CoA produced can also enter the 
citric acid cycle and produce further FADH2 and NADH. The FADH2 and 
NADH are then oxidized by the respiratory electron transport chain to 
yield energy in the form of ATP.
4.1. Activation
Fatty acid breakdown occurs in the cytosol of prokaryotes and in the 
mitochondrial matrix of eukaryotes. Before entering the mitochondrial 
matrix, the fatty acid is activated by forming a thioester link with
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CoA.This reaction is catalyzed by acyl CoA synthase (also called fatty 
acid thiokinase), which is present on the outer mitochondrial membrane, 
and uses a molecule of ATP. The overall reaction is irreversible due to the 
subsequent hydrolysis of PPi to two molecules of Pi.
/ /O  A cy l C o A  sy n th a se  / / 3
R — C  + A T P  +  H S —C o A  < ■ > R —C ~ S  —C o A  +  A M P  +  PP i
4 0'
4.2. Transport into mitochondria
Small- and medium-chain acyl CoA molecules (up to 10 carbon atoms) 
are readily able to cross the inner mitochondrial membrane by diffusion. 
However, longer chain acyl CoAs do not readily cross the inner 
mitochondrial membrane, and require a specific transport mechanism. To 
achieve this, the longer chain acyl CoAs are conjugated to the polar 
carnitine molecule, which is found in both plants and animals. This 
reaction, catalyzed by an enzyme on the outer face of the inner 
mitochondrial membrane (carnitine acyltransferase I), removes the CoA 
group and substitutes it with a carnitine molecule (Fig. 3). The 
асу learn itine is then transported across the inner mitochondrial membrane 
by a carnitine/acylcarnitine translocase. This integral membrane 
transport protein transports acylcarnitine molecules into the mitochondrial 
matrix and free carnitine molecules out. Once inside the mitochondrial 
matrix the acyl group is transferred back on to CoA, releasing free 
carnitine, by the enzyme carnitine acyltransferase II which is located on 
the matrix side of the inner mitochondrial membrane (Fig. 3).
тЕпмемвдане: 
'sfste; v
JNNER W TOCHO NDR lAL M EM BRANE
Catnffir*,. ficflCoA
AcykJamWr» —  CoASH
; Ф » :  Carnitine aqyftransferesel.
Fig. 3. Transport o f  fatty acids across the inner mitochondrial membrane
4.3. p-Oxidation pathway
The individual reactions involved in the degradation of fatty acids, 
by P-pathway oxidation are as follows (Fig. 4):
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1. Oxidation of the fatty acyl Co A to enoyl CoA forming a trans Д2- 
double bond on the fatty acyl chain and producing FADH2 
(catalyzed by acyl CoA dehydrogenase).
2. Hydration of the trans Д-enoyl CoA to form 3-hydroxyacyl CoA 
(catalyzed by enoyl CoA hydratase).
3. Oxidation of 3-hydroxyacyl CoA to 3-ketoacyl CoA producing 
NADH (catalyzed by hydroxyacyl CoA dehydrogenase).
4. Cleavage, or thiolysis, of 3-ketoacyl CoA by a second CoA 
molecule, giving acetyl CoA and an acyl CoA shortened by two 
carbon atoms (catalyzed by p-ketothiolase).
Thus, the breakdown of individual fatty acids occurs as a repeating 
sequence of four reactions: oxidation (by FAD), hydration, oxidation (by 
NAD+) and thiolysis. These four reactions form one 'round' of fatty acid 
degradation (Fig. 4) and their overall effect is to remove two-carbon 
units sequentially in the form of acetyl CoA from the fatty acid chain. 
The cleavage of the Д2 (or P) bond of the fatty acyl chain gives fatty acid 
breakdown its alternative name, p-oxidation. The shortened acyl CoA then 
undergoes further cycles of p-oxidation until the last cycle, when the acyl 
CoA with four carbon atoms is split into two molecules of acetyl CoA. 
Thus a Ci6 saturated acyl CoA, such as palmitoyl CoA, would be 
completely degraded into eight molecules of acetyl CoA by seven rounds 
of degradation, leading to the overall equation:
palmitoyl CoA + 7 FAD + 7 NAD+ + 7 CoA + 7 H ,0 —'►
8 acetyl CoA + 7 FADH2 + 7 NADH + 7FT
Mitochondria contain three acyl CoA dehydrogenases, which act on 
short-, medium- and long-chain acyl CoAs, respectively. In contrast, there 
is just one each of the enzymes enoyl CoA hydratase, hydroxyacyl CoA 
dehydrogenase and p-ketothiolase which all have a broad specificity with 
respect to the length of the acyl chain.
In animals the acetyl CoA produced from fatty acid degradation cannot 
be converted into pyruvate or oxaloacetate. Although the two carbon atoms 
from acetyl CoA enter the citric acid cycle, they are both oxidized to C 02 
in the reactions catalyzed by isocitrate dehydrogenase and a-ketoglutarate 
dehydrogenase. Thus, animals cannot convert fatty acids into glucose. 
In contrast, plants have two additional enzymes, isocitrate lyase and 
malate synthase, that enable them to convert the carbon atoms of acetyl 
CoA into oxaloacetate. This is accomplished via the glyoxylate pathway, a 
route involving enzymes of both the mitochondrion and the glyoxysome, a 
specialized membranous plant organelle.
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Unsaturated fatty acids require the action of additional enzymes in 
order to be completely degraded by (3-oxidation.
Fatty acids having an odd number of carbon atoms give rise to 
acetyl CoA (two carbon atoms) and propionyl CoA (three carbon atoms) in 
the final round of fatty acid degradation.
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Fig. 4. Summary o f the reactions involved in the degradation o ffa tty  acids 
4.4. Regulation
The major point of control of p-oxidation is the availability of fatty 
acids. The major source of free fatty acids in the blood is from the 
breakdown of triacylglycerol stores in adipose tissue, which is regulated 
by the action of hormone-sensitive triacylglycerol lipase. Fatty acid 
breakdown and fatty acid synthesis are coordinately controlled so as to 
prevent a futile cycle.
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4.5. Energy yield
For each round of degradation, one FADH2, one NADH and one acetyl 
CoA molecule are produced. Each NADH generates three ATP molecules, 
and each FADH2 generates two ATPs during oxidative phosphorylation. In 
addition, each acetyl CoA yields 12 ATPs on oxidation by the citric acid 
cycle. The total yield for each round of fatty acid degradation is therefore 
17 ATP molecules.
The complete degradation of palmitoyl CoA (C16:0) requires seven 
rounds of degradation and hence produces 7 X 5 = 35 ATP molecules. A 
total of eight acetyl CoA molecules are produced and hence another 8 x 1 2  
= 96 ATP. Thus the total ATP yield per molecule of palmitate degraded is 
35 + 96 = 131 ATP. However, one ATP is hydrolyzed to AMP and PP, in 
the activation of palmitate to palmitoyl CoA, resulting in two high-energy 
bonds being cleaved. Thus the net yield is 130 ATPs (Table 2).
The yield o f ATP is reduced slightly for unsaturated fatty acids, since 
the additional metabolic reactions which enable them to be degraded by 
the p-oxidation pathway either involve using NADPH or bypass an 
FADH2- producing reaction (Fig. 4).
Table 2. Calculation o f  the A TP yield from the complete oxidation o f  palmitate
Degradative step ATPyield
7x5 ATP for oxidation of NADH and FADH2 produced by 
each round of degradation
35
8x12 ATP for the breakdown of acetyl CoA by the citric 
acid cycle
96
ATP equivalents for the activation of palmitate -1
Total=130
[5 x (n/2-1) + n/2 x 12] -  1, where
5- amount of ATP for oxidation of NADH and FADH2 produced by 
each round o f degradation
n/2-1 - amount of rounds of degradation 
n/2- amount of acetyl CoA o f degradation
12 -amount of ATP for the breakdown of acetyl CoA by the citric 
acid cycle
1- amount of ATP equivalents for the activation of fatty acid
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5. Transport of lipids
5.1. Structure and function of lipoproteins
Triacylglycerols, phospholipids and cholesterol are relatively 
insoluble in aqueous solution. Hence, they are transported around the 
body in the blood as components of lipoproteins. These globular, micelle­
like particles consist of a hydrophobic core of triacylglycerols and 
cholesterol esters surrounded by an amphipathic coat of protein, 
phospholipid and cholesterol. The protein components of lipoproteins are 
called apolipoproteins (or apoproteins). At least 10 different apoproteins 
are found in the different human lipoproteins. Their functions are to help 
solubilize the hydrophobic lipids and to act as cellular targeting signals. 
Lipoproteins are classified into five groups on the basis of their physical 
and functional properties (Table 3):
1. chylomicrons are the largest and least dense lipoproteins. They 
transport dietary (exogenous) triacylglycerols and cholesterol from 
the intestines to other tissues in the body.
2. Very low density lipoproteins (VLDLs), intermediate density 
lipoproteins (IDLs) and low density lipoproteins (LDLs) are a 
group of related lipoproteins that transport internally produced 
(endogenous) triacylglycerols and cholesterol from the liver to the 
tissues.
3. High density lipoproteins (HDLs) transport endogenous 
cholesterol from the tissues to the liver.
Table 3. Characteristics o f  the five  classes o f  lipoproteins
L ip o p ro te in M o le c u la r  
m ass  (k D a)
D e n s ity  
(g  m l '1)
%  P ro te in M a jo r
lip id s
A p o p ro te in s
C h y lo m ic ro n s > 4 0 0 0 0 0 < 0 .9 5 1.5-2 .5 T G A , В -4 8 , С , E
V L D L s 1 0 0 0 0 -
8 0 0 0 0
< 1 .0 0 6 5 -1 0 T G , P L , 
C E
В -1 0 0 , С , E
ID L s 5 0 0 0 -1 0 0 0 0 1 .0 0 6 - 
1 .019
1 5-20 C E , T G , 
P L
В -1 0 0 , С , E
L D L s 2 3 0 0 1 .0 1 9 -
1 .063
2 0 -2 5 C E , P L B -1 0 0
H D L s 1 7 5 -3 6 0 1 .0 6 3 -
1 .210
4 0 -5 5 P L , C E A , C , D , E
5.2. Chylomicrons
Chylomicrons, the largest of the lipoproteins, are synthesized in the 
intestine. They transport ingested triacylglycerols to other tissues, mainly 
skeletal muscle and adipose tissue, and transport ingested cholesterol to the
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liver (Fig. 5). At the target tissues the triacylglycerols are hydrolyzed by 
the action of lipoprotein lipase, an enzyme located on the outside of the 
cells that is activated by apoC-II, one of the apoproteins on the 
chylomicron surface. The released fatty acids and monoacylglycerols are 
taken up by the tissues, and either used for energy production or re- 
esterified to triacylglycerol for storage. As their triacylglycerol content is 
depleted, the chylomicrons shrink and form cholesterolrich chylomicron 
rem nants, which are transported in the blood to the liver (Fig. 5). Here 
they bind to a specific cell-surface remnant receptor and are taken up into 
the liver cells by receptor-mediatedendocytosis.
Fig. 5. The transport o f triacylglycerol and cholesterol by lipoproteins.
5.3. VLDLs, IDLs and LDLs
VLDLs are synthesized in the liver and transport a variety of lipids 
(Table 1) to other tissues, again mainly adipose tissue and skeletal 
muscle. As with chylomicrons, the triacylglycerols in VLDLs are acted on 
by lipoprotein lipase and the released fatty acids taken up by the tissues 
(Fig. 5). The VLDL remnants remain in the blood, first as IDLs and then as 
LDLs. In the transformation to LDLs, much of the cholesterol is esterified 
on its hydroxyl group on C-3 by the addition of a fatty acid chain from 
phosphatidylcholine (lecithin) by the enzyme lecithin-cholesterol acyl
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transferase (LCAT). In addition, all of the apoproteins other than apoB- 
100 are removed.
LDLs are then taken up by target cells through receptor-mediated 
endocytosis. The LDL receptor, a transmembrane glycoprotein on the 
surface of the target cells, specifically binds apoB-100 in the LDL coat. 
The receptors then cluster into clathrin-coated pits and are internalized. 
Once in the lysosomes, the LDLs are digested by lysosomal enzymes, with 
the cholesterol esters being hydrolyzed by a lysosomal lipase to release 
the cholesterol (Fig. 5). This is then incorporated into the cell membrane 
and any excess is re-esterified for storage by acyl CoA cholesterol 
acyltransferase (ACAT).
To prevent the build up o f cholesterol and its ester derivatives in 
the cell, high levels o f cholesterol:
1. decrease the synthesis o f the LDL receptor, thereby reducing 
the rate of uptake o f cholesterol by receptor-mediated 
endocytosis, and
2. inhibit the cellular biosynthesis of cholesterol through inhibition 
o f HMG CoA reductase
5.4. HDLs
HDLs have the opposite function to that of LDLs in that they remove 
cholesterol from the tissues. The HDLs are synthesized in the blood 
mainly from components derived from the degradation of other 
lipoproteins. HDLs then acquire their cholesterol by extracting it from 
cell membranes and converting it into cholesterol esters by the action 
o f LCAT (Fig.5). The HDLs are then either taken up directly by the 
liver or transfer their cholesterol esters to VLDLs, of which about half 
are taken up by the liver by receptor-mediated endocytosis (Fig. 5). The 
liver is the only organ that can dispose of significant quantities of 
cholesterol, primarily in the form of bile salts.
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1. Ketone bodies
When the level of acetyl CoA from P-oxidation increases in excess of 
that required for entry into the citric acid cycle, the acetyl CoA is converted 
into acetoacetate and D-3-hydroxybutyrate by a process known as 
ketogenesis. D-3-hydroxybutyrate, acetoacetate and its nonenzymic 
breakdown product acetone are referred to collectively as ketone bodies 
(Fig. 1).
Two molecules of acetyl CoA initially condense to form acetoacetyl 
CoA in a reaction, which is essentially the reverse of the thiolysis, step in 
p-oxidation. The acetoacetyl CoA reacts with another molecule of acetyl 
CoA to form 3-hydroxy-3-methylglutaryl CoA (HMG CoA) (Fig. I). 
This molecule is then cleaved to form acetoacetate and acetyl CoA. (HMG 
CoA is also the starting point for cholesterol biosynthesis) The acetoacetate 
is then either reduced to D-3-hydroxybutyrate in the mitochondrial matrix 
or undergoes a slow, spontaneous decarboxylation to acetone (Fig.l). In 
diabetes, acetoacetate is produced faster than it can be metabolized. Hence 
untreated diabetics have high levels of ketone bodies in their blood, and 
the smell of acetone can often be detected on their breath.
C O A
0 II
C “  s  ~1CH,}
c = oICH,
Acetoanertyt C o A
^ ■
acetyl C o A  C o A
О И
G “ S -  COAJ
CH *  
H O - O - C H j
C H j
t
С О С Г
3-Hydraxy-3^ nwi$i0M^boA
C H 30=0 ____  I! он,
AcwytCoA l
С О С Г
Aaeto***«e .
H. b
H0~0;
CH*
СНг
CQO-
<v3-Hyc»T»Q«jytyrerte
№1Ш ++Г* N ,^00*
.°b U
Acetone
Fig. I. Conversion o f  acetyl CoA to the ketone bodies: acetoacetate, acetone and 
D-3-hydroxy butyrate.
Acetoacetate and D-3-hydroxybutyrate are produced mainly in the 
liver and are not just degradation products of little physiological value.
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They are used in preference to glucose as an energy source by certain 
tissues such as the heart muscle and kidney cortex. Although glucose is 
normally the major fuel for the brain, under conditions of starvation or 
diabetes this organ can switch to using predominantly acetoacetate.
2. Fatty acid synthesis
Fatty acids are synthesized by the condensation of two-carbon units. 
However, in terms of the enzymic steps involved, the process is not the 
reverse of p-oxidation. Fatty acid synthesis involves a separate series of 
reactions to build up long-chain hydrocarbons from acetyl CoA units. The 
key differences between fatty acid synthesis and breakdown are:
1 . fatty acid synthesis occurs in the cytosol of both prokaryotes and 
eukaryotes whereas their degradation occurs in the mitochondria 
of eukaryotes;
2. fatty acid synthesis uses NADPH as the reductant whereas NADH 
is produced in P-oxidation;
3. during their synthesis, fatty acids are covalently linked to an acyl 
ca rrie r protein (ACP) as opposed to CoA in their degradation;
4 . the enzyme activities of fatty acid synthesis in higher organisms are 
present in a single, multifunctional polypeptide chain (as a dimer) 
called fatty acid synthase, whereas in p-oxidation the individual 
activities are present on separate enzymes.
2.1 Transport into the cytosol
Fatty acids are synthesized in the cytosol, but acetyl CoA is 
produced from pyruvate in the mitochondria. Thus the acetyl CoA must 
be transferred from the mitochondria into the cytosol tp allow fatty acid 
synthesis to occur. However, the inner m itochondrial membrane is not 
readily permeable to this molecule. This problem is overcome by the 
condensation of acetyl CoA with oxaloacetate to form citrate (Fig. 2). This 
is then transported into the cytosol where it is cleaved to regenerate acetyl 
CoA and oxaloacetate by ATP-citrate lyase in an energy-requiring 
process. The oxaloacetate, which also cannot cross the inner 
mitochondrial membrane, is returned to the mitochondrial matrix 
through conversion first to malate (catalyzed by malate dehydrogenase) 
and then to pyruvate (catalyzed by NADP+-linked malate enzyme) (Fig. 
2). This latter decarboxylation reaction generates NADPH, which can be 
used in fatty acid synthesis. The remaining NADPH required for fatty acid 
synthesis is provided by the pentose phosphate pathway. Once back in the 
mitochondrial matrix, pyruvate is carboxylated to form oxaloacetate by
Synthesis o f lipids.
pyruvate carboxylase with the hydrolysis of a further molecule of ATP
(Fig- 2).
Fig. 2. Transport o f acetyl CoA from the mitochondrial matrix into the cytosol.
The first committed step in fatty acid biosynthesis is the carboxylation 
of acetyl CoA to form malonyl CoA using C 0 2 in the form of bicarbonate 
HCO3 (Fig.3). This reaction is catalyzed by the enzyme acetyl CoA 
carboxylase which has biotin as a prosthetic group, a common feature in 
C 02-binding enzymes. One molecule of ATP is hydrolyzed in the reaction, 
which is irreversible. The elongation steps of fatty acid synthesis all 
involve intermediates linked to the terminal sulfhydryl group of the 
phosphopantetheine reactive unit in ACP; phosphopantetheine is also 
the reactive unit in CoA. Therefore, the next steps are the formation of 
acetyl-ACP and malonyl-ACP by the enzymes acetyl transacylase and 
malonyl transacylase, respectively (Fig. 3). (For the synthesis of fatty 
acids with an odd number of carbon atoms the three-carbon propionyl- 
ACP is the starting point instead of malonyl-ACP).
MmxHcwoRON crroscx
2.2. The pathway
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К AoMytACP
AotyЁтгюасукиь
Fig.3. Formation o f  acetyl- and malonyl-acyl carrier protein (ACP)
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The elongation cycle of fatty acid synthesis has four stages for each 
round of synthesis (Fig. 4). For the first round of synthesis these are:
1. Condensation of acetyl-ACP and malonyl-ACP to form 
acetoacetyl-ACP, releasing free ACP and C 0 2 (catalyzed by acyl- 
malonyi-ACP condensing enzyme).
2. Reduction of acetoacetyl-ACP to form D-3-hydroxybutyryl-ACP, 
using NADPH as reductant (catalyzed by p-ketoacyl-ACP 
reductase).
3. Dehydration of D-3-hydroxybutyryI-ACP to produce crotonyl- 
ACP (catalyzed by 3-hydroxyacyl-ACP dehydratase).
4. Reduction of crotonyl-ACP by a second NADPH molecule to give 
butyryl-ACP (catalyzed by enoyl-ACP reductase).
This first round of elongation produces the four-carbon butyryl-ACP. 
The cycle now repeats with malonyl-ACP adding two-carbon units in each 
cycle to the lengthening acyl-ACP chain. This continues until the 16- 
carbon palmitoyi-ACP is formed. This molecule is not accepted by the 
acyl-malonyl-ACP condensing enzyme, and so cannot be elongated 
further by this process. Instead it is hydrolyzed by a thioesterase to give 
palmitate and ACP.
The overall stoichiometry for the synthesis of palmitate is:
8 acetyl CoA + 7 ATP + 14 NADPH + 6 H+—*
palmitate + 14 NADP+ + 8 CoA + 6 H20  + 7 ADP + 7 Pi
For each of the seven rounds of fatty acid elongation, one ATP is used 
in the synthesis of malonyl-CoA and two NADPH are used in the 
reduction reactions.
In eukaryotes the elongation of fatty acids beyond C16 palmitate is 
carried out by enzymes located on the cytosolic surface of the smooth 
endoplasmic reticulum (SER). Malonyl CoA is used as the two-carbon 
donor, and the fatty acid is elongated as its CoA derivative rather than its 
ACP derivative.
In prokaryotes, each of the reactions of fatty acid synthesis is catalyzed 
by a separate enzyme. However, in eukaryotes, the enzymes of the fatty 
acid synthesis elongation cycle are present in a single polypeptide chain, 
multifunctional enzyme complex, called fatty acid synthase. The fatty 
acid synthase complex exists as a dimer, with the ACP moiety shuttling 
the fatty acyl chain between successive catalytic sites, and from one 
subunit of the dimer to the other. It is, in effect, a highly efficient 
production line for fatty acid biosynthesis.
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Fig. 4. The elongation cycle o f  fatty acid synthesis.
2.3. Formation of double bonds
In eukaryotes the SER has enzymes able to introduce double bonds 
into fatty acyl CoA molecules in an oxidation reaction that uses molecular 
oxygen. This reaction is catalyzed by a membrane-bound complex of three 
enzymes: NADH-cytochrome bs reductase, cytochrome bs and a 
desaturase. The overall reaction is:
saturated fatty acyl CoA + NADH + H* + 0 2
mono-unsaturated acyl CoA + NAD+ + 2 H20
The reaction may be repeated to introduce more than one double bond 
into a fatty acid.
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Mammals lack the enzymes to insert double bonds at carbon atoms 
beyond C-9 in the fatty acid chain. Thus they cannot synthesize linoleate 
and linolenate, both of which have double bonds later in the chain than 
C-9 (linoleate has cis, cis A9, A 12 double bonds, and linolenate has all-cis A , 
A12, A15 double bonds). Hence, in mammals linoleate and linolenate are 
called essential fatty acids since they have to be supplied in the diet. 
These two unsaturated fatty acids are also the starting points for the 
synthesis of other unsaturated fatty acids, such as arachidonate. This C 
20:4 fatty acid is the precursor of several biologically important molecules, 
including the prostaglandins, prostacyclins, thromboxanes and 
leukotrienes.
2.4. Regulation
The key control point of fatty acid synthesis is acetyl CoA carboxylase 
which catalyzes the formation of malonyl CoA. Acetyl CoA carboxylase is 
inactivated by phosphorylation by an AMP-activated protein kinase. Thus 
when the energy charge of the cell is low (high AMP, low ATP) acetyl CoA 
carboxylase is inactive. It is reactivated by dephosphorylation by protein 
phosphatase 2A. Glucagon and epinephrine inhibit fatty acid synthesis by 
inhibiting protein phosphatase 2A, whereas insulin stimulates fatty acid 
synthesis by activating the phosphatase. Acetyl CoA carboxylase is also 
allosterically regulated: citrate activates the enzyme, whereas palmitoyl 
CoA inhibits it.
3. Synthesis of triacylglycerols.
Triacylglycerols are synthesized from fatty acyl CoAs and glycerol 3- 
phosphate (Fig. 5). The glycolytic intermediate dihydroxyacetone 
phosphate is first reduced to glycerol 3-phosphate, which is, in turn, 
acylated by glycerol-3-phosphate acyltransferase to form 
lysophosphatidic acid. This is then reacted with a further acyl CoA 
molecule to form phosphatidic acid. Removal of the phosphate group 
from phosphatidic acid generates diacylglycerol (DAG), which is 
further acylated with a third acyl CoA molecule to form triacylglycerol 
(Fig. 5). ATP is not involved in the biosynthesis of triacylglycerols. Instead 
the reactions are driven by the cleavage of the high-energy thioester bond 
between the acyl moiety and CoA. Both phosphatidic acid (phosphatidate) 
and DAG are also used in the synthesis of membrane phospholipids.
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Fig. 5. Synthesis o f  triacylglycerols.
4. Biosynthesis of cholesterol
Animals are able to synthesize cholesterol de novo by an elegant 
series of reactions in which all 27-carbon atoms of cholesterol are derived 
from acetyl CoA. The acetate units are first converted into C5 isoprene 
units, which are then condensed to form a linear precursor to the cyclic 
cholesterol.
The first stage in the synthesis of cholesterol is the formation of 
isopentenyl pyrophosphate (Fig. 6). Acetyl CoA and acetoacetyl CoA 
combine to form 3-hydroxy-3-methyIglutaryI CoA (HMG CoA). This
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process takes place in the liver, where the HMG CoA in the mitochondria 
is used to form ketone bodies during starvation, whereas that in the cytosol 
is used to synthesize cholesterol in the fed state (under the influence of 
cholesterol). HMG CoA is then reduced to mevalonate by HMG CoA 
reductase (Fig. 6). This is the committed step in cholesterol biosynthesis 
and is a key control point. Mevalonate is converted into 3-isopentenyl 
pyrophosphate by three consecutive reactions each involving ATP, with 
CCb being released in the last reaction (Fig. 6).
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Fig. 6. Synthesis o f  isopentenyl pyrophosphate.
The C5 isoprene units in isopentenyl pyrophosphate are then 
condensed to form the C30 compound squalene (Fig. 7). First, isopentenyl 
pyrophosphate isomerizes to dimethylallyl pyrophosphate (Fig. 7a), 
which reacts with another molecule of isopentenyl pyrophosphate to form 
the CIO compound geranyl pyrophosphate (Fig. 7b). Another molecule 
of isopentenyl pyrophosphate then reacts with geranyl pyrophosphate to
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form the C15 compound farnesyl pyrophosphate. Next, two molecules 
of farnesyl pyrophosphate condense to form squalene (Fig. 7b).
Squalene is then converted into squalene epoxide in a reaction that 
uses 0 2 and NADPH (Fig. 7b). The squalene epoxide cyclizes to form 
lanosterol, and finally cholesterol is formed from lanosterol by the 
removal of three methyl groups, the reduction of one double bond by 
NADPH, and the migration of the other double bond (Fig. 7b).
Farnesyl pyrophosphate and the C20 compound geranylgeranyl 
pyrophosphate (which is formed by the condensation of another 
isopentenyl pyrophosphate with farnesyl pyrophosphate) are covalently 
linked to cysteine residues in a number of proteins, promoting their 
association with membranes. Dolichol, which contains some 20 isoprene 
units is used to carry the biosynthetic precursor of the N-linked 
oligosaccharides that are subsequently attached to proteins.
4.1. Regulation of cholesterol biosynthesis
Cholesterol can be obtained either from the diet or it can be 
synthesized de novo, mainly in the liver. Cholesterol is transported round 
the body in lipoprotein particles. The rate of synthesis of cholesterol is 
dependent on the cellular level of cholesterol. High levels of cholesterol 
and its metabolites control cholesterol biosynthesis by:
1. feedback-inhibiting the activity of HMG CoA reductase, the 
enzyme which catalyzes the committed step in cholesterol 
biosynthesis;
2. decreasing the amount of HMG CoA reductase by reducing the 
synthesis and translation of its mRNA;
3. decreasing the amount o f HMG CoA reductase by increasing its 
rate o f degradation.
In addition, HMG CoA reductase, like acetyl CoA carboxylase in fatty 
acid synthesis, is inactivated by phosphorylation by an AMP-activated 
protein kinase, retained in this form under the influence of glucagon 
during starvation.
HMG CoA reductase can be inhibited therapeutically by administering 
the drug lovastatin, based on the fungal products mevinolin and 
compactin, which competitively inhibit the enzyme and hence decrease 
the rate of cholesterol biosynthesis. Therefore, these compounds are 
routinely used for the treatment of hypercholesterolemia (high levels of 
blood cholesterol).
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ATHEROSCLEROSIS
1. The exogenous lipid cycle
Dietary lipid is absorbed in the small intestine and incorporated into 
chylomicrons, which are secreted into the lymphatics and reach the 
bloodstream via the thoracic duct. In the circulation, triglyceride is 
gradually removed from these lipopoproteins by the action of lipoprotein 
lipase. This enzyme is present in the capillaries of a number of tissues, 
predominantly adipose tissue and skeletal muscle. As it loses 
triglyceride, the chylomicron becomes smaller and deflated, with folds of 
redundant surface material. These remnants are removed by the liver. The 
cholesterol may be utilized by the liver to form cell membrane 
components or bile salts, or may be excreted in the bile. The liver 
provides the only route by which cholesterol leaves the body in significant 
amounts.
2. The endogenous lipid cycle
The liver synthesizes VLDL particles, which undergo the same form 
of delipidation as chylomicrons by the action of lipoprotein lipase. This 
results in the formation of an interm ediate density lipoprotein (IDL) 
which becomes low density lipoprotein (LDL) when further delipidated. 
LDL may be removed from the circulation by the high affinity LDL 
receptor or by other less well defined scavenger routes which are thought 
to be important at high LDL levels and the main way in which 
cholesterol is incorporated into atheromatous plaques. HDL particles 
are derived from both liver and gut. They act as cholesteryl ester shuttles, 
removing the sterol from the peripheral tissues and returning it to the 
liver. The HDL is taken up either directly by the liver, or indirectly by 
being transferred to other circulating lipoproteins, which then return it 
to the liver. This process is thought to be antiatherogenic, and an 
elevated HDL-cholesterol level has been shown to confer a decreased 
risk of coronary heart disease on an individual.
Apolipoproteins are the protein components o f the lipoproteins. They 
are important in:
1. maintaining the structural integrity of the lipoproteins
2. regulating certain enzymes which act on lipoproteins receptor 
recognition (Fig. 1).
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Fig. 1. Lipoprotein metabolism
3. The LDL receptor
The LDL receptor (Fig. 2), a glycoprotein present on the surface of all 
cells, spans the cell membrane and is concentrated in special membrane 
recesses, called 'coated' pits. It binds to lipoproteins containing 
apolipoprotein В and E, and internalizes them for breakdown within the 
cell. Receptors are then recycled to the cell surface. The number and 
function of receptors dictate the level of circulating LDL. When the cell 
has sufficient cholesterol, the synthesis of receptors is down-regulated; 
when the cell is cholesterol depleted, the receptors increase in number. 
Inherited malfunction or absence of these receptors leads to familial 
hypercholesterolaemia.
A specific mutation of apolipoprotein В results in defective binding of 
LDL to its receptor and produces an identical clinical picture to familial 
hypercholesterolaemia.
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Fig.2. The LDL receptor pathway.
4. Clinical disorders of lipid metabolism
Lipoprotein disorders are some of the commonest metabolic diseases 
seen in clinical practice. They may present with their various sequelae 
which include:
1. coronary heart disease (CHD)
2. acute pancreatitis
3. failure to thrive and weakness
4. cataracts.
4.1. Classification
Currently there is no satisfactory comprehensive classification of 
lipoprotein disorders. Genetic classifications have been attempted but are 
becoming increasingly complex as different mutations are discovered 
(Table 1).
Familial hyper-cholesterolaemia (FH) which presents with 
xanthelasma, tendon xanthomas, severe hypercholesterolaemia and 
premature coronary heart disease may be due to any of over 150 different 
mutations of the LDL receptor gene. Mutations of the apolipoprotein apo-B 
gene can give an identical syndrome.
Familial hyperchylomicronaemia which presents with recurrent 
abdominal pain and pancreatitis may result from genetic mutations of the 
lipoprotein lipase or apo-C-II genes. Eruptive xanthomas are characteristic 
of hypertriglyceridaemia. Until gene therapy and/or specific substitution 
therapy become more available, genetic classifications, while biologically 
very illuminating, are unlikely to prove very useful in practice. In practice, 
lipoprotein disorders are simplistically classified as being:
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1. Primary—when the disorder is not due to an identifiable underlying 
disease.
2. Secondary—when the disorder is a manifestation of some other 
disease.
Table 1. Some genetic causes o f dyslipidaemia
D ise a se G en e tic  d e fec t F re d ric k so n R isk
F am ilia l h y p e r-  
ch o lis te ro la e m ia
R e d u c e d  n u m b e rs  o f  
fu n c tio n a l L D L  
re c e p to rs
H a o r  l ib C H D
F am ilia l h y p e r-  
tro g ly c e rid a e m ia
P o ss ib ly  s in g le  g en e  
d e fe c t
IV  o r V
F am ilia l c o m b in ed  
h y p e r iip id a e m ia
P o ss ib ly  s in g le  g en e  
d e fe c t
I la , l ib , 
IV  o r  V
C H D
L ip o p ro te in  lip a se  
d e fic ien cy
R e d u c e d  lev e ls  o f  
fu n c tio n a l L P L
I P an c rea titis
A p o -C -H
d efic ien cy
In ab ility  to  sy n th e s iz e  
ap o  C -II (c o fa c to r  fo r 
lip o p ro te in  lip ase )
1 P a n c rea titis
A b e ta lip o p ro -
te in a e m ia
In a b ility  to  sy n th e s iz e  
apo  В
N o rm al F a t so lu b le  v ita m in  
d e fic ien ce s , n e u ro lo g e c a l 
d e fic it
A n a lp h a lip o p ro -
te in a e m ia
In a b ility  to  sy n th e s iz e  
a p o  A
N o rm a l N e u ro lo g ic a l d e fic it. 
C h o le s te ry l e s te r  s to ra g e  
in ab n o rm a l s ite s
4.1.1. Primary
The Fredrickson or World Health Organization classification is the most 
widely accepted for the primary hyperlipidaemias. It relies on the findings 
of plasma analysis, rather than genetics. As a result, patients with the same 
genetic defect may fall into different groups, or may change grouping as 
the disease progresses or is treated (Table 1). The major advantage of this 
classification is that it is widely accepted and gives some guidance for 
treatment.
The six types o f hyperlipoproteinaemia defined in the Fredrickson 
Classification are not equally common. Types I and V are rare, while types 
Ha, lib and IV are very common. Type III hyper-lipoproteinaemia, also 
known as familial dysbetalipoproteinaemia, is intermediate in frequency, 
occuring in about 1/5000 of the population (Fig.3).
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Fig. 3 Fredrickson (WHO) classification o f  dyslipidaemia. This is based on the 
appearance o f  a fasting plasma sample after standing fo r  12 hours at 4 ' C and analysis 
o f  its cholesterol and triglyceride content.
4.1.2. Secondary
Secondary hyperlipoproteinaemia is a well-recognized feature of a 
number of diseases (Table 2), which divide broadly into two categories:
1. Clinically obvious diseases such as renal failure, nephrotic syndrome 
and cirrhosis of the liver.
2. Covert conditions which may present as hyperlipidaemia. These 
include hypothyroidism, diabetes mellitus and alcohol abuse.
Table 2. Common causes o f  secondary hyperlipidaemia
Disease Usual dominant lipid abnormality
Diabetes mellitus Increased triglyceride
Alcohol excess Increased triglyceride
Chronic renal failure Increased triglyceride
Drugs, e g. thiazide diuretics 
nonselective p-blockers
Increased triglyceride
Hypothyroidism Increased cholesterol
Nephrotic syndrome Increased cholesterol
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4.2. Atherogenic profiles
The casual association of certain forms of hyperlipidaemia and CHD is 
clearly the major stimulus for the measurement of plasma lipids and 
lipoproteins in clinical practice. The most common lipid disorder linked 
with atherogenesis and an increased risk of CHD is an elevated 
plasma LDL cholesterol level, but increasingly it is being recognized that 
individuals with low plasma HDL cholesterol and 
hypertriglyceridaemia are also at increased risk.
5. Hyperlipidaemia
The management of hyperlipidaemia is an important aspect of 
coronary heart disease (CHD) risk factor correction. Modifying 
hyperlipidaemia together with the other non-lipid risk factors has been 
repeatedly shown to reduce the risk of developing CHD and to delay or 
even reverse the progression of established CHD. Risk factors for CHD 
(Table 3) fall into two groups: those which can be corrected (such as 
smoking, hypertension and obesity) and those, which cannot be influenced 
(such as age and sex).
Table 3. Non-lipid coronary heari disease risk factors
1. A g e  (years)
1.1 M en  >  45
1.2 W o m en  >  55 o r  w ith  p rem atu re  m en o p au se  w ith o u t e s tro g en  rep lacem en t
2. F am ily  h isto ry  o f  p rem a tu re  C H D
3. S m o k in g
4. H y p erten sio n
5. D iab e te s  m e llitu s
Because the management of primary and secondary hyperlipidaemia is 
fundamentally different, the two groups of conditions must be 
distinguished. The main secondary hyperlipidaemias are due to:
1. diabetes mellitus
2. alcohol misuse
3. hypothyroidism
4. nephrotic syndrome.
6. Dietary management
The first-line management of any primary hyperlipidaemia should 
always be dietary modification. This may be time-consuming and difficult 
but its importance should not be underestimated. Dietary management as 
a sole therapy should be pursued for 3-6 months before its effect is 
evaluated. This diagram illustrates the standard lipid-lowering dietary
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guidelines, which are currently recommended, but these obviously require 
some translation for patient use.
In essence, it is recommended that red meat and dairy consumption be 
reduced while that of vegetables, fruit and pulses is increased together 
with more fish (especially oily fish such as mackerel, salmon and tuna). In 
addition to modifying the composition of the diet, weight reduction to 
achieve idea! body weight coupled with exercise are important as these 
will frequently improve glucose tolerance and lower; blood pressure in 
addition to their effects on plasma lipids.
7. Drug therapy
Drug therapy for hyperlipidaemia, if required, should be viewed as an 
adjunct to dietary management and other lifestyle changes. There is currently a 
range of lipid-lowering drugs available with a variety of actions (Table 4). The 
commonest drugs for the treatment of primary hypercholesterolaemia are the 
bile acid sequestrant resins and the HMG CoA reductase inhibitors (the 
'statins'). The commonest drugs for the treatment of primary 
hypertriglyceridaemia or combined hyperlipidaemia are the fibrates or 
nicotinic acid and its derivatives.
Table 4. Lipid-towering drugs
D ru g  g ro u p
P rin c ip a l a c tio n s
B ile  ac id  se q u e s tra n t B lo ck  b ile  ac id  re a b so rp tio n  and  lo w e r  to ta l and  L D L
resin s c h o le s te ro l
H M G  C o A  re d u c ta se In h ib it c h o le s te ro l b io sy n th e s is  an d  lo w e r  to ta l an d  L D L
in h ib ito rs ch o le s te ro l
F ib ra te s A c tiv a te  lip o p ro te in  lip a se  an d  lo w e r  tr ig ly c e rid e , to ta l and  
L D L  ch o les te ro l.
N ic o tin ic  a c id  and M ay  in c rea se  H D L  c h o le s te ro l
d e r iv a tiv e s In h ib it l ip o ly s is  w ith in  a d ip o c y te s  an d  lo w e r  tr ig ly ce rid e s .1 In c re ase  H D L  c h o le s te ro l
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METABOLISM OF PROTEINS, AMINO ACIDS
1. Digestion and absorption of proteins
The digestion of protein begins in the stomach. The gastric secretion is 
known as gastric juice. It is a clear, pale yellow fluid of 0.2-0.5% HCI, with 
a pH o f about 1.0. The gastric juice is 97-99% water. The remainder 
consists o f mucin and inorganic salts, the digestive enzymes (pepsin and 
rennin).
The parietal (oxyntic) cells are the source of gastric HCI. As a result of 
contact with gastric HCI, proteins are denatured; ie, the tertiary protein 
structure is lost as a result of the destruction of hydrogen bonds. This allows 
the polypeptide chain to unfold, making it more accessible to the actions of 
proteolytic enzymes (proteases). The low pH also has the effect of destroying 
most microorganisms entering the gastrointestinal tract
Pepsin is produced in the chief cells as the inactive zymogen, pepsinogen. 
This is activated to pepsin by IT, which splits off a protective polypeptide to 
expose active pepsin; and by pepsin, which rapidly activates further molecules 
of pepsinogen (autocatalysis). Pepsin transforms denatured protein into 
proteoses and then peptones, which are large polypeptide derivatives. Pepsin 
is an endopeptidase, since it hydrolyzes peptide bonds within the main 
polypeptide structure rather than adjacent to N- or C-terminal residues, 
which is characteristic of exopeptidases. It is specific for peptide bonds formed 
by aromatic amino acids (eg, tyrosine) or dicarboxylic amino acids (eg, 
glutamate).
Rennin (Chymosin, Rennet) causes the coagulation of milk. It is 
important in the digestive processes of infants, because it prevents the rapid 
passage of milk from the stomach. In the presence of calcium, rennin changes 
casein of milk irreversibly to a paracasein, which is then acted on by pepsin. 
Rennin is reported to be absent from the stomach of adults. It is used in the 
making of cheese.
The stomach contents, or chyme, are intermittently introduced during 
digestion into the duodenum through the pyloric valve. The alkaline content 
of pancreatic and biliary secretions neutralizes the acid of the chyme and 
changes the pH of this material to the alkaline side; this shift of pH is 
necessary for the activity of the enzymes contained in pancreatic and intestinal 
juice but it inhibits further action of pensin.
Pancreatic secretion is a nonviscid watery fluid that is similar to saliva in its 
content of water and contains some protein and other organic and inorganic 
compounds - mainly Na+, K+, HC03‘, and СГ, but Ca +, Zn2+, HP042’ and
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S042' are also present in small amounts. The pH of pancreatic secretion is dis­
tinctly alkaline, 7.5-8.0 or higher.
Many enzymes are found in pancreatic secretion, some are secreted as 
zymogens.
The proteolytic action of pancreatic secretion is due to the 3 
endopeptidases trypsin, chymotrypsin, and elastase, which attack proteins 
and polypeptides released from the stomach, to produce polypeptides, 
peptides, or both. Trypsin is specific for peptide bonds of basic amino 
acids, and chymotrypsin is specific for peptide bonds containing uncharged 
amino acid residues, such as aromatic amino acids. Elastase, in spite of its 
name, has rather broad specificity in attacking bonds next to small amino acid 
residues such as glycine, alanine, and serine. All 3 enzymes are secreted as 
zymogens. Activation of trypsinogen is due to another proteolytic enzyme, 
enterokinase, secreted by the intestinal mucosa. This hydrolyzes a lysine 
peptide bond in the zymogen, releasing a small polypeptide that allows the 
molecule to unfold as active trypsin. Once trypsin is formed, it will attack not 
only additional molecules of trypsinogen but also the other zymogens in the 
pancreatic secretion, chymotrypsinogen, proelastase, and 
procarboxypeptidase, liberating chymotrypsin, elastase, and carboxypeptidase, 
respectively.
The intestinal juice secreted by the glands of Brunner and of Lieberkiihn 
contains digestive enzymes, including the following:
Aminopeptidase, which is an exopeptidase attacking peptide bonds 
next to N-terminal amino acids of polypeptides and oligopeptides; and 
dipeptidases of various specificity, some of which may be within the 
intestinal epithelium. The latter complete digestion of dipeptides to free 
amino acids.
Under normal circumstances, the dietary proteins are almost 
completely digested to their constituent amino acids, and these end 
products of protein digestion are then rapidly absorbed from the intestine 
into the portal blood. It is possible that some hydrolysis, eg, of dipeptides, 
is completed in the intestinal wall. Animals may be successfully maintained 
when a complete amino acid mixture is fed to them.
The natural L isomer but not the D isomer o f an amino acid is actively 
transported across the intestine from the mucosa to the serosa; vitamin B6 
(pyridoxal phosphate) may be involved in this transfer. This active transport 
of the L-amino acids is energy-dependent, as evidenced by the fact that 2,4- 
din itrophenol, the uncoupler of oxidative phosphorylation, inhibits 
transport. Amino acids are transported through the brush border by a 
multiplicity of carriers, many having Na+ -dependent mechanisms similar to 
the glucose carrier system. Of the Na+-dependent carriers, there is a neutral 
amino acid carrier, a phenylalanine and methionine carrier, and a carrier 
specific for imino acids such as proline and hydroxyproline. Na+-
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independent carriers specializing in the transport of neutral and lipophilic 
amino acids (eg, phenylalanine and leucine) or of cationic amino acids (eg, 
lysine) have been characterized.
Clinical aspects. Individuals in whom an immunologic response to 
ingested protein occurs must be able to absorb some unhydrolyzed protein, 
since digested protein is nonantigenic. This is not entirely undocumented, 
since the antibodies of the colostrum are known to be available to the 
infant.
There is increasing support for the hypothesis that the basic defect in 
nontropical sprue is located within the mucosal cells of the intestine and 
permits the polypeptides resulting from the peptic and tryptic digestion of 
gluten, the principal protein of wheat, not only to exert a local harmful effect 
within the intestine but also to be absorbed into the circulation and thus to 
elicit the production of antibodies. It has been established that circulating 
antibodies to wheat gluten or its fractions are frequently present in patients 
with nontropical sprue. The harmful entity is a polypeptide composed of 6 
or 7 amino acids.
These observations on a disease entity that is undoubtedly the adult 
analog of celiac disease in children advance the possibility that protein 
fragments of larger molecular size than amino acids are absorbed from the 
intestine under certain conditions.
2. Biosynthesis of amino acids
Plants and microorganisms can synthesize all of the 20 standard amino 
acids. Mammals, however, cannot synthesize all 20 and must obtain some 
of them in their diet. Those amino acids that are supplied in the diet are 
referred to as essential, whereas the remainder that can be synthesized by 
the organism are termed nonessential. This designation refers to the needs 
of an organism under a particular set of conditions. In humans the 
nonessential amino acids are Ala, Arg, Asn, Asp, Cys, Glu, Gin, Gly, Pro, 
Ser and Tyr, while the essential ones are His, lie, Leu, Lys, Met, Phe, Thr, 
Trp and Val. The pathways for the biosynthesis of amino acids are diverse 
and often vary from one organism to another. However, they all have an 
important feature in common: their carbon skeletons come from key 
intermediates in central metabolic pathways. The amino acids can be 
grouped together into six biosynthetic pathways depending on the 
intermediate from which they are derived (Fig. 1). The primary amino 
group usually comes from transamination of glutamate.
156
Metabolism ofproteins, amino acids.
IOki lAsp
,  :
G futam m e
• terrtfy ■
3-Pho*phog)yo»r«t*
S e r
/  \  
С у »  Gfy
S&rin& (auntty
t_ya
Ata vai
f*yruv&t<3 t&mtfy
Fig. 1. BtosynthGtic t&mRb&s of amino acfcfe.
3. Amino acid degradation
As there is no store for excess amino, acids, and as proteins are 
constantly being turned over, amino acids have to be continually 
degraded. The a-amino group is removed first and the resulting carbon 
skeleton is converted into one or more major metabolic intermediates and 
used as metabolic fuel. The carbon skeletons of the 20 standard amino 
acids are tunneled into only seven molecules: pyruvate, acetyl CoA, 
acetoacetyl CoA, a-ketoglutarate, succinyl CoA, fumarate and oxaloacetate 
(Fig. 2). Amino, acids that are degraded to pyruvate, a-ketoglutarate, 
succinyl CoA, fumarate and oxaloacetate are termed glucogenic as they 
can give rise to the net synthesis of glucose. This is because the citric acid 
cycle intermediates and pyruvate can be converted into 
phosphoenolpyruvate and then into glucose via gluconeogenesis. In 
contrast, amino acids that are degraded to acetyl CoA or acetoacetyl CoA 
are termed ketogenic because they give rise to ketone bodies; the acetyl 
CoA or acetoacetyl CoA can also be used to synthesize lipids. O f the
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standard set of 20 amino acids, only Leu and Lys are solely ketogenic. 
lie, Phe, Trp and Тут are both ketogenic and glucogenic as some of their 
carbon atoms end up in acetyl CoA or acetoacetyl CoA, whereas others 
end up in precursors of glucose. The remaining 14 amino acids are 
classified as solely glucogenic.
4. Transamination
Prior to the metabolism of their carbon skeletons into a major metabolic 
intermediate, the a-amino group of the amino acid has first to be 
removed by a process known as transamination. In this process the a- 
amino group of most amino acids is transferred to a-ketoglutarate to form 
glutamate and the corresponding a-keto acid:
a  -amino acid + a-ketoglutarate > a -keto acid + glutamate 
The enzymes that catalyze these reactions are called transaminases 
(aminotransferases) and in mammals are found predominantly in the 
liver. For example, aspartate transaminase catalyzes the transfer of the 
amino group of aspartate to a-ketoglutarate (Fig. 3a), while alanine 
transaminase catalyzes the transfer of the amino group of alanine to a- 
ketoglutarate (Fig. 3b).
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Pyridoxal phosphate
The coenzyme (or prosthetic group) of all transaminases is pyridoxal 
phosphate, which is derived from pyridoxine (vitamin B6), and which is 
transiently converted into pyridoxamine phosphate during transamination 
(Fig. 4). In the absence of substrate, the aldehyde group of pyridoxal 
phosphate forms a covalent Schiff base linkage (imine bond) with the 
amino group in the side-chain of a specific lysine residue in the active site 
of the enzyme. On addition o f substrate, the a-amino group of the 
incoming amino acid displaces the amino group of the active site lysine 
and a new Schiff base linkage is formed with the amino acid substrate. 
The resulting amino acid-pyridoxal phosphate-Schiff base that is formed 
remains tightly bound to the enzyme by multiple noncovalent 
interactions.
i‘> ы
Fig. 4. Structures o f  (a) pyridoxine (vitamin 5 *  (b) pyridoxal phosphate and (c) 
pyridoxamine phosphate.
The amino acid is then hydrolyzed to form an a-keto acid and 
pyridoxamine phosphate, the a-amino group having been temporarily 
transferred from the amino acid substrate on to pyridoxal phosphate 
(Fig. 5). These steps constitute one half of the overall transamination 
reaction. The second half occurs by a reversal of the above reactions with a
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second a-keto acid reacting with the pyridoxamine phosphate to yield a 
second amino acid and regenerate the enzyme-pyridoxal phosphate 
complex (Fig. 5).
The reactions catalyzed by transaminases are anergonic as they do not 
require an input o f metabolic energy. They are also freely reversible, the 
direction of the reaction being determined by the relative concentrations 
of the amino acid-keto-acid pairs. Pyridoxal phosphate is not just used as 
the coenzyme in transamination reactions, but is also the coenzyme for 
several other reactions involving amino acids including decarboxylations, 
deaminations, racemizations and aldol cleavages.
COO* 
f
ON,I
CH.{с — оicoo-
Fig. 5. The overall reaction o f  transaminase
5. Oxidative deamination of glutamate
The a-amino groups that have been funneled into glutamate from the 
other amino acids are then converted into ammonia by the action of 
glutamate dehydrogenase (Fig. 6). This enzyme is unusual in being able 
to utilize either NAD+ or NADP+. In the biosynthesis of glutamate, the 
NADP+ form of the coenzyme is used, whereas NAD+ is used in its 
degradation. Glutamate dehydrogenase consists of six identical subunits 
and is subject to allosteric regulation. GTP and ATP are allosteric 
inhibitors, whereas GDP and ADP are allosteric activators. Hence, 
when the energy charge of the cell is low (i.e. there is more ADP and 
GDP than their triphosphate forms) glutamate dehydrogenase is activated 
and the oxidation o f amino acids increases. The resulting carbon skeletons 
are then utilized as metabolic fuel, feeding into the citric acid cycle and 
ultimately giving rise to energy through oxidative phosphorylation.
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Fig. 6. Oxidative deamination o f  glutamate by glutamate dehydrogenase.
6. Amino acid oxidases
The major route for the deamination of amino acids is transamination 
followed by the oxidative deamination of glutamate. However, a minor 
route also exists that involves direct oxidation of the amino acid by L- 
amino acid oxidase. This enzyme utilizes flavin mononucleotide (FMN) as 
its coenzyme, with the resulting FMNH2 being reoxidized by molecular 0 2, 
a process that also generates the toxic H20 2 (Fig. 7).
The H20 2 is rendered harmless by the action of catalase. Kidney and 
liver are also rich in the FAD-containing D-amino acid oxidase. However, 
the function of this enzyme in animals is unclear, since the D-isomers of 
amino acids are rare in nature, only occurring in bacterial cell walls.
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Fig. 7. Action o f  L-amino acid oxidase.
Lecture 19
Lecture 19
CATABOLISM OF AMINO ACID NITROGEN
1. Biomedical importance
Ammonia, derived mainly from deamination of the a-amino nitrogen 
of amino acids, is toxic to all animals. Human tissues therefore initially 
detoxify ammonia by converting it to glutamine for transport to the liver. 
Deamination of glutamine in the liver releases ammonia, which then is 
efficiently converted to the nontoxic, nitrogen-rich compound urea. Efficient 
biosynthesis o f urea is essential for health. Where liver function is 
seriously compromised, eg, in individuals with massive cirrhosis or severe 
hepatitis, ammonia accumulates in the blood and generates clinical signs and 
symptoms. Rare but injurious metabolic disorders of all five urea cycle 
enzymes have been reported. Appropriate management of those few 
infants born with a deficiency in the activity of an enzyme of the urea cycle 
requires an understanding of the biochemistry of urea synthesis. Future 
advances in gene therapy offer promise for treating these metabolic 
diseases.
2. Ammonia intoxication is life-threatening
Ammonia generated by enteric bacteria is absorbed into the portal 
venous blood, which thus contains higher levels of ammonia than does 
systemic blood. Since a healthy liver promptly removes this ammonia from 
the portal blood, peripheral blood is virtually ammonia-free. This is 
essential, since even traces of ammonia are toxic to the central nervous 
system. Should portal blood bypass the liver, ammonia in the systemic 
blood may rise to toxic levels. This follows severely impaired hepatic 
function or development of collateral communications between the portal 
and systemic veins, as may occur in cirrhosis. Symptoms of ammonia 
intoxication include tremor, slurred speech, blurred vision, and in severe 
cases, coma and death. These symptoms resemble those o f hepatic coma, 
which occurs when blood and brain ammonia levels are elevated. 
Treatment stresses measures designed to reduce blood ammonia levels.
3. Glutamine synthetase fixes ammonia as glutamine
While ammonia is constantly produced in the tissues, it is rapidly 
removed from the circulation by the liver and converted to glutamate,
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glutamine, and ultimately to urea. Ammonia thus normally is present only 
in traces in peripheral blood (10-20 pg/dL). In addition to fixation of 
ammonia via the glutamate dehydrogenase reaction, formation of glutamine 
is catalyzed by glutamine synthetase (Fig.l), a mitochondrial enzyme 
present in high quantities in renal tissue. Synthesis of the amide bond of 
glutamine is accomplished at the expense of hydrolysis of one equivalent 
o f ATP to ADP and Pi. The reaction is thus strongly favored in the 
direction of glutamine synthesis.
Although brain tissue can form urea, this tissue does not appear to play 
a significant role in ammonia removal. In brain tissue, the major 
mechanism for detoxification of ammonia is glutamine formation. 
However, if blood ammonia levels are elevated, the supply of blood 
glutamate available to the brain is inadequate for formation of glutamine. 
The brain therefore also must synthesize glutamate from a-ketoglutarate. 
This would rapidly deplete citric acid cycle intermediates unless they were 
replaced by C 0 2 fixation, converting pyruvate to oxaloacetate. Fixation of 
C 0 2 into amino acids indeed occurs in brain tissue. After infusion of 
ammonia, citric acid cycle intermediates are diverted to the synthesis of a- 
ketoglutarate and subsequently of glutamine.
Hydrolytic release of the amide nitrogen of glutamine as ammonia, 
catalyzed by glutaminase (Fig.2), strongly favors glutamate formation. 
Glutamine synthetase and glutaminase thus catalyze inter-conversion of 
free ammonium ion and glutamine (Fig.3). An analogous reaction is 
catalyzed by L-asparaginase. Since certain tumors exhibit abnormally high 
requirements for glutamine and asparagine, asparaginase and glutaminase 
have been tested as antitumor agents.
3. Glutaminase and asparaginase deamidate glutamine 
and asparagine
1
О
1 1
О
о о
L-Glutamine
Fig. I. The glutamine synthase 
reaction. The reaction strongly 
favors glutamine synthesis.
Fig.2. The glutaminase reaction proceeds 
essentially irreversibly in the direction o f
glutamate and N H f formation.
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Fig.3. Interconversion o f  ammonium ion and o f glutamine catalyzed by glutamine 
synthetase and glutamincise. Both reactions are strongly favored in the directions indicated 
by the arrows. Glutaminase thus serves solely fo r  glutamine deamidation and glutamine 
synthetase solelyfor synthesis o f  glutamine from glutamate.
5. Formation and secretion of ammonia maintain acid-base balance
Excretion into the urine of the ammonia produced by renal tubular cells 
facilitates cation conservation and regulation of acid-base balance. Derived 
from intracellular renal amino acids, particularly glutamine, from which it is 
released by renal glutaminase, ammonia production increases in metabolic 
acidosis and decreases in metabolic alkalosis.
6. Inter-organ exchange maintains circulating levels of amino acids
The maintenance of steady-state concentrations of circulating plasma 
amino acids between meals depends on the net balance between release from 
endogenous protein stores and utilization by various tissues. Muscle generates 
over half of the total body pool of free amino acids, while liver is the site of 
the urea cycle enzymes necessary for disposal of excess nitrogen. Muscle and 
liver thus play major roles in maintaining circulating amino acid levels.
Fig. 4 summarizes the postabsorptive state. Free amino acids, particularly 
alanine and glutamine, are released from muscle into the circulation. Alanine, 
which appears to be the vehicle of nitrogen transport in the plasma, is 
extracted primarily by the liver. Glutamine is extracted by the gut and the 
kidney, both of which convert a significant portion to alanine. Glutamine also 
serves as a source of ammonia for excretion by the kidney. The kidney 
provides a major source of serine for uptake by peripheral tissues, including 
liver and muscle. Branched-chain amino acids, particularly valine, are 
released by muscle and taken up predominantly by the brain.
Alanine serves .as a key gluconeogenic amino acid (Fig.5). In the liver, 
the rate of glucose synthesis from alanine is far higher than from all other 
amino acids. The capacity of the liver for gluconeogenesis from alanine does
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not reach saturation until the alanine concentration reaches 20-30 times its 
physiologic level.
Following a protein-rich meal, the splanchnic tissues release amino 
acids (Fig.6) while the peripheral muscles extract amino acids, in both 
instances predominantly branched-chain amino acids. Branched-chain 
amino acids thus serve a special role in nitrogen metabolism, both in the 
fasting state, when they provide the brain with an energy source, and after 
feeding, when they are extracted predominantly by muscles, having been 
spared by the liver.
Fig. 4. Inter-organ amino acid exchange in 
normal postabsorptive humans. The key 
role o f alanine in amino acid output from  
muscle and gut and uptake by the liver is 
shown.
Fig.5. The glucose-alanine cycle. Alanine is 
synthesized in muscle by transamination o f  
glucose-derived pyruvate, released into the 
bloodstream and taken up by the liver. In the 
liver, the carbon skeleton o f alanine is 
reconverted to glucose and released into the 
bloodstream where, it is available fo r uptake 
by muscle and resynthesis o f alanine.
(60% Branched-chain amino acids)
F ig.6. Summary o f  amino acid  exchange between organs 
immediately after feeding.
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7. Ammonia excretion
There is no store for nitrogen-containing compounds as there is for 
carbohydrate (glycogen) or lipids (triacylglycerol). Thus nitrogen ingested 
in excess of what is required by the organism has to be excreted. The 
excess nitrogen is first converted into ammonia and is then excreted from 
living organisms in one of three ways. Many aquatic animals simply 
excrete the ammonia itself directly into the surrounding water. Birds and 
terrestrial reptiles excrete the ammonia in the form of uric acid, while most 
terrestrial vertebrates convert the ammonia into urea before excretion. 
These three classes of organisms are called: ammonotelic, uricotelic and 
ureotelic, respectively.
8. The urea cycle
Urea is synthesized in the liver by the urea cycle. It is then secreted 
into the bloodstream and taken up by the kidneys for excretion in the 
urine. The urea cycle was the first cyclic metabolic pathway to be 
discovered by Hans Krebs and Kurt Henseleit in 1932, 5 years before 
Krebs discovered the citric acid cycle. The overall reaction of the pathway 
is:
NHL,+ + НСОз' + H20  + 3ATP + aspartate---->
urea + 2ADP + AMP + 2Pi + PPi + fumarate 
One of the nitrogen atoms of urea comes from ammonia, the other is 
transferred from the amino acid aspartate, while the carbon atom comes 
from C 0 2. Ornithine, an amino acid that is not in the standard set of 20 
amino acids and is not found in proteins, is the carrier of these nitrogen 
and carbon atoms. Five enzymatic reactions are involved in the urea cycle 
(Fig. 7), the first two of which take place in mitochondria, the other three in 
the cytosol:
1. Carbamoyl phosphate synthetase, which is technically not a 
member of the urea cycle, catalyzes the condensation and 
activation of ammonia (from the oxidative deamination of 
glutamate by glutamate dehydrogenase) and C 0 2 (in the form of 
bicarbonate, HC03 ) to form carbamoyl phosphate. The hydrolysis 
of two ATP molecules makes this reaction essentially irreversible.
2. The second reaction also occurs in the mitochondria and involves 
the transfer of the carbamoyl group from carbamoyl phosphate to 
ornithine by ornithine transcarbamoylase. This reaction forms 
another nonstandard amino acid citrulline, which then has to be 
transported out of the mitochondrion into the cytosol where the 
remaining reactions of the cycle take place.
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3. The citrulline is then condensed with aspartate, the source of the 
second nitrogen atom in urea, by the enzyme argininosuccinate 
synthetase to form argininosuccinate. This reaction is driven by the 
hydrolysis of ATP to AMP and PP„ with subsequent hydrolysis of 
the pyrophosphate. Thus both of the high-energy bonds in ATP are 
ultimately cleaved.
4. Argininosuccinase then removes the carbon skeleton of 
aspartate from argininosuccinate in the form of fumarate, leaving 
the nitrogen atom on the other product arginine. As the urea cycle 
also produces arginine, this amino acid is classified as 
nonessential in ureotelic organisms. Arginine is the immediate 
precursor of urea.
5. The urea is then formed from arginine by the action of arginase 
with the regeneration of ornithine. The ornithine is then 
transported back into the mitochondrion ready to be combined 
with another molecule of carbamoyl phosphate.
«, t o  f-?»jуш Ш т Ш г г 1*
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Fig. 7. The urea cycle. The enzymes involved in this cycle are: (I) carbamoyi phosphate 
synthetase; (2) ornithine transcarbamoylase; (3) argininosuccinate synthetase; (4) 
arginosuccinase; and (5) arginase.
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Link to the citric acid cycle
The synthesis o f fumarate by argininosuccinase links the urea cycle 
to the citric acid cycle (Fig. 8). Fumarate is an intermediate of this 
latter cycle, which is then hydrated to malate, which in turn is oxidized 
to oxaloacetate
Oxaloacetate has several possible fates:
1. transamination to aspartate which can then feed back into 
the urea cycle;
2. condensation with acetyl CoA to form citrate which then continues 
on round the citric acid cycle;
3. conversion into glucose via gluconeogenesis;
4. conversion into pyruvate.
ин,»сол
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phosphate a-Keto acid
Fig. 8. The urea cycle and the citric acid cycle are linked by fumarate and the 
transamination o f  oxaloacetate to aspartate.
9. Hyperammonemia
Why do organisms need to detoxify ammonia in the first place? The 
answer to this question is obvious when one considers what happens if 
there is a block in the urea cycle due to a defective enzyme. A block in any 
of the urea cycle enzymes leads to an increase in the amount of ammonia in 
the blood, so-called hyperammonemia. The most common cause of such a 
block is a genetic defect that becomes apparent soon after birth, when the 
afflicted baby becomes lethargic and vomits periodically. If left untreated, 
coma and irreversible, brain damage will follow. The reasons for this are 
not entirely clear but may be because the excess ammonia leads to the 
increased formation of glutamate and glutamine. These reactions result via 
depletion of the citric acid cycle intermediate a-ketoglutarate, which may 
then compromise energy production, especially in the brain. It also leads to
168
Catabolism o f amino acid nitrogen.
an increase in the acidic amino acids glutamate and glutamine, which may 
directly cause damage to the brain.
NH3 NH3
a-Ketoglutarate < ? Glutamate Glutamine 
Glutamate Glutamine
dehydrogenase synthetase
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Lecture 20
METABOLISM OF PHENYLALANINE AND 
TYROSINE. TRANSMETHYLATION.
1. Metabolism of phenylalanine
The metabolism of phenylalanine will now be considered in some 
detail, as two inborn errors of metabolism are known that affect this 
pathway. Phenylalanine is first hydroxylated by phenylalanine 
hydroxylase to form another aromatic amino acid tyrosine (Fig.1). The 
coenzyme for this reaction is the reductant tetrahydrobiopterin which is 
oxidized to dihydrobiopterin. Phenylalanine hydroxylase is classified as a 
monooxygenase as one of the atoms of 0 2 appears in the product and the 
other in H20 . The tyrosine is then transaminated to p- 
hydroxyphenylpyruvate, which is in turn converted into homogentisate 
by p-hydroxyphenylpyruvate hydroxylase. This hydroxylase is an example 
of a dioxygenase, as both atoms of 0 2 become incorporated into the 
product (Fig.l). The homogentisate is then cleaved by homogentisate 
oxidase, another dioxygenase, before fumarate and acetoacetate are 
produced in a final reaction. The fumarate can feed into the citric acid 
cycle, whereas acetoacetate can be used to form ketone bodies. Thus 
phenylalanine and tyrosine are each both glucogenic and ketogenic.
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Fig. I. The metabolism of phenylalanine.
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2. Inborn errors of metabolism
Two inborn errors of metabolism are known that affect phenylalanine 
metabolism. These are inherited metabolic disorders caused by the 
absence of one of the enzymes in the pathway. One of these disorders, 
alkaptonuria, is caused by the absence of homogentisate oxidase. This 
results in the accumulation of homogentisate that is subsequently excreted 
in the urine, and which oxidizes to a black color on standing. This defect is 
harmless, in contrast with the other disorder, phenylketonuria. In 
phenylketonuria there is a block in the hydroxylation of phenylalanine to 
tyrosine caused by an absence or deficiency of phenylalanine 
hydroxylase or, more rarely, of its tetrahydrobiopterin coenzyme. The 
result is a 20-fold increase in the levels of phenylalanine in the blood with 
its subsequent transamination to phenylpyruvate. If untreated, severe 
mental retardation occurs, with a life expectancy of on average 20 years. 
With an incidence of 1:20 000 this condition is now screened for at birth, 
with treatment being to restrict the intake of phenylalanine (by putting the 
individual on a low phenylalanine diet) and thus minimize the need to 
metabolize the excess. However, enough phenylalanine must be provided 
to meet the needs for growth and replacement.
3. Tyrosine forms epinephrine and norepinephrine
Tyrosine is a precursor of epinephrine and norepinephrine, which are 
formed in cells of neural origin. Although dopa is an intermediate in the 
formation of both melanin in melanocytes and norepinephrine in neuronal 
cells, different enzymes carry out the tyrosine hydroxylation reactions in 
different cell types. The enzyme tyrosine hydroxylase forms dopa in 
neuronal and adrenal cells on the pathway to norepinephrine and epinephrine 
production (Fig.2). Dopa decarboxylase, a pyridoxa! phosphate-dependent 
enzyme, forms dopamine. The latter is subjected to further hydroxylation by 
dopamine B-oxidase, a copper-dependent enzyme that seems to utilize vitamin 
C to generate norepinephrine. In the adrenal medulla, phenylethanolamine- 
N-methy (transferase utilizes S-adenosylmethionine to methylate the primary 
amine of norepinephrine to form epinephrine (Fig.2).
Tyrosine is also a precursor of the thyroid hormones triiodothyronine and 
thyroxine.
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Fig.2. Conversion o f  tyrosine to epinephrine and norepinephrine in neuronal and 
adrenal cells (PLP, pyridoxal phosphate).
4. Creatinine excreted is a function of muscle mass
Creatine is present in muscle, brain, and blood both as phosphocreatine 
and in the free state. Traces of creatine are also normally present in urine. 
Creatinine, the anhydride of creatine, is formed largely in muscle by 
irreversible nonenzymatic dehydration of creatine phosphate (Fig.3). The 
24-hour excretion of creatinine in the urine of a given subject is remarkably 
constant from day to day and proportionate to muscle mass.
For synthesis of creatine, 3 amino acids—glycine, arginine, and 
methionine—are directly involved. The first reaction is transamidination 
from arginine to glycine to form guanidoacetate (glycocyamine). This occurs 
in the kidney, but not in the liver or in heart muscle. Synthesis of creatine is
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completed by methylation of glycocyamine by "active methionine" in the 
liver (Fig. 3).
4.1. Formation of creatine phosphate
The urea cycle is also the starting point for the synthesis of another 
important metabolite creatine phosphate. This phosphagen provides a 
reservoir of high energy phosphate in muscle cells as the energy released 
upon its hydrolysis is greater than that released upon the hydrolysis of 
ATP (AG for creatine phosphate hydrolysis = -10.3 kcal m of1 compared 
with -7.3 kcal m of1 for ATP hydrolysis). The first step in the formation of 
creatine phosphate is the condensation of arginine and glycine to form 
guanidinoacetate (Fig. 3). Ornithine is released in this reaction and can 
then be re-utilized by the urea cycle. The guanidinoacetate is then 
methylated by the methyl group donor S-adenosyl methionine to form 
creatine, which is in turn phosphorylated by creatine kinase to form 
creatine phosphate (Fig. 3).
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Fig. 3. Biosynthesis o f  creatine and creatinine.
5. The activated methyl cycle
S-Adenosyl methionine serves as a donor of methyl groups in
numerous biological reactions (e.g. in the formation o f creatine phosphate 
and in the synthesis of nucleic acids). It is formed through the action of the 
activated methyl cycle (Fig. 4). During donation of its methyl group to
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another compound, S-adenosyl methionine is converted into S-adenosyl 
homocysteine. To regenerate S-adenosyl methionine, the adenosyl 
group is removed from the S-adenosyl homocysteine to form 
homocysteine. This is then methylated by the enzyme homocysteine 
methyltransferase, one of only two vitamin B12-containing enzymes found 
in eukaryotes, to form methionine. The resulting methionine is then 
activated to S-adenosyl methionine with the release of all three of the 
phosphates from ATP.
Fig. 4. The activated methyl cycle
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DNA STRUCTURE AND REPLICATION
1. Bases
The bases in DNA have carbon-nitrogen ring structures; because o f 
the nitrogen atoms they are called nitrogenous bases. There are two 
types o f ring structure. A denine and guanine are purines (Fig. la), 
each having two joined carbon-nitrogen rings but with different side- 
chains. Thym ine and cytosine are pyrim idines (Fig. la); each has 
only one carbon-nitrogen ring and again they differ in their side- 
chains.
In RNA, the nucleosides have ribose as the sugar component and 
so are ribonucleosides. In DNA the sugar is deoxyribose (Fig. lb) (i.e. 
the 2'-OH group in ribose is replaced by a hydrogen atom; hence 
'deoxy') and so the nucleosides are deoxynucleosides. For DNA these 
are deoxyadenosine, deoxyguanosine, deoxythym idine and
deoxycytidine. In each case, the C-l o f the sugar is joined to the base 
via one o f its nitrogen atoms. If the base is a pyrimidine, the nitrogen 
at the 1 position (i.e. N-l) is involved in bonding to the sugar. If the 
base is a purine, the bonding is to the N-9 position of the base (Fig. lb).
A nucleotide is a phosphate ester o f a nucleoside. It consists o f a 
phosphate group joined to a nucleoside at the hydroxyl group attached to 
C-5 of the sugar, that is it is a nucleoside 5'-phosphate or a 5'- 
nucleotide. The primed number denotes the atom o f the sugar to which 
the phosphate is bonded. In DNA the nucleotides have deoxyribose 
as the sugar and hence are called deoxynucleotides. Deoxynucleotides 
may have a single phosphate group (deoxynucleoside 5'-
monophosphates, dNMPs), two phosphate groups (deoxynucleoside 5'- 
diphosphates, dNDPs) or three phosphate groups (deoxynucleoside 5'- 
triphosphates, dNTPs). Deoxynucleoside triphosphates are the 
precursors for DNA synthesis. These are deoxyadenosine 5'- 
triphosphate (dATP) (Fig.lc), deoxyguanosine 5'-triphosphate (dGTP), 
deoxycytidine 5’-triphosphate (dCTP) and deoxythymidine 5'-triphosphate 
(dTTP). In each case th e 'd ' in the abbreviation (for example in dATP) 
indicates that the sugar in the nucleotide is deoxyribose. During DNA 
synthesis, two of the phosphates of each deoxynucleotide are split off (as 
pyrophosphate) so that only a single phosphate (the phosphate) is 
incorporated into DNA.
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Fig. I. (a) The purines, adenine and guanine, and the pyrimidines, thvmine and 
cytosine; (b) deoxvribose and two deoxynucleosides, deoxycylidine and deoxyadenosine; 
(c) a deoxynucleotide, deoxyadenosine 5' triphosphate (dATP).
2. 3 '5 ' phosphodiester bonds
In a DNA molecule, the different nucleotides are covalently joined to 
form a long polymer chain by covalent bonding between the phosphates 
and sugars. For any one nucleotide, the phosphate attached to the 
hydroxyl group at the 5’ position of the sugar is in turn bonded to the 
hydroxyl group on the 3’ carbon of the sugar of the next nucleotide. Since 
each phosphate-hydroxyl bond is an ester bond, the linkage between the 
two deoxynucleotides is a 3’5’ phosphodiester bond (Fig.2). Thus, in a 
DNA chain, all of the 3' and 5' hydroxyl groups are involved in 
phosphodiester bonds except for the first and the last nucleotide in the 
chain. The first nucleotide has a 5' phosphate not bonded to any other 
nucleotide and the last nucleotide has a free 3' hydroxyl. Thus each DNA 
chain has polarity; it has a 5 ’ end and a 3' end.
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3. DNA double helix
in 1953, Watson and Crick worked out the three-dimensional structure 
of DNA, starting from X-ray diffraction photographs taken by Franklin and 
Wilkins. They deduced that DNA is composed of two strands wound 
round each other to form a double helix, with the bases on the inside and 
the sugar-phosphate backbones on the outside. In the double helix (Fig. 3), 
the two DNA strands are organized in an antiparallel arrangement (i.e. 
the two strands run in opposite directions, one strand is oriented 5'—►З' and 
the other is oriented 31-* 5')- The bases of the two strands form hydrogen 
bonds to each other; A pairs with T and G pairs with C. This is called 
complementary base pairing (Fig. 4). Thus a large two-ringed purine is 
paired with a smaller single-ringed pyrimidine and the two bases fit neatly 
in the gap between the sugar-phosphate strands and maintain the correct 
spacing. There would be insufficient space for two large purines to pair 
and too much space for two pyrimidines to pair, which would be too far 
apart to bond. The G:C and A:T base pairing also maximizes the number 
of effective hydrogen bonds that can form between the bases; there are 
three hydrogen bonds between each G:C base pair and two hydrogen 
bonds between each A:T base pair. Thus A:T and G:C base pairs form the 
most stable conformation both from steric considerations and from the 
point of view of maximizing hydrogen bond formation.
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Fig. 3. The DNA double helix.
Fig. 4. The DNA base pairs. Hydrogen bonds are shown as dashed lines. dR. 
deoxvribose
4. Nucleosomes
The first level of packaging involves the binding of the chromosomal 
DNA to histones. Overall, in chromosomes, the ratio of DNA to histones on 
a weight basis is approximately 1:1. There are five main types of histones 
called HI, H2A, H2B, H3 and H4. Histones are very basic proteins; about 
25% of their amino acids are lysine or arginine so histones have a large 
number of positively charged amino acid side chains. These positively 
charged groups therefore bind to the negatively charged phosphate groups 
of DNA. Not surprisingly given their importance in packaging DNA, the 
amino acid sequences of histones have been highly conserved in evolution. 
The most conserved are histones H3 and H4; for example, H3 and H4 from 
peas and cows differ in only four and two amino acids respectively 
Histone HI is the least conserved histone, which reflects its somewhat 
different role in packaging DNA compared with the other histones. In 
sperm heads, DNA is particularly highly condensed and here the histones 
are replaced with small basic proteins called protamines.
When chromosomes are gently 'decondensed', they have the 
appearance under the electron microscope of ‘beads on a string' (Fig. 
5). The 'beads' are called nucleosomes and consist of DNA complexed 
with histones. The 'string' is linear double-stranded DNA between 
adjacent nucleosomes and is called linker DNA (Fig. 5). The average 
distance between nucleosomes, that is the length of the linker DNA, is
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typically about 55 base pairs (bp) but varies from organism to organism 
in the range 8-114 bp. Even in a single nucleus, the distance between 
adjacent nucleosomes varies depending on, for example, the presence of 
other sequence-specific DNA-binding proteins. If a chromatin preparation 
is incubated with micrococcal nuclease, an enzyme that degrades DNA, 
the linker DNA is destroyed leaving nucleosome core particles in 
which the histones protect the associated DNA from digestion. Each 
nucleosome core particle contains a double-stranded DNA fragment 
146 bp long bound to a complex of eight histones, the histone octamer, 
consisting of two molecules each of histones H2A, H2B, H3 and H4 
(Fig. 6). The DNA is wound round the outside of the histone octam er in 
about 1.8 turns of a left-handed supercoil. DNA-histone contacts are 
made along the inside face of this superhelix. Overall the packing ratio is 
about 7 that is the DNA length is shortened about sevenfold by winding 
around the nucleosome.
Fig. 6. Schematic diagram o f a nucleosome consisting o f  the DNA double helix wound 
1.8 limes round a histone octamer (two molecules each o f  histones H2A, H2B, H i and
If nuclei are lysed very gently, the chromatin is seen to exist as a 30 
nm diameter fiber. This diameter is larger than a single nucleosome and 
suggests that the nucleosomes are organized into a higher order structure. 
The fiber is formed by a histone HI molecule binding to the linker DNA 
of each nucleosome at the point where it enters and leaves the nucleosome 
(Fig. 6). The histone HI molecules interact with each other, pulling the 
nucleosomes together. One possibility is that the nucleosomes wind up
Released nucleosomes (core particles)
Fig. 5. 'Beads-on-a-slring' structure o f  chromatin
:( HI
H4).
5. 30 nm fiber
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into a higher order helix with six nucleosomes per turn to form a solenoid 
(Fig. 7). This would give a fiber three nucleosomes wide, which is indeed 
the diameter observed. In such a solenoid-the linear length of the DNA has 
been reduced by a further factor of 6 (equivalent to six nudeosomes per 
turn of the solenoid). Coupled with the packing ratio of 7 for the 
nucleosome itself (see above), this gives a packing ratio for the solenoid 
of approximately 6 X 7  (i.e. about 40).
DNA polymerase III from E. coli catalyzes the stepwise addition of 
deoxyribonucleotides to the 3'-OH end of a DNA chain:
(DNA)„ тай» + dNTP -► (DNAV, + PPi
The enzyme has the following requirements:
1. all four dNTPs (dATP, dGTP, dTTP and dCTP) must be present to 
be used as precursors; Mg2+ is also required;
2. a DNA tem plate is essential, to be copied by the DNA 
polymerase;
3. a prim er with a free 3'-OH that the enzyme can extend.
DNA polymerase III is a template-directed enzyme, that is it 
recognizes the next nucleotide on the DNA template and then adds a 
complementary nucleotide to the З'-OH of the primer, creating a 3'5’ 
phosphodiester bond, and releasing pyrophosphate. The reaction is shown 
in Fig. 8. It involves nucleophilic attack of the З '-OH o f the primer on 
the a-phosphate group o f the incoming nucleotide. The primer is 
extended in a 5*—►З’ direction.
DNA polymerase III also corrects mistakes in DNA by removing 
mismatched nucleotides (i.e. it has proof-reading activity). Thus, during 
polymerization, if the nucleotide that has just been incorporated is 
incorrect (mismatched), it is removed using a 3'-* 5' exonuclease activity. 
This gives very high fidelity; an error rate of less than 10'8 per base pair. 
DNA polymerase also has a 5'-*-3' exonuclease activity; it can hydrolyze 
nucleic acid starting from the 5' end of a chain. This activity plays a key 
role in removing the RNA primer used during replication. Thus, overall, 
DNA polymerase III has three different active sites on its single
Fig.  7. S c h em a t i c  d iagram  o f  p r o p o s e d  s o len o id  
s truc tu re  o f  ch ro m a t in  to y i e l d  a 30 nm f ib e r .
The s truc tu re  consis ts  o f  six n u d e o s o m e s  p e r  
turn  o f  the  helix  a n d  hen ce  Moul d  be three  
n u d e o s o m e s  wide.  In the  d i a g r a m , only  three  
n u d e o s o m e s  o f  each  turn are  v is ib le;  the o th e r  
three  n u d e o s o m e s  p e r  turn are  h id d en  f r o m  view.
6. D N A  replication in bacteria
6.1. DNA polymerases
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polypeptide chain; 5'—► 3' polymerase, 3' ->-5' exonuclease and 5' -*• 3' 
exonuclease.
Fig. 8. DNA synthesis. In this schematic diagram, the incoming dTTP hydrogen bonds 
with the adenine on the template DNA strand and a 3'5' phosphodiester bond is formed, 
releasing pyrophosphate.
6.2. Replication forks
When the bacterial circular chromosome is replicated, replication starts 
at a single origin. The double helix opens up and both strands serve as 
template for the synthesis of new DNA. DNA synthesis then proceeds 
outward in both directions from the single origin (i.e. it is bi-directional; 
Fig. 9). The products of the reaction are two daughter double-stranded 
DNA molecules each of which has one original template strand and one 
strand of newly synthesized DNA. Thus, replication is semi-conservative. 
The region of replicating DNA associated with the single origin is called 
a replication bubble or replication eye and consists of two replication 
forks moving in opposite directions around the DNA circle (Fig. 9).
W  Re*»e*tiort bubbfc 0 )  fleiptoefion folks
Fig. 9. Replication o f  the bacterial circular chromosome. Replication starts from  a 
single origin and proceeds Ы-directionally (a) moving around the chromosome with time 
(b). The two replication forks eventually meet and fuse. The two circular daughter DNA 
molecules produced each have one original template DNA strand (thin line) and one new 
strand (thick line).
6.3. Okazaki fragments
Double-stranded DNA is antiparallel; one strand runs 5'~*3' and the 
complementary strand runs 3' -►5'. As the original double-stranded DNA
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opens up at a replication fork, new DNA is made against each template 
strand. Superficially, therefore, one might expect new DNA to be made 5'-* 
3' for one daughter strand and 3'-* 5' for the other daughter strand. 
However, all DNA polymerases make DNA only in the 5’-*-3' direction and 
never in the 3 5 '  direction. What actually happens is that on the template 
strand with 3'-*1 5' orientation, new DNA is made in a continuous piece in 
the correct 5’ “*■ 3' direction. This new DNA is called the leading strand 
(Fig. 10). On the other template strand (that has a 5'—*-3' orientation), DNA 
polymerase synthesizes short pieces of new DNA (about 1000 nucleotides 
long) in the 5'-*- 3' direction (Fig. 10) and then joins these pieces together. 
The small fragments are called Okazaki fragments after their discoverer. 
The new DNA strand which is made by this discontinuous method is 
called the lagging strand.
Fig. 10. Synthesis o f DNA at a replication fork. As the parental DNA (thin line) opens 
up, each o f the two parental strands acts as a template fo r new DNA synthesis (thick 
lines). The leading strand is synthesized continuously but the lagging strand is 
synthesized as short (Okazaki) DNA fragments that are then joined together.
6.4. RNA primer
DNA polymerase cannot start DNA synthesis without a primer. Even 
on the lagging stand, each Okazaki fragment requires an RNA primer 
before DNA synthesis can start. The primer used in each case is a short 
(approximately ten nucleotides long) piece of RNA and is synthesized by 
an RNA polymerase called primase (Fig. 11a). Primase can make RNA 
directly on the single-stranded DNA template because, like all RNA 
polymerases, it does not require a primer to begin synthesis. The RNA 
primer made by primase (Fig. lib )  is then extended by DNA polymerase 
III (Fig. lie). DNA polymerase III synthesizes DNA for both the leading 
and lagging strand. After DNA synthesis by DNA polymerase III, DNA 
polymerase I uses its 5'-*-3' exonuclease activity to remove the RNA primer 
and then fills the gap with new DNA (Fig. l i e  andf). DNA polymerase 
III cannot carry out this task because it lacks the 5'-+- 3' activity of DNA 
polymerase I. Finally, DNA ligase joins the ends of the DNA fragments 
together (Fig. 1 Ig).
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Fig. 11. Details o f DNA replication, (a) Primase binds to the DNA template strand (thin 
line) and (b) synthesizes a short RNA primer (dotted line); (c) DNA polymerase III now 
extends the RNA primer by synthesizing new DNA (thick line) ; (d) during synthesis o f the 
lagging stand, adjacent Okazaki fragments are separated by the RNA primers; 'el the RNA 
primers are now removed and the gaps filled with DNA by DNA polymerase I (fi 
generating adjacent DNA fragments that are then (g) joined by DNA ligase.
6.5. Accessory proteins
DMA polymerases I and III, primase and DNA ligase are not the only 
proteins needed for replication of the bacterial chromosome. The DNA 
template is a double helix with each strand wound tightly around the 
other and hence the two strands must be unwound during replication. 
How is this unwinding problem solved? A DNA helicase is used to 
unwind the double helix (using ATP as energy source) and SSB (single- 
stranded DNA-binding) protein prevent the single-stranded regions 
from base-pairing again so that each of the two DNA strands is accessible 
for replication. In principle, for a replication fork to move along a piece of 
DNA, the DNA helix would need to unwind ahead of it, causing the 
DNA to rotate rapidly. However, the bacterial chromosome is circular 
and so there are no ends to rotate. The solution to the problem is that an 
enzyme called topoisomerase I breaks a phosphodiester bond in one 
DNA strand (a single-strand break) a small distance ahead of the fork, 
allowing the DNA to rotate freely (swivel) around the other (intact) strand. 
The phosphodiester bond is then re-formed by the topoisomerase.
After the bacterial circular DNA has been replicated, the result is two 
double-stranded circular DNA molecules that are interlocked. 
Topoisomerase II separates them as follows. This enzyme works in a 
similar manner to topoisomerase I but causes a transient break in each
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strand (a double-strand break) of a double-stranded DNA molecule. Thus 
topoisomerase II binds to one double-stranded DNA circle and causes a 
transient double-strand break that acts as a 'gate' through which the other 
DNA circle can pass (Fig. 12). Topoisomerase II then re-seals the strand 
breaks.
In eukaryotes, the cell cycle consists of G l5 S, G2 and M phases. 
Most differences in the cycle times of different cells are due to differences 
in the length of the G, phase. Quiescent cells are said to be in the G0 phase.
DNA replication occurs only in the S phase. It occurs at many 
chromosomal origins, is bi-directional and semi-conservative. Sets of 20-80 
replicons act as replication units that are activated in sequence.
DNA polymerases a and 5 replicate chromosomal DNA, DNA 
polymerases p and e repair DNA, and DNA polymerase у replicates 
mitochondrial DNA.
DNA polymerase a synthesizes the lagging strand, via Okazaki 
fragments, and DNA polymerase 5 synthesizes the leading strand. The 
RNA primers are synthesized by DNA polymerase a  which carries a 
primase subunit.
Telomerase, a DNA polymerase that contains an integral RNA that acts 
as its own primer, is used to replicate DNA at the ends of chromosomes 
(telomeres).
Nucleosomes do not dissociate from the DNA during DNA replication; 
rather they must open up to allow the replication apparatus to pass.
ttro iB O W iM e  fnuw * *trwr«J
brw*K. fl#to|w*TQ cnt-m r DMA еЛпзЦ» 
to pass trwcoon t!x> tore»*, m en r*-*oi 
t t »  DM A svanOs to m craM e ttw» DM A carcfc*
Fig. 12. Separation o f  daughter DNA circles by topoisomerase II.
7. D N A  re p lic a tio n  in eukaryotes
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8. RNA structure
8.1. Covalent structure
Like DNA, RNA is a long polymer consisting o f nucleotides joined 
by 3'5' phosphodiester bonds. However, there are some differences:
1. the bases in RNA are adenine (abbreviated A), guanine (G), uracil 
(U) and cytosine (C). Thus thymine in DNA is replaced by uracil in 
RNA, a different pyrimidine (Fig. 13a). However, like thymine, 
uracil can form base pairs with adenine.
2. The sugar in RNA is ribose rather than deoxyribose as in DNA 
(Fig. 13b).
The corresponding ribonucleosides are adenosine, guanosine, cytidine 
and uridine. The corresponding ribonucleotides are adenosine 5’- 
triphosphate (ATP), guanosine 5'-triphosphate (GTP), cytidine 5'- 
triphosphate (CTP) and uridine 5'-triphosphate (UTP).
As with DNA, the nucleotide sequence of RNA is also written as a 
base sequence in the 5'-*'3' direction. Thus GUCAAGCCGGAC is the 
sequence of one short RNA molecule.
<•> 1Ы
UeacH (U> P itto en
Fig. 13. (a) Uracil, (b) ribose 
8.2. RNA secondary structure
Most RNA molecules are single-stranded but an RNA molecule may 
contain regions which can form complementary base-pairing where the 
RNA strand loops back on itself (Fig. 14). If so, the RNA will have some 
double-stranded regions. Ribosomal RNAs (rRNAs) and transfer RNAs 
(tRNAs) exhibit substantial secondary structure, as do some messenger 
RNAs (mRNAs).
Fig. 14. An example o f se lf complementarity in RNA forming an internal double- 
stranded region; hydrogen bonding between bases is shown by the symbol'.
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9. Transcription in prokaryotes
9.1. Three phases of transcription
Gene transcription by E. coli RNA polymerase takes place in three 
phases: initiation, elongation and term ination. During initiation, 
RNA polymerase recognizes a specific site on the DNA, upstream from 
the gene that will be transcribed, called a prom oter site and then 
unwinds the DNA locally. During elongation the RNA polymerase uses 
the antisense (-) strand  of DNA as template and synthesizes a 
complementary RNA molecule using ribonucleoside 5' triphosphates as 
precursors. The RNA produced has the same sequence as the non-template 
strand, called the sense (+) strand (or coding strand) except that the RNA 
contains U instead of T. At different locations on the bacterial 
chromosome, sometimes one strand is used as template, sometimes the 
other, depending on which strand is the coding strand for the gene in 
question. The correct strand to be used as template is identified for the 
RNA polymerase by the presence of the promoter site. Finally, the RNA 
polymerase encounter at termination signal and ceases transcription, 
releasing the RNA transcript and dissociating from the DNA.
9.2. Promoters and initiation
In E. coli, all genes are transcribed by a single large RNA polymerase 
with the subunit structure a2pp’coa. This complete enzyme, called the 
holoenzyme, is needed to initiate transcription since the о factor is 
essential for recognition oil the promoter; it decreases the affinity of the 
core enzyme for nonspecific DNA binding sites and increases its affinity 
for the promoter. It is common for prokaryotes to have several о factors 
that recognize different types of promoter (in E. coli, the most common о 
factor is o70).
The holoenzyme binds to a promoter region about 40-60 bp in size 
and then initiates transcription a short distance downstream (i.e. 3’ 
to the promoter). Within the promoter lie two 6-bp sequences that are 
particularly important for promoter function and which are therefore 
highly conserved between species. Using the convention of calling the 
first nucleotide of a transcribed sequence as +1, these two prom oter 
elements lie at positions -10 and -35, that is about 10 and 35 bp, 
respectively, upstream of where transcription will begin (Fig. 15).
1. The -10 sequence has the consensus TATAAT. Because this 
element was discovered by Pribnow, it is also known as the Pribnow box. 
It is an important recognition site that interacts with the a factor of RNA 
polymerase.
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2. The -35 sequence has the consensus TTGACA and is important in 
DNA unwinding during transcriptional initiation.
The actual sequence between the -10 sequence and the -35 sequence 
is raw conserved (i.e. it varies from promoter to promoter) but the 
distance between these two sites is extremely important for correct 
functioning of the promoter.
Promoters differ by up to 1000-fold in their efficiency of initiation 
o f transcription so that genes with strong promoters are transcribed very 
frequently whereas genes with weak promoters are transcribed far less 
often. The -10 and -35 sequences of strong promoters correspond well 
with the consensus sequences shown in Fig. 15 whereas weaker promoters 
may have sequences that differ from these at one or more nucleotides. The 
nature of the sequences around the transcriptional start site can also 
influence the efficiency of initiation. RNA polymerase does not need a 
primer to begin transcription; having bound to the promoter site, the RNA 
polymerase begins transcription directly.
1 8 -1 8  bp 
T T G A C A  .............................
-  35 sequence
Fig. 15. Prokaryotic promoter showing the -10 sequence and -35 sequence. By 
convention the first nucleotide o f the template DNA that is transcribed into RNA is 
denoted + 1, the transcriptional start site.
5 - 8  bp
-10 sequence 
{PrtbnowbcaJ
Tfanecrtptonal 
start she
9.3. Elongation
After transcription initiation, the a factor is released from the 
transcriptional complex to leave the core enzyme (a2pp’o>), which 
continues elongation of the RNA transcript. Thus the core enzyme 
contains the catalytic site for polymerization, probably within the p 
subunit. The first nucleotide in the RNA transcript is usually pppG or 
pppA. The RNA polymerase then synthesizes RNA in the 5L+-3' direction, 
using the four ribonucieoside 5' triphosphates (ATP, CTP, GTP, UTP) as 
precursors. The З'-OH at the end o f the growing RNA chain attacks the a 
phosphate group of the incoming ribonucieoside 5’ triphosphate to form a 
3'5' phosphodiester bond (Fig. 16). The complex o f RNA polymerase, 
DNA template and new RNA transcript is called a ternary complex 
(i.e. three components) and the region of unwound DNA that is 
undergoing transcription is called the transcription bubble (Fig, 17). 
The RNA transcript forms a transient RNA-DNA hybrid helix with its 
template strand but then peels away from the DNA as transcription 
proceeds. The DNA is unwound ahead o f the transcription bubble and 
after the transcription complex has passed, the DNA rewinds.
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Fig 16. Transcription by RNA polymerase. In each step the incoming ribonucleotide 
selected is that which can base-oair with the next base o f  the DNA template strand. In the 
diagram, the incoming nudeotide is rUTP to base-pair with the A residue o f  the template 
DNA. A 3'5' phosphodiester bond is formed, extending the RNA chain by one nucleotide, 
and pyrophosphate is released. Overall the RNA molecule grows in a 5' to 3 'direction.
ол-гап-п
Fig. 17. A transcription bubble. The DNA double helix is unwound and RNA 
polymerase then synthesizes an RNA copy o f the DNA template strand. The nascent RNA 
transiently forms an RNA-DNA hybrid helix but then peels away from the DNA which is 
subsequently rewound into a helix once more.
9.4. Termination
Transcription continues until a termination sequence is reached. The 
most common termination signal is a GC-rich region that is a 
palindrome, followed by an AT-rich sequence. The RNA made from the 
DNA palindrome is self-complementary and so base-pairs internally to 
form a hairpin structure rich in GC base pairs followed by four or more 
U residues (Fig. 18). However, not all termination sites have this hairpin 
structure. Those that lack such a structure require an additional protein, 
called rho (p), to help recognize the termination site and stop 
transcription.
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Fig. 18. A typical hairpin structure form ed by the 3' end o f  an RNA molecule during 
termination o f  transcription.
9.5. RNA processing
In prokaryotes, RNA transcribed from protein-coding genes (messenger 
RNA, mRNA), requires little or no modification prior to translation. In 
fact, many mRNA molecules begin to be translated even before RNA 
synthesis has finished. However, ribosomal RNA (rRNA) and transfer 
RNA (tRNA) are synthesized as precursor molecules that do require 
post-transcriptional processing.
10. Transcription of protein coding genes in eukaryotes
10.1. Gene organization
Most protein-coding genes in eukaryotes consist of coding sequences 
called exons interrupted by noncoding sequences called introns. The 
number of introns and their size varies from gene to gene. The primary 
transcript (pre-mRNA) undergoes processing reactions to yield mature 
mRNA.
Most promoter sites for RNA polymerase II have a TATA box located 
about 25 bp upstream of the transcriptional start site. RNA polymerase 
binding to the promoter requires the formation of a transcription initiation 
complex involving several general (basal) transcription factors that 
assemble in a strict order. Some protein-coding genes lack a TATA box 
and have an initiator element instead, centered around the transcriptional 
start site. The initiation of transcription of these genes requires an 
additional protein to recognize the initiator element and facilitate 
formation of the transcription initiation complex; many o f the same 
transcription factors for initiation o f TATA box promoters are also involved 
here. Yet other promoters lack either a TATA box or an initiator element 
and transcription starts within a broad region of DNA rather than at a 
defined location.
189
Lecture 21
Elongation continues until transcription comes to a halt at varying 
distances downstream of the gene, releasing the primary RNA transcript, 
pre-mRNA. This molecule then undergoes processing reactions to yield 
mRNA.
11. Processing of eukaryotic PRE-mRNA
The primary RNA transcript from a protein-coding gene in a eukaryotic 
cell must be modified by several RNA processing reactions in order to 
become a functional mRNA molecule. The 5' end is modified to form a 5' 
cap structure. Most pre-mRNAs are then cleaved near the 3' end and a 
poly(A) tail is added. Intron sequences are removed by RNA splicing.
Immediately after transcription, the 5’ phosphate is removed, guanosyl 
transferase adds a G residue linked via a 5'-5' covalent bond, and this is 
methylated to form a 7-methylguanosine (m7G) cap (methylated in N-7 
position of the base). The ribose residues of either the adjacent one or two 
nucleotides may also be methylated by methyl group addition to the 2' OH 
of the sugar. The cap protects the 5’ end of the mRNA against ribonuclease 
degradation and also functions in the initiation of protein synthesis.
Most pre-mRNA transcripts are cleaved post-transcriptionally near the 
3' end between a polyadenylation signal (5'-AAUAAA-3 ) and 5'-YA-3' 
(where Y=a pyrimidine). A GU-rich sequence may also be located further 
downstream. Specific proteins bind to these sequence elements to form a 
complex. One of the bound proteins, poly(A) polymerase, then adds a 
poly(A) tail of up to 250 A residues to the new 3' end of the RNA molecule 
and poly(A) binding protein molecules bind to this. The poly(A) tail 
protects the 3' end of the final mRNA against nuclease degradation and also 
increases translational efficiency of the mRNA. Some pre-mRNAs (e.g. 
histone pre-mRNAs) are cleaved near the 3' end but no poly(A) tail is 
added.
Intron sequences are removed by RNA splicing that cleaves the RNA at 
exonintron boundaries and ligates the ends of the exon sequences together. 
The cleavage sites are marked by consensus sequences that are 
evolutionarily conserved. In most cases the intron starts with GU and ends 
with AG, a polypyrimidine tract lies upstream of the AG, and a conserved 
branchpoint sequence is located about 20-50 nt upstream of the 3' splice 
site. The splicing reaction involves two transesterification steps which 
ligate the exons together and release the intron as a branched lariat 
structure containing a 2'5' bond with a conserved A residue in the 
branchpoint sequence. The RNA splicing reactions require snRNPs and 
accessory proteins that assemble into a spliceosome at the intron to be 
removed. The RNA components of the snRNPs are complementary to the 
5' and 3' splice site sequences and to other conserved sequences in the
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intron and so can base-pair with them. Some introns start with AU and 
end with AC, instead of GU and AG respectively. The splicing of these 
'AT-AC introns' requires a different set of snRNPs than those used for 
splicing of the major form of intron, except both classes of intron use U5 
snRNP.
Some pre-mRN As contain more than one set of sites for 3' end cleavage 
and polyadenylation, such that the use of alternative sites can lead to 
mRNA products that contain different 3' noncoding regions (which may 
influence the lifetime of the mRNA) or have different coding capacities. 
Alternative splice pathways also exist whereby the exohs that are retained 
in the final mRNA depends upon the pathway chosen, allowing several 
different proteins to be synthesized from a single gene.
The sequence of an mRNA molecule may be changed after synthesis and 
processing by RNA editing. Individual nucleotides may be substituted, 
added or deleted. In human liver, apolipoprotein В pre-mRNA does not 
undergo editing and subsequent translation yields apolipoprotein B100. In 
cells of the small intestine, RNA editing converts a single C residue in 
apolipoprotein В pre-mRNA to U, changing a codon for glutamine (CAA) 
to a termination codon (UAA). Translation of the edited mRNA yields the 
much shorter protein, apolipoprotein B48, with a restricted function in that 
it lacks a protein domain for receptor binding. Many other examples of 
editing occur, including trypanosome mitochondrial mRNAs, where RNA 
editing results in over half of the uridines in the final mRNA being 
acquired through the editing process.
12. Ribosomal RNA
A prokaryotic 70S ribosome comprises two subunits (50S and 30S). The 
50S subunit has 23S and 5S rRNAs complexed with 34 polypeptides 
whereas the 30S subunit contains 16S rRNA and 21 polypeptides. A 
eukaryotic 80S ribosome comprises two subunits (60S and 40S). The 50S 
subunit has 28S, 5.8S and 5S rRNAs complexed with approx. 49 
polypeptides whereas the 40S subunit contains 18S rRNA and about 33 
polypeptides.
E. coli has seven rRNA transcription units, each containing one copy 
each of the 23S, 16S and 5S rRNA genes as well as one to four tRNA 
genes. Transcription produces a 30S pre-rRNA transcript. This fold up to 
form stem-loop structures, ribosomal proteins binds, and a number of 
nucleotides become methylated. The modified pre-rRNA transcript is then 
cleaved at specific sites by RNAse III and the ends are trimmed by 
ribonucleases M5, M6 and M23 to release the mature rRNAs.
The 28S, 18S and 5.8S rRNA genes are present as multiple copies 
clustered together as tandem repeats. These rRNA transcription units are
191
Lecture 21
transcribed, in the nucleolus, by RNA Pol I. The promoter contains a core 
element that straddles the transcriptional start site and an upstream control 
element (UCE) about 50-80 bp in size, located at about position — 100. 
Transcription factors, one of which is TATA binding protein (TBP) bind to 
these control elements and, together with RNA Pol I, form a transcription 
initiation complex. Transcription produces a 45S pre-rRNA which has 
external transcribed spacers (ETSs) at the 5' and 3' ends and internal 
transcribed spacers (ITSs) internally separating rRNA sequences. The pre- 
rRNA folds up to form a defined secondary structure with stem-loops, 
ribosomal proteins bind to selected sequences, and methylation of over 100 
nucleotides occurs, guided by interaction of the pre-rRNA with snoRNAs 
(as snoRNPs). The 45S pre-rRNA molecule is then cleaved by 
ribonucleases, releasing 32S and 20S precursor rRNAs that are processed 
further to generate mature 28S, 18S and 5.8S rRNAs.
In Tetmhymena, the pre-rRNA molecule contains an intron that is 
removed by self-splicing (in the presence of guanosine, GMP, GDP or 
GTP) without the need for involvement of any protein. This was the first 
ribozyme discovered but many have since been reported.
Eukaryotic cells contain multiple copies of the 55 rRNA gene. Unlike 
other eukaryotic rRNA genes, the 55 rRNA genes are transcribed by RNA 
Pol III. Two control elements, an A box and a C box, lie downstream of the 
transcriptional start site. The C box binds TFIIIA which then recruits TFIIIC. 
TFIIIB now binds and interacts with RNA Pol HI to form the transcription 
initiation complex Transcription produces a mature 55 rRNA that requires 
no processing.
13. Transfer RNA
Transfer RNA (tRNA) molecules play an important role in protein 
synthesis. Each tRNA becomes covalently bonded to a specific amino 
acid to form aminoacyl-tRNA which recognizes the corresponding 
codon in mRNA and ensures that the correct amino acid is added to the 
growing polypeptide chain. The tRNAs are small molecules, only 74-95 nt 
long, which form distinctive cloverleaf secondary structures (Fig. 19a) 
by internal base pairing. The stem-loops of the cloverleaf are known as 
arms:
1. the anticodon arm contains in its loop the three nucleotides of the 
anticodon which will form base-pairs with the complementary 
codon in mRNA during translation;
2. the D or DHU arm (with its D loop) contains dihydrouracil, an 
unusual pyrimidine;
3. the T or TiyC arm (with its T loop) contains another unusual 
base, pseudouracil (denoted ) in the sequence T\|/C;
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4. Some tRNAs also have a variable arm (optional arm) which is 
3-21 nt in size.
The other notable feature is the amino acid acceptor stem. This is 
where the amino acid becomes attached, at the 3' OH group of the З'-ССА 
sequence.
The three dimensional structure of tRNA (Fig. 19b) is even more 
complex because of additional interactions between the various units of 
secondary structure.
Fig. 19. (a) Cloverleaf secondary structure o f  tRNA; (b) tertiary structure o f  tRNA
14. The genetic code
The genetic code is the rules that specify how the nucleotide sequence 
of an mRNA is translated into the amino acid sequence of a polypeptide. 
The nucleotide sequence is read as triplets called codons. The codons 
UAG, UGA and UAA do not specify amino acids and are called 
termination codons or Stop codons. AUG codes for methionine and also 
acts as an initiation (Start) codon.
Most amino acids in proteins are specified by more than one codon (i.e. 
the genetic code is degenerate). Codons that specify the same amino acid 
(synonyms) often differ only in the third base, the wobble position, where 
base-pairing with the anticodon may be less stringent than for the first two 
positions of the codon.
The genetic code is not universal but is the same in most organisms. 
Exceptions are found in mitochondrial genomes where some codons 
specify different amino acids to that normally encoded by nuclear genes. 
In mitochondria, the UGA codon does not specify termination of 
translation but instead encodes for tryptophan. Similarly, in certain 
protozoa UAA and UAG encode glutamic acid instead of acting as 
termination codons.
The mRNA sequence can be read by the ribosome in three possible
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reading frames. Usually only one reading frame codes for a functional 
protein since the other two reading frames contain multiple termination 
codons. In some bacteriophage, overlapping genes occur which use 
different reading frames.
An open reading frame (ORF) is a run of codons that starts with ATG 
and ends with a termination codon, TGA, TAA or TAG. Coding regions of 
genes contain relatively long ORFs unlike noncoding DNA where ORFs 
are comparatively short. The presence of a long open reading frame in a 
DNA sequence therefore may indicate the presence of a coding region. 
Computer analysis of the ORF can be used to deduce the sequence of the 
encoded protein.
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TRANSLATION IN PROKARYOTES
1. Overview
A ribosome binds to an mRNA molecule and reads the nucleotide 
sequence from the 5' to 3' direction, synthesizing the corresponding 
protein from amino acids in an N-terminal (amino-terminal) to C-terminal 
(carboxyl terminal) direction. The amino acids used are covalently bound 
to tRNA (transfer RNA) molecules to form aminoacyl-tRNAs. Each 
aminoacyl-tRNA bears a triplet of bases, called an anticodon. The 
ribosome reads each triplet codon of the mRNA in turn and an aminoacyl- 
tRNA molecule with an anticodon that is complementary to the codon 
binds to it via hydrogen bonding. A peptide bond is then formed between 
the incoming amino acid and the growing end of the polypeptide chain.
Overall, protein synthesis (or translation) takes place in three stages; 
initiation, elongation and term ination. During initiation, the mRNA- 
ribosome complex is formed and the first codon (always AUG) binds the 
first aminoacyl-tRNA (called initiator tRNA). During the elongation 
phase, the other codons are read sequentially and the polypeptide grows 
by addition of amino acids to its C-terminal end. This process continues 
until a termination codon (Stop codon), which does not have a 
corresponding aminoacyl-tRNA with which to base-pair, is reached. At this 
point, protein synthesis ceases (termination phase) and the finished 
polypeptide is released from the ribosome. Usually at any one time, many 
ribosomes are translating an mRNA simultaneously, forming a structure 
called a polyribosome or polysome.
2. Synthesis of aminoacyl-tRNA
A tRNA molecule is about 74-95 nucleotides long, making these some of 
the smallest RNA molecules in the cell. Each tRNA molecule has a 
cloverleaf secondary structure with the anticodon accessible at the end of 
the anticodon stem loop (Fig. 1). During synthesis of the aminoacyl-tRNA, 
the amino acid is covalently bound to the A residue of the CCA sequence at 
the 3' end (Fig. 1). Each tRNA molecule carries only a single amino acid. 
However, because of the redundancy of the genetic code, several codons 
may encode the same amino acid and so there will also exist several types 
of tRNA with corresponding anticodons all bearing the same amino acid. 
The correct nomenclature is, for example, tRNAay for the tRNA that will 
accept glycine whereas the corresponding aminoacyl-tRNA is Gly-tRNAciy, 
and is the aminoacyl-tRNA shown in Fig. 1.
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Fig. / .  Structure o f an aminoacyl-tPNA.
Synthesis of aminoacyl-tRNAs is crucially important for two reasons. 
First each amino acid must be covalently linked to a tRNA molecule in 
order to take part in protein synthesis, which depends upon the 'adaptor' 
function of tRNA to ensure that the correct amino acids are incorporated. 
Second, the covalent bond that is formed between the amino acid and the 
tRNA is a high energy bond that enables the amino acid to react with the 
end of the growing polypeptide chain to form a new peptide bond. For this 
reason, the synthesis of aminoacyl-tRNA is also referred to as amino acid 
activation. Amino acids that are not linked to tRNAs cannot be added to 
the growing polypeptide.
The attachment of an amino acid to a tRNA is catalyzed by an enzyme 
called aminoacyl-tRNA synthetase. A separate aminoacyl-tRNA 
synthetase exists for every amino acid, making 20 synthetases in total. The 
synthesis reaction occurs in two steps. The first step is the reaction o f an 
amino acid and ATP to form an aminoacyl-adenylate (also known as 
aminoacyl-AMP).
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In the second step, without leaving the enzyme, the aminoacyl group of 
aminoacyl-AMP is transferred to the 3’ end of the tRNA molecule to form 
aminoacyl-tRNA:
aminoacyl-AMP + tR N A ---- ► aminoacyl-tRNA + AMP
The overall reaction is:
amino acid + ATP + tRNA ---- ► aminoacyl-tRNA + AMP + PP,
and is driven by the subsequent hydrolysis of the pyrophosphate to 
inorganic phosphate.
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3. Initiation of protein synthesis
Each prokaryotic ribosome, shown schematically in Fig. 2, has three 
binding sites for tRNAs, The aminoacyl-tRNA binding site (or A site) is 
where, during elongation, the incoming aminoacyl-tRNA binds. The 
peptidyl-tRNA binding site (or P site) is where the tRNA linked to the 
growing polypeptide chain is bound. The exit site (or E site) is a binding 
site for tRNA following its role in translation and prior to its release from 
the ribosome.
Fig. 2. Schematic o f  a prokaryotic /OS ribosome showing the peptidyl-tRNA site (P 
site), aminoacyl-tRNA site (A site) and exit site (E site).
The first codon translated in all mRNAs is AUG, which codes for 
methionine. This AUG is called the start codon or initiation codon. 
Naturally, other AUG codons also occur internally in an mRNA where they 
encode methionine residues internal to the protein. Two different tRNAs are 
used for these two types of AUG codon; tRNAfMet is used for the initiation 
codon and is called the initiator tRNA whereas tRNAmMel is used for 
internal AUG codons. In prokaryotes the first amino acid of a new 
protein is /V-formylmethionine (abbreviated fMet). Hence the 
aminoacyl-tRNA used in initiation is fMet-tRNAfMe'. It is essential that 
the correct AUG is used as the initiation codon since this sets the correct 
reading frame for translation. A short sequence rich in purines (5- 
AGGAGGU-3'), called the Shine-Dalgarno sequence, lies 5' to the AUG 
initiation codon (Fig. 3) and is complementary to part of the 16S rRNA in the 
small ribosomal subunit. Therefore this is the binding site for the 30S 
ribosomal subunit which then migrates in a 3' direction along the mRNA 
Ur,til it encounters the AUG initiation codon. Thus the Shine- Dalgamo 
sequence delivers the ribosomal subunit to the correct AUG for initiation 
f°r translation.
S h in e -  O ila e m o  sequence
И » « э т * Ь о с в п о я а д  inffiauoft codo n
S ' - ----------------------------------------------------------- A  G  G  A  G  G  U ------------------- ---------------A U G  ----------------— --------- 3 '
3 ~ 1 0 n t
Fig-3. The Shine-Dalgarno sequence in prokaryotic mRNA
* Initiation of protein synthesis is catalyzed by proteins
initiation factors (IFs). In prokaryotes, three initiation factors ( >
IF2 and IF3) are essential. Because o f  the com plexity o f  the process,
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the exact order of binding of IF1, IF2, IF3, fMet-tRNAMa 
mRNA is still unclear. One current model is shown in Fig 4 
described below. 31
Initiation begins with the binding of IF1 and IF3 to the small 
ribosomal subunit.
The small subunit then binds to the mRNA via the Shine-DaW. 
sequence and moves 3’ along the mRNA until it locates the a\jq 
initiation codon.
the initiator tRNA charged with /V-formylmethionine and in 
complex with IF2 and GTP (fMet-tRNAfMel/IF2/GTP) now binds. * 
IF3 is released.
The complex of mRNA, fMet-tRNAfMel, IF1, IF2 and the 30S ribosomal 
subunit is called the 30S initiation complex.
The large (50S) ribosomal subunit now binds, with the release of IF| 
and IF2 and hydrolysis of GTP, to form a 70S initiation complex.
Fig. 4. Initiation o f  protein synthesis in prokaryotic cells.
One important point to note is that, unlike all other aminoacyl-tRNA 
molecules (which bind to the A site), the binding of fMet-tRNAfMd 
occurs directly into the P site.
4. Elongation
At the start of the first round of elongation (Fig. 5), the initiation 
codon (AUG) is positioned in the P site with fMet-tRNAfMrt bound to it via 
codon-anticodon base-pairing. The next codon in the mRNA is positioned 
in the A site.
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Fig. 5. The elongation phase o f  protein synthesis in prokaryotic cells.
Elongation of the polypeptide chain occurs in three steps called the 
'elongation cycle, namely aminoacyl-tRNA binding, peptide bond 
{formation and translocation:
• Aminoacyl-tRNA binding: in this first step, the corresponding 
aminoacyl-tRNA for the second codon binds to the A site via 
codon-anticodon interaction (Fig. 5). Binding of the aminoacyl- 
tRNA requires elongation factor EF-Tu and GTP which bind as an 
aminoacyl-tRNA/EF-Tu/GTP complex. Following binding, the 
GTP is hydrolyzed and the EF-Tu is released, now bound to 
GDP (Fig. 5). Before the EF-Tu molecule can catalyze the binding of 
another charged tRNA to the ribosome, it must be regenerated by a 
process involving another elongation factor, EF-Ts. This 
regeneration is called the EF-Tu-EF-Ts exchange cycle (Fig. 6). 
First, EF-Ts binds to EF-Tu and displaces the GDP. Then GTP binds 
to the EF-Tu and displaces EF-Ts. The EF-Tu-GTP is now 
ready to take part in another round o f elongation.
• Peptide bond formation: the second step, peptide bond formation, is 
catalyzed by peptidyl transferase, part of the large ribosomal subunit. 
In this reaction the carboxyl end of the amino acid bound to the tRNA 
in the P site is uncoupled from the tRNA and becomes joined by a
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peptide bond to the amino group of the amino acid linked to the 
tRNA in the A site (Fig. 5). A protein with peptidvl 
transferase activity has never been isolated. The reason is now clear; jn 
E. coli at least, the peptidyl transferase activity is associated with part 
of the 23S rRNA inthe large ribosomal subunit. In other words 
peptidyl transferase is a ribozyme, a catalytic activity that resides in 
an RNA molecule.
• Translocation: in the third step, a complex of elongation factor 
EF-G (also called translocase) and GTP (i.e. EF-G/GTP) binds to 
the ribosome. Three concerted movements (Fig. 3c) now occur, 
collectively called translocation; the deacylated tRNA moves from 
the P site to the E site, the dipeptidyl-tRNA in the A site moves to 
the P site, and the ribosome moves along the mRNA (5' 
to 3') by three nucleotides to place the next codon in the A site. 
During the translocation events, GTP is hydrolyzed to GDP and 
inorganic phosphate, and EF-G is released ready to bind more GTP 
for another round of elongation.
After translocation, the A site is empty and ready to receive the next 
aminoacyl-tRNA. The A site and the E site cannot be occupied 
simultaneously. Thus the deacylated tRNA is released from the E site 
before the next aminoacyl-tRNA binds to the A site to start a new round of 
elongation. Elongation continues, adding one amino acid to the C- 
terminal end of the growing polypeptide for each codon that is read, with 
the peptidyl-tRNA moving back and forth from the P site to the A site as 
it grows.
5. Termination
Eventually, one of three termination codons (also called Stop codons) 
becomes positioned in the A site (Fig. 7). These are UAG, UAA and 
UGA. Unlike other codons, prokaryotic cells do not contain aminoacyl- 
tRNAs complementary to Stop codons. Instead, one of two release 
factors (RF1 and RF2) binds instead. RF1 recognizes UAA and UAG 
whereas RF2 recognizes UGA. A third release factor, RF3, is also needed 
to assist RF1 or RF2. Thus either RF1 + RF3 or RF2 + RF3 bind 
depending on the exact termination codon in the A site. RF1 (or RF2) 
binds at or near the A site whereas RF3/GTP binds elsewhere on the 
ribosome. The release factors cause the peptidyl transferase to transfer 
the polypeptide to a water molecule instead of to aminoacyl-tRNA, 
effectively cleaving the bond between the polypeptide and tRNA in the P 
site. The polypeptide, now leaves the ribosome, followed by the mRNA 
and free tRNA, and the ribosome dissociates into 30S and 50S subunits 
ready to start translation afresh.
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Fig. 7. Termination o f  protein synthesis in prokaryotic cells.
Translation in eukaryotes
Eukaryotic ribosomes are larger (80S) and more complex than 
prokaryotic ribosomes (70S). Initiation is basically similar in prokaryotes 
and eukaryotes except that in eukaryotes at least nine initiation factors are 
involved (cf. three factors in prokaryotes), the initiating amino acid is 
methionine (cf. iV-formylmethionine in prokaryotes), eukaryotic mRNAs 
do not contain Shine-Dalgamo sequences (so the AUG initiation codon is 
detected by the ribosome scanning instead), and eukaryotic mRNA is 
monocistronic (cf. some polycistronic mRNAs in prokaryotes). Initiation in 
eukaryotes involves the formation of a 48S preinitiation complex between 
the 40S ribosomal subunit, mRNA, initiation factors and Met-tRNAfM".
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The ribosome then scans the mRNA to locate the AUG initiation codon. 
The 60S ribosomal subunit now binds to form the 80S initation complex.
Elongation in eukaryotes requires three eukaryotic initiation factors that 
have similar functions to the corresponding prokaryotic proteins.
A single eukaryotic release factor recognizes all three termination 
codons and requires ATP for activity.
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SIGNAL TRANSDUCTION
Signal transduction.
1. Cell signaling
In multicellular organisms there is a need for the cells to 
communicate with one another in order to coordinate their growth and 
metabolism. The principal way by which cells communicate with each 
other is by means of extracellular signaling molecules or hormones. 
These molecules are synthesized and secreted by signaling cells and 
produce a specific response in target cells that have specific receptors 
for the signaling molecule. Different cells can respond differently to the . 
same signaling molecule depending on the type of receptor and the 
intracellular reactions initiated. Cell signaling can be classified into three 
distinct types based on the distance over which the signaling molecule 
acts. In endocrine signaling, the signaling molecule (e.g. insulin) acts on 
target cells distant from its site of synthesis in cells of an endocrine 
organ (e.g. the pancreas; Fig. la). The endocrine cells secrete the signaling 
molecule into the bloodstream (if an animal) or the sap (if a plant) which 
carries it to the target cells elsewhere in the organism. In paracrine 
signaling, the signaling molecule affects only target cells close to the cell 
from which it was secreted (Fig. lb). The communication from one nerve 
cell to another by chemical neurotransmitters is an example of paracrine 
signaling. The third type of cell signaling is autocrine signaling, where a 
cell responds to a molecule that it has produced itself (Fig. lc).
Secretory c e l N N r t iy  target ce « Tercet receotix* o n  *s*aem e c e l
Fig. 1. Cellular signaling, (a) Endocrine, (b) paracrine, (c) autocrine.
2. Hormones
The signaling molecules or hormones can be classified based on their 
solubility and the location of their receptor.
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Lipophilic hormones with intracellular receptors
Small lipophilic (lipid-soluble) hormones diffuse across the plasma 
membrane and then interact with intracellular receptors in the cytosol 
or nucleus. The resulting hormone-receptor complex often binds to 
regions of the DNA and affects the transcription of certain genes. Small 
lipophilic hormones with intracellular receptors include the steroid 
hormones which are synthesized from cholesterol (e.g. the female sex 
hormones estrogen and progesterone), thyroxine which is produced by 
thyroid cells and is the principal iodinated compound in animals, retinoic 
acid which is derived from vitamin A, and vitamin D which is 
synthesized in the skin in response to sunlight.
Cholesterol is the precursor of the five major classes of steroid 
hormones (Table I). The synthesis of steroid hormones is initiated by the 
removal of a six-carbon unit from carbon 20 of the cholesterol side chain 
to form pregnenolone, the common precursor of all steroid hormones (Fig. 
2). A series of reactions catalyzed by cytochrome P-450 modify 
pregnenolone to give rise to the individual hormones (Fig. 2).
Ta ble  1. C la sse s o f s te ro id  horm on e
C lass Site of synthesis Hprmori© Action
Pro gestagens C o rp u s  luteum P rogesterone P repares uterine lining for e g g  implantation; 
m aintenance of pregnancy
A nd ro ge n s Testis Testosterone D e velopm ent o f m ale  s econdary sex characteristics
Estrog ens O v a ry Estrone D e velopm ent of fem ale secondary sex characteristics'
G lu co co rtico id s A drenal co rtex Cortisol P ro m o tes  gtuco neogenesis and glycog en form ation; 
enh a nc es  fat and  protein degradation
M ineraiocorticoids A drenal cortex Aldosterone Increases reabsorption of N a ’ and  excretion of K* and 
H* by kidney tubules
G to to s to it% 2 7 )
Ргсдпоп&сс* (C21)
Progestagens fC24)
X  I \
GMMOorttco«s * Androgw»
KBnefstooorttowde(C21) ... ..VI. ' '
EstrogensfCi B)
Fig. 2. Biosynthetic pathway for the synthesis o f  the steroid hormones.
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Lipophilic hormones with cell-surface receptors
The principal lipophilic (lipid-soluble) hormones that bind to 
receptors located in the plasma membrane are the prostaglandins, a family 
of structurally similar compounds that are found in both vertebrates and 
invertebrates. Prostaglandins are synthesized from arachidonic acid (a 20- 
carbon fatty acid with four unsaturated double bonds) and act as paracrine 
signaling molecules. Aspirin and other anti-inflam m atory agents 
inhibit the synthesis o f prostaglandins.
Hydrophilic hormones with cell-surface receptors
All hydrophilic (water-soluble) molecules (which cannot diffuse across 
the hydrophobic interior of the lipid bilayer) bind to receptors in the 
plasma membrane. There are two subclasses of hydrophilic hormones:
(1) peptide hormones such as insulin and glucagon;
(2) small charged molecules, often biogenic amines, such as 
epinephrine (adrenalin) and histamine that are derived from amino 
acids and function as hormones and neurotransmitters.
3. Cell-surface receptors
Hydrophilic and some lipophilic hormones bind to cell-surface 
receptors. These are integral membrane proteins situated in the plasma 
membrane that bind the signaling molecule (ligand) with high affinity. 
The ligand binds to a specific site on the receptor in much the same way 
as a substrate binds to an enzyme. Binding of the ligand to the receptor 
causes a conformational change in the receptor that initiates a sequence 
of reactions in the target cell (often referred to as signal transduction) 
leading to a change in cellular function. The distribution of receptors varies 
on different cells, and there is often more than one type of receptor for a 
particular ligand, allowing different target cells to respond differently to 
the same signaling molecule. Cell-surface receptors can be classified into 
three classes depending on how they transfer the information from the 
ligand to the interior of the cell: enzyme-linked receptors, ion channel- 
linked receptors and G protein-linked receptors.
Enzyme-linked receptors
On binding of the ligand to its extracellular face, the cell-surface 
receptor undergoes a conformational change and activates an intrinsic 
enzyme activity (Fig. 3). In the case of the insulin receptor which is a 
complex of two a- and two P-subunits held together by disulfide bonds, 
the polypeptide hormone insulin (the ligand) binds to the extracellular face
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of the <x-subunits (Fig. 3). The receptor then undergoes a conformational 
change leading to the autophosphorylation (self-phosphorylation) of the 
cytosolic domain of the P-subunit. Specifically the hydroxyl groups in the 
side chains of certain tyrosine residues are phosphorylated, with ATP 
being the phosphate donor. The phosphorylated receptor is then recognized 
by other proteins in the cytosol that in turn modulate various intracellular 
events, allowing the cell to respond to the hormone appropriately. In 
addition, the P-subunit can directly phosphorylate other target proteins 
within the cell.
Fig.3. Signal transduction through an enzyme-linked receptor such as the insulin 
receptor.
Ion channel-linked receptors
Here binding of the ligand again causes a conformational change in 
the protein but this time such that a specific ion channel is opened (Fig. 
4). This allows a certain ion to flow through that subsequently alters the 
electric potential across the membrane. For example, at the nerve-muscle 
junction the neurotransm itter acetylcholine binds to specific receptors 
that allow Na+ ions to flow into and КГ ions out of the target cell.
ii>OPiACeujjuv4
Fig.4. Signal transduction through an ion channel-linked receptor.
G protein-linked receptors
On binding its ligand, a G protein-linked receptor activates G 
proteins (guanyl nucleotide (GTP)-binding proteins) which in turn 
activate or inhibit either an enzyme that generates a specific second 
messenger or an ion channel, causing a change in the membrane
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potential (Fig.5a). Epinephrine and glucagon act through interaction with 
G protein-linked receptors. The majority of G protein-linked receptors 
contain seven transm em brane a-helices. Thus they have a similar 
overall shape to that of bacteriorhodopsin (which is not a receptor). G 
proteins are localized on the cytosolic face of the plasma membrane and 
act as on-off molecular switches. When it has guanosine diphosphate 
(GDP) bound, the G protein is in the 'off state. The activated receptor 
causes it to release the GDP and exchange it for GTP, converting it to 
the 'on' state (Fig. 5a and 5b). The activated G protein with its bound 
GTP then dissociates from the receptor and binds to and activates an 
effector enzyme (e.g. adenylate cyclase) which in turn catalyzes the 
formation of a second messenger (e.g. cAMP). The G protein then 
hydrolyzes the bound GTP, causing it to revert back to the 'off state (Fig. 
5b). Cholera toxin acts by inhibiting the intrinsic GTPase activity of the G 
protein (Fig. 5b), with the result that once activated to the GTP-bound 
state the G protein cannot be turned off again.
<•> U&ana • (b)
tJOaoa-receoto» cunwtox 
«с Л я й в в  »tvs stet>
trtrjnsie C TP a s e  actMty 
rrycimv*** О  I P  to G O P  
nod P,
G O P
Fig 5. (a) Signal transduction through a G protein-linked receptor and 
(b) the cycling o f  the G protein
4. Second messengers
The binding of ligands to many G protein-linked receptors leads to 
a shortlived increase in the concentration of certain intracellular 
signaling molecules called second messengers. (The hormone/ligand can 
be considered as the first messenger.) The major second messengers are 
3',5'-cyclic AMP (cAMP), 3',5'-cyclic GMP (cGMP), inositol 1,4,5- 
trisphosphate (IP3), 1,2-diacylglycerol (DAG) and Ca2+. The elevation in 
the level of one or other of these second messengers then leads to a rapid 
alteration in cellular function.
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cAMP and cGMP are derived from ATP and GTP by the actions of 
adenylate cyclase (Fig. 5a) and guanylate cyclase, respectively. For 
example, the action of glucagon on glycogen metabolism is mediated 
through the second messenger cAMP.
IP3 and DAG are derived from the membrane lipid 
phosphatidylinositol 4,5-bisphosphate (which is a phosphorylated 
derivative of phosphatidylinositol; by, the action of phospholipase C 
which is also located in the plasma membrane and, like adenylate 
cyclase, is activated by G proteins (Fig. 6). One of the main actions of the 
polar IP3 is to diffuse through the cytosol and interact with Ca"+ channels in 
the membrane of the ER (Fig. 6), causing the release of stored Ca2+ ions 
which in turn mediate various cellular responses. The DAG produced by 
the hydrolysis of phosphatidylinositol 4,5-bisphosphate, along with Ca2+ 
ions released from the ER, activates protein kinase C, a membrane-bound 
enzyme that phosphorylates various target proteins, again leading to 
alterations in a variety of cellular processes (Fig. 6).
Fig.6. Generation o f  the intracellular second messengers inositol 1.4,5- 
trisphosphate (IPs). 1,2-diacv/glycerol (DAG) andCa2*.
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PITUITARY AND HYPOTHALAMIC 
HORMONES
Introduction
The anterior pituitary, under control of hypothalamic hormones, secretes 
a number of hormones (trophic hormones) that regulate the growth and 
function of other endocrine glands or influence metabolic reactions in other 
target tissues. The posterior pituitary produces hormones that regulate 
water balance and milk ejection from the Iactating mammary gland.
The loss of anterior pituitary function (panhypopituitarism) results in 
atrophy of the thyroid, adrenal cortex, and gonads. Secondary effects due to 
the absence of the hormones secreted by these target glands affect most body 
organs and tissues and many general processes such as protein, fat. 
carbohydrate, and fluid and electrolyte metabolism. The loss of posterior pitui­
tary function results in diabetes insipidus, the inability to concentrate the 
urine.
A C R O N Y M S  U S E D  IN  T H IS  L E C T U R E
A C T H Adrenocorticotropic hormone
A D H Antidiuretic hormone
C G Chorionic gonadotropin
C L I P Corticotropinlike intermediate lobe peptide
C R H Corticotropin-releasing hormone
C S Chorionic somatomammotropin; placental lactogen
F S H Follicle-stimulating hormone
G H Growth hormone
G H R H  o r  G R H  Growth hormone-releasing hormone
G H R IH Growth hormone release-inhibiting hormone; somatostatin
G n R J I Gonadotropin-releasing hormone
IG F - I ,  - I I Insulinlike growth factors I and LI
L H Luteinizing hormone
L P H Lipotropin
M S H Melanocyte-stimulating hormone
P O M C Pro-opiomelanocortin peptide family
P R I H  o r  P IH Prolactin release-inhibiting hormone
P R L Prolactin
S R IH Somatotropin release-inhibiting hormone
T 3 Triiodothyronine
T 4 Thyroxine; tetraiodothyronine
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TRH Thyrotropin-releasing hormone
TSH Thyroid-stimulating hormone
VIP Vasoactive intestinal polypeptide
1. Hypothalamic hormones regulate the anterior pituitary.
The release (and in some cases production) of each of the pituitary 
hormones listed in Tablet is under tonic control by at least one hypothalamic 
hormone. The hypothalamic hormones are released from the hypothalamic 
nerve fiber endings around the capillaries of the hypothalamic-hypophyseal 
system in the pituitary stalk and reach the anterior lobe through the special 
portal system that connects the hypothalamus and the anterior lobe.
The hypothalamic hormones are released in a pulsatile manner, and 
isolated anterior pituitary target cells respond better to pulsatile administration 
of these hormones than to continuous exposure. The release of LH and FSH is 
controlled by the concentration of one releasing hormone, GnRH; this in turn 
is primarily a function of circulating levels of gonadal hormones that reach the 
hypothalamus (Similar feedback loops exist for all of the hypothalamic- 
pituitary-target gland systems <Tablel). The release of ACTH is primarily 
controlled by CRH, but a number of other hormones, including ADH, 
catecholamines, VIP, and angiotensin II, may be involved. CRH release is 
influenced by cortisol, a glucocorticoid hormone secreted by the adrenal. TSH 
release is primarily affected by TRH, which in turn is regulated by the thyroid 
hormones T3 and T4; but TSH release is also inhibited by somatostatin. Growth 
hormone release and production are under tonic control by both stimulating and 
inhibiting hypothalamic hormones. In addition, a peripheral feedback loop is 
involved in GH regulation.
Tablet. Hypotlialamic-hypohyseal targe! gland hormones form integratedfeedback loops.
H y p o th a la m ic  H o rm o n e A cro n y m P itu ita ry  H o rm o n e  
A ffec ted
T a rg e t G lan d  
H o rm o n e  A ffec ted
C o rtic o tro p in -re le a s in g
h o rm o n e
C R H A C T H  (L P H , 
M S H , en d o rp h in s)
H y d ro c o rtiso n e
T h y ro tro p in -re le a s in g
h o rm o n e
T R H T S H  (P R L ) T 3 an d  T 4
G o n a d o tro p in -re le a s in g
h o rm o n e
G n R H
(L H R H ,
F S H R H )
L H , F S H A n d ro g en s , e s tro ­
g en s , p ro g e s tin s
G ro w th  h o rm o n e -re le a s in g  
h o rm o n e  G ro w th  h o rm o n e  
re le a se -in h ib itin g  h o rm o n e ; 
s o m a to s ta tin ; so m a to tro p in  
re le a se -in h ib itin g  h o rm o n e
G H R H  o r 
G R H  
G H R IH  
o r  S H IH
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IGF-I (somatomedin C), which mediates some of the effects of GH, 
stimulates the release of somatostatin (GHRIH) while inhibiting the release of 
GHRH. The regulation of PRL synthesis and secretion is primarily under tonic 
inhibition by hypothalamic agents. It is unique because of the combined neural 
(nipple stimulation) and neurotransmitter/neurohormone link. Dopamine 
inhibits PRL synthesis (by inhibiting transcription of the PRL gene) and 
release, but does not account for overall PRL inhibition. Recently, a 56-amino- 
acid neuropeptide was discovered that has both GnRH and PRIH activities - 
thus the name GnRH-associated peptide (GAP). GAP is a potent inhibitor of 
PRL release and may be the elusive PRIH peptide. GAP may explain the 
curious link between GnRH and PRL secretion that is particularly obvious in 
some species. Many of the hypothalamic hormones, in particular TRH, CRH, 
and somatostatin, are found in other portions of the nervous system and in a 
variety of peripheral tissues.
Although cAMP was originally thought to mediate the action of releasing 
hormones on the adenohypophysis, recent studies with GnRH and TRH 
suggest that a calcium-phospholipid mechanism, similar to that described 
above, is involved. Whether the .releasing hormones also affect the synthesis 
of the corresponding pituitary hormone has been argued, but recently GHRH 
has been shown to stimulate the rate of transcription of the GH gene, and TRH 
has a similar effect on the prolactin gene.
2. The anterior pituitary produces a large number of hormones 
that stimulate a variety or physiologic and biochemical 
processes in target tissues.
The anterior pituitary hormones have traditionally been discussed 
individually, but recent studies dealing with the mechanism of synthesis and 
with the intracellular mediators of action (Table 1) allow one to classify these 
hormones into 3 categories: (1) the growth hormone-prolactin-chorionic 
somatomammotropin group, (2) the glycoprotein hormone group, and (3) the 
proopiomelanocortin peptide family.
2.1. Growth Hormone (GH).
Synthesis and structure: Growth hormone is synthesized in
somatotropes, a subclass of the pituitary acidophilic cells; somatotropes are the 
most abundant cells in the gland. The concentration of GH in the pituitary is 5- 
15 mg/g, which is much higher than the pg/g quantities of other pituitary 
hormones. Growth hormone is a single polypeptide, with a molecular weight of 
about 22,000 in all mammalian species. The general structure of the 191-amino 
acid human growth hormone molecule is shown in Fig. I. Although there is a 
high degree of sequence homology between various mammalian growth
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hormones, only human growth hormone or that of other higher primates is 
active in humans. Human GH made by recombinant DNA techniques is now 
available for therapeutic use.
Fig. 1. The structures o f  human growth hormone (left) and ovine prolactin (right) are 
compared. Growth hormone has disulfide bonds between residues 53-165 and 182- 
189. Prolactin has disulfide bonds between residues 4-11, 58-73. and 190-198.
Physiologic and biochemical actions: GH is essential for postnatal growth 
and for normal carbohydrate, lipid, nitrogen, and mineral metabolism. The 
growth-related effects are primarily mediated by 1GF-I, a member of the 
insulinlike gene family. This was originally known as "sulfation factor" 
because of its ability to enhance the incorporation of sulfate into cartilage. It 
next was known as somatomedin C. Structurally, it is similar to proinsulin. 
Another closely related peptide found in human plasma, 1GF-11, has activity 
similar or identical to what is often referred to in the rat as multiplication- 
stimulating activity (MSA). IGF-1 and 1GF-II both bind to membrane receptors; 
however, they can be differentiated on the basis of specific radioimmunoassays. 
IGF-1 has 70 amino acids, and IGF-П has 67. Plasma levels of IGF-I1 are twice 
those of IGF-I, but it is IGF-1 that correlates most directly with GH effects. 
Individuals who lack sufficient IGF-I but have IGF-II (GH-deficient dwarfs and 
pygmies) fail to grow normally.
GH has several actions:
1. Protein synthesis - GH increases the transport of amino acids into 
muscle cells and also increases protein synthesis by a mechanism separate from 
the transport effect. Animals treated with GH show positive nitrogen balance, 
reflecting a generalized increase in protein synthesis and a decrease in plasma 
and urinary levels of amino acids and urea. This is accompanied by increased 
synthesis of RNA and DNA in some tissues. In these respects GH actions 
resemble some of the actions of insulin.
2. Carbohydrate metabolism - GH generally antagonizes the effects of 
insulin. Hyperglycemia after growth hormone administration is the combined 
result of decreased peripheral utilization of glucose and increased hepatic 
production via gluconeogenesis. In liver, GH increases liver glycogen, 
probably from activation of gluconeogenesis from amino acids. Impairment of 
glycolysis may occur at several steps, and the mobilization of fatty acids from
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triacylglycerol stores may also contribute to the inhibition of glycolysis in 
muscle. Prolonged administration of GH may result in diabetes mellitus.
3. Lipid metabolism - GH promotes the release of free fatty acids and 
glycerol from adipose tissue, increases circulating free fatty acids, and 
causes increased oxidation of free fatty acids in the liver. Under conditions of 
insulin deficiency (eg, diabetes), increased ketogenesis may occur. These 
effects and those on carbohydrate metabolism probably are not mediated by 
IGF-I.
4. Mineral metabolism - GH, or more likely IGF-1, promotes a positive 
calcium, magnesium, and phosphate balance and causes the retention of 
Na+, K+, and СГ. The first effect probably relates to the action of GH in bone, 
where it promotes growth of long bones at the epiphyseal plates in growing 
children and appositional or acral growth in adults. In children, GH also 
increases formation of cartilage.
5. Prolactinlike effects - GH binds to lactogenic receptors and thus has 
many of the properties of prolactin, such as stimulation of the mammary 
glands, lactogenesis, and stimulation of the pigeon crop sac.
Growth Hormone pathophysiology: Deficient amounts of GH, whether 
from panhypopituitarism or isolated GH deficiency, are most serious in 
infancy because affected infants fail to grow properly. The other metabolic 
effects are less troublesome. Several types of dwarfism help illustrate the 
importance of the various steps in GH action. GH-deficient dwarfs respond 
normally to exogenous GH. Two types of target organ resistance have been 
described. Laron type dwarfs have excessive amounts of GH-N, but they lack 
hepatic GH receptors. Pygmies apparently have a post-GH receptor defect, 
and this may be limited to the action GH exerts through IGF-I.
GH excess, usually from an acidophilic tumor, causes gigantism if it 
occurs before the epiphyseal plates close, since there is accelerated growth of 
the long bones. Acromegaly results from excessive release of GH that begins 
after epiphyseal closure and the cessation of long bone growth. Acral bone 
growth causes the characteristic facial changes (protruding jaw, enlarged 
nose) and enlargement of the hands, feet, and skull. Other findings include 
enlarged viscera, thickening of the skin, and a variety of metabolic problems, 
including diabetes mellitus.
A knowledge of GH regulation allows one to understand the clinical tests 
used to confirm these diagnoses. GH-deficient patients fail to increase GH 
levels in response to induced hypoglycemia or administration of arginine or 
levodopa. Patients with increased GH from a tumor (gigantism or acromegaly) 
fail to suppress GH levels in response to glucose administration.
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2.2. Prolactin (PRL: Lactogenic Hormone, Mammotropin, 
Luteotropic Hormone)
Synthesis and structure: PRL is a protein hormone with a molecular 
weight of about 23,000; its general structure is compared to that of GH in 
Fig. 1. It is secreted by lactotropes, which are acidophilic cells in the anterior 
pituitary. The number of these cells and their size increase dramatically during 
pregnancy. The similarities between the structures and functions of PRL, GH, 
and CS are noted above.
Prolactin physiologic and biochemical actions: PRL is involved in the 
initiation and maintenance of lactation in mammals. Physiologic levels act 
only upon breast tissue primed by female sex hormones, but excessive levels 
can trigger breast development in ovariectomized females or in males. In 
rodents, PRL is capable of maintaining the corpus luteum - hence the name 
luteotropic hormone. Related molecules appear to be responsible for the 
adaptation of saltwater fish to fresh water, for the molting of reptiles, and for 
crop-sac milk production in birds. The intracellular mediator of PRL action is 
unknown. A peptide has been proposed, but this has not been verified.
Prolactin pathophysiology: Tumors of prolactin-secreting cells cause 
amenorrhea (cessation of menses) and galactorrhea (breast discharge) in 
women. Excessive PRL has been associated with gynecomastia (breast 
enlargement) and impotence in men.
2.3. The Glycoprotein Hormones are another group.
The most complex protein hormones yet discovered are the pituitary and 
placental glycoproteins: thyroid-stimulating hormone (TSH), luteinizing 
hormone (LH), follicle-stimulating hormone (FSH), and chorionic 
gonadotropin (CG). These hormones affect diverse biologic processes and yet 
have remarkable structural similarities. This class of hormones is found in all 
mammals. These molecules, like other peptide and protein hormones, interact 
with cell surface receptors and activate adenylate cyclase; thus, they employ 
cAMP as their intracellular messenger.
The Gonadotropins (FSH, LH, and hCG): These hormones are 
responsible for gametogenesis and steroidogenesis in the gonads. Each is a 
glycoprotein with a molecular weight of about 25,000.
1. Follicle-Stimulating Hormone (FSH) - FSH binds to specific 
receptors on the plasma membranes of its target cells, the follicular cells in the 
ovary and the Sertoli cells in the testis. This results in activation of adenylate 
cyclase and increased cAMP production.
2. Luteinizing Hormone (LH) - LH binds to specific plasma membrane 
receptors and stimulates the production of progesterone by corpus luteum cells 
and of testosterone by the Leydig cells. The intracellular signal of LH action is
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cAMP. This nucleotide mimics the actions of LH, which include enhanced 
conversion of acetate to squalene (the precursor for cholesterol synthesis) and 
enhanced conversion of cholesterol to 2a-hydroxycholesterol, a necessary step 
in the formation of progesterone and testosterone. There is tight coupling 
between the binding of LH and the production of cAMP, but steroidogenesis 
occurs when very small increases of cAMP have occurred. There thus are 
spare receptors in this response. Prolonged exposure to LH results in 
desensitization, perhaps owing to down-regulation of LH receptors. This 
phenomenon may be exploited as an effective means of birth control.
3. Human Chorionic Gonadotropin (hCG) - hCG is a glycoprotein 
synthesized in the syncytiotrophoblast cells of the placenta. It has the a [5-dimer 
structure characteristic of this class of hormones and most closely resembles LH.
It increases in blood and urine shortly after implantation; hence, its detection is 
the basis of many pregnancy tests.
Thyroid-Stimulating Hormone (TSH): TSH is a glycoprotein of a(5- 
dimer structure with a molecular weight of about 30,000. Like other hormones 
of this class, TSH binds to plasma membrane receptors and activates adenylate 
cyclase. The consequent increase of cAMP is responsible for the action of TSH 
in thyroid hormone biosynthesis. Its relationship to the trophic effects of 
TSH on the thyroid is less certain. TSH has several acute effects on thyroid 
function. These occur in minutes and involve increases of all phases of T3 and 
T4 biosynthesis, including iodide concentration, organification, coupling, and 
thyroglobulin hydrolysis. TSH also has several chronic effects on the thyroid. 
These require several days and include increases in the synthesis of proteins, 
phospholipids, and nucleic acids and in the size and number of thyroid cells. 
Long-term metabolic effects of TSH are due to the production and action of 
the thyroid hormones. _ /
2.4. Action and regulation of specific peptides:
1. Adrenocorticotropic hormone (ACTH) structure and 
mechanism of action - ACTH, a single-chain polypeptide consisting of 
39 amino acids, regulates the growth and function of the adrenal cortex. 
ACTH, like other peptide hormones, binds to a plasma membrane receptor. 
Within a few seconds of this interaction, intracellular cAMP levels increase 
markedly. cAMP analogs mimic the action of ACTH, but calcium also is 
involved.
2. ACTH pathophysiology - Excessive production of ACTH by the 
pituitary or by ectopic production from a tumor results in Cushing's 
syndrome. The weak MSH-like activity of ACTH or associated release of (3- 
or ct-MSH results in hyperpigmentation. The metabolic manifestations are 
due to excessive production of adrenal steroids and include (1) negative 
nitrogen, potassium, and phosphorus balance; (2) sodium retention, which
215
Lecture 24
can result in hypertension, edema, or both; (3) glucose intolerance or overt 
diabetes mellitus; (4) increased plasma fatty acids; and (5) decreased 
circulating eosinophils and lymphocytes, with increased polymorphonuclear 
leukocytes. Patients with Cushing's syndrome may have muscle atrophy and 
a peculiar redistribution of fat, ie, truncal obesity. Loss of ACTH owing to 
tumor, infection, or infarction of the pituitary results in an opposite 
constellation of findings.
Endorphins: P-Endorphin consists of the carboxy-terminal 31 amino 
acids of P-LPH (Fig.2). The а-and y-endorphins are modifications of P- 
endorphin from which 15 and 14 amino acids, respectively, are removed 
from the C-terminal end. These peptides are found in the pituitary, but they 
are acetylated there and probably are inactive. In other sites (eg, central 
nervous system neurons), they are not modified and hence probably serve as 
neurotransmitters or neuromodulators. Endorphins bind to the same central 
nervous system receptors as do the morphine opiates and may play a role in 
endogenous control of pain perception. They have higher analgesic 
potencies (18-30 times on a molar basis) than morphine. The sequence for 
enkephalin is present in POMC, but it is not preceded by dibasic amino acids 
and presumably is not cleaved or expressed.
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Fig.2. Products o f  pro-opiomelctnocortin (POMC) cleavage. MSH. a  melanocyte- 
stimulating hormone. CLIP, cor-licotropinlike intermediate lobe peptide; LPH, 
lipotropin.
Melanocyte-Stimulating Hormone (WISH): MSH stimulates
melanogenesis in some species by causing the dispersion of intracellular 
melanin granules, resulting in darkening of the skin.
Patients with insufficient production of glucocorticoids (Addison's 
disease) have hyperpigmentation associated with increased plasma MSH 
activity. This could be due to ACTH but is more likely the result of 
concomitant secretion of p- and y-LPH, with their associated MSH activity.
2.5. The posterior pituitary contains 2 active hormones, 
Vasopressin and Oxytocin.
Vasopressin, originally named because of its ability to increase blood 
pressure when administered in pharmacologic amounts, is more 
appropriately called antidiuretic hormone (ADH) because its most important
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physiologic action is to promote reabsorption of water from the distal renal 
tubules. Oxytocin is also named for an effect of questionable physiologic 
significance, the acceleration of birth by stimulation of uterine smooth 
muscle contraction. Its probable physiologic role is to promote milk ejection 
from the mammary gland.
Both hormones are produced in the hypothalamus and transported by 
axoplasmic flow to nerve endings in the posterior pituitary' where, upon 
appropriate stimulation, the hormones are released into the circulation. The 
probable reason for this arrangement is to escape the blood-brain barrier. 
ADH is primarily synthesized in the supraoptic nucleus and oxytocin in the 
paraventricular nucleus. Each is transported through axons in association 
with specific carrier proteins called neurophysins. Neurophysins I and II 
are synthesized with oxytocin and ADH, respectively, each as a part of a 
single protein (sometimes referred to as propressophysin) from a single 
gene. Neurophysins I and II are unique proteins with molecular weights of 
19,000 and 21,000, respectively. ADH and oxytocin are secreted separately 
into the bloodstream along with their appropriate neurophysins. They 
circulate unbound to proteins and have very short plasma halflives, on 
the order of 2-4 minutes.
Oxytocin
Regulation of Secretion: The neural impulses that result from 
stimulation of the nipples are the primary stimulus for oxytocin release. 
Vaginal and uterine distention are secondary stimuli. PRL is released by 
many of the stimuli that release oxytocin, and a fragment of oxytocin has 
been proposed as prolactin-releasing factor. Estrogen stimulates the 
production of oxytocin and of neurophysin I, and progesterone inhibits the 
production of these compounds.
Mechanism of Action: The mechanism of action of oxytocin is 
unknown. It causes contraction of uterine smooth muscle and thus is used in 
pharmacologic amounts to induce labor in humans. Interestingly, pregnant 
animals in which the hypothalamic-hypophyseal tract has been destroyed 
do not necessarily have trouble delivering their young. The most likely 
physiologic function of oxytocin is to stimulate contraction of 
myoepithelial cells surrounding the mammary alveoli. This promotes the 
movement of milk into the alveolar duct system and allows for milk ejec­
tion. Membrane receptors for oxytocin are found in both uterine and 
mammary tissues. These receptors are increased in number by estrogens and 
decreased by progesterone. The concomitant rise in estrogens and fall in 
progesterone occurring immediately before parturition probably explains the 
onset of lactation prior to delivery. Progesterone derivatives are commonly 
used to inhibit postpartum lactation in humans. Oxytocin and neurophysin I
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appear to be produced in the ovary, wherein oxytocin may inhibit 
steroidogenesis.
Antidiuretic Hormone (ADH; Vasopressin)
Regulation of Secretion: The neural impulses that trigger ADH release 
are activated by a number of different stimuli. Increased osmolality of 
plasma is the primary physiologic stimulus. This is mediated by 
osmoreceptors located in the hypothalamus and by baroreceptors located in 
the heart and other regions of the vascular system. Hemodilution (decreased 
osmolality) has the opposite effect. Other stimuli include emotional and 
physical stress and pharmacologic agents including acetylcholine, 
nicotine, and morphine. Most of these effects involve increased synthesis 
of ADH and neurophysin II, since the depletion of stored hormone is not 
associated with this action. Epinephrine and agents that expand plasma 
volume inhibit ADH secretion, as does ethanol.
Mechanism of Action: The most important physiologic target cells of 
ADH in mammals are those of the distal convoluted tubules and collecting 
structures of the kidney. These ducts pass through the renal medulla, in 
which the extracellular solute pool has an osmolality gradient up to 4 times 
that of plasma. These cells are relatively impermeable to water, so that in the 
absence of ADH, the urine is not concentrated and may be excreted in 
amounts exceeding 2 L/d. ADH increases the permeability of the cells to 
water and permits osmotic equilibration of the collecting tubule urine with 
the hypertonic interstitium, resulting in urine volumes in the range of 0.5-1 
L/d. ADH receptors exist on the mucosal (urinary) membrane of these 
epithelial cells. This receptor is linked to adenylate cyclase, and cAMP is 
thought to mediate the effects of ADH in the renal tubule. This physiologic 
action is the basis of the name "antidiuretic hormone". cAMP and inhibitors 
of phosphodiesterase activity (caffeine for example) mimic the actions of 
ADH. In vivo, an elevated level of calcium in the medium bathing the 
mucosal surface of the tubular cells inhibits the action of ADH on water 
movement, apparently by inhibiting the action of adenylate cyclase, since it 
does not diminish the action of cAMP per se. This may account, in part, for 
the excessive volumes of urine that are characteristic of patients with 
hypercalcemia.
Pathophysiology: Abnormalities of ADH secretion or action lead to 
diabetes insipidus, which is characterized by the excretion of large volumes 
of dilute urine. Primary diabetes insipidus, an insufficient amount of the 
hormone, is usually due to destruction of the hypothalamic-hypophyseal tract 
from a basal skull fracture, tumor, or infection, but it can be hereditary. In 
hereditary nephrogenic diabetes insipidus, ADH is secreted normally but the 
target cell is incapable of responding, presumably because of a receptor
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defect. This hereditary lesion is distinguished from acquired nephrogenic 
diabetes insipidus, which most often is due to the pharmacologic 
administration of lithium for manic-depressive illness. The inappropriate 
secretion of ADH occurs in association with ectopic production by a variety 
of tumors (usually tumors of the lung) but can also occur in conjunction with 
diseases of the brain, pulmonary infections, or hypothyroidism. It is called 
inappropriate secretion because ADH is produced at a normal or increased 
rate in the presence of hypoosmolality, thus causing a persistent and 
progressive dilutional hyponatremia with excretion of hypertonic urine.
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HORMONES OF THE GONADS.
Introduction
The gonads are bifunctional organs that produce germ cells and the sex 
hormones. These 2 functions are closely approximated, for high local 
concentrations of the sex hormones are required for germ cell development. 
The ovaries produce ova and the steroid hormones estrogen and 
progesterone; the testes produce spermatozoa and testosterone. As in the 
adrenal, a number of steroids are produced, but only a few are active as 
hormones. The production of these hormones is tightly regulated through a 
feedback loop that involves the pituitary and the hypothalamus. The gonadal 
hormones act by a nuclear mechanism similar to that employed by the adrenal 
steroid hormones.
Proper functioning of the gonads is crucial for reproduction and, hence, 
survival of the species. Conversely, an understanding of the endocrine 
physiology and biochemistry of the reproductive process is the basis of many 
approaches to contraception. The gonadal hormones have other important 
actions; for example, they are anabolic and thus required for maintenance of 
metabolism in skin, bone, and muscle.
ACRONYMS USED IN THIS LECTURE
ACTH Adrenocorticotropic hormone
ABP Androgen-binding protein
CBG Corticosteroid-binding globulin
DHEA Dehydroepiandrosterone
DHT D ihyd rotestosterone
Ez Estradiol
FSH Follicle-stimulating hormone
GnRH Gonadotropin-releasing hormone
hCG Human chorionic gonadotropin
hCS Human chorionic somatomammotropin
LH Luteinizing hormone
MIF Miillerian inhibiting factor
3J5-OHSD 3 P-Hydroxysteroid dehydrogenase
17JJ-OHSD 17p-Hydroxysteroid dehydrogenase
PL Placental lactogen
SHBG Sex hormone-binding globulin
TBG Thyroid-binding globulin
TEBG Testosterone-estrogen-binding globulin
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1. The testes produce testosterone (the male sex hormone) and 
spermatozoa (the male germ cells)
These functions are carried out by 3 specialized cell types; (1) the 
spermatogonia and more differentiated germ cells, which are located in the 
seminiferous tubules; (2) the Leydig cells (also called interstitial cells), 
which are scattered in the connective tissue between the coiled 
seminiferous tubules and which produce testosterone in response to LH; 
and (3) the Sertoli cells, which form the basement membrane of the 
seminiferous tubules and provide the environment necessary for germ cell 
differentiation and maturation. Spermatogenesis is stimulated by FSH and 
LH from the pituitary. It requires an environment conducive to germ cell 
differentiation and a concentration of testosterone in excess of that found in 
the systemic circulation - a requirement that can be met because the Leydig 
cells and seminiferous tubules are in close approximation.
Testicular androgens are synthesized in the interstitial tissue by the Leydig 
cells. The immediate precursor of the gonadal steroids, as with the adrenal 
steroids, is cholesterol.
The conversion of pregnenolone to testosterone requires the action of 5 
enzymes. These enzymes are: ( 1) 3P-hydroxysteroid dehydrogenase (3P - 
OHSD); (2) Д5,4 isomerase; (3) 17 a -hydroxylase; (4) Q 7-20 lyase; and (5) 17P - 
hydroxysteroid dehydrogenase (17p - OHSD). This sequence, referred to as the 
progesterone (or A4) pathway, is shown on the right side of Fig. I. 
Pregnenolone can also be converted to testosterone by the 
dehydroepiandrosterone (or A3) pathway, which is illustrated on the left side of 
Fig.l. The A route appears to be preferred in human testes; however, since 
these are seldom available for study, most information about these pathways 
comes from studies in other animals. There may be significant species 
differences.
The 5 enzymes are localized in the microsomal fraction in rat testes, and 
there is a close functional association between the activities of 3P-OHSD 
and A • isomerase and between those of 17a-hydroxylase and C 17.20 lyase. 
These enzyme pairs are shown in the general reaction sequence in Fig. 1.
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Fig. I. Pathways o f  testosterone biosynthesis. The pathw ay on the left side o f  the 
figure  is called the zP or dehydroepiandroslerone pathway; the pathway on the right 
side is called the A 4 or progesterone pathway.
Dihydrotestosterone (DHT) is formed from testosterone by the 
reduction of the a ring through the action of 
the enzyme 5a-reductase.
Human testes secrete about 50-100 pg of DHT per day, but most DHT is 
derived from peripheral conversion. The testes also make small but significant 
amounts of 17p-estradiol (E2), the female sex hormone, but most of the E2 
produced by the male is derived from peripheral aromatization of testosterone 
and androstenedione. The Leydig cells, the Sertoli cells, and the seminiferous 
tubules are thought to be involved in E2 production. The role of E2 in the male 
has not been determined, but it may contribute to FSH regulation. Abnormally 
high plasma levels of E2 and changes in the free E2: testosterone ratio have
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been associated with pubertal or postpubertal gynecomastia (male breast 
enlargement), particularly in older individuals and in patients with chronic 
liver disease or hyperthyroidism.
There are remarkable age-related changes in 
testicular hormone production
Testosterone is the dominant hormone in the fetal and neonatal rat, but the 
testes make only androsterone soon afterbirth. The ability to produce 
testosterone is restored at puberty and continues throughout life. Similar 
observations have been made in other species, and these age-related changes 
may also occur in humans.
Testosterone binds to a specific plasma protein
Most mammals, humans included, have a plasma P-globuiin that binds 
testosterone with specificity, relatively high affinity, and limited capacity. This 
protein, usually called sex hormone-binding globulin (SHBG), or testosterone- 
estrogen-binding globulin (TEBG), is produced in the liver. Its production is 
increased by estrogens (women have twice the serum concentration of SHBG 
as men), certain types of liver disease, and hyperthyroidism; it is decreased by 
androgens, advancing age, and hypothyroidism. Since SHBG and albumin 
bind 97-99% of circulating testosterone, only a small fraction of the hormone 
in circulation is in the free (biologically active) form. The primary function of 
SHBG may be to restrict the free concentration of testosterone in the serum. 
Testosterone binds to SHBG with higher affinity than does estradiol. Therefore, 
a change in the level of SHBG causes a greater change in the free testosterone 
level than in the free estradiol level. An increase of SHBG may contribute to the 
increased free E2: testosterone ratio noted in aging, cirrhosis, and 
hyperthyroidism and hence contribute to the attendant signs and symptoms of 
"estrogenization" alluded to above.
A number of steroids are present in testicular venous blood, but testosterone 
is the major steroid secreted by the adult testes.
The secretion rate of testosterone is about 5 mg/d in normal adult men. Like 
other steroid hormones, testosterone seems to be released as it is produced.
Many of the metabolites of testosterone are inactive; others, such as 
dihydrotestosterone and estradiol, have increased or different activities
Metabolic pathways: Testosterone is metabolized by 2 pathways. One 
involves oxidation at the 17-position, and the other involves reduction of the A 
ring double bond and the 3-ketone. Metabolism via the first pathway occurs in 
many tissues, including liver, and produces 17-ketosteroids that are generally 
inactive or less active than the parent compound. Metabolism via the second
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pathway, which is less efficient, occurs primarily in target tissues and produces 
the potent metabolite DHT.
Metabolites of testosterone: The most significant metabolic product of 
testosterone is DHT, since in many tissues, including seminal vesicles, prostate, 
external genitalia, and some areas of the skin, this is the active form of the 
hormone. The plasma content of DHT in the adult male is about one-tenth that 
of testosterone, and approximately 400 pg of DHT is produced daily, as 
compared to about 5 mg of testosterone. The reaction is catalyzed by 5a- 
reductase, an NADPH-dependent enzyme.
T * * to  j t * r о n a  O l h y d r g t t R o t t t r o n c  (D H T )
Testosterone can thus be considered a prohormone, since it is converted 
into a much more potent compound (dihydrotestosterone) and since most of 
this conversion occurs outside the testes. A small percentage of testosterone 
is also converted into estradiol by aromatization, a reaction that is especially 
important in the brain, where these hormones help determine the sexual 
behavior of the animal. Androstanediol, another potent androgen, is also 
produced from testosterone.
Testosterone
Estradiol ArxlrottanecUot Oihyd ro test 08 ter one (DHT)
The major 17-ketosteroid metabolites, androsterone and 
etiocholanolone, are conjugated with glucuronide and sulfate in the liver to 
make water-soluble, excretable compounds.
2. Regulation of testicular function is multihornional 
Testicular steroidogenesis is stimulated by LH
LH stimulates Steroidogenesis and testosterone production by binding to 
receptors on the plasma membrane of the Leydig cells (an analogous LH 
receptor is found in the ovary on cells of the corpus luteum) and activating 
adenylate cyclase, thus increasing intracellular cAMP. This action enhances 
the rate of cholesterol side-chain cleavage. The similarity between this action 
of LH and that of ACTH on the adrenal is apparent. Testosterone provides 
for feedback control at the hypothalamus through inhibition of GnRH release, 
GnRH production, or both (Fig. 2).
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Fig-2. Mechanism o f  androgen action. LH  - luteinizing hormone; T- 
lestosterone; DHT - dihydrolestoslerone;  R - androgen receptor.
Spermatogenesis is regulated by FSH and testosterone
FSH binds to the Sertoli cells and promotes the synthesis of androgen- 
binding protein (АВР). ABP is glycoprotein that binds testosterone. It is 
distinct from the intracellular androgen receptor but is homologous with 
SHBG. ABP is secreted into the lumen of the seminiferous tubule, and in 
this process testosterone produced by the Leydig cells is transported in very 
high concentration to the site of Spermatogenesis. This appears to be a critical 
step, since normal systemic levels of testosterone, such as might be 
achieved by replacement therapy, do not support Spermatogenesis.
Androgens affect several complex physiologic prosesses
The androgens, principally testosterone and DHT, are involved in (1) 
sexual differentiation, (2) Spermatogenesis, (3) development of secondary 
sexual organs and ornamental structures, (4) anabolic metabolism and gene 
regulation, and (5) male-pattern behavior (Fig.2). The numerous target tissues 
involved in these complex processes are defined according to whether they are 
affected by testosterone or DHT. The classic target cells for DHT (and those 
which coincidentally have the highest 5a-reductase activity) are the prostate, 
seminal vesicles, external genitalia, and genital skin. Targets for testosterone 
include the embryonic wolffian structures, spermatogonia, muscles, bone, 
kidney, and brain. The specific androgen involved in regulating the many 
other processes mentioned above has not been determined.
Androgens act by a nuclear mechanism similar to that 
employed by the adrenal steroids
The current concept of androgen action is shown in Fig.2. Free 
testosterone enters cells through the plasma membrane by either passive or 
facilitated diffusion. Target cells retain testosterone, presumably because the 
hormone associates with a specific intracellular receptor. Although there is 
considerable tissue-to-tissue variability, most of the retained hormone is found
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in the cell nucleus. The cytoplasm of many (but not all) target cells contains 
the enzyme 5a-reductase, which converts testosterone to DHT. Whether there 
are distinct receptors for testosterone and DHT has been a point of controversy, 
but the consensus is that while there is but a single class of receptors, the 
affinity of the receptor for DHT exceeds that for testosterone. Single gene 
mutations in mice result in loss of binding of both testosterone and DHT to the 
receptor in various tissues, suggesting that a single protein is involved. The 
affinity difference, coupled with the ability of a target tissue to form DHT from 
testosterone, may determine whether the testosterone-receptor complex or the 
DHT-receptor complex is active.
Nuclear localization of the testosterone/DHT-receptor complex is a 
prerequisite for androgen action. Binding of the receptor-steroid complex to 
chromatin may involve a prior activation step, and specificity is afforded by 
the androgen response element.
In keeping with other steroid (and some peptide) hormones, the 
testosterone/DHT receptor activates specific genes. The protein products of 
these genes mediate many (if not all) of the effects of the hormone. 
Testosterone stimulates protein synthesis in male accessory organs, an effect 
that is usually associated with increased accumulation of total cellular RNA, 
including mRNA, tRNA, and rRNA. A more specific example involves the 
effect of testosterone on the synthesis of ABP. The hormone increases the 
rate of transcription of the ABP gene, which results in an increased amount 
of the mRNA that codes for this protein. Another well-studied example is a2u 
globulin, the major protein excreted in the urine of male rats. The rate of 
synthesis of a^, globulin is directly related to the amount of the cognate 
mRNA, which in turn is related to the rate of transcription of the a2u 
globulin gene. All are stimulated by androgens.
The kidney is a major target tissue for androgens. These hormones cause a 
general enlargement of the kidney and induce the synthesis of a number of en­
zymes in various species.
Androgens also stimulate the replication of cells in some target tissues, an 
effect that is poorly understood. Testosterone or DHT, in combination with E2, 
appears to be implicated in the extensive and uncontrolled division of prostate 
cells that results in benign prostatic hypertrophy, a condition that afflicts as 
many as 75% of men over the age of 60 years.
3. The pathophysiology of the male reproductive system 
relates to hormonal defects.
The lack of testosterone synthesis is called hypogonadism. If this occurs 
before puberty, secondary sex characteristics fail to develop, and if it occurs 
in adults, many of these features regress. Primary hypogonadism is due to 
processes that affect the testes directly and cause testicular failure, whereas
2 2 6
Hormones o f the gonads.
secondary hypogonadism is due to defective secretion of the gonadotropins. 
Isolated genetic deficiencies help to establish the importance of specific 
steps in the biosynthesis and action of androgens. Fig.3 represents the 
pathway involved in androgen action from testosterone biosynthesis through 
postreceptor actions of testosterone and DHT. At least 5 distinct genetic de­
fects in testosterone biosynthesis have been described.
In addition, a 5a-reductase deficiency is known; there are a number of 
instances in which either no testosterone/DHT receptor is detected or the 
receptor is abnormal in some manner; and there are a number of cases in 
which all measurable entities, including the receptor, are normal, but the 
patients (always genetic males) have variable degrees of feminization. The 
extent of the abnormality of differentiation is related to the severity of the 
deficit. Persons who completely lack a biosynthetic enzyme appear to be 
phenotypic females but have an XY (male) genotype, while the mildest 
cases may have only an abnormally located penile urethra. Genetic males 
who completely lack functioning receptors have testes and produce testos­
terone but have complete feminization of the external genitalia (the so-called 
testicular feminization syndrome). It is interesting that no comparable 
deficiencies in estrogen synthesis or action have been identified.
ТАЖ З ЕТ C E L L
(5 ) O xiditlon of A  ring to A*-3-k«toat«roid
Fig.3 Steps involved in androgen resistance. Four stages at which mutations have been 
identified are shown. T- testosterone, DHT - dihydrotestosterone, R - androgen
receptor.
4. The ovaries produce the female sex hormones (estrogens and 
progestins) and the female germ cells (OVA)
Biosynthesis and metabolism of ovarian hormones is 
similar to those of male hormones
The estrogens are a family of hormones synthesized in a variety of 
tissues. 17p-Estradiol is the primary estrogen o f ovarian origin. In some 
species, estrone, synthesized in numerous tissues, is more abundant. In 
pregnancy, relatively more estriol is produced and this comes from the 
placenta. The general pathway and the subcellular localization of the 
enzymes involved in the early steps of estradiol synthesis are the same as 
those involved in androgen biosynthesis. Features unique to the ovary are 
illustrated in Fig.4.
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Estrogens are formed by the aromatization of androgens in a complex 
process that involves 3 hydroxylation steps, each of which requires 0 2 and 
NADPH. The aromatase enzyme complex is thought to include a P-450 
mixed-function oxidase. Estradiol is formed if the substrate of this enzyme 
complex is testosterone, whereas estrone results from the aromatization of 
androstenedione.
The cellular source of the various ovarian steroids has been difficult to 
unravel, but it now appears that 2 cell types are involved. These cells are 
the major sources of androstenedione (the principal androgen produced by 
the ovary), and of 17a-hydroxyprogesterone. Granulosa cells produce 
estradiol from the latter. Progesterone is produced and secreted by the 
corpus luteum, which also makes some estradiol.
E s tr io l
Fig. 4. Biosynthesis o f  estrogens.
Significant amounts of estrogens are produced by the peripheral 
aromatization of androgens. In human males, the peripheral aromatization 
of testosterone to estradiol (E2) accounts for 80% of the production rate of 
the latter. In females, adrenal androgens tire important substrates, since as 
much as 50% of the Ег produced during pregnancy comes from the 
aromatization of androgens. Finally, the conversion ,of androstenedione to 
estrone is the major source of estrogens in postmenopausal women. 
Aromatase activity is present in adipose cells and also in liver, skin, and 
other tissues. Increased activity of this enzyme may contribute to the 
"estrogenization" that characterizes such diseases as cirrhosis of the liver, 
hyperthyroidism, aging, and obesity.
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Estrogens and progestins are bound in varying degrees to 
plasma transport proteins
Estrogens are bound to SHBG and progestins to CBG. SHBG binds 
estradiol about 5 times less avidly than it binds testosterone or DHT, while 
progesterone and cortisol have little affinity for this protein. In contrast, 
progesterone and cortisol bind with nearly equal affinity to CBG, which in 
turn has little avidity for estradiol and even less for testosterone, DHT, or 
estrone.
These plasma transport proteins play no apparent role in the mechanism 
of action of these hormones at the cellular level, and (as with other steroids) 
probably only the free (unbound) hormone has biologic activity.
The binding proteins do provide a circulating reservoir of hormone, and 
because of the relatively large binding capacity, they probably buffer against 
sudden changes in the plasma level. The metabolic clearance rates of these 
steroids are inversely related to the affinity of their binding to SHBG; hence, 
estrone is cleared more rapidly than estradiol, which in turn is cleared more 
rapidly than testosterone or DHT. In this regard, the conjugated derivatives of 
these hormones (see below) are not bound by either SHBG or CBG. The 
factors that regulate the production of SHBG are discussed above.
The rate of secretion of ovarian steroids varies considerably during the 
menstrual (or estrous) cycle and is directly related to rate of production in the 
ovary. There is no storage of these compounds; they are secreted when they 
are produced.
Estrogens and progestins are actively metabolized by the liver
Estrogens: The liver converts estradiol and estrone to estriol by the 
pathways shown in Fig. 4. Estradiol, estrone, and estriol are substrates for 
hepatic enzymes that add glucuronide or sulfate moieties. Activity of these 
conjugating enzymes varies among species. Rodents have such active 
metabolizing enzyme systems that estrogens are almost completely metabo­
lized by the liver and thus are essentially without activity when given orally. 
These enzyme systems are less active in primates, so that oral estrogens are 
more effective. The conjugated steroids are water soluble and do not bind to 
transport proteins; thus, they are excreted readily in the bile, feces, and urine.
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Progestins: Because the liver actively metabolizes progesterone to 
several compounds, progesterone is ineffective when given orally. Sodium 
pregnanediol-20-glucuronide is the major progestin metabolite found in 
human urine (Fig.5). Certain synthetic steroids, eg, derivatives of 17a- 
hydroxyprogesterone and 17a-alkyl-substituted 19-nortestosterone com­
pounds, have progestational activity and avoid hepatic metabolism. Thus, they 
are widely used in oral contraceptives.
t
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Fig. 5. Biosynthesis o f progesterone and major pathway for its metabolism. Other 
metabolites are also found.
5. The maturation fnd maintenance of the female reproductive 
system is the major function of the ovarian hormones
These hormones prepare the structural determinants of the female 
reproductive system for reproduction by (1) maturing the primordial germ 
cells; (2) developing the tissues that will allow for implantation of the 
blastocyst; (3) providing the "hormonal timing" for ovulation; (4) 
establishing the milieu required for the maintenance of pregnancy; and (5) 
providing the hormonal influences for parturition and lactation.
Estrogens stimulate the development of tissues involved in 
reproduction. In general, these hormones stimulate the size and number of 
cells by increasing the rate of synthesis of protein, rRNA, tRNA, mRNA, and 
DNA. Under estrogen stimulation, the vaginal epithelium proliferates and 
differentiates; the uterine endometrium proliferates and the glands 
hypertrophy and elongate; the myometrium develops an intrinsic, rhythmic
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motility; and breast ducts proliferate. Estradiol also has anabolic effects on 
bone and cartilage, and so it is growth promoting. By affecting peripheral 
blood vessels, estrogens typically cause vasodilation and heat dissipation.
Progestins reduce the proliferative activity of the estrogens on the 
vaginal epithelium and convert the uterine epithelium from proliferative to 
secretory (increased size and function of secretory glands and increased 
glycogen content), thus preparing the uterine epithelium for implantation of 
the fertilized ovum. Progestins enhance development of the acinar portions of 
breast glands after estrogens have stimulated ductal development. Progestins 
decrease peripheral blood flow, thereby decreasing heat loss, so that body 
temperature tends to increase during the luteal phase of the menstrual cycle, 
when these steroids are produced. This temperature increase, usually 0.5 °C, is 
used as an indicator of ovulation.
Progestins generally require the previous or concurrent presence of 
estrogens, perhaps because estrogens stimulate production of the progesterone 
receptor. The two classes of hormones often act synergistically, although 
they can be antagonists.
The number of oogonia in the human female ovary reaches a maximum of 
6-7 million at about the fifth month of gestation. This decreases to about 2 
million by birth and is further diminished to 100,000-200,000 by the onset of 
menarche. Some 400-500 of these develop into mature oocytes; the rest are 
gradually lost through a process that is not understood, although ovarian 
androgens have been implicated. Follicular maturation begins in infancy, and 
the ovaries gradually enlarge in prepubertal years owing to increased volume 
of the follicles because of the growth of granulosa cells, to the accumulation 
of tissue from atretic follicles, and to the increased mass of medullary stromal 
tissue with the interstitial and theca cells that will produce the steroids.
The concentration of sex hormones is low in childhood, although 
exogenous gonadotropins increase production; hence, the immature ovary has 
the capacity to synthesize estrogen. It is thought that these low levels of sex 
steroids inhibit gonadotropin production in prepubertal girls and that at puberty 
the hypothalamic-pituitary system becomes less sensitive to suppression. At 
puberty, the pulsatile release of GnRH begins stimulating LH and this causes 
a dramatic increase of ovarian hormone production. FSH, the main stimulus for 
estrogen secretion, stimulates a follicle to ripen, and ovulation ensues.
6. The menstrual cycle depends on a complex interaction 
among three endocrine glands
Hormones determine the frequency of ovulation and receptivity to mating. 
Monestrous species ovulate and mate once a year, whereas polyestrous species 
repeat this cycle several times a year. Primates have menstrual cycles, with 
shedding of the endometrium at the end of each cycle, and mating behavior is
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not tightly coupled to ovulation. The human menstrual cycle results from a 
complex interaction between the hypothalamus, pituitary, and ovary. The cycle 
normally varies between 25 and 35 days in length (average, 28 days). It can be 
divided into a follicular phase, a luteal phase, and menstruation (Fig.6).
Fig.6. Homwnal and physiologic changes during a typical human menstrual cycle. M. 
menstruation; IRP-hMG, international reference standard fo r  gonadotropins.
Follicular Phase: For reasons that are not clear, a particular follicle begins 
to enlarge under the general influence of FSH. E2 levels are low during the first 
week of the follicular phase, but they begin to rise progressively as the follicle 
enlarges. E2 reaches its maximal level 24 hours before the LH (FSH) peak and 
sensitizes the pituitary to GnRH. LH is released either in response to this 
high level of E2 in a "positive feedback" manner or in response to a sudden 
decline of E2 from this high level. Continual administration of high doses of 
estrogen (as in oral contraceptives) suppresses LH and FSH release and inhibits 
the action of GnRH on the pituitary. Progesterone levels are very low during 
the follicular phase. The LH peak heralds the end of the follicular phase and 
precedes ovulation by 16-18 hours.
Luteal Phase: After ovulation, the granulosa cells of the mptured follicle 
luteinize and form the corpus luteum, a structure that soon begins to produce 
progesterone and some estradiol. Estradiol peaks about midway through the 
luteal phase and then declines to a very low level. The major hormone of the 
luteal portion of the cycle is progesterone, which (as noted above) is
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required for preparation and maintenance of the secretory endometrium that 
provides early nourishment for the implanted blastocyst. LH is required for 
the early maintenance of the corpus luteum, and the pituitary supplies it for 
about 10 days. If implantation occurs (day 22-24 of the average cycle), this 
LH function is assumed by chorionic gonadotropin (hCG), a placenta) 
hormone that is very similar to LH and is made by the cytotrophoblastic cells 
of the implanted early embryo. hCG stimulates progesterone synthesis by the 
corpus luteum until the placenta beings making large amounts of this steroid. 
In the absence of implantation (and hCG), the corpus luteum regresses and 
menstruation ensues; after the endometrium is shed, a new cycle commences. 
The luteal phase is always 14 ± 2 days in length. Variations in cycle length are 
almost always due to an altered follicular phase.
7. Pregnancy activates placental hormones
The implanted blastocyst forms the trophoblast, which is subsequently 
organized into the placenta. The placenta provides the nutritional connection 
between the embryo and the maternal circulation and produces a number of 
hormones.
Human Chorionic Gonadotropin (hCG): The primary function of the 
glycoprotein hormone hCG is to support the corpus luteum until the placenta 
produces amounts of progesterone sufficient to support the pregnancy. hCG 
can be detected within a few days of implantation, and this provides the basis 
of early diagnostic tests for pregnancy. Peak hCG levels are reached in the 
middle of the first trimester, after which there is a gradual decline throughout 
the remainder of pregnancy.
Progestins: The corpus luteum is the major source of progesterone for the 
first 6-8 weeks of the pregnancy, and then the placenta assumes this function. 
The corpus luteum continues to function, but late in pregnancy the placenta 
makes 30-40 times more progesterone than does the corpus luteum. The 
placenta does not synthesize cholesterol and so depends upon a maternal 
supply.
Estrogens: Plasma concentrations of estradiol, estrone, and estriol 
gradually increase throughout pregnancy. Estriol is produced in the largest 
amount, and its formation reflects a number of fetoplacental functions. The 
fetal adrenal produces DHEA and DHEA sulfate, which are converted to 
I6a-hydroxyderivatives by the fetal liver. These are converted to estriol by 
the placenta; travel via the placental circulation to the maternal liver, where 
they are conjugated to glucuronides; and then are excreted in the urine (Fig.7). 
The measurement of urinary estriol levels is used to document the function of a 
number of maternal-fetal processes.
Another interesting exchange of substrates is required for fetal cortisol 
production. The fetal adrenal lacks the familiar 3p-hydroxysteroid
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dehydrogenase A5,4isomerase complex and hence depends upon the placenta 
for the progesterone required for cortisol synthesis (Fig. 7).
Placental Lactogens: The placenta makes a hormone called placental 
lactogen (PL). PL is also called chorionic somatomammotropin or placental 
growth hormone because it has biologic properties of prolactin and growth 
hormone. The physiologic function of PL is uncertain, since women who 
lack this hormone appear to have normal pregnancies and deliver normal 
babies.
8. Mammary gland development is stimulated by estradiol and 
progesterone and lactation by prolactin
The differentiation and function of the mammary gland are regulated by 
the concerted action of several hormones. The female sex hormones initiate 
this process, since estrogens are responsible for ductal growth and 
progestins stimulate alveolar proliferation. Some growth of glandular 
tissue occurs during puberty, along with deposition of adipose tissue, but 
extensive development occurs during pregnancy when glandular tissue is 
exposed to high concentrations of estradiol and progesterone. Complete 
differentiation, studied mostly in rat mammary gland explants, requires the 
additional action of prolactin, glucocorticoids, insulin or a growth peptide, 
and an unidentified serum factor. Of these hormones, only the concentration 
of prolactin changes dramatically in pregnancy; it increase from < 2 ng/dL 
to > 200 ng/dL in late pregnancy. The effects of these hormones on the 
synthesis of various milk proteins, including lactalbumin, lactoglobulin, and 
casein, have been studied in detail. These hormones increase the rate of 
synthesis of these proteins by increasing amounts of the specific mRNAs, 
and in the case of casein at least, this is due to an increase in gene 
transcription and to stabilization of the mRNA.
Progesterone, required for alveolar differentiation, inhibits milk 
production and secretion in late pregnancy. Lactation commences when levels 
of this hormone decrease abruptly after delivery. Prolactin levels also fall 
rapidly postpartum but are stimulated with each episode of suckling, thereby 
ensuring continual lactation. Lactation gradually decreases if suckling is not 
allowed and can be rapidly terminated by administration of a large parenteral 
dose of an androgen before suckling is allowed.
Suckling also results in the release of oxytocin from the posterior pituitary. 
Oxytocin stimulates contraction of the myoepithelial cells that surround the 
alveolar ducts, thus expelling milk from the gland.
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Fig. 7 Steroid metabolism by the fetal-maternal unit DHEA - dehydroepiandrosterone.
9. Menopause is complete with the loss of 
ovarian estrogen production
Women in the western hemisphere cease having regular menstrual cycles at 
about age 53, coincident with loss of all follicles and ovarian estrogen 
production. There is no alternative source of progesterone, but substantial 
amounts of a weak estrogen, estrone, are produced by the aromatization of 
androstenedione (Fig.4). The levels of estrone are not suificient to suppress 
pituitary gonadotropin levels; thus, marked increases of LH and FSH are 
characteristic of the postmenopausal years. Postmenopausal women are 
particularly prone to 2 problems associated with tissue catabolism. Estrone 
is not always able to prevent the atrophy of secondary sex tissues, particularly 
the epithelium of the lower urinary tract and vagina. Osteoporosis is a major 
health problem in older individuals, and women with the most severe 
decrease in bone mass have lower than normal estrone levels.
10. Synthetic agonists and antagonists are used to promote and 
prevent conception and to inhibit tumor growth
Estrogens: Several synthetic compounds have estrogenic activity and one 
or more favorable pharmacologic features. Most modifications are designed to 
retard hepatic metabolism, so that the compounds can be given orally. One of 
the first developed was diethylstilbestrol. Other examples of modified steroids 
include 17a-ethinyI-estradiol and mesttanol, which are used in oral 
contraceptives.
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Numerous compounds with antiestrogenic activity have been 
synthesized, and several of these have clinical applications. Most of these 
antagonists act by competing with estradiol for its intracellular receptor.
Clomiphene citrate (Clomid) has a particular affinity for the estrogen 
feceptor in the hypothalamus. Climophene was originally designed as an 
antifertility drug but, interestingly, it is now used for the opposite effect. 
Climophene competes with estradiol for hypothalamic receptor sites; thus, 
GnRH release is not restrained and excessive amounts of LH and FSH are 
released. Multiple follicles often mature simultaneously in response to 
clomiphene, and multiple pregnancies can ensue. Nafoxidine, a 
nonsteroidal compound, and tamoxifen combine with the estrogen receptor to 
form very stable complexes with chromatin; hence, the receptor cannot 
recycle and these agents inhibit the action of estradiol for prolonged periods. 
These antagonists are used in the treatment of estrogen-dependent breast 
cancer.
Progestins: It has been difficult to synthesize compounds that have 
progestin activity but no estrogenic or androgenic action. The 17a-alkyl- 
substituted 19-nortestosterone derivatives (eg, norethindrone) have minimal 
androgenic activity in most women and are used in oral contraceptives. 
Another potent progestin is medroxyprogesterone acetate (Provera). 
Medroxyprogesterone inhibits ovulation for several months when given as an 
intramuscular depot injection. However, since progestins inhibit cell growth, 
this compound is more frequently used for treating well-differentiated 
endometrial carcinoma.
Estrogens and progestins act by regulating gene expression
These hormones act through their ability to combine with intracellular 
receptors that then bind to specific regions of chromatin or DNA (or both) 
to effect changes in the rate of transcription of specific genes. Much
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information has been learned from the analysis of how estradiol and 
progesterone stimulate transcription of the avian eggwhite protein genes, 
especially ovalbumin and conalbumin. The determination of exactly how 
these hormones activate gene transcription is under intense investigation.
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HORMONES OF THE ADRENAL CORTEX
Introduction
The adrenal cortex synthesizes dozens of different steroid molecules, but 
only a few of these have biologic activity. These sorts into 3 classes of 
hormones: glucocorticoids, mineralocorticoids, and androgens. These 
hormones initiate their actions by combining with specific intracellular 
receptors, and this complex binds to specific regions of DNA to regulate 
gene expression. This results in altered rates of synthesis of a small number 
of proteins, which, in turn, affect a variety of metabolic processes, eg, 
gluconeogenesis and Na+ and K+ balance.
The hormones of the adrenal cortex, particularly the glucocorticoids, are 
an essential component of adaptation to severe stress. The 
mineralocorticoids are required for normal Na+ and K+ balance. Synthetic 
analogs of both classes are used therapeutically. In particular, many 
glucocorticoid analogs are potent anti-inflammatory agents. Excessive or 
deficient plasma levels of any of these 3 classes of hormones, whether due 
to disease or therapeutic use, result in serious, sometimes life-threatening, 
complications. A series of inherited enzyme deficiencies helps define the 
steps involved in steroidogenesis and illustrates the capacity of the adrenal 
cortex to alter the relative rates of production of these different hormones.
ACRONYMS USED IN THIS LECTURE
ACTH Adrenocorticotropic hormone
ADII Antidiuretic hormone
CBG Corticosteroid-binding globulin
CRH Corticotropin-releasing hormone
DHEA Dehydroepiandrosterone
DOC Deoxycorticosterone
GH Growth hormone
Sp-OHSD Sp-Hydroxysteroid dehydrogenase
PEPCK Phosphoenolpyruvate carboxykinase
POMC Pro-opiomelanocortin
PTH Parathyroid hormone
TBG Thyroid-binding globulin
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1. The adrenal cortex makes 3 kinds of hormones
The adult cortex has 3 distinct layers or zones. The subcapsular area is 
called the zona glomerulosa and is associated with the production of 
mineralocorticoids. Next is the zona fasciculata, which, with the zona 
reticularis, produces glucocorticoids and androgens. Some 50 steroids 
have been isolated and crystalized from adrenal tissue. Most of these are 
intermediates; only a small number are secreted in significant amounts; and 
few have significant hormonal activity. The adrenal cortex makes 3 general 
classes of steroid hormones, which are grouped according to their dominant 
action. There is an overlap of biologic activity, since all natural 
glucocorticoids have mineralocorticoid activity and vice versa. This can 
now be understood on the basis of the commonality of the hormone response 
elements that mediate the effects of these hormones (and progestins) at the 
gene level.
The glucocorticoids are 21-carbon steroids with many actions, the 
most important of which is to promote gluconeogenesis. Cortisol is the 
predominant glucocorticoid in humans, and it is made in the zona 
fasciculata. Corticosterone, made in the zonae fasciculata and 
glomerulosa, is less abundant in humans, but it is the dominant 
glucocorticoid in rodents. Mineralocorticoids are also 21-carbon steroids. 
The primary action of these hormones is to promote retention of Na+ and 
excretion of K+ and 1Г, particularly in the kidney. Aldosterone is the most 
potent hormone in this class, and it is made exclusively in the zona 
glomerulosa. The zonae fasciculata and reticularis of the adrenal cortex also 
produce significant amounts of the androgen precursor 
dehydroepiandrosterone and of the weak androgen androstenedione. 
These steroids are converted into more potent androgens in extra-adrenal 
tissues and become pathologic sources of androgens when specific 
steroidogenic enzymes are deficient. Estrogens are not made in the normal 
adrenal in significant amounts, but in certain cancers of the adrenal they 
may be produced, and androgens of adrenal origin are important precursors 
of estrogen (converted by peripheral aromatization) in postmenopausal 
women.
A schematic representation of the pathways involved in the synthesis of 
the 3 major classis of adrenal steroids is presented in Fig. /
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Fig. I. Pathways involved in the synthesis o f the 3 major classis of adrenal steroids. 
Enzymes are shown in the rectangular boxes, and the modifications at each step are 
shaded.
2. The secretion, transport, and metabolism of adrenal steroid 
hormones affect bioavailability
2.1. Secretion of Steroid Hormones
There is little, if any, storage of steroid hormones within the adrenal (or 
gonad) cell, since these hormones are released into the plasma when they are 
made. Cortisol release occurs with a periodicity that is regulated by the 
diurnal rhythm of ACTH release.
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2.2. Plasma transport
Glucocorticoids: Cortisol circulates in plasma in protein-bound and free 
forms. The main plasma binding protein is a a-globulin called transcortin 
or corticosteroid-binding globulin (CBG). CBG is produced in the liver, 
and its synthesis, like that of thyroid-binding globulin (TBG), is increased 
by estrogens. CBG binds most of the hormone when plasma cortisol-levels 
are within the normal range; much smaller amounts of cortisol are bound to 
albumin. The avidity of binding helps determine the biologic half-lives of 
various glucocorticoids. Cortisol binds tightly to CBG and has a t^  of 1.5-2 
hours, while corticosterone, which binds less tightly, has a tia of less than 1 
hour. Binding to CBG is not restricted to glucocorticoids. 
Deoxycorticosterone and progesterone interact with CBG with sufficient 
affinity to compete for cortisol binding. The unbound, or free, fraction 
constitutes about 8% of the total plasma cortisol and represents the 
biologically active fraction of cortisol.
Mineralocorticoids: Aldosterone, the most potent natural
mineralocorticoid, does not have a specific plasma transport protein, but it 
forms a very weak association with albumin. Corticosterone and 11-de­
oxycorticosterone, other steroids with mineralocorticoid effects, bind to 
CBG. These observations are important in understanding the mechanism of 
action of aldosterone.
2.3. Metabolism and excretion rates depend on the presence 
or absence of carrier proteins
Glucocorticoids: Cortisol and its metabolites constitute about 80% of 
the 17-hydroxycorticoids in plasma; the other 20% consist of cortisone and 
11-deoxycortisol. About half of the cortisol (as well as cortisone and 11- 
deoxycortisol) circulates in the form of the reduced dihydro- and 
tetrahydro- metabolites that are produced from reduction of the A ring 
double bond by NADPH-requiring hydrogenases and from reduction of the 
3-ketone group by a reversible dehydrogenase reaction. Substantial amounts 
of all of these compounds are also modified by conjugation at the Ci 
position with glucuronide or, to a lesser extent, with sulfate. These 
modifications occur primarily in the liver and make the lipophilic steroid 
molecule water-soluble and excretable. In humans, most of the conjugated 
steroids that enter the intestine by biliary excretion are reabsorbed by the 
enterohepatic circulation. About 70% of the conjugated steroids are 
excreted in the urine, 20% leave in feces, and the rest exit through the skin.
Mineralocorticoids: Aldosterone is very rapidly cleared from the 
plasma by the liver, no doubt because it lacks a plasma carrier protein. The
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liver forms tetrahydroaldosterone 3-glucuronide, which is excreted in the 
urine.
Androgens: Androgens are excreted as 17-keto compounds including 
DHEA (sulfate) as well as androstenedione and its metabolites. 
Testosterone, secreted in small amounts by the adrenal, is not a 17-keto 
compound, but the liver converts about 50% of testosterone to androsterone 
and etiocholanolone, which are 17-keto compounds.
3. The synthesis of adrenal steroid hormones is regulated by very 
different mechanisms
Glucocorticoid Hormones
The secretion of cortisol is dependent on ACTH, which in turn is 
regulated by corticotropin-releasing hormone (CRH). These hormones are 
linked by a classic negative feedback loop.
Mineralocorticoid Hormones
The production of aldosterone by the glomerulosa cells is regulated in a 
completely different manner. The primary regulators are the 
reninangiotensin system and potassium. Sodium, ACTH, and neural 
mechanisms are also involved.
The Renin-Angiotensin System: This system is involved in the 
regulation of blood pressure and electrolyte metabolism. The primary 
hormone in these processes is angiotensin II, an octapeptide made from 
angiotensinogen (Fig.2). Angiotensinogen, an a 2-globulin made in liver, is 
the substrate for renin, an enzyme produced in the juxtaglomerular cells of 
the renal afferent arteriole. The position of these cells makes them 
particularly sensitive to blood pressure changes, and many of the 
physiologic regulators of renin release act through renal baroreceptors. The 
juxtaglomerular cells are also sensitive to changes of Na+ and СГ 
concentration in the renal tubular fluid; therefore, any combination of 
factors that decreases fluid volume (dehydration, decreased blood pressure, 
fluid or blood loss) or decreases NaCl concentration stimulates renin release. 
Renal sympathetic nerves that terminate in the juxtaglomerular cells mediate 
the central nervous system and postural effects on renin release independent 
of the baroreceptor and salt effects, a mechanism that involves the [)- 
adrenergic receptor.
Renin acts upon the substrate angiotensinogen to produce the decapeptide 
angiotensin I. The synthesis of angiotensinogen in liver is enhanced by 
glucocorticoids and estrogens. Hypertension associated with these hormones 
may be due in part to increased plasma levels of angiotensinogen. Since this
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protein circulates at about the K,„ for its interaction with renin, small changes 
could markedly affect the generation of angiotensin П.
Degradation products
Fig. 2. Formation and metabolism o f angiotensisns. Small arrows indicate cleavage 
sites.
Angiotensin-converting enzyme, a glycoprotein found in lung, 
endothelial cells, and plasma, removes 2 carboxy-terminal amino acids from 
the decapeptide angiotensin I to form angiotensin II in a step that is not 
thought to be rate-limiting. Various nonapeptide analogs of angiotensin I and 
other compounds act as competitive inhibitors of converting enzyme and are 
used to treat renin-dependent hypertension. Converting enzyme also 
degrades bradykinin, a potent vasodilator; thus, this enzyme increases 
blood pressure in 2 distinct ways.
Angiotensin II increases blood pressure by causing vasoconstriction of 
the arteriole and is a very potent vasoactive substance. It inhibits renin 
release from the juxtaglomerular cells and is a potent stimulator of 
aldosterone production. Although angiotensin II stimulates the adrenal 
directly, it has no effect on cortisol production.
In some species, angiotensin П is converted to the des-Asp1 heptapeptide 
angiotensin III (Fig.2), an equally potent stimulator of aldosterone 
production. In humans, the plasma level of angiotensin П is 4 times greater 
than that of angiotensin III, so most effects are exerted by the octapeptide. 
Angiotensins II and III are rapidly inactivated by angiotensinases.
Angiotensin П binds to specific glomerulosa cell receptors. The hormone- 
receptor interaction does not activate adenylate cyclase, and cAMP does not 
appear to mediate the action of this hormone. The actions of angiotensin II, 
which are to stimulate the conversion of cholesterol to pregnenolone and of
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corticosterone to 18-hydroxycorticosterone and aldosterone, may involve 
changes in the concentration of intracellular calcium and of phospholipid 
metabolites.
Potassium: Aldosterone secretion is sensitive to changes in plasma 
potassium level; an increase as small as 0.1 meq/L stimulates production, 
whereas a similar decrease reduces aldosterone production and secretion. K' 
affects the same enzymatic steps as does angiotensin II, although the 
mechanism involved is obscure. Like angiotensin II, K.+ does not affect the 
biosynthesis of cortisol.
Other Effectors: In special circumstances ACTH and sodium may be 
involved in aldosterone production in humans.
4. Adrenal steroid hormones have numerous and diverse 
metabolic effects
Loss of adrenal cortical function results in death unless replacement 
therapy is instituted. In humans, treatment of adrenal insufficiency with 
mineralocorticoids is generally not sufficient; glucocorticoids seem to be 
more critical in this regard. Rats, in contrast, do quite well with 
mineralocorticoid replacement. Excessive or deficient plasma levels of either 
of these classes of hormones, whether due to disease or therapeutic use, cause 
a number of serious complications directly related to their metabolic actions.
Glucocorticoid Hormones affect basal metabolism, host 
defense mechanisms, blood pressure, and response to stress
A detailed discussion of the various metabolic effects of the 
glucocorticoid hormones is found in standard physiology texts. A brief 
description of the effects is presented in Table /.
Table 1. The diverse effects o f  glucocorticoids
1. Effects on intermediary metabolism
a Increase glucose production in liver by:
1. increasing the delivery of amino acids (the gluconeogenic substrate) from 
peripheral tissues
2. increasing the rate of gluconeogenesis by increasing the amount (and activity) of 
several key enzymes
3. "permitting" other key metabolic reactions to operate at maximal rates
b. Increase hepatic glycogen deposition by promoting the activation of glycogen 
synthetase.
c. Promote lipolysis (in extremities) but can cause lipogenesis in other sites (face and 
trunk) especially at higher than physiologic levels.
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d. Promote protein and RNA metabolism. This is an anabolic effect at physiologic 
levels, but can be catabolic in certain conditions and at higher than physiologic 
levels.
II. Effects on host defense mechanisms
a  Suppress the immune response. These hormones cause a species- and cell-type- 
specific lysis of lymphocytes, 
b. Suppress tire inflammatory response by:
I decreasing the number of circulating leukocytes and the migration of tissue 
leukocytes
2. inhibiting fibroblast proliferation
3. inducing lipocortins, which, by inhibiting phospholipase A2, blunt the production 
of the potent anti-inflammatory molecules, the prostaglandins and leukotrienes.
III. Other effects
a Necessary for maintenance of normal blood pressure and cardiac output.
b. Required for maintenance of normal water and electrolyte balance, perhaps by 
restraining ADH release (ЬЬО) and by increasing angiotensinogen (Na*). These 
effects contribute to the effect on blood pressure
c. Necessary, with the hormones of the adrenal medulla, in allowing the organism to 
respond to stress.
Mineralocorticoid Hormones affect electrolyte 
balance and ion transport
Mineralocorticoid hormones act in the kidney to stimulate active Na+ 
transport by the distal convoluted tubules and collecting tubules, the net 
result being NaT retention. These hormones also promote the secretion of 
K+, H \ and NH4* by the kidney and affect ion transport in other epithelial 
tissues including sweat glands, intestinal mucosa, and salivary glands. 
Aldosterone is 30-50 times more potent than I I-deoxycorticosterone (DOC) 
and 1000 times more potent than cortisol or corticosterone. As the most 
potent naturally occurring mineralocorticoid, aldosterone accounts for most 
of this action in humans. Cortisol, although far less potent, has a much 
higher production rate and thus has a significant effect on Na+ retention and 
K+ excretion. Since the amount of DOC produced is very small, it is much 
less important in this regard. RNA and protein synthesis are required for the 
action of aldosterone, which appears to involve the production of specific 
gene products.
Adrenal steroid hormones act by similar mechanisms
Glucocorticoid hormones initiate their action in a target cell by 
interacting with a specific receptor.
This step is necessary for entry into the nucleus and DNA binding. There 
is generally a high correlation between the association of a steroid with 
receptor and the elicitation of a given biologic response. This correlation 
holds true for a wide range of activities, so that a steroid with one-tenth the
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binding affinity evokes a correspondingly decreased biologic effect at a 
given steroid concentration. There are generally no "spare receptors" 
involved in steroid hormone action.
The biologic effect of a steroid depends upon both its ability to bind to 
the receptor and the concentration of free hormone in the plasma. Cortisol, 
corticosterone, and aldosterone all bind with high affinity to the 
glucocorticoid receptor, but in physiologic circumstances cortisol is the 
dominant glucocorticoid because of its much greater plasma concentration. 
Corticosterone is an important glucocorticoid in certain pathologic 
conditions (17a -hydroxylase deficiency), but aldosterone never reaches a 
concentration in plasma sufficient to exert glucocorticoid effects.
5. Receptors that bind aldosterone with high affinity (Kd ~ 1 nmoI/L) 
are found in the cytoplasm and nuclei of target cells
These cells include those of the kidney, the parotid, and the colon and of 
other cells not thought to be targets of aldosterone action (hippocampus and 
heart). These receptors have equal affinity for aldosterone, cortisol, and 
corticosterone and are called type I receptors to distinguish them from the 
classical glucocorticoid receptor (type II).
Given the fact that the plasma level of aldosterone is much lower than that 
of either of the other 2 steroids, one might suppose that these would 
preferentially occupy the type I sites and that aldosterone would exert little 
effect. Recall that DOC and corticosterone are avidly bound to 
corticosteroid-binding globulin, the plasma glucocorticoid transport protein, 
while aldosterone has no specific carrier protein. Consequently, the 
effective "free" concentration of aldosterone in plasma is greater than that 
of either corticosterone or DOC. Aldosterone therefore is readily able to 
enter cells, and this ensures a competitive advantage for aldosterone with 
respect to occupying the type I receptor in vivo. The important action of 
aldosterone is assured by an additional "failsafe" mechanism. The receptor in 
mineralocorticoid target tissues has absolute selectivity for aldosterone 
because of the presence of the enzyme 11 p-hydroxysteroid dehydrogenase. 
This enzyme converts cortisol and corticosterone to their 11P metabolites but 
it is not active on aldosterone. These metabolites cannot bind to the type I 
receptor, so aldosterone has unimpeded access.
6. The major actions of aldosterone are on ion transport
The molecular mechanisms of aldosterone action on Na+ transport have 
not been elucidated, but several studies point to the following hypothesis. 
Na+ from the luminal fluid bathing the apical surface of the renal cell enters 
passively through Na+ channels. Na+ is then transported into the interstitial
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fluid through the serosal side of the cell by the Na+/K+ -dependent 
ATPase pump. ATP provides the energy required for this active process.
Aldosterone increases the number of apical membrane Na+ channels, 
and this presumably increases intracellular Na+. Aldosterone also increases 
the activity of several mitochondrial enzymes, and this could result in the 
generation of the ATP required to drive the serosal membrane Na+/K+ pump. 
The NADH:NAD ratio increases as a result of aldosterone action, as do the 
activities of several mitochondrial enzymes including citrate synthase. The 
increased activity of citrate synthase involves a true induction (perhaps 
mediated by the gene transcription effects alluded to above), and the 
temporal increase of this protein correlates highly with the effect of 
aldosterone on Na+ transport. Aldosterone has not been shown to have an 
effect on the Na' pump itself: therefore, it appears that the hormone 
increases the intracellular concentration of Na+ and creates the energy 
source required for removal of this ion through the serosal pump. Other 
mechanisms, involving different aldosterone-reguiated proteins, may be 
involved in the handling of К and H +.
7. Pathophysiology of the adrenal cortex
7.1. Disorders of glucocorticoid hormone insufficiency and excess
Primary adrenal insufficiency (Addison's disease) results in 
hypoglycemia, extreme sensitivity to insulin, intolerance to stress, 
anorexia, weight loss, nausea, and severe weakness. Patients with Addison's 
disease have low blood pressure, decreased glomerular filtration rate, and 
decreased ability to excrete a water load. They often have a history of salt 
craving. Plasma Na' levels are low, K+ levels are high, and blood 
lymphocyte and eosinophil counts are increased. Such patients often show 
increased pigmentation of skin and mucous membranes because of the 
exaggerated compensatory secretion of ACTH and associated products of 
the POMC gene. Secondary adrenal insufficiency is due to a deficiency of 
ACTH resulting from tumor, infarction, or infection. This results in a 
similar metabolic syndrome without hyperpigmentation.
Glucocorticoid excess, commonly called Cushing's syndrome, is 
usually due to the pharmacologic use of steroids, but it may result from an 
ACTH-secreting pituitary adenoma, from adrenal adenomas or carcinomas, 
or from the ectopic production of ACTH by a neoplasm. Patients with 
Cushing's syndrome typically lose the diurnal pattern of ACTH/cortisol 
secretion.
They have hyperglycemia or glucose intolerance (or both) because of 
accelerated gluconeogenesis. Related to this are severe protein catabolic 
effects, which result in thinning of the skin, muscle wasting, osteoporosis,
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extensive lymphoid tissue involution, and generally a negative nitrogen 
balance. There is a peculiar redistribution of fat, with truncal obesity and the 
typical "buffalo hump." Resistance to infections and inflammatory 
responses is impaired, as is wound healing. Several findings, including 
hypernatremia, hypokalemia, alkalosis, edema, and hypertension, are due to 
the mineralocorticoid actions of cortisol.
7.2. Disorders of mineralocorticoid excess
Small adenomas of the glomerulosa cells result in primary 
aldosteronism (Conn’s syndrome), the classic manifestations of which 
include hypertension, hypokalemia, hypernatremia, and alkalosis. Patients 
with primary aldosteronism do not have evidence of glucocorticoid hormone 
excess, and plasma renin and angiotensin II levels are suppressed.
Renal artery stenosis, with the attendant decrease in perfusion pressure, can 
lead to hyperplasia and hyperfunction of the juxtaglomerular cells and cause 
elevated levels of renin and angiotensin II. This action results in secondary 
aldosteronism, which resembles the primary form, except for the elevated 
renin and angiotensin II levels.
7.3. Congenital adrenal hyperplasia is due to enzyme deficiency
Insufficient amounts of steroidogenic enzymes result in the deficiency 
of end products, the accumulation of intermediates, and the exaggerated 
production of steroids from alternative pathways. A common feature of most 
of these syndromes, which develop in utero, is deficient cortisol production 
with ACTH overproduction and adrenal hyperplasia - hence, the term 
congenital adrenal hyperplasia. The overproduction of adrenal androgens is 
another common feature. This hormone excess results in increased body 
growth, virilization, and ambiguous external genitalia - hence, the alternative 
designation adrenogenital syndrome.
Two types of 21-hydroxylase deficiency (partial, or simple virilizing, and 
complete, or salt wasting) account for more than 90% of cases of congenital 
adrenal hyperplasia, and most of the rest are due to lip-hydroxylase 
deficiency. Only a few cases of other deficiencies (3P-hydroxy steroid 
dehydrogenase, 17ot-hydroxylase, cholesterol desmolase, 18-hydroxylase, and 
18-dehydrogenase) have been described. The 18-hydroxylase and - 
dehydrogenase deficiencies affect only aldosterone biosynthesis and so do not 
cause adrenal hyperplasia. The cholesterol desmolase deficiency prevents any 
steroid biosynthesis and so is usually incompatible with extrauterine life.
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Lecture 27
HORMONES OF THE ADRENAL MEDULLA
Introduction
The sympathoadrenal system consists of the parasympathetic nervous 
system with its cholinergic pre- and postganglionic nerves, the 
sympathetic nervous system with cholinergic preganglionic and 
adrenergic postganglionic nerves, and the adrenal medulla. The latter is 
actually an extension of the sympathetic nervous system, since 
preganglionic fibers from the splanchnic nerve terminate in the adrenal 
medulla, where they innervate the chromaffin cells that produce the 
catecholamine hormones dopamine, norepinephrine, and epinephrine. 
The adrenal medulla is thus a specialized ganglion without axonal 
extensions. Its chromaffin cells synthesize, store, and release products that 
act on distant sites, so that it also functions as an endocrine organ.
The hormones of the sympathoadrenal system, while not necessary to 
life, are required for adaptation to acute and chronic stress. Epinephrine, 
norepinephrine, and dopamine are the major elements in the response to 
severe stress. This response involves an acute, integrated adjustment of 
many complex processes in the organs vital to the response (brain, muscles, 
cardiopulmonary system, and liver) at the expense of other organs that are 
less immediately involved (skin, gastrointestinal system, and lymphoid 
tissue). Catecholamines do not facilitate the stress response alone but are 
aided by the glucocorticoids, growth hormone, vasopressin, angiotensin II, 
and glucagon.
ACRONYMS USED IN THIS LECTURE
COMT Catechol-O-methyltransferase
DBH Dopamine |3-hydroxylase
MAO Monoamine oxidase
PNMT Phenylethanolamine-N-methyltransferase
VMA Vanillylmandelic acid
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1. The catecholamine hormones are 3,4-dihydroxy 
derivatives of phenylethylamine
These amines, dopamine, norepinephrine, and epinephrine, are 
synthesized in the chromaffin cells of the adrenal medulla, so named because 
they contain granules that develop a red-brown color when exposed to 
potassium dichromate. Collections of these cells are also found in the 
heart, liver, kidney, gonads, adrenergic neurons of the postganglionic 
sympathetic system, and central nervous system.
The major product of the adrenal medulla is epinephrine. This 
compound constitutes about 80% of the catecholamines in the medulla, and 
it is not made in extramedullary tissue. In contrast, most of the 
norepinephrine present in organs innervated by sympathetic nerves is 
made in situ (-80% of the total), and most of the rest is made in other nerve 
endings and reaches the target sites via the circulation. Epinephrine and 
norepinephrine may be produced and stored in different cells in the adrenal 
medulla and other chromaffin tissues.
The conversion of tyrosine to epinephrine requires 4 sequential steps: (1) 
ring hydroxylation; (2) decarboxylation; (3) side chain hydroxylation; and 
(4) N-methylation. The biosynthetic pathway and the enzymes involved are 
illustrated in Fig 1.
Fig.l. Biosynthesis o f catecholamines. PNMT phenylethanolamine-N-methyhransferase.
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2. Catecholamines are stored released
2.1. Storage is in chromaffin granules
The adrenal medulla contains the chromaffin granules - organelles 
capable of the biosynthesis, uptake, storage, and secretion of 
catecholamines. These granules contain a number of substances in addition 
to the catecholamines, including ATP-Mg2+, Ca2\  DBH, and the protein 
chromagranin A. Catecholamines enter the granule via an ATP-dependent 
transport mechanism and bind this nucleotide in a 4:1 ratio (hormone: 
ATP). Norepinephrine is stored in these granules but can exit to be N- 
methylated; the epinephrine formed then enters a new population of 
granules.
2.2. Release is calcium dependent
Neural stimulation of the adrenal medulla results in the fusion of the 
membranes of the storage granules with the plasma membrane, and this leads 
to the exocytotic release of norepinephrine and epinephrine. This is a 
calcium-dependent process and, like most exocytotic events, is stimulated 
by cholinergic and P-adrenergic agents and inhibited by a-adrenergic agents. 
Catecholamines and ATP are released in proportion to their intragranular 
ratio, as are the other contents including DBH, calcium, and chromagranin 
A.
Neuronal reuptake of catecholamines is an important mechanism for 
conserving these hormones and for quickly terminating hormonal or 
neurotransmitter activity. The adrenal medulla, unlike the sympathetic 
nerves, does not have a mechanism for the reuptake and storage of 
discharged catecholamines. The epinephrine discharged from the adrenal 
goes to the liver and skeletal muscle but then is rapidly metabolized. Very 
little adrenal norepinephrine reaches distal tissues. Catecholamines 
circulate in plasma in a loose association with albumin. They have an 
extremely short biologic half-life (10-30 seconds).
3. Catecholamines are rapidly metabolized
Very little epinephrine (<5%) is excreted in the urine. Catecholamines 
are rapidly metabolized by catechol-O-methyltransferase and monoamine 
oxidase to form the inactive O-methylated and deaminated metabolites. 
Most catecholamines are substrates for both of these enzymes and these 
reactions can occur in any sequence.
Catechol-O-methyltransferase (COMT) is a cytosol enzyme found in 
many tissues. It catalyzes the addition of a methyl group, usually at the 3 
position (meta) on the benzene ring, to a variety of catecholamines. The
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reaction requires a divalent cation, and S-adenosylmethionine is the methyl 
donor. The result of this reaction, depending on the substrate, is the 
production of homovaniliic acid, normetanephrine, and metanephrine.
Monoamine oxidase (MAO) is an oxidoreductase that deaminates 
monoamines. It is located in many tissues, but it occurs in highest 
concentrations in the liver, stomach, kidney, and intestine. At least 2 
isozymes of MAO have been described. MAO-A is found in neural tissue 
and deaminates serotonin, epinephrine, and norepinephrine, while MAO- 
B is found in extraneural tissues and is most active against 2- 
phenylethylamine and benzylamine. Dopamine and tyramine are 
metabolized by both forms. Much research effort is directed at correlating 
affective disorders with increases or decreases of the activity of these 
isozymes. MAO inhibitors have been used to treat hypertension and 
depression, but serious reactions with foods or drugs that contain 
sympathomimetic amines limit their usefulness.
O-Methoxylated derivatives are further modified by conjugation with 
glucuronic or sulfuric acid.
A bewildering number of metabolites of catecholamines are formed. 
Two classes of these have diagnostic significance, since they are found in 
readily measurable amounts in urine. Metanephrines represent the 
methoxy derivatives of epinephrine and norepinephrine, while the O- 
methylated deaminated product of epinephrine and norepinephrine is 3- 
methoxy-4-hydroxymandelic acid (also called vanillylmandelic acid 
[VMA], The concentration of metanephrines or VMA in urine is elevated 
in more than 95% of patients with pheochromocytoma. These tests have 
excellent diagnostic precision, particularly when coupled with a 
measurement of plasma or urine catecholamines.
4. The synthesis of catecholamines is regulated by nerve impulses
Stimulation of the splanchnic nerve, which supplies the preganglionic 
fibers to the adrenal medulla, results in the exocytotic release of 
catecholamines, the granule carrier protein, and DBH. Such stimulation is 
controlled by the hypothalamus and brain stem, but the exact feedback loop 
has not been described.
Nerve stimulation also results in increased synthesis of catecholamines. 
Norepinephrine synthesis increases after acute stress, but the amount of 
tyrosine hydroxylase is unchanged even though tyrosine hydroxylase 
activity increases. Tyrosine hydroxylase is a substrate for cAMP-dependent 
protein kinase, and so this activation may involve phosphorylation. 
Prolonged stress accompanied by chronic sympathetic nerve activity 
results in an induction (increased amount) of tyrosine hydroxylase. A 
similar induction of DBH has also been reported. The induction of these
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enzymes of the catecholamine biosynthetic pathway is a means of adapting 
to physiologic stress and depends upon neural (tyrosine hydroxylase and 
DBH induction) and endocrine (PNMT induction) factors.
5. Catecholamines can be classified by their mechanism of action
The mechanism of action of the catecholamines has attracted the attention 
of investigators for nearly a century. Indeed, many of the general concepts of 
receptor biology and hormone action can be traced to these early studies.
The catecholamines act through 2 major classes of receptors. These are 
designated a-adrenergic and p-adrenergic, and each consists of 2 
subclasses, ie, alpha], alpha2, beta], and beta2 (Table I). This classification 
is based on the relative order of binding of various agonists and antagonists. 
Epinephrine binds to and activates both alpha and beta receptors, so that its 
action in a tissue which has both depends on the relative affinity of these 
receptors for the hormone. Norepinephrine at physiologic concentrations 
primarily binds to alpha receptors.
Table 1. Actions mediated through various adrenergic receptors.
i Alpliai Alpha; Beta i Beta,
Increased Smooth muscle Stimulation of increased aepatic
glycogenolysis relaxation lipolysis gluconeogenesis
Smooth muscle 
contraction
Gastointestinal tract Myocardial
contraction
Increased hepatic 
glycogenolysis
Blood vessels Smooth muscle 
contraction
Increased rale Increased muscle 
slvcosenolvsis 1
Genitourinary
tract
Some vascular beds 
Inhibition of: 
Lipolysts 
Renin release 
Platelet aggregation 
Insulin secretion
Increased force Increased release of: 
insulin, glucagon, 
rennin, smooth 
muscle relaxation 
bronchi, blood 
vessels, genitouri­
nary tract,
gastrointestinal tract
6. The structure of the p-adrenergic receptor is known
Molecular cloning of the gene and cDNA for the mammalian P- 
adrenergic receptor revealed some surprising features. First, the gene has no 
introns and thus joins the histone and interferon genes as mammalian genes 
that lack these structures. Second, the p-adrenergic receptor is closely 
homologous to rhodopsin (in 3 peptide regions, at least), the protein that 
initiates the process which converts light into the visual response. Further 
similarities are discussed below.
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Three of these adrenergic receptor subgroups are coupled to the 
adenylate cyclase system
Hormones that bind to the pb and fa receptors activate adenylate cyclase, 
whereas hormones that bind to a2-receptors inhibit this enzyme. 
Catecholamine binding induces the coupling of the receptor to a G protein 
that then binds GTP. This either stimulates (Gs) or inhibits (Gj) adenylate 
cyclase, thus stimulating or inhibiting the synthesis of cAMP. The response 
terminates when the a subunit-associated GTPase hydrolyzes the GTP. a r  
Receptors are coupled to processes that alter intracellular calcium 
concentrations or modify phosphatidylinositide metabolism (or both). A 
separate G protein complex is involved in this response.
7. Pheochromocynomas are tumors of the adrenal medulla
These tumors are usually not detected unless they produce and secrete 
enough epinephrine or norepinephrine to cause a severe hypertension 
syndrome. The ratio of norepinephrine to epinephrine is often increased in 
pheochromocytoma. This may account for differences in clinical 
presentation, since norepinephrine is thought to be primarily responsible for 
hypertension and epinephrine for hypermetabolism.
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HORMONES OF THE PANCREAS
Hormones of the Pancreas.
Introduction
The pancreas is 2 very different organs contained within one structure. 
The acinar portion of the pancreas has an exocrine function, secreting into 
the duodenal lumen the enzymes and ions used for the digestive process. 
The endocrine portion consists of the islets of Langerhans. The 1-2 million 
islets of the human pancreas make up 1-2% of its weight and are 
collections of the several different cell types listed in Table 1.
The pancreatic islets secrete at least 4 hormones: insulin, glucagon, 
somatostatin, and pancreatic polypeptide. The hormones are released 
into the pancreatic vein, which empties into the portal vein - a convenient 
arrangement, since the liver is a primary site of action of insulin and 
glucagon. These 2 hormones are chiefly involved in regulating carbohydrate 
metabolism but affect many other processes. Somatostatin, first identified in 
the hypothalamus as the hormone that inhibits growth hormone secretion, is 
present in higher concentration in the pancreatic islets than in the 
hypothalamus and is involved in the local regulation of insulin and 
glucagon secretion. Pancreatic polypeptide affects gastrointestinal 
secretion.
The gastrointestinal tract secretes many hormones, perhaps more than 
any other single organ. The purpose of the gastrointestinal tract is to propel 
foodstuffs to sites of digestion, to provide the proper milieu (enzymes, pH, 
salt, etc) for the digestive process, to move the digested products across the 
intestinal mucosa through the mucosal cells and into the extracellular space, 
to move those products to distant cells via the circulation, and to expel waste 
products. The gastrointestinal hormones assist in all of these functions.
Table I. Cell types in the islets o f Langerhans.
Cell Type Relative Abundance Hormone Produced
A (or oc> -25% Glucagon
В (or P) -70% Insulin
D (or o) <5% Somatostatin
F Trace
------------------------------------------------------------ —
Pancreatic polypeptide
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ACRONYMS USED IN THIS LECTURE
ACTH Adrenocorticotropic hormone
EGF Epidermal growth factor
FGF Fibroblast growth factor
GIF Gastric inhibitory polypeptide
IGF Insulinlike growth factor
LDL Low-density lipoproteins
IDDM Insulin-dependent diabetes mellitus
NIDDM Non-insulin-dependent diabetes mellitus
PDGF Platelet-derived growth factor
PEPCK Phosphoenolpyruvate carboxykinase
PGF 2a Prostaglandin Fy,
PP Pancreatic polypeptide
VLDL Very low density lipoproteins
1. Biomedical importance
Insulin has been the model peptide hormone in many ways, being the 
first purified, crystallized, and synthesized by chemical and molecular 
biologic techniques. Studies of its biosynthesis led to the important concept 
of the propeptide. Insulin has important medical implications. Five percent of 
the population in developed countries has diabetes mellitus, and an equal 
number are liable to develop this disease. Diabetes mellitus is due to 
insufficient action of insulin, owing either to its absence or to resistance to 
its action. Glucagon, acting unopposed, aggravates this condition.
Disease syndromes due to excessive production of several of the 
gastrointestinal hormones have been described. Signs and symptoms often 
involve many organ systems, and accurate diagnosis can be difficult unless 
the physician is aware of these syndromes. The gastrointestinal hormones are 
of interest also because of their close link to neuropeptides.
Historical perspective: Langerhans identified the islets in the 1860s but 
did not understand their function - nor did von Mering and Minkowski, 
who demonstrated in 1889 that pancreatectomy produced diabetes. The link 
between the islets and diabetes was suggested by de Mayer in 1909 and by 
Sharpey-Schaifer in 1917, but it was Banting and Best who proved this 
association in 1921. These investigators used acid-ethanol to extract from 
the tissue an islet cell factor that had potent hypoglycemic activity. The 
factor was named insulin, and it was quickly learned that bovine and 
porcine islets contained insulin that was active in humans. Within a year, 
insulin was in widespread use for the treatment of diabetes and proved to 
be lifesaving.
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Having large quantities of bovine or porcine insulin to study had an 
equally dramatic effect on biomedical research. Insulin was the first protein 
proved to have hormonal action, the first protein crystallized (Abel, 1926), 
the first protein sequenced (Sanger et al, 1955), the first protein synthesized 
by chemical techniques (Du et al; Zahn; Katsoyanis; -1964), the first 
protein shown to be synthesized as a larger precursor molecule (Steiner et 
al, 1967), and the first protein prepared for commercial use by recombinant 
DNA technology. In spite of this impressive list of «firsts», less is known 
about how insulin works at the molecular level than about how most other 
hormones work at that level.
2. Insulin is a heterodimeric polypeptide
Insulin is a polypeptide consisting of 2 chains, A and B, linked by 2 
interchain disulfide bridges that connect A7 to B7 and A20 to В19. A third 
intrachain disulfide bridge connects residues 6 and 11 of the A chain. The 
location of these 3 disulfide bridges is invariant, and the A and В chains 
have 21 and 30 amino acids, respectively, in most species. Substitutions 
occur at many positions within either chain without affecting bioactivity 
and are particularly common in positions 8, 9, and 10 of the A chain. Thus, 
this legion is not crucial for bioactivity. Several positions and regions are 
highly conserved, however, including (1) the positions of the 3 disulfide 
bonds, (2) the hydrophobic residues in the C-terminal region of the В 
chain, and (3) the N- and C-terminal regions of the A chain. Chemical 
modification or substitution of specific amino acids in these regions has 
allowed investigators to formulate a composite active recion. The C- 
terminal hydrophobic region of the В chain is also involved in the 
dimerization of insulin.
Porcine insulin differs by a single amino acid, an alanine for threonine 
substitution at B30, while bovine insulin has this modification plus the 
substitutions of alanine for threonine at A8 and valine for isoleucine at 
A10. These modifications result in no appreciable change in biologic^ 
activity and very little antigenic difference. Although all patients given 
heterologous insulin develop low tilers of circulating antibodies against the 
molecule, few develop clinically significant liters. Porcine and bovine 
insulins were standard therapy for diabetes mellitus until human insulin 
was produced by recombinant DNA technology. Despite a wide variation in 
primary structure, biologic activity is about 25-30 IU/mg dry weight for all 
insulins.
Insulin forms very interesting complex structures. Zinc is present in high 
concentration in the В cell and forms complexes with insulin and proinsulin. 
Insulins from all vertebrate species form isologous dimers through 
hydrogen bonding between the peptide groups of the B24 and B26 residues
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of 2 monomers, and at high concentrations these are organized as 
hexamers, each with 2 atoms of zinc. This higher-order structure made 
studies of the crystalline structure of insulin feasible. Insulin is probably in 
the monomeric form at physiologic concentrations.
Insulin is synthesized as a preprohormone (MW -11,500) and is the 
prototype for peptides that are processed from larger precursor molecules. 
The hydrophobic 23-amino-acid pre-, or leader, sequence directs the 
molecule into the cisternae of the endoplasmic reticulum and then is 
removed. This results in the 9000-MW proinsulin molecule that provides 
the conformation necessary for forming the proper disulfide bridges. 
The arrangement of proinsulin, starting from the amino terminus, is В 
chain—connecting (C) peptide—A chain. The proinsulin molecule 
undergoes a series of site-specific peptide cleavages that result in the 
formation of equimolar amounts of mature insulin and C peptide.
Proinsulin is synthesized by ribosomes on the rough endoplasmic 
reticulum, and the enzymatic removal of the leader peptide (pre-segment), 
disulfide bond formation, and folding, occur in the cisternae of this 
organelle. The proinsulin molecule is transported to the Golgi apparatus 
wherein proteolysis and packaging into the secretory granules begin. 
Granules continue to mature as they traverse the cytoplasm toward the 
plasma membrane. Proinsulin and insulin both combine with zinc to form 
hexamers, but since about 95% of the proinsulin is converted to insulin, it is 
the crystals of the latter that confer morphologic distinctness to the granules. 
Equimolar amounts of C peptide are present within these granules, but these 
molecules do not form a crystalline structure. Upon appropriate 
stimulation, the mature granules fuse with the plasma membrane and 
discharge their contents into the extracellular fluid by emiocytosis.
Proinsulins vary in length from 78 to 86 amino acids, with the variation 
occurring in the length of the C-peptide region. Proinsulin has the same 
solubility and isoelectric point as insulin; it also forms hexamers with zinc 
crystals, and it reacts strongly with insulin antisera. Proinsulin has less 
than 5% of the bioactivity of insulin, indicating that most of the active site 
of the latter is occluded in the precursor molecule. Some proinsulin is 
released with insulin and in certain conditions (islet cell tumors) in larger 
than usual amounts. Since the plasma half-life of proinsulin is significantly 
longer than that of insulin and since proinsulin is strongly cross-reactive with 
insulin antisera, a radioimmunoassay for “insulin” may occasionally 
overestimate the bioactivity of “insulin” in plasma. The C peptide has no 
known biologic activity. It is a distinct molecule from an antigenic standpoint. 
Thus, C-peptide immunoassays can distinguish insulin secreted endogenously 
from insulin administered exogenously and can quantitate the former when 
antiinsulin antibodies preclude the direct measurement of insulin. The C 
peptides of different species have a high rate of amino acid substitution, an
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observation which underscores the statement that this fragment probably 
has no biologic activity.
3. Insulin secretion is precisely regulated
The human pancreas secrets 40-50 units of insulin daily, which 
represents about 15-20% of the hormone stored in the gland. Insulin 
secretion is an energy-requiring process that involves the microtubule- 
microfilament system in the В cells of the islets. A number of mediators 
have been implicated in insulin release.
Glucose: An increase in plasma glucose concentration is the most 
important physiologic regulator of insulin secretion. The threshold 
concentration for secretion is the fasting plasma glucose level (80-100 
mg/dL), and the maximal response is obtained at glucose levels between 
300 and 500 mg/dL. Two different mechanisms have been proposed to 
explain how glucose regulates insulin secretion. One hypothesis suggests 
that glucose combines with a receptor, possibly located on the B-cell 
membrane, which activates the release mechanism. The second hypothesis 
suggests that intracellular metabolites or the rate of metabolite flux through a 
pathway such as the pentose-phosphate shunt, the citric acid cycle, or the 
glycolytic pathway, is involved. There is experimental evidence to support 
both positions.
Hormonal factors: numerous hormones affect insulin release, a-
Adrenergic agonists, principally epinephrine, inhibit insulin release even 
when this process has been stimulated by glucose, p-Adrenergic agonists 
stimulate insulin release, probably by increasing intracellular cAMP.
Chronic exposure to excessive levels of growth hormone, cortisol, 
placental lactogen, estrogens, and progestins also increases insulin secretion. 
It is therefore not surprising that insulin secretion increases markedly during 
the later stages of pregnancy.
Pharmacologic agents: Many drugs stimulate insulin secretion, but the 
sulfonylurea compounds are used most frequently for therapy in humans. 
Drugs such as tolbutamide stimulate insulin release by a mechanism 
different from that employed by glucose and have achieved widespread use 
in the treatment of type П (non-insulin-dependent) diabetes mellitus.
4. Insulin is rapidly metabolized
Unlike the insulinlike growth factors, insulin has no plasma carrier 
protein; thus, its plasma half-life is less than 3-5 minutes under normal 
conditions. The major organs involved in insulin metabolism are the liver, 
kidneys, and placenta; about 50% of insulin is removed in a single pass 
through the liver. Mechanisms involving 2 enzyme systems are responsible
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for the metabolism of insulin. The first involves an insulin-specific protease 
found in many tissues but in highest concentration in those listed above. This 
protease has been purified from skeletal muscle and is known to be 
sulfhydryl-dependent and active at physiologic pH. The second mechanism 
involves hepatic glutathione-insulin transhydrogenase. This enzyme 
reduces the disulfide bonds, and then the individual A and В chains are 
rapidly degraded. It is not clear which of these mechanisms is most active 
under physiologic conditions, nor is it clear whether either process is 
regulated.
5. The central role of insulin in carbohydrate, lipid, and protein 
metabolism can be best appreciated by examining the 
consequences of insulin deficiency in humans
The cardinal manifestation of diabetes mellitus is hyperglycemia, which 
results from (1) decreased entry of glucose into cells, (2) decreased 
utilization of glucose by various tissues, and (3) increased production of 
glucose (gluconeogenesis) by the liver (Fig. 1).
Insulin deficiency 
tend glucagon excess)
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Fig. 1. Pathophysiology o f insulin deficiency. (Courtesy o f RJ Havel).
Polyuria, polydipsia, and weight loss in spite of adequate caloric intake 
are the major symptoms of insulin deficiency. How is this explained? The 
plasma glucose level rarely exceeds 120 rng/dL in normal humans, but 
much higher levels are routinely found in patients with deficient insulin 
action. After a certain plasma glucose level is attained (generally > 180 mg/dL 
in humans), the maximum level of renal tubular reabsorption of glucose is 
exceeded, and sugar is excreted in the urine (glycosuria). The urine volume 
is increased owing to osmotic diuresis and coincident transporter translocation 
is temperature - and energy-dependent and is protein synthesis-independent
Insulin does not promote the facilitated diffusion of glucose into 
hepatocytes, but it indirectly enhances net inward flu\ by converting 
intracellular glucose to glucose 6-phosphate through the action of glucokinase, 
an enzyme induced by insulin. This rapid phosphorylation keeps the free
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glucose concentration very low in the hepatocyte, thus favoring entry by 
simple diffusion down a concentration gradient.
Insulin also promotes the entry o f  amino acids into cells, particularly in 
muscle, and enhances the movem ent o f  K+, Ca2+, nucleosides, and inorganic 
phosphate. These effects are independent o f  the action o f  insulin on glucose 
entry.
Effects on glucose utilization: Insulin influences the intracellular 
utilization o f  glucose in a num ber o f  ways, as illustrated below. In a normal 
person, about h a lf o f  the glucose ingested is converted to energy through 
the glycolytic pathw ay and about h a lf  is stored as fat or glycogen. 
G lycolysis decreases in the absence o f  insulin, and the anabolic processes 
o f  glycogenesis and lipogenesis are im peded. Indeed, only 5%  o f  an 
ingested glucose load is converted to fat in an insulin-deficient diabetic.
Insulin increases hepatic glycolysis by increasing the activity and 
am ount o f  several key enzym es including glucokinase, 
phosphofructokinase, and pyruvate kinase. Enhanced glycolysis increases 
glucose utilization and thus indirectly decreases glucose release into 
plasma. Insulin also decreases the activity o f  glucose-6-phosphatase, an 
enzym e found in liver but not in muscle. Since glucose 6-phosphate cannot 
exit from the plasm a m em brane, this action o f  insulin results in the 
retention o f  glucose w ithin the liver cell.
Insulin stim ulates lipogenesis in adipose tissue by (1) providing the 
acetyl-CoA and NADPH required for fatty' acid synthesis; (2) m aintaining a 
normal level o f  the enzym e acetyl-CoA  carboxylase, which catalyzes the 
conversion o f  acetyl-CoA to m alonyl-CoA ; and (3) providing the glycerol 
involved in triacy Iglycerol synthesis. In insulin deficiency, all o f  these are 
decreased; thus, lipogenesis decreases. Another reason for the decreased 
lipogenesis in insulin deficiency is that fatty acids, released in large 
amounts by several horm ones when unopposed by insulin, feedback-inhibit 
their own synthesis by inhibiting acetyl-C oA  carboxylase. The net effect o f  
insulin on fat is therefore anabolic.
The final action o f  insulin on glucose utilization involves another 
anabolic process. In liver and m uscle, insulin stim ulates the conversion o f  
glucose to glucose 6-phosphate, w hich then undergoes isom erization to 
glucose 1-phosphate and is incorporated into glycogen by the enzym e 
glycogen synthase, the activity o f  w hich is stim ulated by insulin. This 
action is indirect and dual in nature. Insulin decreases intracellular cA M P 
levels by activating a phosphodiesterase. Since cA M P-dependent 
phosphorylation inactivates glycogen synthase, low  levels o f  this 
nucleotide allow  the enzym e to stay in the active form. Insulin also 
activates a phosphatase that dephosphorylates glycogen synthase, thereby 
resulting in the activation o f  this enzyme. Finally, insulin inhibits 
phosphorylase by a m echanism  involving cA M P and phosphatase as
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described above, and this decreases glucose liberation from glycogen. The 
net effect o f  insulin on glycogen metabolism is also anabolic.
Effects on glucose production (G luconeogenesis): The actions o f 
insulin on glucose transport, glycolysis, and glycogenesis occur within 
seconds or minutes, since they primarily involve the activation or 
inactivation o f  enzym es by phosphorylation or dephosphorylation. A more 
long-term effect on plasm a glucose involves the inhibition o f  
gluconeogenesis by insulin. The form ation o f  glucose from 
noncarbohydrate precursors involves a series o f  enzym atic steps, many o f  
w hich are stim ulated by glucagon (acting through cAM P), by 
glucocorticoid horm ones, and to a lesser extent by a -  and (3-adrenergic 
agents, angiotensin II, and vasopressin. Insulin inhibits these same steps. 
The key gluconeogenic enzym e in the liver is phosphoenolpyruvate 
carboxykinase (PEPCK.), which converts oxaloacetate to 
phosphoenolpyruvate. Recent studies show that insulin decreases the 
am ount o f  this enzym e by selectively inhibiting transcription o f  the gene 
that codes for the mRNA for PEPCK.
Effects on glucose m etabo lism : The net action o f all o f  the above 
effects o f  insulin is to decrease the blood glucose level. In this action, 
insulin stands alone against an array o f  horm ones that attem pt to counteract 
this effect. This no doubt represents one o f  the organism 's most im portant 
defense mechanism s, since prolonged hypoglycem ia poses a potentially 
lethal threat to the brain and m ust be avoided.
Effects on lip id  m etabo lism : The lipogenic actions o f insulin were 
discussed in the context o f  glucose utilization. Insulin also is a potent 
inhibitor o f  lipolysis in liver and adipose tissue and thus has an indirect 
anabolic effect. This is partly due to the ability o f  insulin to decrease tissue 
cAM P levels (w hich are increased in these tissues by the lipolytic 
horm ones glucagon and epinephrine) but also to the fact that insulin 
inhibits horm one-sensitive lipase activity. This inhibition is presum ably 
due to the activation o f  a phosphatase that dephosphorylates and thereby 
inactivates the lipase or cA M P-dependent protein kinase. Insulin therefore 
decreases circulating free fatty acids. This contributes to the action o f  
insulin on carbohydrate metabolism , since fatty acids inhibit glycolysis at 
several steps and stim ulate gluconeogenesis. This illustrates the point that 
one cannot discuss m etabolic regulation in the context o f  a single horm one 
or m etabolite. R egulation is a  com plex process in w hich the flux through a 
given pathw ay is the result o f  the interplay o f  a num ber o f  horm ones and 
m etabolites.
In patients w ith insulin deficiency, lipase activity increases, resulting in 
enhanced lipolysis and increased concentration o f  free fatty acids in plasm a 
and liver. G lucagon levels also increase in these patients, and this enhances 
the release o f  free fatty acids. (G lucagon opposes m ost o f  the actions o f
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insulin, and the metabolic state in the diabetic is a reflection o f  the relative 
levels o f  glucagon and insulin.) A portion o f  the free fatty acids is 
m etabolized to acetyl-CoA  (the reverse o f  lipogenesis) and then to C 0 2 and 
H20 via the citric acid cycle. In patients w ith insulin deficiency,, the 
capacity o f  this process is rapidly exceeded and the acetyl-CoA  is 
converted to acetoacetyl-CoA  and then to acetoacetic and (3-hydroxybutyric 
acids. Insulin reverses this pathway.
Insulin apparently affects the formation or clearance o f  VLDL and LDL, 
since levels o f  these particles, and consequently the level o f  cholesterol, are 
often elevated in poorly controlled diabetics. A ccelerated atherosclerosis, a 
serious problem  in many diabetics, is attributed to this m etabolic defect.
E ffects on p ro te in  m etabo lism : Insulin generally has an anabolic effect 
on protein metabolism in that it stim ulates protein synthesis and retards 
protein degradation. Insulin stimulates the uptake o f  neutral amino acids into 
muscle, an effect that is not linked to glucose uptake or to subsequent 
incorporation o f  the amino acids into protein. The effects o f  insulin on 
general protein synthesis in skeletal and cardiac muscle and in liver are 
thought to be exerted at the level o f  mRNA translation.
In recent years insulin has been shown to influence the synthesis o f 
specific proteins by effecting changes in the corresponding mRNAs. This 
action o f  insulin, which may ultim ately explain many o f  the effects the 
horm one has on the activity or am ount o f  specific proteins, is discussed in 
m ore detail below.
E ffects on cell rep lica tion : Insulin stim ulates the proliferation o f  a 
num ber o f  cells in culture, and it may also be involved in the regulation o f  
growth in vivo. Cultured fibroblasts are the most frequently used cells in 
studies o f  grow th control. In such cells, insulin potentiates the ability o f  
fibroblast grow th factor (FG F), p latelet-derived grow th factor (PD G F), 
epiderm al growth factor (EOF), tum or-prom oting phorbol esters, 
prostaglandin F2j (PGF2.J ,  vasopressin, and cA M P analogs to stim ulate cell 
cycle progression o f  cells arrested  in the G , phase  o f  the cyc le  by serum  
deprivation.
An exciting new area o f  research involves the investigation o f  tyrosine 
kinase activity. The insulin receptor, along w ith receptors for many other 
grow th-prom oting peptides including those o f  PDGF and EGF, has 
tyrosine kinase activity. Interestingly, at least 10 oncogene products, many 
o f  which are suspected to be involved in stim ulating m alignant cell 
replication, are also tyrosine kinases. M am m alian cells contain analogs o f  
these oncogenes (p ro to o n co g en es), w hich may be involved in the 
replication o f  normal cells. Support for the theory that they are involved 
com es from recent observations that the expression o f  at least 2 
protOoncogene products, c-fos  and c-myc, increases follow ing addition o f  
serum  PDGF or insulin grow th-arrested cells.
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6. The mechanism of action of insulin is being elucidated
Insulin action begins when the horm one binds to a specific glycoprotein 
receptor on the surface o f  the target cell. The diverse actions o f  the 
horm one can occur w ithin seconds or m inutes (transport, protein 
phosphorylation, enzym e activation and inhibition, RNA synthesis) or after 
a few hours (protein and DNA synthesis and cell growth).
The insulin receptor has been studied in great detail using biochem ical 
and recom binant DNA techniques. It is a  heterodim er consisting o f  2 
subunits, designated a and p, in the configuration  a ; -P:, linked by 
disulfide bonds. Both subunits are extensively glycosylated, and removal o f 
sialic acid and galactose decreases insulin binding and insulin action. Each of 
these glycoprotein subunits has a unique structure and function. The ol 
subunit (MW 135,000) is entirely extracellular, and it binds insulin, probably 
via a cysteine-rich domain. The p subunit (MW 95,000) is a transmembrane 
protein that performs the second major function o f a receptor, ie, signal 
transduction. The cytoplasmic portion o f  the P subunit has tyrosine kinase 
activity and an autophosphorylation site. Both o f  these are thought to be 
involved in signal transduction and insulin action Indeed, several regions o f 
the P subunit have sequence homology with the EOF receptor.
The insulin receptor is constantly being synthesized and degraded, and its 
half-life is 7-12 hours. The receptor is synthesized as a single-chain peptide 
in the rough endoplasmic reticulum and is rapidly glycosylated in the Golgi 
region. The precursor o f  the human insulin receptor has 1382 amino acids, 
has a molecular weight o f 190,000. and is cleaved to form the mature -i and p 
subunits. The hum an insulin receptor gene is located on chrom osom e 19.
Insulin receptors are found on most mammalian cells, in concentrations 
of up to 20,000 per cell, and often on cells not typically thought of as being 
insulin targets. Insulin has a well-known set of effects on metabolic 
processes but also is involved in growth and replication of cells as well as 
in fetal organogenesis and differentiation and in tissue repair and 
regeneration. The structure of the insulin receptor and the ability of different 
insulins to bind to receptors and elicit biologic responses are virtually 
identical in all cells and all species. Thus, porcine insulin is always 10-20 
times more effective than porcine proinsulin, which in turn is 10—20 times 
more effective than guinea pig insulin, even in the guinea pig. The insulin 
receptor has apparently been highly conserved, more so than even insulin 
itself.
When insulin binds to the receptor, several events occur. (1) There is a 
conformational change of the receptor; (2) the receptors crosslink and form 
microaggregates; (3) the receptor is internalized; and (4) one or more signals 
are generated. The significance of the conformational change is unknown,
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and internalization probably represents a m eans o f  controlling receptor 
concentration and turnover. In conditions in which plasm a insulin levels are 
high, eg, obesity or acrom egaly, the num ber o f  insulin receptors is 
decreased and target tissues become less sensitive to insulin. This “down- 
regulation’' results from the loss o f  receptors by internalization, the process 
whereby insulin-receptor com plexes enter the cell through endoevtosis in 
clathrin-coated vesicles. Down-regulation explains part o f  the insulin 
resistance in obesity and type II diabetes mellitus.
A lthough the m echanism  o f  insulin action has been under investigation 
for 60 years, certain critical points, such as the nature o f  the intracellular 
signal, remain obscure. Insulin is not unique in th is respect - the in­
tracellu lar m essenger has not been identified fo r a large num ber o f  
hormones. A variety o f  different molecules have been proposed as the intra­
cellular second m essenger for insulin. These include insulin itself, 
calcium , cyclic nucleotides (cA M P. cGM P), Н Л ,  m em brane-derived 
peptides, m em brane phosphoinositol glycans, m onovalent cations, and 
tyrosine kinase (the insulin receptor). None has w ithstood rigorous testing.
Many o f  the metabolic effects o f insulin, particularly those which occur 
rapidly, are mediated by influencing protein phosphorylation and 
dephosphon lation reactions that in turn alter the enzym atic activity o f  the 
protein. A list o f  enzym es affected in this way is presented in Table 2. In 
som e instances, insulin decreases intracellular cAM P levels (by activating a 
c A M P-phosphodiesterasc), thereby-decreasing the activity state o f  cA M P- 
dependent protein kinase: exam ples o f  this action include glycogen synthase 
and phosphorylase. In other instances, this action is independent o f  c AMP 
and is exerted by activating, other protein kinases (as is the case with the 
insulin receptor, tyrosine kinase); by inhibiting other protein kinases; or, 
more com m only, by stim ulating the activity o f  phosphoprotein 
phosphatases. Dephosphory lation increases the activity o f  a number o f  key 
enzymes. These covalent m odifications allow  for alm ost im m ediate 
changes in the activity' o f  enzym es.
Table 2. Enzymes whose degree o f pliosphoiylation and activity are altered by insulin
JVs E n zy m e C h a n g e  in 
A c tiv ity
P o ss ib le  M e c h a n ism
1. cA M P  m etab o lism
P hosphod ies te rase  (low  K m) Increase P h osphory la tion
Protein  k inase  (cA M P -dependen t) D ecrease A sso ca tio n  o f  R an d  C subunits
2. G ly co g en  m e ta b o lism :
G lycogen  syn thase Increase D ep h o sphory la tion
P hosphory lase  k inase D ecrease D ep h o sphory la tion
P hosphory lase D ecrease D eph o sp h o ry la tio n
3. G lyco lysis  a n d  g lu co n eo g en es is
Pyruvate deh y d ro g en ase Increase D ephosphory la tion
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P yruvate  k inase Increase D ephosphory lation
6-P hosphofruc to -2 -k inase Increase D ephosphory lation
F ruc tose-2 ,6 -b isphosphatase D ecrease D ephosphory lation
4. L ip id  m e tab o lism
A cety l-C oA  reductase
Increase Phosphory lation
H V G -C oA  reductase Increase D ephosphory lation
T riacy lg lycero l lipase D ecrease D ephosphory lation
5. O th e r
T y ro sin e  k inase 9 Phosphory lation
7. Pathophysiology involving insulin is mostly expressed as diabetes
Insulin deficiency or resistance to the action o f  insulin results in diabetes 
mellitus. About 90%  o f  persons with diabetes have non-insulin dependent 
(type II) diabetes m ellitus (NIDDM ). Such patients are usually obese, have 
elevated plasma insulin levels, and have dow n-regulated insulin receptors. 
The other 10% have insulin-dependent (type 1) diabetes mellitus (IDDM). 
The metabolic derangem ents discussed earlier most typically apply to the 
type I diabetic.
Certain rare conditions illustrate essential features about insulin action. A 
tew  individuals produce antibodies directed against their insulin receptors. 
These antibodies prevent insulin from binding to the receptor so that such 
persons develop a syndrom e o f  severe insulin resistance. Tum ors o f  B-cell 
origin cause hyperinsulinism  and a syndrom e characterized by severe 
hypoglycemia. The role o f  insulin (or perhaps o f  IGF-I or IGF-II) in 
organogenesis and developm ent is illustrated by the rare cases o f  
leprechaunism . This syndrom e is characterized by low birth weight, 
decreased muscle mass, decreased subcutaneous fat, elfin facies, insulin 
resistance w ith markedly elevated plasm a levels o f  biologically active 
insulin, and early death. Several individuals with leprechaunism have been 
shown to lack insulin receptors or to have defective receptors.
8. Glucagon is an insulin antagonist
The early commercial preparations of insulin increased the plasma 
glucose level before lowering it, owing to the presence of a contaminating 
peptide, glucagon, which was the second pancreatic islet cell hormone 
discovered.
Glucagon, synthesized mainly in the A cells of the pancreatic islets, is a 
single-chain polypeptide (MW 3485) consisting of 29 amino acids. 
Glucagon is synthesized as a much larger (MW~9000) proglucagon 
precursor. Molecules larger than this have been detected, but whether they 
represent glucagon precursors or closely related peptides is unclear. Only 30
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- 40%  o f  the im m unoreactive "glucagon" in plasm a is pancreatic glucagon; 
the rest consists o f  biologically inactive larger molecules.
G lucagon  shares som e im m uno log ic  and physiologic properties w ith 
enteroglucagon, a peptide extracted from the duodenal mucosa, and 14 o f  
the 29 amino acid residues o f  secretin are identical to those o f  glucagon.
G lucagon circulates in plasm a in the free form. Since it does not 
associate with a transport protein, its plasm a half-life is short ( -5  minutes). 
G lucagon is inactivated by the liver, w hich has an enzym e that removes the 
first 2 amino acids from the N-termina! end by cleaving between Set 2 and 
Gin 3. Since the liver is the first stop for glucagon after it is secreted and since 
the liver rapidly inactivates the horm one, the level o f  glucagon in the portal 
vein is much higher than that in the peripheral circulation.
It is not clear whether glucose directly inhibits glucagon secretion or 
whether this is mediated through the actions o f  insulin or IGF-!, since both o f  
these islet cell hormones directly inhibit glucagon release. Many other 
substances, including amino acids, fatty acids and ketones, gastrointestinal 
tract hormones, and ncurotransm itters, affect glucagon secretion.
W hereas insulin prom otes energy storage by stim ulating glycogenesis, 
lipogenesis. and protein synthesis, glucagon causes the rapid m obilization 
o f  potential energy sources into glucose by stim ulating glycogenolysis and 
into fatty acids by stim ulating lipolysis. G lucagon is also the most potent 
gluconeogenic horm one, and it is ketogenic.
The liver is the primary target o f  glucagon action. Glucagon binds to 
specific receptors in the hepatic cell plasm a membrane, and this activates 
adenylate cyclase. The cAM P generated activates phosphorylase, which 
enhances the rate o f glycogen degradation while inhibiting gly cogen synthase 
and thus glycogen formation. There is hormone and tissue specificity in this 
effect, since glucagon has no effect on glycogenolysis in m uscle, "whereas 
epinephrine is active in both muscle and liver.
The elevated cAM P level stim ulates the conversion o f  amino acids to 
glucose by inducing a num ber o f  enzymes involved in the gluconeogenic 
pathway. Principal am ong these is PEPCK. Glucagon, through cAM P, 
increases the rate o f  transcription o f  mRNA from the PEPCK gene, and this 
stimulates the synthesis o f  more PEPCK. This is the opposite o f  the effect o f 
insulin, which decreases PEPCK gene transcription. Other examples are 
illustrated in Table 3. The net action o f  glucagon in the liver is increased 
glucose production; since much o f  this glucose exits the liver, the plasma 
glucose concentration increases in response to glucagon.
Glucagon is a potent lipolytic agent, it increases adipose cell cAMP 
levels, and this activates the hormone-sensitive lipase. The increased fatty 
acids can be metabolized for energy or converted to the ketone bodies 
acetoacetate and P-hydroxybutyrate. This is an important aspect o f  metabolism
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in the diabetic, since glucagon levels are always increased in insulin 
deficiency.
Table 3. Enzyme’s induced or repressed by insulin or glucagon.
E n zy m es in d u c e d  by  a h ig h  in su ! in :g lu c a g o n  r a t io  a n d  rep re sse d  by  a low 
in su lin :g lucagon  ra tio
1. G iucokinase
2. C itrate cleavage enzym e
3. A cetyl-C oA  carboxylase
4. H M G -C oA  reductase
5. Pyruvate kinase
6. 6-Phosphofructo-1 -kinase
7. 6-Phosphofructo-2-kinase/fructose-2.6-bisphosphatase
E nzym es induced  by  a low insu lin .-g lucagon  ra tio  an d  rep re ssed  b> a high 
in su lin :g lucagon  ra tio
I G lucose-6-phosphatase
2. Phosphoenolpyruvate carboxvkinase (PFPC K )
3. Fructose-1.6-bisphosphatase
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THYROID HORMONES
Introduction
Thyroid hormones regulate gene expression, tissue differentiation, and 
general developm ent. The thyroid gland produces 2 iodoamino acid 
hormones, 3,5,3'-triiodothyronine (T3) and 3,5,3',5'-tetraiodothyronine 
(T4, thyroxine), w hich have long been recognized for their importance in 
regulating general m etabolism , developm ent, and tissue differentiation. 
These horm ones, w hose structures are illustrated in Fig.], regulate gene 
expression using mechanisms similar to those employed by steroid hormones.
Diseases o f the thyroid are among the most common afflictions involving 
the endocrine system. Diagnosis and therapy are firmly based on the principles 
o f thyroid hormone physiology and biochemistry. The availability of 
radioisotopes o f iodine has greatly aided in the elucidation o f these principles. 
Radioactive iodine, because it localizes in the gland, is widely used in the 
diagnosis and treatm ent o f thyroid disorders. Radioiodine has a dangerous 
aspect as well, since excessive exposure, such as from nuclear fallout, is a  major 
risk factor for thyroid cancer. This is especially true in infants and 
adolescents, whose thyroid cells are still actively dividing.
ACRONYMS USED IN THIS LECTURE
DIT D iiodotyrosine
MIT M onoiodotyrosine
T, T riiodothyronine
T4 T hyroxine; tetraiodothyronine
TBG T hyroxine-binding globulin
TBPA T hyroxine-binding prealbum in
TRH T hyrotropin-stim ulating  horm one
TSH T hyroid-stim ulating  horm one
TSI T hyroid-stim ulating  IgG
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Fig. I. Structure o f thyroid hormones and related compounds.
1. Thyroid hormone biosynthesis involves thyroglobulin 
and iodide metabolism
Thyroid hormones are unique in that they require the trace element iodine 
for biologic activity. In most parts o f the world, iodine is a scarce component of 
soil, and hence there is little in food. A complex mechanism has evolved to 
acquire and retain this crucial elem ent and to convert it into a form suitable for 
incorporation into organic com pounds. At the sam e time, the thyroid must 
synthesize thyronine, and this synthesis takes place in thyroglobulin. These 
processes will be discussed separately, although they occur concurrently.
Biosynthesis: T hyroglobulin  is the p recurso r o f T4 and T 3. It is a 
large, iodinated, glycosylated protein with a m olecular w eight o f 660,000. 
C arbohydrate accounts for 8-10%  o f the w eight o f thyroglobulin and 
iodide fo r about 0 .2-1% , depend ing  upon the iodine content in the diet. 
Thyroglobulin is com posed o f 2 subunits. It contains 115 tyrosine residues, 
each o f which is a potential site o f iodination. About 70%  o f the iodide in 
thyroglobulin exists in the inactive precursors, m onoiodotyrosine (M IT) 
and diiodotyrosine (DIT), while 30% is in the iodothyronyl residues, T4 and 
T3. W hen iodine supplies are sufficient, the T4:T3 ratio is about 7:1. In 
iodine deficiency, this ratio  decreases, as does the D IT :M IT  ratio. The
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reason for synthesizing a molecule of 5000 amino acids to generate a few 
molecules of a modified diamino acid seems to be that the conformation of 
this large structure is required for tyrosyl coupling or iodide 
organification. Thyroglobulin is synthesized in the basal portion of the 
cell, moves to the lumen, where it is stored in the extracellular colloid, and 
reenters the cell and moves in an apical to basal direction during its 
hydrolysis into the active T3 and T4 hormones. All of these steps are 
enhanced by TSH, and this hormone (or cAMP) also enhances transcription 
of the thyroglobulin gene.
Hydrolysis: Thyroglobulin is a storage form of T3 and T4 in the colloid: 
a several weeks' supply of these hormones exists in the normal thyroid. 
Within minutes after the stimulation of the thyroid by TSH (or c AMP), there 
is a marked increase of microvilli on the apical membrane. This 
microtubule-dependent process entraps thyroglobulin, and subsequent 
pinocytosis brings it back into the follicular cell. These phagosomes fuse 
with lysosomes to form phagolysosomes in which various acid proteases and 
peptidases hydrolyze the thyroglobulin into amino acids, including the 
iodothyronines. T4 and T3 are discharged from the basal portion of the cell, 
perhaps by a facilitated process, into the blood. The T4:T3 ratio in this 
blood is lower than that in thyroglobulin, so that some selective 
deiodination of T4 must occur in the thyroid. About 50 pg of thyroid 
hormone iodide is secreted each day. With an average uptake of iodide (25- 
30% of the iodide ingested), the daily iodide requirement is between 150 
and 200 pg.
As mentioned above, most of the iodide in thyroglobulin is not in 
iodothyronine; about 70% is in the inactive compounds МГГ and DIT. 
These amino acids are released when thyroglobulin is hydrolyzed and the 
iodide is scavenged by an environmentally conscious enzyme, deiodinase. 
This NADPH-dependent enzyme is also present in kidney and liver. The 
iodide removed from MIT and DIT constitutes an important pool within the 
thyroid, as distinguished from that Г which enters from blood. Under 
steady-state conditions, the amount of iodide that enters the thyroid 
matches the amount that leaves. If one-third of the iodide in thyroglobulin 
leaves (as T4 and T3), it follows that two-thirds of the iodide available for 
biosynthesis comes from the deiodination of MIT and DIT within the 
thyroid.
The thyroid (Fig.2). along with several other epithelial tissues 
including mammary gland, chorion, salivary gland, and stomach, is able to 
concentrate I against a strong electrochemical gradient. This is an energy- 
dependent process and is linked to the ATPase-dependent Na+/K+ pump. 
The activity of the thyroidal Г pump can be isolated from subsequent steps 
in hormone biosynthesis by inhibiting organification of Г with drugs of the 
thiourea class (Fig. 3). The ratio of iodide in thyroid to iodide in serum (T:S
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ratio) is a reflection of the activity of this pump or concentrating mechanism. 
This activity is primarily controlled by TSH and ranges from 500 in animals 
chronically stimulated with TSH to 5 or less in hypophysectomized 
animals. The T:S ratio in humans on a normal iodine diet is about 25.
Fig.2. Model o f iodide metabolism in the thyroid follicle. A follicular cell is shown 
facing the follicular lumen (stippled area) and the extracellular space (at bottom). Iodide 
enters the thyroid by a pump and by passive diffusion. Thyroid hormone synthesis occurs in 
the follicular space through a series o f reactions, пишу o f which are peroxidase-mediated. 
Thyroid hormones are released from thyroglobulin by hydrolysis. Tgb, thyroglobulin; MIT, 
monoiodotyrosine; DIT, diiodotyrosine; 7), triiodothyronine; T4, tetraiodothyronine. 
Asterisks indicate steps or processes that are inherited enzyme deficiencies which cause 
congenital goiter and often result in hypothyroidism.
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Fig. 3. Thiourea class o f antithyroid drugs
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A very small amount of iodide also enters the thyroid by diffusion. Any 
intracellular Г that is not incorporated into MIT or DIT (generally < 10%) is 
free to leave by this mechanism.
The thyroid is the only tissue that can oxidize I to a higher valence state, 
an obligatory step in I organification and thyroid hormone 
biosynthesis. This step involves a heme-containing peroxidase and occurs 
at the luminal surface of the follicular cell.
Thyroperoxidase, a tetrameric protein with a molecular weight of 
60,000, requires hydrogen peroxide as an oxidizing agent. The H2O2 is 
produced by an NADPH-dependent enzyme resembling cytochrome c 
reductase. A number of compounds inhibit Г oxidation and therefore its 
subsequent incorporation into MIT and DIT. They are known as 
antithyroid drugs because of their ability to inhibit thyroid hormone 
biosynthesis at this step.
Oxidized iodide reacts with the tyrosyl residues in thyroglobulin in a 
reaction that probably also involves thyroperoxidase. The 3 position of 
the aromatic ring is iodinated first and then the 5 position to form MIT and 
DIT, respectively. This reaction, sometimes called organification, occurs 
within seconds in luminal thyroglobulin. Once iodination occurs, the iodine 
does not readily leave the thyroid. Free tyrosine can be iodinated, but it is 
not incorporated into proteins, since no tRNA recognizes iodinated 
tyrosine.
The coupling of two DIT molecules to form T4 or of an МГГ and DIT to 
form T3 occurs within the thyroglobulin molecule, although the addition of 
a free MIT or DIT to a bound DIT has not been conclusively excluded. A 
separate coupling enzyme has not been found, and since this is an oxidative 
process, it is assumed that the same thyroperoxidase catalyzes this 
reaction by stimulating free radical formation of iodotyrosine. This 
hypothesis is supported by the observation that the same drugs which 
inhibit Г oxidation also inhibit coupling. The formed thyroid hormones 
remain as integral parts of thyroglobulin until the latter is degraded, as 
described above. Thyroglobulin hydrolysis is stimulated by TSH but is 
inhibited by Г; this latter effect is occasionally exploited by using K1 to 
treat hyperthyroidism.
2. Thyroid hormones are transported bound and metabolized
One-half to two-thirds of T4 and T3 in the body is extrathyroidai, and 
most of this circulates in bound form, ie, bound to 2 specific binding 
proteins, thyroxine-binding globulin (TBG) .and thyroxine-binding 
prealbumin (TBPA). TBG, a glycoprotein of 50,000 MW, is 
quantitatively the more important. It binds T4 and T3 with 100 times the 
affinity of TBPA and has the capacity to bind 20 pg/dL of plasma. Under
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normal circumstances, TBG binds, noncovalently, nearly all of the T4 and 
T3 in plasma. The small, unbound (free) fraction is responsible for the 
biologic activity. In spite of the great difference in total amount, the free 
fraction of T3 approximates that of T4, but the plasma half-life of T4 is 4-5 
times that of T3.
TBG is also subject to regulation, an important consideration in 
diagnostic testing of thyroid function, since most assays of T4 or T3 measure 
the total amount in plasma rather than the free hormone. TBG is produced in 
liver, and its synthesis is increased by estrogens (pregnancy and birth control 
pills). Decreased production of TBG occurs following androgen or 
glucocorticoid therapy and in certain liver diseases. Inherited increases or 
decreases of TBG also occur. All of these conditions result in changes of total 
T4 and T3 without a change of the free level. Phenytoin and salicylates compete 
with T3 and T4 for binding to TBG. This decreases the total level of hormone 
without changing the free fraction and must be considered when interpreting 
diagnostic tests.
Extrathyroidal deiodination converts T4 toT3. Since T3 binds to the thyroid 
receptor in target cells with 10 times the affinity of T4, T3 is thought to be the 
preponderant metabolically active form of the molecule. About 80% of 
circulating T4 is converted to T3 or reverse T3 (T3) in the periphery, and this 
conversion accounts for most of the production of T3. Reverse T3 is a very 
weak agonist that is made in relatively larger amounts in chronic disease, in 
carbohydrate starvation, and in the fetus. Propylthiouracil and propranolol 
decrease the conversion of T4 to T3.
Other forms of thyroid hormone metabolism include total deiodination and 
inactivation by deamination or decarboxylation. Hepatic glucuronidation and 
sulfation result in a more hydrophilic molecule that is excreted into bile, 
reabsorbed in the gut, deiodinated in the kidney, and excreted as the 
glucuronide conjugate in the urine.
3. Thyroid hormones have a nuclear mechanism of action
Thyroid hormones bind to specific high-affinity receptors in the target 
cell nucleus; T3 binds with approximately 10 times the affinity of T4. The 
question as to whether all biologic activity of the thyroid hormones is 
mediated by T3 is thus moot; both T3 and T4 are active. Thyroid hormones bind 
to low-affinity sites in cytoplasm, but this is apparently not the same protein as 
the nuclear receptor. The cytoplasmic binding may serve to keep thyroid 
hormones "in the neighborhood."
The general metabolic function of thyroid hormones is to increase oxygen 
consumption. Edelman and co-workers hypothesize that much of the energy 
utilized by a cell is for driving the Na+/K+ - ATPase pump. Thyroid 
hormones enhance the function of this pump by increasing the number of
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pump units. Since all cells have this pump and virtually all cells respond to 
thyroid hormones, this increased utilization of ATP and the associated 
increase of oxygen consumption via oxidative phosphorylation could be the 
basic mechanism of thyroid hormone action.
Another major effect of Т/Г4 is to enhance general protein synthesis and 
cause positive nitrogen balance. Thyroid hormones, like steroids, induce or 
repress proteins by increasing or decreasing gene transcription. In the case of 
T 3/ T 4 the fransacting factor is the hormone-receptor complex, which always 
seems to reside in the nucleus. The m-acting DNA hormone response 
element that binds this complex consists of the core sequence 
GATCAnnnnnnTGACC.
There is a curious association between the 2 classes of hormones related to 
growth, the thyroid hormones and growth hormone itself. T3 and 
glucocorticoids enhance transcription of the GH gene, so that more GH is 
produced. This explains a classic observation in which the pituitaries of T3- 
deficient animals were found to lack GH, and it may account for some of the 
general anabolic effects of T3. Very high concentrations of T3 inhibit protein 
synthesis and cause negative nitrogen balance.
Thyroid hormones are known to be important modulators of developmental 
processes. This is most apparent in amphibian metamorphosis. Thyroid 
hormones are required for the conversion of a tadpole into a frog, a process that 
involves resorption of the tail, limbbud proliferation, conversion from fetal to 
adult hemoglobin, stimulation of urea cycle enzymes (carbamoyl phosphate 
synthase) so that urea is excreted rather than ammonia, and epidermal changes. 
These effects probably result from the regulation of specific gene expression. 
Thyroid hormones are required for normal development in humans. 
Intrauterine or neonatal hypothyroidism results in cretinism, a condition 
characterized by multiple congenital defects and severe, irreversible mental 
retardation.
4. The pathophysiology of many thyroid diseases 
relates to TSH and T3,T4
A goiter is an enlarged thyroid
Any enlargement of the thyroid is referred to as a goiter. Simple goiter 
represents an attempt to compensate for decreased thyroid hormone 
production; thus, in all of these situations, elevated TSH is the common 
denominator. Causes include iodide deficiency; iodide excess, when an 
autoregulatory mechanism fails; and a variety of rare inherited metabolic defects 
that illustrate the importance of various steps in thyroid hormone biosynthesis. 
These defects include (1) Г transport defect; (2) iodination defect; (3) 
coupling defect; (4) deiodinase deficiency; and (5) production of abnormal
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iodinated proteins. Partial deficiencies of these functions may cause simple 
goiter in adults. Any of these causes of simple goiter can, when severe, 
cause hypothyroidism. Simple goiter is treated with exogenous thyroid 
hormone. Supplementation or restriction of iodide intake is appropriate for 
specific types of goiter.
Insufficient amounts of free T3 or T4 result in hypothyroidism
This is usually due to thyroid failure but can be due to disease of the 
pituitary or hypothalamus. In hypothyroidism, the basal metabolic rate is 
decreased, as are other processes dependent upon thyroid hormones. 
Prominent features include slow heart rate, diastolic hypertension, sluggish 
behavior, sleepiness, constipation, sensitivity to cold, dry skin and hair, and a 
sallow complexion. Other features depend upon the age at onset. 
Hypothyroidism later in childhood results in short stature but no mental 
retardation. The various kinds of hypothyroidism are treated with exogenous 
thyroid hormone replacement.
Hyperthyroidism, or thyrotoxicosis, is due to the excessive 
production of thyroid Hormone
There are many causes, but most cases in the USA are due to Graves' 
disease, which results from the production of thyroid-stimulating IgG (TSI) 
that activates the TSH receptor. This causes a diffuse enlargement of the 
thyroid and excessive, uncontrolled production of T3 and T4, since the 
production of TSI is not under feedback control. Findings are multisystemic 
and include rapid heart rate, widened pulse pressure, nervousness, inability to 
sleep, weight loss in spite of increased appetite, weakness, excessive sweating, 
sensitivity to heat, and red, moist skin. The hyperthyroidism of Graves' 
disease is treated by blocking hormone production with an antithyroid drug, 
by ablating the gland with a radioactive isotope of iodide (such as l31I), or by a 
combination of these 2 methods. Occasionally, the gland is removed 
surgically.
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HORMONES THAT REGULATE CALCIUM 
METABOLISM
Introduction
Calcium ion regulates a number of important physiologic and 
biochemical processes. These include neuromuscular excitability, blood 
coagulation, secretory processes, membrane integrity and plasma 
membrane transport, enzyme reactions, the release of hormones and 
neurotransmitters, and the intracellular action of a number of hormones. In 
addition, the proper extracellular fluid (ECF) and periosteal concentrations 
of Ca2+ and P O 4 3' are required for bone mineralization. To ensure that these 
processes operate normally, the plasma Ca2+ concentration is maintained 
within very narrow limits. The purpose of this chapter is to explain how 
this is accomplished.
Deviations of the ionized calcium from the normal range cause many 
disorders and can be life-threatening. As many as 3% of hospitalized 
patients may have disorders of calcium homeostasis.
1. Calcium occurs in bone and extracellular fluid
There is approximately 1 kg of calcium in the human body. Ninety-nine 
percent of this is located in bone where, with phosphate, it forms the 
hydroxyapatite crystals that provide the inorganic and structural component 
of the skeleton. Bone is a dynamic tissue, and it undergoes constant 
remodeling as stresses change; in the steady-state condition, there is a 
balance between new bone formation and bone resorption. Most of the 
calcium in bone is not freely exchangeable with extracellular fluid (ECF) 
calcium. Thus, in addition to its mechanical role, bone serves as a large 
reservoir of calcium. About 1% of skeletal Ca2+ is in a freely exchangeable 
pool and this, with another 1% of the total found in the periosteal space, 
constitutes the miscible pool of Ca2+. The hormones discussed in this 
chapter regulate the amount of calcium in the ECF by influencing the 
transport of calcium across the membrane that separates the ECF space 
from the periosteal fluid space. This transport is primarily stimulated by 
parathyroid hormone (PTH) but calcitriol is also involved.
Plasma calcium exists in 3 forms: (1) completed with organic acids, (2) 
protein-bound, and (3) ionized. About 6% of total calcium is complexed with 
citrate, phosphate, and other anions. The remainder is divided nearly equally 
between a protein-bound form (bound primarily to albumin) and an ionized
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(unbound) form. The ionized calcium (Ca2+), which is maintained at 
concentrations between 1.1 and 1.3 mmol/L in most mammals, birds, and 
freshwater fish, is the biologically active fraction. The organism has very 
little tolerance for significant deviation from this normal range. If the ionized 
calcium level falls, the animal becomes increasingly hyperexcitable and may 
develop tetanic convulsions. A marked elevation of plasma calcium may 
result in death owing to muscle paralysis and coma.
Calcium ion and the counter-ion, phosphate, exist at or near their solubility 
product in plasma; hence, protein binding may protect against precipitation 
and ectopic calcification. An alteration of the plasma protein concentration 
(primarily albumin, but globulins also bind calcium) results in parallel 
changes in total plasma calcium. For example, hypoalbuminemia results in a 
decrease of total plasma calcium of approximately 0.8 mg/dL for each g/dL of 
albumin decrease. The converse is noted when the plasma albumin is 
increased. The association of calcium with plasma proteins is pH-dependent; 
acidosis favors the ionized form, whereas alkalosis enhances binding and 
rinses a concomitant decrease in Ca2+. The latter probably accounts for the 
numbness and tingling associated with the hyperventilation syndrome, which 
causes acute respiratory alkalosis.
2. Parathyroid Hormone (PTH)
This hormone (MW 9500) contains no carbohydrate or other covalently 
bound molecules.
2.1. The synthesis, secretion, and metabolism of PTH is regulated
Regulation of synthesis: The rate of synthesis and degradation of proPTH 
is unaffected by the ambient Ca2+ concentration, even though the rate of for­
mation and secretion of PTH is always markedly enhanced at low Ca2+ 
concentrations. Indeed, 80-90% of the proPTH synthesized cannot be 
accounted for as intact PTH in cells or in the incubation medium of 
experimental systems. This led to the conclusion that most of the proPTH 
synthesized is quickly degraded. It was later discovered that this rate of 
degradation decreases when Ca2+ concentrations are low and increases when 
Ca2+ concentrations are high. This indicates that calcium affects PTH 
production through control of degradation and not synthesis. The 
constitutive synthesis of proPTH is reflected in PTH mRNA levels, which 
also do not change in spite of wide fluctuations of extracellular Ca2+. It 
appears that the only way that the organism can enhance PTH synthesis is 
to increase the size and number of PTH-producing chief cells in the 
parathyroid glands.
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Regulation of metabolism: The degradation of PTH begins about 20 
minutes after proPTH is synthesized, is initially unaffected by Ca2+ 
concentration, and occurs after the hormone is in secretory vesicles. Newly 
formed PTH can either be secreted immediately or be placed in storage 
vesicles for subsequent secretion. Degradation occurs as soon as the 
secretory vesicle begins to enter the storage compartment.
Regulation of secretion: PTH secretion is inversely related to the 
ambient concentration of ionized calcium and magnesium, as is the circulating 
level of immunoreactive PTH. Serum PTH declines in a rectilinear fashion in 
relation to serum calcium levels between 4 mg/dL and 10.5 mg/dL. The 
presence of biologically active PTH when the serum calcium level is 10.5 
mg/dL or greater is an indication of hyperparathyroidism.
There is a linear relationship between PTH release and the parathyroid 
intracellular level of cAMP. The intracellular Ca2+ level may be involved in 
this process, since there is an inverse relationship between the intracellular 
concentrations of calcium and cAMP. Calcium may exert this effect through 
its known action on phosphodiesterase (via Ca2+/calmodulin-dependent 
protein kinase) or through a similar mechanism by inhibiting adenylate 
cyclase. Phosphate has no effect on PTH secretion.
Parathyroid glands have relatively few storage granules and contain 
enough hormone to maintain maximal secretion for only 1.5 hours. This is in 
contrast to the pancreatic islets, which contain insulin stores sufficient for 
several days, and to the thyroid, which contains hormone stores adequate 
for several weeks. PTH must therefore be continually synthesized and 
secreted.
PTH binds to a single membrane receptor protein of approximately 
70,000 MW. This receptor appears to be identical in bone and kidney, and 
it is not found in nontarget cells. The hormone-receptor interaction initiates 
a typical cascade: activation of adenylate cyclase -*■ increased intracellular 
cAMP -► increased intracellular calcium ~+ phosphorylation of specific 
intracellular proteins by kinases -*• activation of the intracellular enzymes or 
proteins that finally mediate the biologic actions of the hormone. The PTH 
response system, like that for many other peptide and protein hormones, is 
subject to down-regulation of receptor number and to "desensitization," 
which may involve a post-cAMP mechanism.
2.2. PTH has a major effect on calcium homeostasis
The central role of PTH in calcium metabolism is underscored by the 
observation that the first evolutionary appearance of this hormone was in 
animals attempting to adapt to a terrestrial existence. The physiologic 
maintenance of calcium balance depends on the long-term effects of PTH 
acting on intestinal absorption through the formation of calcitriol. If in the
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face of prolonged dietary Ca2+ deficiency intestinal calcium absorption is 
inadequate, a complex regulatory system involving PTH is brought into 
play. PTH restores normal ECF calcium concentration by acting directly on 
bone and kidney and by acting indirectly on the intestinal mucosa (through 
stimulation of synthesis of calcitriol). PTH (1) increases the rate of 
dissolution of bone, including both organic and inorganic phases, which 
moves Ca2+ into ECF; (2) reduces the renal clearance or excretion of calcium, 
hence increasing the ECF concentration of this cation; and (3) increases the 
efficiency of calcium absorption from the intestine by promoting the 
synthesis of calcitriol. The most rapid changes occur through the action on 
the kidney, but the largest effect is from bone. Therefore, although PTH 
prevents hypocalcemia in the face of dietary calcium deficiency, it does so 
at the expense of bone substance.
PTH also affects phosphate homeostasis
The usual counterion for Ca2+ is phosphate, and the hydroxyapatite 
crystal in bone consists of calcium phosphate. Phosphate is released with 
calcium from bone whenever PTH increases dissolution of the mineral 
matrix. PTH increases renal phosphate clearance; thus, the net effect of PTH 
on bone and kidney is to increase the ECF calcium concentration and 
decrease the ECF phosphate concentration. Importantly, this prevents the 
development of a supersaturated concentration of calcium and phosphate 
in plasma.
2.3. Pathophysiology
Insufficient amounts of PTH result in hypoparathyroidism. The 
biochemical hallmarks of this condition are decreased serum ionized 
calcium and elevated serum phosphate levels. Symptoms include neu­
romuscular irritability which, when mild, causes muscle cramps and tetany. 
Severe, acute hypocalcemia results in tetanic paralysis of the respiratory 
muscles, laryngospasm, severe convulsions, and death. Longstanding 
hypocalcemia results in cutaneous changes, cataracts, and calcification of 
the basal ganglia of the brain. The usual cause of hypoparathyroidism is 
accidental removal or damage of the glands during neck surgery (secondary 
hypoparathyroidism), but the disorder occasionally results from 
autoimmune destruction of the glands (primary hypoparathyroidism).
Hyperparathyroidism, the excessive production of PTH, is usually 
due to the presence of a functioning parathyroid adenoma but can be due 
to parathyroid hyperplasia or to ectopic production of PTH in a 
malignant tumor. The biochemical hallmarks of hyperparathyroidism are 
elevated serum ionized calcium and PTH and depressed serum phosphate
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levels. In long-standing hyperparathyroidism, findings include extensive 
resorption of bone and a variety of renal effects, including kidney stones, 
nephrocalcinosis, frequent urinary tract infections, and (in severe cases) 
decreased renal function. Secondary hyperparathyroidism, characterized 
by hyperplasia of the glands and hypersecretion of PTH, may be seen in 
patients with progressive renal failure. Hyperparathyroidism in these 
patients is presumably due to the decreased conversion of 250H-D3 to 
l,25(OH)2-D3 in the diseased renal parenchyma, which results in inefficient 
calcium absorption in the gut and the secondary release of PTH in a 
compensatory attempt to maintain normal ECF calcium levels.
3. Calcitriol [1,25(ОН)г - D3]
Historical perspective: Rickets, a childhood disorder characterized by 
deficient mineralization of the skeleton and severe, crippling bone 
deformities, was epidemic in North America and Western Europe early in this 
century. Results of a series of studies suggested that rickets was due to a 
dietary deficiency. After the discovery that rickets could be prevented by 
ingestion of cod-liver oil and that the active ingredient in this agent was not 
vitamin A, the preventive factor was termed fat-soluble vitamin D. About the 
same time, it was found that ultraviolet light, either artificial or from sunlight, 
would also prevent the disorder. It was subsequently determined that there was 
an adult equivalent to rickets. Osteomalacia, in which there is a failure to 
mineralize bone, also responded to vitamin D. Clues to further developments 
resulted from the observation that patients with liver or kidney disease did not 
respond normally to vitamin D. For the last 50 years, efforts to elucidate the 
structure of vitamin D and to define its mechanism of action have 
proceeded, greatly accelerated during the last several years.
3.1. The principal biological role of calcitriol is to stimulate 
intestinal absorption of calcium and phosphate
Calcitriol is the only hormone that can promote this translocation of calcium 
against the concentration gradient, which exists across the intestinal cell 
membrane. Since the production of calcitriol is tightly regulated, a fine 
mechanism exists for controlling ECF Ca2+ in spite of marked fluctuations of 
the calcium content of food. This ensures a proper concentration of calcium 
and phosphate for deposition, as hydroxyapatite crystals, onto the collagen 
fibrils in bone.. In vitamin D deficiency (calcitriol deficiency), new bone 
formation slows and bone remodeling is also impaired. These processes are 
primarily regulated by PTH acting on'bone cells, but small concentrations of 
calcitriol are also required. Calcitriol may also augment the actions of PTH on 
renal calcium reabsorption.
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3.2. The synthesis and metabolism of calcitriol
Biosynthesis: Calcitriol is a hormone in every respect. It is produced by a 
complex series of enzymatic reactions that involve the plasma transport of 
precursor molecules to a number of different tissues. The active molecule, 
Calcitriol, is transported to other organs where it activates biologic processes in 
a manner similar to that employed by the steroid hormones.
1. Skin - Small amounts of vitamin D occur in food (fish-liver oil, egg 
yolk), but most of the vitamin D available for calcitriol synthesis is produced in 
the malpighian layer of the epidermis from 7-dehydrocholesterol in an 
ultraviolet light-mediated, nonenzymatic photolysis reaction. The extent of 
this conversion is directly related to the intensity of the exposure and 
inversely related to the extent of pigmentation in the skin. There is an age- 
related loss of 7-dehydrocholesterol in the epidermis that may be related to the 
negative calcium balance associated with old age.
2. Liver - A specific transport protein called the D-binding protein binds 
vitamin D3 and its metabolites and moves D3 from the skin or intestine to the 
liver where it undergoes 25-hydroxylation, the first obligatory reaction in the 
production of calcitriol. 25-Hydroxylation occurs in the endoplasmic 
reticulum in a reaction that requires magnesium, NADPH, molecular oxygen, 
and an uncharacterized cytoplasmic factor. Two enzymes, an NADPH- 
dependent cytochrome P-450 reductase and a cytochrome P-450, are 
involved. This reaction is not regulated, and it also occurs with low efficiency 
in kidney and intestine. The 250H-D3 enters the circulation, where it is the 
major form of vitamin D found in plasma, and is transported to the kidney by 
the D-binding protein.
3. Kidney-250H-D3 is a weak agonist and must be modified by 
hydroxylation at position C, for full biologic activity. This is accomplished in 
mitochondria of the renal proximal convoluted tubule in a complex, 3-compo­
nent monooxygenase reaction that requires NADPH. Mg2+, molecular 
oxygen, and at least 3 enzymes: (1) a flavoprotein, renal ferredoxin reductase; 
(2) an iron sulfur protein, renal ferredoxin; and (3) cytochrome P-450. This 
system produces 1.25(OH), -D3, which is the most potent naturally occurring 
metabolite of vitamin D.
4. Other tissues—The placenta has la-hydroxylase that appears to be an 
important extrarenal source of calcitriol. Enzyme activity is found in a variety 
of other tissues, including bone; however, the physiologic significance of 
this appears to be minimal, since very little calcitriol is found in nonpregnant, 
nephrectomized animals.
Regulation of metabolism and synthesis: Like other steroid hormones, 
calcitriol is subject to tight feedback regulation. Low-calcium diets and 
hypocalcemia result in marked increases of la-hydroxylase activity in intact 
animals. This effect requires PTH, which is also released in
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response to hypocalcemia. The action of PTH is as yet unexplained, but it 
stimulates la-hydroxylase activity in both vitamin D-deficient and vitamin D- 
treated animals. Low-phosphorus diets and hypophosphatemia also induce la- 
hydroxylase activity, but this appears to be a weaker stimulus than that 
provided by hypocalcemia.
Calcitriol is an important regulator of its own production. High levels of 
calcitriol inhibit renal la-hydroxylase and stimulate the formation of a 24- 
hydroxylase that leads to the formation of 24,25(OH)2-D3, an apparently 
inactive by-product. Estrogens, progestins, and androgens cause marked 
increases of la-hydroxylase in ovulating birds. The role that these 
hormones, along with insulin, growth hormone, and prolactin, play in 
mammals is uncertain.
3.3. Calcitriol acts at the cellular level in a manner similar 
to other steroid hormones
Studies using radioactive calcitriol revealed localization in the nuclei of 
intestinal villus and crypt cells, osteoblasts, and distal renal tubular cells. 
There also is nuclear accumulation of this hormone in cells not previously 
suspected of being targets, including cells in the malpighian layer of the skin; 
pancreatic islet cells; some brain cells; some cells in the pituitary, ovary, testis, 
placenta, uterus, mammary gland, and thymus; and myeloid precursors. 
Calcitriol binding has also been noted in parathyroid cells, which leads to the 
intriguing possibility that it might be involved in PTH metabolism.
The calcitriol receptor: The calcitriol receptor is a member of the steroid 
receptor family. 2+
Effects of calcitriol on intestinal mucosa: The transfer of Ca2+ or 
P043' across the intestinal mucosa requires (1) uptake across the brush border 
and microvillar membrane; (2) transport across the mucosal cell membrane; 
and (3) efflux across the basal lateral membrane into the ECF. It is clear that 
calcitriol enhances one or more of these steps, but the precise mechanism has 
not been established. СВР was thought to be actively involved until it was 
observed that Ca2 + translocation occurs within 1-2 hours after administration 
of calcitriol, well before СВР increases in response to calcitriol. СВР may 
bind Ca2* and protect the mucosa cell against the large fluxes of Ca2+ 
coincident with the transport process. Several investigators are searching for 
other proteins that may be involved in Ca2+ transport, whereas others 
suggest that the process, particularly the early increase of Ca2+ flux, may be 
mediated by a membrane change. Metabolites of polyphosphoinositides have 
been implicated.
Pathophysiology: Rickets is a childhood disorder characterized by low 
plasma calcium and phosphorus levels and by poorly mineralized bone with 
associated skeletal deformities. Rickets is most commonly due to vitamin D
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deficiency. There are 2 types of vitamin D-dependent rickets. Type I is an 
inherited autosomal recessive trait characterized by a defect in the conversion 
of 25OH-D3 to ealcitriol. Type II is an autosomal recessive disorder in which 
there is a single amino acid change in one of the zinc fingers of the DNA- 
binding domain. This results in a nonfunctional receptor.
Vitamin D deficiency in the adult results in osteomalacia. Calcium and 
phosphorus absorption are decreased, as are the ECF levels of these ions. 
Consequently mineralization of osteoid to form bone is impaired, and such 
undermineralized bone is structurally weak.
When substantial renal parenchyma is lost or diseased, the formation of 
ealcitriol is reduced and calcium absorption decreases. When hypocalcemia 
ensues, there is a compensatory increase of PTH, which acts on bone in an 
attempt to increase ECF Ca . The associated extensive bone turnover, 
structural changes, and symptoms are known as renal osteodystrophy. Early 
treatment with vitamin D will blunt this process.
4. The role of calcitonin (CT) in human calcium 
homeostasis is unclear
CT is a 32-amino-acid peptide secreted by the parafollicular C cells of the 
human thyroid (less commonly, the parathyroid or thymus) or by similar cells 
located in the ultimobranchial gland of other species. These cells originate in the 
neural crest and are biochemically related to cells in a variety of other endocrine 
glands.
The entire CT molecule, including the 7-member N-terminal loop, formed 
by a Cys-Cys bridge, is required for biologic activity. There is tremendous 
interspecies variation of the amino acid sequence of CT (human and porcine 
CT share only 14 of 32 amino acids), but in spite of these differences there is 
cross-species bioactivity. The most potent naturally occuring CT is isolated 
from salmon.
CT has a history unmatched by any other hormone. Within a 7-year span 
(1962-1968), CT was discovered, isolated, sequenced, and synthesized; yet its 
role in human physiology is still uncertain.
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STRUCTURE AND FUNCTION OF THE 
WATER-SOLUBLE VITAMINS
Introduction
Vitamins are organic nutrients that are required in small quantities for a 
variety of biochemical functions and which, generally, cannot be synthesized 
by the body and must therefore be supplied by the diet. The first discovered 
vitamins, A and B, were found to be fat and water soluble, respectively. As 
more vitamins were discovered they were also shown to be either fat or 
water soluble, and this property was used as a basis for their classification. The 
water-soluble vitamins were all designated members of the В complex (apart 
from vitamin C), and the newly discovered fat-soluble vitamins were given 
alphabetic designations (eg, vitamins D, E, K). Apart from their solubility 
characteristics, the water-soluble vitamins have little in common from the 
chemical point of view.
Absence or relative deficiency of vitamins in the diet leads to 
characteristic deficiency states and diseases. Deficiency of a single vitamin of 
the В complex is rare, since poor diets are most often associated with 
multiple deficiency states. Nevertheless, definite syndromes are characteristic 
of deficiencies of specific vitamins. Among the water-soluble vitamins the 
following deficiency states are recognized: beriberi (thiamin deficiency); 
cheilosis, glossitis, seborrhea, and photophobia (riboflavin deficiency); 
pellagra (niacin deficiency); peripheral neuritis (pyridoxine deficiency); 
megaloblastic anemia, methylmalonic aciduria, and pernicious anemia 
(cobalamin deficiency); megaloblastic anemia (folic acid deficiency); and 
scurvy (ascorbic acid deficiency). Vitamin deficiencies are avoided by 
consumption of food of a wide variety in adequate amounts.
The В vitamins essential for human nutrition are: (1) thiamin (vitamin 
B|), (2) riboflavin (vitamin B2), (3) niacin (nicotinic acid, nicotinamide) 
(vitamin B3), (4) pantothenic acid (vitamin B5), (5) vitamin B6 (pyridoxine, 
pyridoxal, pyridoxamine), (6) biotin, (7) vitamin BI2 (cobalamin), and (8) 
folic acid (pteroylglutamic acid).
Because of their water solubility, excesses of these vitamins are excreted 
in urine and so rarely accumulate in toxic concentrations. For the same 
reason, their storage is limited (apart from cobalamin) and as a consequence 
they must be provided regularly.
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1. Thiamin
Thiamin consists of a substituted pyrimidine joined by a methylene bridge 
to a substituted thiazole (Fig.l).
An ATP-dependent thiamin diphosphotransferase present in brain and 
liver is responsible for the conversion of thiamin to its active form, thiamin 
diphosphate (pyrophosphate) (Fig. 1).
There are two types of such reactions: (1) an oxidative decarboxylation 
of a-keto acids (eg, a-ketoglutarate, pyruvate, and the a-keto analogs of 
leucine, isoleucine, and valine); and (2) transketolase reactions (eg, in the 
pentose phosphate pathway). All of these reactions are inhibited in thiamin 
deficiency. In each case, the thiamin diphosphate provides a reactive carbon 
on the thiazole that forms a carbanion, which is then free to add to the 
carbonyl group of, for instance, pyruvate. The addition compound then 
decarboxylates, eliminating C 02. This reaction occurs in a multienzyme 
complex known as the pyruvate dehydrogenase complex.
* C-S i I
,.м -4 i -o-p-O-P-O'
7 Г н-‘ т  * «‘ H '  * ft A
Cx C-H C=C~CHrCH,-OH " 01
CH, СИ,
2,5, Dimethyl' A-Metfsyt-S-hydroxy-
6-am irepy rimi dine ethyithiezoie
Fig. 1. Thiamin. In thiamin diphosphate, the -OH group is replaced by pyrophosphate
The oxidative decarboxylation of a-ketoglutarate to succinyi-CoA and 
C 02 is catalyzed by an enzyme complex structurally very similar to the 
pyruvate dehydrogenase complex. Again, the thiamin diphosphate provides 
a stable carbanion to react with the a carbon of a-ketoglutarate. A similar 
oxidative decarboxylation of the a-ketocarboxylic acid derivatives of the 
branched-chain amino acids utilizes thiamin diphosphate. The role of 
thiamin diphosphate as a coenzyme in the transketolase reactions is very 
similar to that described above for the oxidative decarboxylations.
In the thiamin-deficient human, thiamin diphosphate-dependent 
reactions are prevented or severely limited, leading to accumulation of the 
substrates of the reactions, eg, pyruvate, pentosugars, and the a-keto- 
carboxylate derivatives of the branched-chain amino acids leucine, 
isoleucine, and valine.
Thiamin is present in almost all plant and animal tissues commonly used 
as food, but the content is usually small. Unrefined cereal grains and meat are
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good sources of the vitamin. Beriberi is caused by carbohydrate-rich/iow- 
thiamin diets, eg, polished rice or other highly refined foods such as sugar 
and white flour acting as the staple food source. Early symptoms include 
peripheral neuropathy, exhaustion, and anorexia, which lead on to edema 
and cardiovascular, neurological, and muscular degeneration. Wernicke's 
encephalopathy is a condition associated with thiamin deficiency. It is 
found frequently in chronic alcoholics consuming little other food. Certain 
raw fish contain a heat-labile enzyme (thiaminase) that destroys thiamin, 
but this is not considered to be critical in human nutrition.
2. Riboflavin
Riboflavin consists of a heterocyclic isoalloxazine ring attached to the 
sugar alcohol, ribitol (Fig.2). It is a colored, fluorescent pigment that is rela­
tively heat stable but decomposes in the presence of visible light.
FMN is formed by ATP-dependent phosphorylation of riboflavin (Fig. 
2), whereas FAD is synthesized by a further reaction with ATP in which the 
AMP moiety of ATP is transferred to FMN (Fig. 3).
Flavin
Fig. 2. Riboflavin. In riboflavin phosphate (flavin m ononucleotide. FM N). the - 
O H  is rep laced  by phosphate.
Pyrophosphate
F la v in
Fig. 3. F lav in  a d en in e  d in u c leo tid e  (FAD ).
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FM N and FA D 1 serve as prosthetic groups o f  oxidoreductase enzymes. 
These enzym es are know n as flavopro te ins. T he  prosthetic groups are 
usually tightly but not covalently  bound to  the ir apoproteins. M any 
flavoprotein  enzym es con tain  one o r m ore m etals, eg, m olybdenum  and 
iron, as essential cofactors and are know n as m eta llo flavopro te ins.
Flavoprotein enzym es are w idespread and are represented by several 
im portant oxidoreductases in m am m alian  m etabolism , eg, a -am ino  acid 
oxidase in am ino acid deam ination, xanthine oxidase in pu rine degradation , 
aldehyde dehyd rogenase  in the degradation  o f  a ldehydes, m itochondrial 
g Iycero !-3 -phosphate  dehydrogenase in transporting  reducing equivalents 
from the cytosol into m itochondria, succinate dehydrogenase in the citric 
acid cycle , acy l-C oA  dehydrogenase and the e lec tron-transferring  
flavoprotein  in fatty acid  oxidation , and dihydrolipoyl dehydrogenase in the 
oxidative decarboxy la tion  o f  py ruva te  and  cx-ketoglutarate; NADFl 
dehydrogenase is a m ajor com ponent o f  the respiratory chain in 
m itochondria. A ll o f  these enzym e system s are im paired in riboflavin 
deficiency.
In their role as coenzym es, flavopro te ins undergo reversib le reduction  o f  
the isoalloxazine ring  to  yield the reduced form s FM NFT and FA D H ;.
In view  o f  its w idespread m etabolic functions it is su rprising  that 
riboflavin  defic iency  does not lead to  m ajor life-th rea ten ing  cond itions. 
H ow ever, w hen there is deficiency, various sym ptom s are seen, including 
angular stom atitis, cheilosis, glossitis, seborrhea, and photophobia.
R iboflavin is syn thesized  by p lan ts and m icroorgan ism s, bu t not by 
m am m als. Y east, liver, and kidney are good sources o f  the vitam in, w hich is 
absorbed in the intestine by a  phosphory lation-dephosphory lation  sequence 
in the m ucosa. H orm ones (eg, thyroid horm one and A C TH ), d rugs (eg, 
chlorprom azine, a com petitive inhibitor), and nu tritional factors affect the 
conversion o f  riboflavin to  its cofactor form s. B ecause  o f  its light sensitiv ity , 
riboflavin defic iency  m ay occur in new born infants w ith hyper­
bilirubinem ia w ho are treated  by phototherapy.
3. Niacin
N iac in  is th e  generic  nam e for n ico tin ic  acid  and nicotinam ide either o f  
w hich m ay act as a  source o f  the vitam in in th e  diet. N ico tin ic  acid  is a  
m onocarboxylic ac id  d eriv a tiv e  o f  p y rid ine  (F ig. 4).
N ico tinate  is th e  form  o f  n iacin required  fo r the syn thesis o f  N A D + and 
N A D P + by  enzym es p resen t in the cy toso l o f  m ost cells. T herefo re  any 
dietary  n ico tinam ide m ust first undergo  deam idation  to  n ico tinate  (F ig .4). 
In th e  cy toso l, n ico tina te  is converted  to  desam ido-N A D * by reaction  first 
w ith 5 -phosp h o rib o sy l-l-p y ro p h o sp h a te  (P R P P ) and then  by adenylation
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with ATP. The am ido group o f  g lu tam ine then contributes to form  the 
coenzym e NAD*. T h is m ay be phospho ry la ted  fu rther to  form  N A D P +.
T he n ico tinam ide  n u c leo tid e s  p lay  a w id esp read  rote as coenzym es to  
m any dehydrogenase  enzym es occurring  both in the cytosol, eg, lactate 
dehydrogenase, and w ith in  th e  m itochondria , eg, m alate  dehydrogenase . 
T hey  are there fo re  key co m p o n en ts  o f  m any  m etab o lic  pa thw ays affec tin g  
carbohyd ra te , lipid, and am ino  acid  m etabolism . G enera lly , N A D -linked  
dehydrogenases cata lyze ox idoreduction  reactions in ox idative  pathw ays, 
eg, the citric acid  cycle , w hereas N A D P-linked  dehydrogenases or 
reductases are often found  in pathw ays concerned  w ith reductive syn theses, 
eg , the pen tose phospha te  pathw ay.
Sym ptom s include w eigh t loss, d igestive  d iso rders , derm atitis, 
depression, and dem entia.
N iacin is found w idely in m ost anim al and plant foods. However, 
assessm ent o f  niacin value o f  a  food m ust take  account o f  the fact that the 
essen tia l am ino acid tryptophan can be converted to NAD*. For every 60 mg 
o f  tryptophan, 1 m g equivalent o f  niacin can be generated. Thus, in order to 
produce niacin deficiency a diet must be poor in both available niacin 
and tryptophan. Such criteria  occur in populations dependent on maize 
(com ) as the staple food, resu lting  in the condition  of pellagra. In m aize, 
niacin is in fact present, but in a bound unavailable form , n iacy tin , from  
w hich niacin can be released  by pretreatm ent with alkali. D ependence on 
sorghum  is also  pellag ragen ic , due not to  low tryp tophan  but to  high 
leucine content. A pparen tly , excess d ietary  leucine can bring  abou t niacin 
defic iency  by inhibiting  quinolinate phosphoribosyl transferase, a key 
enzym e in the conversion  o f  tryp tophan  to  N A D +. It is also o f  note that 
pyridoxal phosphate, the active form o f  vitamin B6, is involved as a cofactor in 
the pathw ay o f  synthesis o f  N A D + from tryptophan and therefore vitam in B6 
deficiency can potentiate a deficiency in niacin.
O ther conditions leading to  sym ptom s o f  pellagra include adm inistration o f  
som e drugs such as isoniazid, malignant carcinoid syndrome in w hich 
tryptophan m etabolism  is d iverted  to serotonin , and Hartnup disease, in 
w hich tryptophan  absorp tion  is impaired.
N ico tin ic  acid (but no t n ico tinam ide) has been used therapeutically  for 
low ering plasm a cholesterol. T his is due to  inhibition  o f  the flux  o f  FFA  
from  ad ipose tissue, w hich leads to  less formation o f  the cholesterol-bearing 
lipoproteins, V LD L, ID L, and LDL.
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Fig. 4 The synthesis and breakdown o f nicotinamide adenine dinucleotide (NAD J. 
The 2 '-hydroxyl group (*) o f  the adenosine moiety is phosphorylated in nicotinamide 
dinucleotide phosphate (NADP"). Humans, but not cats, can provide all o f their niacin 
requirement from tryptophan i f  there is a su fficient amount in the diet. Normally, about 
two-thirds comes from this source. PRPP. 5-phosphoribosyl-l-pyrophosphate OPRT, 
quinolinale phosphoribosyl transferase. PLP, pyndoxal phosphate.
4. Pantothenic acid
Pan to then ic  acid  is fo rm ed by com bination  o f  p an to ic  acid and P- 
alanine (Fig. 5).
P a n to ic  a c id  ,1-AAnne
H ,C  O H  Cf Z  0
* I it H II
H O - C H ,  — С — C H  -  C -  N -  С И ; — С Н г — C -  O H
НЛ
Fig. 5. P a n to th en ic  acid .
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Pantothenic acid is absorbed readily in the intestines and subsequently  
phosphory la ted  by A TP to  form  4 '-phosphopan to thenate . A ddition  o f  
cyste ine  and rem oval o f  its carboxyl g roup  resu lts in the net add ition  o f  
th ioe thano lam ine , genera ting  4'-phosphopantetheine, the prosthetic group 
o f  both C oA  and A CP. L ike the active coenzym es o f  so m any other w ater- 
soluble vitam ins, C oA  contains an adenine nucleotide. T hus, 4'- 
phosphopantetheine is adenylylated by A TP to form  dephospho-CoA. The 
final phosphory lation  occurs w ith  A TP adding  phosphate  to the 3 '-hydroxyl 
group o f  the ribose m oiety to  generate C oA  (Fig.6).
T his occurs w ith C oA  in reactions o f  the citric  acid  cycle, fatty  acid 
oxidation and synthesis, acety lation  reactions (eg, o f  drugs), and cholesterol 
synthesis. A CP partic ipates in reactions concerned  w ith fatty  acid synthesis. 
It is custom ary to abbreviate the structure o f  the free (ie, reduced) C oA  as 
C oA -SH , in w hich the reactive SH group o f  the coenzym e is designated.
T his is because it is w idely  distributed  in foods, being particularly 
abundant in anim al tissues, w hole-grain cereals, and legum es. H ow ever, the 
b u rn in g  foot sy n d ro m e  has been ascribed to pantothenate deficiency in 
prisoners o f  w ar and is associated with reduced capacity  for acetylation.
5. Vitamin B6
Vitam in B b consists o f  3 closely related pyridine derivatives: pyridoxine, 
pyridoxal, and pyridoxamine (Fig. 7) and their corresponding phosphates. 
O f  these, pyridoxine, pyridoxal phosphate, and pyridoxamiKe phosphate are 
the m ain representatives o f  the vitam in in the diet. All 3 have equal vitam in
activity.
All form s o f  vitamin B6 are absorbed from the intestine, but som e 
hydrolysis o f  the phosphate esters occurs during  d igestion . Pyridoxal 
phosphate  is the m ajor form transported  in plasm a. M ost tissues contain the 
enzym e pyridoxal kinase, w hich is able to  ca ta lyze  the phosphory lation  by 
A TP o f  the unphosphoryiated form s o f  the vitamin to their respective 
phosphate  esters (Fig.8). W hile pyridoxal phosphate  is the m ajor coenzym e 
expressing  B6 activ ity , py ridoxam ine phosphate  m ay  also act as an active 
coenzym e.
Pyridoxamine
Fig. 7. N a tu ra lly  o f  v ita m in  B 6
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Fig.S. The phosphorylation o f  pyridoxai by pyridoxai kinase to form pyridoxai 
phosphate.
By entering into a Schifif base combination between its aldehyde group and 
the amino group of an a-amino acid, pyridoxai phosphate can facilitate 
changes in the 3 remaining bonds of the a-amino carbon to allow either 
transamination, decarboxylation, or aldolase activity, respectively.
The coenzyme is an integral part of the mechanism of action of 
phosphorylase, the enzyme mediating the breakdown of glycogen. In this 
action it also forms an initial Schiff base with an a-amino group of a lysine 
residue of the enzyme, which, however, remains intact throughout the 
phosphorolysis of the l->4 glycosidic bond to form glucose-l-phosphate. 
Muscle phosphorylase may account for as much as 70-80% of total body 
vitamin B6.
A deficiency due to lack of vitamin B6 alone is rare, and any deficiency is 
usually part of a general deficiency of В-complex vitamins. Liver, mackerel, 
avocados, bananas, meat, vegetables, and eggs are good sources of the 
vitamin. A possibility of deficiency is recognized in nursing infants whose 
mothers are depleted of the vitamin due to long-term use of oral 
contraceptives. Alcoholics may also be deficient due to metabolism of ethanol 
to acetaldehyde, which stimulates hydrolysis of the phosphate of the 
coenzyme. A widely used antituberculosis drug, isoniazid, can induce vitamin 
B6 deficiency by forming a hydrazone with pyridoxai.
Y
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6. Biotin
Biotin is an imidazole derivative widely distributed in natural foods 
(Fig-9). As a large portion of the human requirement for biotin is met by 
synthesis from intestinal bacteria, biotin deficiency is caused not by simple 
dietary deficiency but by defects in utilization.
Biotin functions as a component of specific multi-subunit enzymes (Table 
1) that catalyze carboxylase reactions. A carboxylate ion is attached to the 
N1 of the biotin, generating an activated intermediate, carboxybiotin- 
enzyme. This step requires HCO:,' ATP, Mg2’, and acetyl-CoA (as an allosteric 
effector). The activated carboxyl group is then transferred to the substrate 
of the reaction, eg, pyruvate.
H  — N  
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_c  ------
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Fig. 9. Biotin
Egg white contains a heat-labile protein, avidin, which combines very 
tightly with biotin, preventing its absorption and inducing biotin deficiency. 
The symptoms include depression, hallucination, muscle pain, and dermatitis. 
Absence of the enzyme holocarboxylase synthase, which attaches biotin to 
the lysine residue of the carboxylase apoenzymes, also causes biotin 
deficiency symptoms, including accumulation of substrates of the biotin- 
dependent enzymes, which can be detected in urine. These metabolites 
include lactate, (3-methylcrotonate, p-hydroxyisovalerate, and P-hy- 
droxypropionate. In some cases children with this deficiency have immune 
deficiency diseases.
Table l . Biotin-dependent enzymes in animals.
Enzyme Role
Pyruvate carboxylase First reaction in pathway that converts 3-carbon 
precursors to glucose (gluconeogenesis)
Replenishes oxaloacetate for citric acid cycle
Acetyl-CoA carboxylase Commits acetate units to fatty acid synthesis by 
forming malonyl-CoA
Propionyl-CoA carboxylase Converts propionate to succinate, which can then 
enter citric acid cvcle
P-Methylcrotonyl-CoA carboxylase Catabolism of leucine and certain isoprenoid 
compounds
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7. Vitamin B12
Vitamin B,? (cobalarriin) has a complex ring structure (corrin ring), similar 
to a porphyrin ring, to which is added a cobalt ion at its center (Fig. 10). The 
vitamin is synthesized exclusively by microorganisms. Thus, it is absent from 
plants - unless they are contaminated by microorganisms - but is conserved in 
animals in the liver, where it is found as methylcobalamin, 
adenosylcobalamin, and hydroxocobalamin. Liver is therefore a good source 
of the vitamin, as is yeast. The commercial preparation is cyanocobalamin.
Fig. 10. Vitamin B n  (cobalamin'.). R may be varied to give the various fo rm s o f  the 
vitamin, eg, R = OV in cyanocobalamin; R = OH  in hydroxocobalamin; R = 5 ‘ - 
deoxyadenosyl in 5'-deo.\yadenosylcobalamin; and R = CH3 in methylcobalamin.
The intestinal absorption of vitamin В is mediated by receptor sites in the 
ileum that require it to be bound by a highly specific glycoprotein, intrinsic 
factor, secreted by parietal cells of the gastric mucosa. After absorption, the 
vitamin is bound by a plasma protein, transcobalamin II, for transport to the 
tissues. It is stored in the liver, which is unique for a water-soluble vitamin, 
bound to transcobalamin I.
After transport in the blood, free cobalamin is released into the cytosol of 
cells as hydroxocobalamin. It is either converted in the cytosol to 
methylcobalamin or enters mitochondria for conversion to 5'- 
deoxyadenosylcobalamin.
This is a key reaction in the pathway of conversion of propionate to a 
member of the citric acid cycle and is, therefore, of significance in the process 
of gluconeogenesis. It is of particular importance in ruminants, as propionate 
is a major product of microbial fermentation in the rumen.
In this reaction, the methyl group bound to cobalamin is transferred to 
homocysteine to form methionine and the cobalamin then removes the methyl
О ic  - -  о
> fi. в  - r-urt47cilf<I rooiery
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group from N5-methyItetrahydrofolate to form tetrahydrofolate. The 
metabolic benefits of this reaction are that stores of methionine are 
maintained and tetrahydrofolate is made available to participate in purine, 
pyrimidine, and nucleic acid syntheses.
When absorption is prevented by lack of intrinsic factor (or by 
gastrectomy) the condition is called pernicious anemia. Vegans are at risk of 
actual dietary deficiency as the vitamin is found only in foods of animal origin 
or from microorganisms, food contaminated with microorganisms being of 
benefit from this point of view. The deficiency leads to impairment of the 
methionine synthase reaction. Anemia results from impaired DNA synthesis 
affecting formation of the nucleus of new erythrocytes. This is due to impaired 
purine and pyrimidine synthesis resulting from tetrahydrofolate deficiency as a 
consequence of folate being trapped as methyltetrahydrofoiate (the "folate 
trap"). Homocystinuria and methylmalonic aciduria also occur. The 
neurologic disorder associated with vitamin B^deficiency may be secondary 
to a relative deficiency of methionine.
Four inherited disorders of cobalamin metabolism have been described. 
Two affect synthesis of deoxyadenosylcobalamin only; in the other two, 
patients are unable to synthesize either deoxyadenosylcobalamin or 
methylcobalamin.
8. Folic acid
Folacin is the generic name covering folic acid and related substances 
having the biochemical activity of folic acid.
Folic acid, or folate, consists of the base pteridine attached to one 
molecule each of P-aminobenzoic acid (PABA) and glutamic acid (Fig. 11). 
Animals are not capable of synthesizing PABA or of attaching glutamate to 
pteroic acid and, therefore, require folate in their diet; yeast, liver, and leafy 
vegetables are major sources. In plants, folic acid exists as a polyglutamate 
conjugate consisting of a у-linked polypeptide chain of 7 glutamate residues. 
In the liver, the major folate is a pentaglutamyl conjugate.
•V*
________________/  Gfrtfrarntc aote*
Pteroyl (pteroic ooxi)
F o lic  a d d
Fig. 11. The structure and numbering o f atoms offolic acid.
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Folate derivatives in the diet are cleaved by specific intestinal enzymes to 
monoglutamyl folate for absorption. Most of this is reduced to 
tetrahydrofolate in the intestinal cell (Fig. 12) by the enzyme folate 
reductase, which uses NADPH as donor of reducing equivalents. 
Tetrahydrofolate polyglutamates are probably the functional coenzymes in 
tissues.
H*N • 1 T
OH  HN
Fofcc acid
M«Uiotf0X3t« OH
Oihydrofoitc acad
I
1 RED U CTA SE.
___  1
ATE I
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NA DPH t- H*
HN N HH?N H
N - J < H'N ^ 9
O H  "
Tetrahydrofolic acid
CH-,
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HN
Fig. 12. The reduction o f folic acid to dihydrofolic acid and dihydrofotic acid to 
tetrahydrofolic acid by the enzyme folate reductase. Trimethoprim is a selective inhibitor 
o f folate reductase in gram-negative bacteria and has little effect on the mammalian 
enzyme. It is therefore used as an antibiotic. Methotrexate (amethopterinj binds more 
strongly and is used as an anticancer drug.
The one-carbon units carried by H4folate represent a series in various 
states of oxidation, viz, methyl, methylene, methenyl, formyl, and 
formimino. All are metabolically interconvertible.
Serine is the major source of a one-carbon unit in the form of a 
methylene group, which it transfers reversibly to H4folate to form glycine and 
N5, NI0-methylene-H4folate, which plays a central role in one-carbon unit 
metabolism. It can be reduced to N5-methyl-H4folate, which has an 
important role in methylation of homocysteine to methionine involving 
methylcobalamin as a cofactor. Alternatively, it can be oxidized to NS,N10-
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methenyI-H4folate, which can then be hydrated to either Nl0-formyl- 
H4folate or to Ns-formyI-H4foIate. The latter is also known as folinic acid, 
a stable form that can be used for administration of reduced folate.
Formiminoglutamate (Figlu), a catabolite of histidine, transfers its 
formimino group to H4folate to form N5-formimino-H4folate. In folate 
deficiency, Figlu will accumulate after oral challenge with histidine.
The explanation for this is similar to that advanced above to account for 
the effects of deficiency of vitamin B12. N5,Nl0-Methylene-H4folate 
provides the methyl group in the formation of thymidylate, a necessary 
precursor of DNA synthesis and erythrocyte formation. Concominant with 
the reduction of the methylene to the methyl group, there is oxidation of 
H4foIate to dihydrofolate, which must be reconverted to H4folate for further 
use. Therefore, cells that synthesize thymidylate (for DNA) are particularly 
vulnerable to inhibitors of folate reductase such as methotrexate.
9, Ascorbic acid (vitamin C)
The structure of ascorbic acid (Fig. 13) is reminiscent of glucose, from 
which it is derived in the majority of mammals. However, in primates, 
including man, and a number of other animals, eg, guinea pigs, some bats, 
birds, fishes, and invertebrates, the absence of the enzyme L-gulonolactone 
oxidase prevents this synthesis.
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Fig. 13. Ascorbic acid, its source in nonprimales, and its oxidation to 
dehydroascorbic acid, ionizes in ascorbate.
When ascorbic acid acts as a donor of reducing equivalents it is oxidized 
to dehydroascorbic acid, which itself can act as a source of the vitamin. 
Ascorbic acid is a reducing agent with a hydrogen potential of +0.08V, 
making it capable of reducing such compounds as molecular oxygen, nitrate, 
and cytochromes a and c. The mechanism of action of ascorbic acid in many 
of its activities is far from clear, but the following are some of the better 
documented processes requiring ascorbic acid.
1: Hydroxylation of proline in collagen synthesis.
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2: In the degradation of tyrosine, the oxidation of p-
hydroxyphenylpyruvate to homogentisate requires vitamin C, which may 
maintain the reduced state of copper necessary for maximal activity. The 
subsequent step is catalyzed by homogentisate dioxygenase, which is a ferrous 
iron-containing enzyme that also requires ascorbic acid.
3: In the synthesis of epinephrine from tyrosine at the dopamine p- 
hydroxylase step.
4: In bile acid formation at the initial 7a-hydroxylase step.
5: The adrenal cortex contains large amounts of vitamin C, which is 
rapidly depleted when the gland is stimulated by adrenocorticotropic hormone. 
The reason for this is obscure, but steroidogenesis involves several 
reductive syntheses.
6: The absorption of iron is significantly enhanced by the presence of 
vitamin C.
7: Ascorbic acid may act as a general water-soluble antioxidant and 
may inhibit the formation of nitrosamines during digestion.
Scurvy is the classical syndrome of vitamin C deficiency. It is related to 
defective collagen synthesis, which is indicated by subcutaneous and other 
hemorrhages, muscle weakness, soft swollen gums, and loose teeth; and is 
cured by consumption of fruits and fresh vegetables. The normal stores of 
vitamin C are sufficient to last 3-4 months before signs of scurvy appear.
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Lecture 32
STRUCTURE AND FUNCTION OF THE 
LIPID-SOLUBLE VITAMINS
Introduction
The lipid-soluble (fat-soluble) vitamins are apolar hydrophobic 
molecules, which are all isoprene derivatives. They cannot be synthesized 
by the body in adequate amounts and must, therefore, be supplied by the 
diet They require normal fat absorption to be occurring in order to be 
absorbed efficiently. Once absorbed, they must be transported in the blood, 
like any other apolar lipid, in lipoproteins or specific binding proteins. 
The lipid-soluble vitamins have diverse functions, eg, vitamin A, vision; 
vitamin D, calcium and phosphate metabolism; vitamin E, antioxidant; 
vitamin K, blood clotting. Although once thought of as a vitamin, in the 
true sense vitamin D (cholecalciferol) is a hormone.
Because of their lipid nature, conditions affecting the digestion and 
absorption of the lipid-soluble vitamins such as steatorrhea and disorders of 
the biliary system can all lead to deficiencies. Dietary deficiencies affect 
the functions of the vitamins mentioned above; viz, vitamin A deficiency 
causes night blindness and xerophthalmia; vitamin D deficiency leads to 
rickets in young children and osteomalacia in adults; in vitamin E 
deficiency, which is rare, neurologic disorders and anemia of the 
newborn may arise; vitamin К deficiency, again very rare in adults, leads to 
bleeding and hemorrhage of the newborn. Because of the body's ability to 
store surplus lipid-soluble vitamins, toxicity can result from excessive 
intake of vitamins A and D. A role in cancer prevention has been ascribed 
to both vitamin A and P-carotene, provitamin A.
1. Vitamin A
Vitamin A, or retinol, is a polyisoprenoid compound containing a 
cyclohexenyl ring. (Fig.l). Vitamin A is a generic term referring to all 
compounds from animal Sources that exhibit the biologic activity of vitamin 
A. They are retinol, retinoic acid, and retinal. Only retinol has full vitamin 
A activity, the others fulfilling some, but not all, vitamin A functions. The 
term retinoids has been used to describe both the natural forms and the 
synthetic analogs of retinol.
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Fig. I. Retinol (vitamin A).
In vegetables, vitamin A exists as a provitamin in the form of the yellow 
pigment P-carotene, which consists of two molecules of retinal joined at the 
aldehyde end of their carbon chains. However, because P-carotene is not 
efficiently metabolized to vitamin A, weight for weight, P-carotene is only 
one-sixth as effective a source of vitamin A as retinol.
Retinol esters dissolved in the fat of the diet are dispersed in bile droplets 
and hydrolyzed in the intestinal lumen, followed by absorption directly into 
the intestinal epithelium. Ingested P-carotenes may be oxidatively cleaved by 
P-carotene dioxygenase. This cleavage utilizes molecular oxygen, is 
enhanced by the presence of bile salts, and generates 2 molecules of 
retinaldehyde (retinal). Also, in the intestinal mucosa, retinal is reduced to 
retinol by a specific retinaldehyde reductase utilizing NADPH. A small 
fraction of the retinal is oxidized to retinoic acid. Most of the retinol is 
esterified with saturated fatty acids and incorporated into lymph chylomicrons, 
which enter the bloodstream. These are converted to chylomicron remnants, 
which are taken up by the liver together with their content of retinol. 
Carotenoids may escape some of these processes and pass directly into the 
chylomicrons.
In the liver, vitamin A is stored as an ester in the lipocytes, probably as a 
lipoglycoprotein complex. For transport to the tissues, it is hydrolyzed and the 
retinol bound to apo-retinol binding protein (RBP). The resulting holo-RBP 
is processed in the Golgi apparatus and secreted into the plasma. Retinoic acid 
is transported in plasma bound to albumin. Once inside extrahepatic cells, 
retinol is bound by a cellular retinol binding protein (CRBP).
Vitamin A toxicity occurs after the capacity of RBP has been exceeded and 
the cells are exposed to unbound retinol.
Retinol and retinal are interconverted in the presence of NAD- or NADP- 
requiring dehydrogenases or reductases, present in many tissues. However, 
once formed from retinal, retinoic acid cannot be converted back to 
retinal, or to retinol. Thus, retinoic acid can support growth and 
differentiation but cannot replace retinal in its role in vision or retinol in 
its support of the reproductive system.
When retinol is taken up into CRBP it is transported about the cell and 
binds to nuclear proteins, where it is probably involved in the control of the 
expression of certain genes. Thus, in this respect vitamin A behaves in a 
manner similar to that of steroid hormones. The requirement of vitamin A for 
normal reproduction may be ascribed to this function.
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Rhodopsin occurs in the rod cells of the retina, which are responsible for 
vision in poor light, 11-m-Retinal, an isomer of all-trans-retinal, is 
specifically bound to the visual protein opsin to form rhodopsin (Fig.2). 
When rhodopsin is exposed to light, it dissociates as it bleaches and forms 
all-fra/is-retinal and opsin. This reaction is accompanied by a conformational 
change that induces a calcium ion channel in the membrane of the rod cell. The 
rapid influx of calcium ions triggers a nerve impulse, allowing light to be 
perceived by the brain.
Fig.2. 11-cis-Retinal, formed from all-tram-retinal, combines with opsin to form 
rhodopsin in the rod cell of the eye. The absorption o f a photon o f light by rhodopsin 
causes it to bleach, generating opsin and all-trans-retinai Retinal is required to 
maintain this cycle o f reactions.
This may account, in part, for the action of retinoic acid in promoting 
growth and differentiation of tissues. It has been proposed that retinoyl 
phosphate functions as a carrier of oligosaccharides across the lipid bilayer of 
the cell, by way of an enzymatic trans-cis isomerization analogous to that 
described above in the trans-cis isomerization of rhodopsin. The evidence that 
retinoic acid is involved in glycoprotein synthesis is compelling, since a 
deficiency of vitamin A results in the accumulation of abnormally low 
molecular weight oligosaccharide-lipid intermediates of glycoprotein 
synthesis.
These are due to malfunction of the various cellular mechanisms in which 
retinoids participate. One of the first indications of vitamin A deficiency is 
defective night vision, which occurs when liver stores are nearly exhausted. 
Further depletion leads to keratinization of epithelial tissues of the eye, 
lungs, gastrointestinal, and genitourinary tracts, coupled with reduction in 
mucous secretion. Deterioration in the tissues of the eye, xerophthalmia, 
leads to blindness. Vitamin A deficiency occurs mainly on poor basic diets 
coupled with a lack of vegetables that would otherwise provide the provitamin, 
p-carotene.
Many human cancers arise in epithelial tissues that depend on retinoids for 
normal cellular differentiation. Some epidemiologic studies have shown an 
inverse relationship between the vitamin A content of the diet and the risk of
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cancer, and experiments have" shown that retinoid administration diminishes 
the effect of some carcinogens.
[5-Carotene is an antioxidant and may play a role in trapping peroxy free 
radicals in tissues at low partial pressures of oxygen. The ability of [5-carotene to 
act as an antioxidant is due to the stabilization of organic peroxide free radicals 
within its conjugated alkyl structure. Since [3-carotene is effective at low 
oxygen concentrations, it complements the antioxidant properties of vitamin E, 
which is effective at higher oxygen concentrations. The antioxidant properties of 
these two lipid-soluble vitamins may well account for their possible anticancer 
activity.
2. Vitamin D
Vitamin D is a steroid prohormone. It is represented by a group of steroids 
that occur chiefly in animals but also in plants and yeast. By various metabolic 
changes in the body they give rise to a hormone known as calcitriol, which 
plays a central role in calcium and phosphate metabolism.
Ergosterol occurs in plants and 7-dehydrocholesterol in animals. 
Ergosterol differs from 7-dehydrocholesterol only in its side chain, which is 
unsaturated and contains an extra methyl group (Fig.3). Ultraviolet irradiation 
from sunlight cleaves the В ring of both compounds. Ergocalciferol (vitamin 
D2) is formed in plants, whereas in animals, cholecalciferol (vitamin D3) is 
formed in exposed skin. Both vitamins are of equal potency, giving rise to 
D2 calcitriol and D3 calcitriol, respectively. Only the latter pathway will be 
described.
Ergoeterol
{plant»)
E/pocataUarot 
(vitamin D2)
—  С  —  С И4
C H ,
7-Oehydrocbo4e*|e«>» , Chotecaiaferol
(*л*т\аЛ) (vitamifi Ds)
Fig.3. Ergosterol and 7-dehydrocholesterol and their conversion by photolysis to 
ergocalciferol and chole-calciferol, respectively.
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Jn the liver, dietary vitamin D3 (or D3) is taken up from the blood 
(bound to a specific globulin) after absorption from micelles in the intestine. 
It is hydroxylated on the 25 position by vitamin D3-25-hydroxylase, an 
enzyme of the endoplasmic reticulum considered to be rate limiting (Fig. 4). 
25-hydroxyD3 is the major form of vitamin D in the circulation and the 
major storage form in the liver. A significant fraction of 25-hydroxyD3 
undergoes enterohepatic circulation and disturbances of this process can 
lead to deficiency of vitamin D.
Fig. 4. Cholecalciferol can be hydroxylated at the C;s position by a liver enzyme. The 
25-hvdro.xycholecalciferol is further metabolized to la,25-dihydroxycholecalciferol or 
to 24.25-dihydroxycholecalciferol. The levels o f  24.25-dihydro.xycho/ecalciferol and 
1,25-dihydroxycholecalciferol are regulated in a reciprocal manner.
In the renal tubules, bone, and placenta, the 25-hydroxyD3 is further 
hydroxylated in position 1 by 25-hydroxyD3l -hydroxylase, a mitochondrial 
enzyme. The product is la,25-dihydroxyD3 (calcitriol), the most potent 
vitamin D metabolite. Its production is regulated by its own 
concentration, parathyroid hormone, and serum phosphate.
25-HydroxyD3 can also be hydroxylated at the 24 position by a 
mitochondrial enzyme present in renal tubules, cartilage, intestine, and 
placenta. The level of the product 24,25-dihydroxyD3 is reciprocally related 
to the level of l,25-dihydroxyD3 in serum.
Rickets occurs in young children and osteomalacia in adults who are not 
exposed to sunlight or who do not receive adequate amounts of vitamin D in 
the diet. It is due to softening of bones resulting from lack of calcium and 
phosphate. Oily fish, egg yolk, and liver are good sources of the vitamin.
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1. Vitamin E (Tocopherol)
There are several naturally occurring tocopherols. All are isoprenoid 
substituted 6-hydroxychromanes ortocols (Fig.5).
C M ,
i C H ,
C H , J f "  if-
HO - Jj., з|
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Fig.5. a-Tocopherol.
CH,
D-a-TocopheroI has the widest natural distribution and the greatest 
biologic activity'.
Impaired fat absorption leads to vitamin E deficiency because 
tocopherol is found dissolved in the fat of the diet and is liberated and 
absorbed during fat digestion. Furthermore, it is transported in the blood by 
lipoproteins, first, by incorporation into chylomicrons, which distribute the 
vitamin to the tissues containing lipoprotein lipase and to the liver in 
chylomicron remnants, and second, by export from the liver in very low density 
lipoproteins. It is stored in adipose tissue.
Vitamin E appears to be the first line of defense against peroxidation of 
polyunsaturated fatty acids contained in cellular and subcellular membrane 
phospholipids. The phospholipids of mitochondria, endoplasmic reticulum, and 
plasma membranes possess affinities for a-tocopherol and the vitamin appeal's 
to concentrate at these sites. The tocopherols act as antioxidants, breaking free- 
radical chain reactions as a result of their ability to transfer a phenolic 
hy drogen to a peroxyl free radical of a peroxidized polyunsaturated fatty acid. 
The phenoxy free radical formed then reacts with a further peroxyl free radical. 
Thus, a-tocopherol does not readily engage in reversible oxidation; the 
chromane ring and the side chain are oxidized to the non-ffee-radical product. 
This oxidation product is conjugated with glucuronic acid via the 2-hydroxyl 
group and excreted in the bile. Unlike some other vitamins, eg, niacin, B12, and 
folate, tocopherol is not recycled after carrying out its function but must be 
replaced totally to continue its biologic role in the cell. The antioxidant action 
of tocopherol is effective at high oxygen concentrations, and thus it is not 
surprising that it tends to be concentrated in those lipid structures that are 
exposed to the highest 0 2 partial pressures, eg, the erythrocyte membrane and 
the membranes of the respiratory tree.
Glutathione peroxidase, of which selenium is an integral component, 
provides a second line of defense against peroxides before they can propagate 
in chain reactions, damaging membranes and other cell components. Thus, 
tocopherol and selenium reduce each other's requirement or reinforce each 
other in their actions against lipid peroxides. In addition, selenium is required
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for normal pancreatic function, which is necessary for the digestion and 
absorption of lipids, including vitamin E. Conversely, vitamin E reduces 
selenium requirements by preventing loss of selenium from the body or 
maintaining it in an active form.
There is a possible need for supplementation of tocopherol in the diet of 
pregnant and lactating women and for newborn infants where anemia can 
arise as a result of insufficiency of vitamin E. Anemia may be due to 
decreasedproduction of hemoglobin and a shortened erythrocyte life span.
The requirement for vitamin E is increased with greater intake o f  
polyunsaturated fat. Intake of mineral oils, exposure to oxygen (as in oxygen 
tents), or diseases leading to inefficient lipid absorption may cause 
deficiencies of the vitamin leading to neurologic disorder.
Vitamin E is destroyed by commercial cooking and food processing, 
including deep-freezing. Wheat germ, sunflower seed and safflower seed oils, 
and com and soya bean oil are all good sources of the vitamin. Although fish 
liver oils are rich sources of vitamins A and D, they have insignificant 
amounts of vitamin E.
2. Vitamin К
Vitamins belonging to the К group are polyisoprenoid-substituted 
napthoquinones. Menadione (K-,), the parent compound of the vitamin К 
series (Fig.6), is not found naturally but if administered it is alkylated in 
vivo to one of the menaquinones (Ki). Phylloquinone (K.,) is the major 
form of vitamin К found in plants. Menaquinone-7 is one of the series of 
polyprenoid unsaturated forms of vitamin К found in animal tissues and 
synthesized by bacteria in the intestine.
0
Menadione tvitamin K-, •
PhyHcKjuinone (vitamin K ; , oftytonadione. Mephvton)
О
M enaqu inone -n  (v ita m in  K j  ;  n  *  8 ,  7 , o* 9 )
Fig. 6. The naturally occurring vitamins K.
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Fat m alabsorp tion  is the com m onest cause o f  vitam in К deficiency. The 
naturally  occurring  К  derivatives are absorbed on ly  in the presence o f  b ile  
salts, like o ther lipids, and are distributed in the bloodstream  v ia  the 
lym phatics, in chy lom icrons. M enad ione, being w ater-soluble, is absorbed 
even in the absence of bile salts, passing  d irectly  into the hepatic portal 
vein. A lthough vitam in К  accum ulates initially  in the liver, its hepatic 
concentration  declines rapidly  and sto rage is lim ited .
V itam in К has been show n to  be involved in the m aintenance o f  norm al 
levels o f  blood clotting factors II, VII, IX and X, all o f  w hich are 
synthesized in the liver initially as inactive p re c u r s o r  proteins.
G eneration o f  the biologically active clotting factors involves the 
posttranslational modification o f  glutam ate (G lu) residues o f  the precursor 
proteins to y-carboxyglutam ate (Gla) residues by a  specific vitamin In­
dependent carboxylase. Prothrom bin (factor II) contains 10 o f  these residues, 
w hich allow chelation of calcium in a specific protein-calcium -phospholipid 
interaction, essential to their biologic role. O ther proteins containing In­
dependent G la residues have now been identified in several tissues.
The vitamin К -dependent carboxylase reaction occurs in the endoplasmic 
reticulum o f  many tissues and requires m olecular oxy gen, carbon dioxide (not 
HOT,'), and the hydroquinone (reduced) form of vitamin K. In the 
endoplasm ic reticulum o f  liver there exists a vitamin К cycle (Fig.7) in which 
the 2,3-epoxide product o f  the carboxylation reaction is converted by 2,3- 
epoxide reductase to the quinone form o f  vitam in K, using an, as yet, 
unidentified dithiol reductant. This reaction is sensitive to inhibition by 4-hy- 
droxydicoumarin (dicumarol) types of anticoagulant, such as warfarin. 
Subsequent reduction o f  the quinone form to the hydroquinone by N A D H  
com pletes the vitamin К cycle for regenerating the active form o f  the vitamin.
tih.» Q  > C O  j Gits
\  4 \
\ fj
Fig. 7. Vitamin К-related metabolic activities in liver. The locus o f  action o f  the 
dicumarol-type anticoagulants is indicated. The details o f  some o f  the reactions are 
still uncertain. I-monooxygenase; 2-carboxylase; 2-2,3-epoxide reductase; 4- 
reductase.
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An important therapeutic use of vitamin К is as an antidote to poisoning 
by dicumarol-type drugs. The quinone forms of vitamin К will bypass the 
inhibited epoxide reductase and provide a potential source of the active 
hydroquinone form of vitamin K.
Vitamin К is widely distributed in plant and animal tissues used as food, 
and production of the vitamin by the microflora of the intestine virtually 
ensures that dietary deficiency does not occur in adults. However, newborn 
infants are vulnerable to the deficiency, because the placenta does not pass the 
vitamin to the fetus efficiently and the gut is sterile immediately after birth. In 
normal infants, the plasma concentration decreases immediately after birth but 
recovers after food is absorbed. If the prothrombin level drops too low, the 
hemorrhagic syndrome may appear.
Vitamin К deficiency can be caused by fat malabsorption, which may be 
associated with pancreatic dysfunction, biliary disease, atrophy of the 
intestinal mucosa, or any cause of steatorrhea. In addition, sterilization of the 
large intestine by antibiotics can result in deficiency when dietary intake is 
limited.
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